# EXHIBIT B

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA  In Re: Bair Hugger Forced Air Warming Products Liability Litigation  This Document Relates To: All Actions MDL No. 15-2666 (JNE/FLM)  DEPOSITION OF JONATHAN BORAK VOLUME I, PAGES 1 - 251 JULY 20, 2017  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  Page 2  Page 2  EXHIBITS DESCRIPTION PAGE MARK  2 EXHIBITS DESCRIPTION PAGE MARK 2 Expert report of Jonathan Borak & Company website download 39  4 Article, Mortality Disparities in Appalachia, by Borak, et al 46  Article, Mortality Disparities in Appalachia, by Borak, et al 46  Email sent September 06, 2002 54  6 Exhibit B to Borak's expert report report 61  7 Kurz deposition excerpt, January 12, 2017 76  9 510(k) Summary of Safety & Effectiveness, January 10, 1996, 3MBH00047382-3 94  10 E-mail string, 3MBH00013261-2 12 E-mail string, 3MBH00130429-32 12 E-mail string, 3MBH01330587-92 12 E-mail string, 3MBH0130587-92 12 E-mail string, 3MBH01330587-92 12 E-mail string, 3MBH0
DISTRICT OF MINNESOTA  In Re:  Bair Hugger Forced Air Warming  Products Liability Litigation  This Document Relates To:  All Actions  MDL No. 15-2666 (JNE/FLM)  DEPOSITION OF JONATHAN BORAK  VOLUME I, PAGES 1 - 251  JULY 20, 2017  The following is the deposition of JONATHAN  BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  2 EXHIBITS  DESCRIPTION  BORAK (1 Expert report of Jonathan  A Borak 7  2 Borak curriculum vitae 8  3 Jonathan Borak & Company website download 39  4 Article, Mortality Disparities in  Appalachia, by Borak, et al 46  5 E-mail sent September 06, 2002 54  11 6 Exhibit B to Borak's expert report 61  7 Kurz deposition excerpt, January  12, 2017 76  13 Femail string, 3MBH0034755 90  16 9 510(k) Summary of Safety & Effectiveness, January 10, 1996, 3MBH00047382-3 94  10 E-mail string, 3MBH00024633-4 113  11 E-mail string, 3MBH00012463-4 113  12 E-mail string, 3MBH00132501-2 124  13 E-mail string, 3MBH001330587-92 128  14 E-mail string, 3MBH01330587-92 128
In Re: Bair Hugger Forced Air Warming Products Liability Litigation  This Document Relates To: All Actions MDL No. 15-2666 (JNE/FLM)  DEPOSITION OF JONATHAN BORAK VOLUME I, PAGES 1 - 251 JULY 20, 2017  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  In Re: Bair Hugger Forced Air Warming  5 2 Borak curriculum vitae 8 A Article, Mortality Disparities in Appalachia, by Borak, et al 46  6 5 5 C-mail sent September 06, 2002 54  11 6 Exhibit B to Borak's expert report 61  7 7 8 12 12 12 12 12 12 12 12 12 13 13 14 15 16 17 18 18 18 18 18 18 18 18 18 18 19 18 18 18 18 18 18 18 18 18 18 18 18 18
In Re: Bair Hugger Forced Air Warming Products Liability Litigation  This Document Relates To: All Actions MDL No. 15-2666 (JNE/FLM)  DEPOSITION OF JONATHAN BORAK VOLUME I, PAGES 1 - 251 JULY 20, 2017  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  In Re: Bair Hugger Forced Air Warming  5 2 Borak curriculum vitae 8 A Article, Mortality Disparities in Appalachia, by Borak, et al 46  6 5 5 C-mail sent September 06, 2002 54  11 6 Exhibit B to Borak's expert report 61  7 7 8 12 12 12 12 12 12 12 12 12 13 13 14 15 16 17 18 18 18 18 18 18 18 18 18 18 19 18 18 18 18 18 18 18 18 18 18 18 18 18
Products Liability Litigation  6 3 Jonathan Borak & Company website download 39  This Document Relates To: All Actions MDL No. 15-2666 (JNE/FLM)  9 Appalachia, by Borak, et al 46  10 5 E-mail sent September 06, 2002 54  11 6 Exhibit B to Borak's expert report 61  DEPOSITION OF JONATHAN BORAK  VOLUME I, PAGES 1 - 251  JULY 20, 2017  15 8 E-mail, 3M00580475 90  16 9 510(k) Summary of Safety & Effectiveness, January 10, 1996, 3MBH00047382-3 94  17 Effectiveness, January 10, 1996, 3MBH00047382-3 94  18 DORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  18 E-mail string, 3MBH00132501-2 124  29 11 E-mail string, 3MBH00130587-92 128  19 12 E-mail string, 3MBH01330587-92 128  19 15 Article, Return to theatre following total hip and knee
Products Liability Litigation  6 3 Jonathan Borak & Company website download 39  This Document Relates To: All Actions MDL No. 15-2666 (JNE/FLM)  9 Appalachia, by Borak, et al 46  10 5 E-mail sent September 06, 2002 54  11 6 Exhibit B to Borak's expert report 61  DEPOSITION OF JONATHAN BORAK  VOLUME I, PAGES 1 - 251  JULY 20, 2017  15 8 E-mail, 3M00580475 90  16 9 510(k) Summary of Safety & Effectiveness, January 10, 1996, 3MBH00047382-3 94  17 Effectiveness, January 10, 1996, 3MBH00047382-3 94  18 DORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  18 E-mail string, 3MBH00132501-2 124  29 11 E-mail string, 3MBH00130587-92 128  19 12 E-mail string, 3MBH01330587-92 128  19 15 Article, Return to theatre following total hip and knee
This Document Relates To: All Actions MDL No. 15-2666 (JNE/FLM)  BEPOSITION OF JONATHAN BORAK VOLUME I, PAGES 1 - 251 JULY 20, 2017  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  This Document Relates To: A Article, Mortality Disparities in Appalachia, by Borak, et al 46  10 5 E-mail sent September 06, 2002 54  11 6 Exhibit B to Borak's expert report 61  Xurz deposition excerpt, January 12, 2017 76  15 8 E-mail, 3M00580475 90  16 9 510(k) Summary of Safety & Effectiveness, January 10, 19 10 E-mail string, 3MBH00024633-4 113  19 6 Exhibit B to Borak's expert report 61  Nurz deposition excerpt, January 10 E-mail, 3M00580475 90  11 E-mail string, 3MBH0003407382-3 94  12 E-mail string, 3MBH00024633-4 113  13 E-mail string, 3MBH00130591-2 124  14 E-mail string, 3MBH00130429-32 126  15 Article, Return to theatre following total hip and knee
This Document Relates To: All Actions MDL No. 15-2666 (JNE/FLM)  9 Appalachia, by Borak, et al 46  10 5 E-mail sent September 06, 2002 54  11 6 Exhibit B to Borak's expert report 61  DEPOSITION OF JONATHAN BORAK VOLUME I, PAGES 1 - 251  JULY 20, 2017  15 8 E-mail, 3M00580475 90  16 9 510(k) Summary of Safety & Effectiveness, January 10,  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  8 4 Article, Mortality Disparities in Appalachia, by Borak, et al 46  10 5 E-mail sent September 06, 2002 54  11 6 Exhibit B to Borak's expert report 61  7 Kurz deposition excerpt, January 12, 2017 76  15 8 E-mail, 3M00580475 90  16 9 510(k) Summary of Safety & Effectiveness, January 10, 1996, 3MBH00047382-3 94  19 10 E-mail string, 3MBH00024633-4 113  20 11 E-mail string, 3MBH000344754-5 119  21 22 E-mail string, 3MBH00132501-2 124  22 13 E-mail string, 3MBH00130429-32 126  23 14 E-mail string, 3MBH01330587-92 128  24 15 Article, Return to theatre following total hip and knee
All Actions MDL No. 15-2666 (JNE/FLM)  Appalachia, by Borak, et al 46  10 5 E-mail sent September 06, 2002 54  11 6 Exhibit B to Borak's expert  12 report 61  DEPOSITION OF JONATHAN BORAK  VOLUME I, PAGES 1 - 251  JULY 20, 2017  15 8 E-mail, 3M00580475 90  16 9 510(k) Summary of Safety &  17 Effectiveness, January 10,  18 1996, 3MBH00047382-3 94  BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  Appalachia, by Borak, et al 46  10 5 E-mail sent September 06, 2002 54  11 12, 2017 76  12 E-mail, 3M00580475 90  12 Effectiveness, January 10,  13 10 E-mail string, 3MBH00047382-3 94  14 E-mail string, 3MBH000544754-5 119  15 E-mail string, 3MBH00132501-2 124  16 Exhibit B to Borak's expert  16 Positive Proportion of Incomplete
10 5 E-mail sent September 06, 2002 54  11 6 Exhibit B to Borak's expert  12 report 61  DEPOSITION OF JONATHAN BORAK  VOLUME I, PAGES 1 - 251  JULY 20, 2017  15 8 E-mail, 3M00580475 90  16 9 510(k) Summary of Safety &  17 Effectiveness, January 10,  18 1996, 3MBH00047382-3 94  BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  10 E-mail sent September 06, 2002 54  11 E-mail sent September 06, 2002 54  12 E-mail sent September 06, 2002 54  13 F Kurz deposition excerpt, January  14 12, 2017 76  15 8 E-mail, 3M00580475 90  16 9 510(k) Summary of Safety &  17 Effectiveness, January 10,  18 1996, 3MBH00047382-3 94  19 10 E-mail string, 3MBH00024633-4 113  11 E-mail string, 3MBH00132501-2 124  12 E-mail string, 3MBH00132501-2 124  13 E-mail string, 3MBH00130429-32 126  14 E-mail string, 3MBH00130587-92 128  15 Article, Return to theatre  10 following total hip and knee
DEPOSITION OF JONATHAN BORAK VOLUME I, PAGES 1 - 251 JULY 20, 2017  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, 1996, 3MBH00047382-3  10 E-mail string, 3MBH00024633-4  113  113  124  125  136  137  147  158  159  169  1996, 3MBH00047382-3  19  19  10 E-mail string, 3MBH00132501-2  112  124  125  125  126  127  128  128  129  129  120  120  120  121  120  121  120  121  121  122  123  124  125  126  127  127  128  129  120  120  120  121  120  121  120  121  120  120  121  120  120  121  120  120  121  120  120  121  120  120  121  120  120  120  120  121  120  12
DEPOSITION OF JONATHAN BORAK VOLUME I, PAGES 1 - 251 JULY 20, 2017  (The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  12 report 61 13 7 Kurz deposition excerpt, January 14 12, 2017 76 15 8 E-mail, 3M00580475 90 16 9 510(k) Summary of Safety & 17 Effectiveness, January 10, 18 1996, 3MBH00047382-3 94 19 10 E-mail string, 3MBH00024633-4 113 20 11 E-mail string, 3MBH00024633-4 119 21 12 E-mail string, 3MBH00132501-2 124 22 13 E-mail string, 3MBH00130587-92 128 24 15 Article, Return to theatre 25 following total hip and knee
DEPOSITION OF JONATHAN BORAK VOLUME I, PAGES 1 - 251  JULY 20, 2017  15 8 E-mail, 3M00580475 90  16 9 510(k) Summary of Safety &  Effectiveness, January 10,  18 1996, 3MBH00047382-3 94  BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  DEPOSITION OF JONATHAN 12, 2017 76  15 8 E-mail, 3M00580475 90  16 9 510(k) Summary of Safety &  Effectiveness, January 10, 18 1996, 3MBH00047382-3 94  19 10 E-mail string, 3MBH00024633-4 113  20 11 E-mail string, 3MBH00132501-2 124  21 12 E-mail string, 3MBH00132501-2 124  22 13 E-mail string, 3MBH01330587-92 128  24 15 Article, Return to theatre 25 following total hip and knee
VOLUME I, PAGES 1 - 251  JULY 20, 2017  15 8 E-mail, 3M00580475 90  16 9 510(k) Summary of Safety &  17 Effectiveness, January 10,  18 1996, 3MBH00047382-3 94  BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  18 19 6, 3MBH00047382-3 94  19 10 E-mail string, 3MBH00024633-4 113  20 11 E-mail string, 3MBH00544754-5 119  21 12 E-mail string, 3MBH00132501-2 124  22 13 E-mail string, 3MBH00130429-32 126  23 14 E-mail string, 3MBH01330587-92 128  24 15 Article, Return to theatre following total hip and knee
JULY 20, 2017  15  8 E-mail, 3M00580475  90  16  9 510(k) Summary of Safety & Effectiveness, January 10,  18  1996, 3MBH00047382-3  94  BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  20  11 E-mail string, 3MBH00024633-4  113  12 E-mail string, 3MBH00132501-2  12 E-mail string, 3MBH00132501-2  12 E-mail string, 3MBH00130429-32  13 E-mail string, 3MBH00130429-32  14 E-mail string, 3MBH01330587-92  15 Article, Return to theatre following total hip and knee
(The following is the deposition of JONATHAN  BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200  Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  16  9  510(k) Summary of Safety & Effectiveness, January 10,  18  1996, 3MBH00047382-3  94  10  E-mail string, 3MBH00024633-4  113  20  11 E-mail string, 3MBH00544754-5  119  21  22  13 E-mail string, 3MBH00132501-2  124  23  14 E-mail string, 3MBH01330587-92  128  24  15 Article, Return to theatre following total hip and knee
(The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  17 Effectiveness, January 10, 18 1996, 3MBH00047382-3 94 10 E-mail string, 3MBH00024633-4 113 20 11 E-mail string, 3MBH00544754-5 119 21 12 E-mail string, 3MBH00132501-2 124 22 13 E-mail string, 3MBH00130429-32 126 23 14 E-mail string, 3MBH01330587-92 128 24 15 Article, Return to theatre following total hip and knee
(The following is the deposition of JONATHAN BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  18 1996, 3MBH00047382-3 94 10 E-mail string, 3MBH00024633-4 113 20 11 E-mail string, 3MBH00132501-2 124 22 13 E-mail string, 3MBH00130429-32 126 23 14 E-mail string, 3MBH01330587-92 128 24 15 Article, Return to theatre following total hip and knee
BORAK, taken pursuant to Notice of Taking Deposition, via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  19 10 E-mail string, 3MBH00024633-4 113 21 12 E-mail string, 3MBH00132501-2 124 22 13 E-mail string, 3MBH00130429-32 126 23 14 E-mail string, 3MBH01330587-92 128 24 15 Article, Return to theatre following total hip and knee
via videotape, at the Marriott Hartford Downtown, 200 Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  20 11 E-mail string, 3MBH00132501-2 124 22 13 E-mail string, 3MBH00130429-32 126 23 14 E-mail string, 3MBH01330587-92 128 24 15 Article, Return to theatre following total hip and knee
Columbus Boulevard, Hartford, Connecticut, commencing at approximately 8:09 o'clock a.m., July 20, 2017.)  21
at approximately 8:09 o'clock a.m., July 20, 2017.)  22  13  E-mail string, 3MBH00130429-32  126  23  14  E-mail string, 3MBH01330587-92  128  24  15  Article, Return to theatre  25  following total hip and knee
23 14 E-mail string, 3MBH01330587-92 128 24 15 Article, Return to theatre 25 following total hip and knee
24 15 Article, Return to theatre 25 following total hip and knee
25 following total hip and knee
Page 2 Page
1 APPEARANCES: 1 replacement, before and after
2 On Behalf of the Plaintiffs: 2 the introduction of rivaroxaban,
3 Jan M. Conlin 3 by Jensen et al 145
CIRESI CUNLIN L.L.F.
223 South off Street, Suite 4000
Minneapolis, Minnesota 55402 5 Force-Air Warming and 5 Surgical Site Infections 154
On Behalf of Defendants: 7 17 Article, Wound Complications
6 8 Following Rivaroxaban Administr
Corey L. Gordon 0 tion by Jameson et al. 154
DEACRALE BORKE I.A.
431 South Seventh Street, Suite 2500 10 18 Reed deposition transcript, Minneapolis, Minnesota 55415 11 December 4, 2016 161
9 ALSO APPEARING: 12 19 Article, Chlorhexidine-Alcohol
10 Ronald M. Huber, Videotechnician 13 versus Povidone-Iodine for
14 Surgical Site Antisansis by
15 D 11 11 170
13 Darouicne, et al 1/0 14 20 Article, Preventing Surgical-
15 26 Attele, Trevening Surgical 17 Site Infections in Nasal
16 La Carriers of Staphylococcus
19 aureus by Rode et al 175
20 21 Article Effects of macomative
20 21 Article, Effects of preoperative 21 warming on the incidence of
21 warming of the incidence of 22 wound infection after clean
22 would infection after clean 23 surgery: A randomised controlled
23 sargery. A tandomised controlled
25 22 Article Prophylactic antibiotics
25 22 Article, Prophylactic antibiotics

1 (Pages 1 to 4)

	Page 5	Page 7
1		1 PROCEEDINGS
1	in elective hip and knee	
2	arthroplasty, by Hickson, et al 193	,
3	23 Article, Implementing effective	3 JONATHAN BORAK
4	SSI surveillance, by Gillson,	4 called as a witness, being first duly sworn,
5	et al 195	5 was examined and testified as follows:
6	24 Article, Surveillance of surgical	6 ADVERSE EXAMINATION
7	site infections in NHS hospitals	7 BY MS. CONLIN:
8	in England, 2015/16 198	8 Q. Good morning, Professor Borak. Is it
9	25 Article, Staphylococcus aureus	9 Do you go by Dr. Borak or Professor Borak?
10	Screening and Decolonization in	10 A. I I guess I'm more comfortable with
11	Orthopaedic Surgery and Reduction	11 doctor.
12	of Surgical Site Infections, by	12 Q. Okay.
13	Chen, et al 203	13 A. I've been a doctor for longer.
14	26 Centers for Disease Control and	Q. Can you spell your last name for the record,
15	Prevention Guidelines for the	15 please or actually your full name.
		16 A. Jonathan, J-o-n-a-t-h-a-n, Benjamin,
16	Prevention of Surgical Site	17 B-e-n-j-a-m-i-n, Borak, B-o-r-a-k.
17	Infection, 2017 204	
18	27 McGovern deposition excerpt,	1
19	January 4, 2017 215	19 a copy?
20	28 McGovern deposition excerpt,	20 MR. GORDON: Are you using new numbering
21	January 5, 2017 230	21 for
22	29 Nachtsheim deposition excerpt,	22 MS. CONLIN: Yeah. We'll go with Borak
23	November 29, 2016 236	23 Exhibit 1.
24	30 Article, The Environment and	24 (Exhibit 1 was marked for
25	Disease: Association or	25 identification.)
	Page 6	Page 8
1	Page 6	Page 8
1	Page 6 Causation? by Hill 239	1 BY MS. CONLIN:
2		1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been
2	Causation? by Hill 239	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that
2 3 4	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case?
2 3 4 5	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE Jonathan Borak Ms. Conlin 7	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct.
2 3 4 5 6	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE Jonathan Borak Ms. Conlin 7 Mr. Gordon 240	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And
2 3 4 5 6 7	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for
2 3 4 5 6	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE Jonathan Borak Ms. Conlin 7 Mr. Gordon 240	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And
2 3 4 5 6 7	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for
2 3 4 5 6 7 8	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for identification.)
2 3 4 5 6 7 8	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN:
2 3 4 5 6 7 8 9	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been
2 3 4 5 6 7 8 9 10	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV?
2 3 4 5 6 7 8 9 10 11 12 13	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question?
2 3 4 5 6 7 8 9 10 11 12 13 14	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV?
2 3 4 5 6 7 8 9 10 11 12 13 14	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV? 15 A. Yeah. There's several more recent
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV? 15 A. Yeah. There's several more recent 16 publications.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV? 15 A. Yeah. There's several more recent 16 publications. 17 Q. Okay. Do you want to, if you know, name
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV? 15 A. Yeah. There's several more recent 16 publications. 17 Q. Okay. Do you want to, if you know, name 18 those, please.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV? 15 A. Yeah. There's several more recent 16 publications. 17 Q. Okay. Do you want to, if you know, name 18 those, please. 19 A. The names are long. They both have to do
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV? 15 A. Yeah. There's several more recent 16 publications. 17 Q. Okay. Do you want to, if you know, name 18 those, please. 19 A. The names are long. They both have to do 20 with elemental mercury exposure. They have just been
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV? 15 A. Yeah. There's several more recent 16 publications. 17 Q. Okay. Do you want to, if you know, name 18 those, please. 19 A. The names are long. They both have to do 20 with elemental mercury exposure. They have just been 21 published in the last week in Critical Reviews in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV? 15 A. Yeah. There's several more recent 16 publications. 17 Q. Okay. Do you want to, if you know, name 18 those, please. 19 A. The names are long. They both have to do 20 with elemental mercury exposure. They have just been
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV? 15 A. Yeah. There's several more recent 16 publications. 17 Q. Okay. Do you want to, if you know, name 18 those, please. 19 A. The names are long. They both have to do 20 with elemental mercury exposure. They have just been 21 published in the last week in Critical Reviews in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV? 15 A. Yeah. There's several more recent 16 publications. 17 Q. Okay. Do you want to, if you know, name 18 those, please. 19 A. The names are long. They both have to do 20 with elemental mercury exposure. They have just been 21 published in the last week in Critical Reviews in 22 Toxicology.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Causation? by Hill 239  WITNESS EXAMINATION BY PAGE  Jonathan Borak Ms. Conlin 7  Mr. Gordon 240  Ms. Conlin 245  Mr. Gordon 246	1 BY MS. CONLIN: 2 Q. I've handed you a copy of or what's been 3 marked as Borak Deposition Exhibit No. 1. Is that 4 your expert report in this case? 5 A. That is correct. 6 Q. And 7 (Exhibit 2 was marked for 8 identification.) 9 BY MS. CONLIN: 10 Q. I've handed you, Dr. Borak, what's been 11 marked as Borak Deposition Exhibit No. 2. Is this a 12 copy of your CV? 13 A. I'm sorry, what was your question? 14 Q. Is this a copy of your CV? 15 A. Yeah. There's several more recent 16 publications. 17 Q. Okay. Do you want to, if you know, name 18 those, please. 19 A. The names are long. They both have to do 20 with elemental mercury exposure. They have just been 21 published in the last week in Critical Reviews in 22 Toxicology. 23 Q. Okay. Other than those additions, to the

2 (Pages 5 to 8)

Page 9 Page 11 1 A. I -- I think so, yes. 1 probably the McGovern study because it was a peer-2 Q. Okay. I'd like to direct your attention 2 reviewed paper, and there was then a discussion of 3 back to your expert report in this case dated June 3 some notable paper or papers that had been retracted, 4 2nd, 2017 that has been marked as Exhibit 1. I'd like 4 and I just wondered in my own head how often that 5 5 to direct your attention, Dr. Borak, to page 23 of occurred. I have been in situations as a member of 6 6 editorial boards where it's been necessary to retract that. 7 7 papers, and I was interested to see whether this was a Do you have it in front of you, sir? 8 8 very common phenomenon. 9 9 Q. Okay. Did you undertake that on your own or Q. Okay. I'd like to direct your attention to 10 10 were you requested to do that by lawyers for 3M? paragraph 74c --11 A. Yes. 11 A. I -- I -- I initiated that on my own. 12 Q. -- where you opine, "The McGovern report 12 Q. Okay. And you indicated you read some 13 deposition testimony related to Ridgeview. Was that 13 relied on truncated and incorrectly tabulated data. When those irregularities are corrected, the study 14 14 by Dr. Augustine? 15 15 A. I -- I did not review deposition testimony data do not provide evidence that BH" -- Bair 16 Hugger -- "is associated with a significant increase 16 that I'm aware of that was related to Ridgeview 17 in SSI." 17 Medical Center, at least I don't remember it as such, 18 That's your opinion; correct? 18 but I looked at a number of documents which were 19 19 A. You read that correctly, yes. either marked as exhibits or had Bates numbers on 20 20 Q. And is that your opinion? them. Q. Who provided those to you? 21 21 A. That's my opinion. 22 Q. Okay. And is that your opinion today? 22 A. Mr. Gordon. 23 23 A. That is my opinion today. MS. CONLIN: Okay. And we'll request an Q. Okay. Have you reviewed anything since the 24 updated list of documents reviewed since he offered 2.4 25 filing of your report on June 2nd of this year? 25 his opinions in this case. Page 10 Page 12 1 A. Yes. 1 MR. GORDON: Sure. 2 Q. What have you reviewed? 2 Q. Directing your attention back to paragraph 3 A. I have reviewed a recent publication by Dr. 3 74c and your opinion that use of Bair Hugger is not 4 Augustine. 4 associated with an increased risk in SSIs, how do you 5 5 define "associated?" Q. Okay. 6 A. I have reviewed a number of exhibits from 6 A. I think that the operative word there is 7 7 what I assume to have been depositions or legal "significant," and I was referring to a statistically 8 8 proceedings related to both Augustine and Ridgeview significant association. 9 Medical Center. 9 Q. My question was a little different. How do 10 10 Q. Okay. Anything else? you define "associated" as that word is used in 11 A. The answer is yes, but you're going to ask 11 paragraph 74c? 12 12 A. I don't think that you can take the word out me to be specific. I have looked at a number of 13 13 publications related to retractions of peer-reviewed of the context. "Associated with a significant 14 literature, I have -- I looked at much but not all of 14 increase" is the statement that I made. 15 15 a rough draft of Dr. Holford's deposition, and I have Q. Well you understand that "association" or 16 certainly looked back in my files. Whether in the 16 "associated" is an epidemiological term; correct? 17 course of that I may have looked at additional 17 A. It is often used in epidemiology, correct. 18 articles, it is possible, but they don't come to mind. 18 Q. Okay. Did you use it in an epidemiologic 19 I'm not trying to withhold anything. 19 way in connection with your use of the term 2.0 Q. And what was the purpose for you looking at 20 "associated" in paragraph 74c? 21 21 materials related to retraction of peer-reviewed A. Only to the extent that association implies 22 22 that there is a relationship -- an apparent 23 23 relationship, and the question here was whether there A. A question arose in my mind based on a 24 24 statement made at least once and possibly multiple was a signif -- a relationship indicating a 25 times by Dr. Samet, who defended reliance upon 25 significant increase.

Page 13 Page 15 1 O. Okay. Would you agree with me that 1 use of the Bair Hugger is associated with an increased 2 "association," as used by epidemiologists, states that 2 risk of infection. 3 events are said to be associated when they occur more 3 A. Yes. Excluding those papers, I have seen no 4 or less frequently together than one would expect by 4 such evidence. 5 5 chance? Q. Okay. And when epidemiologists talk about 6 6 A. That's probably a -- a reasonable events that are said to be associated when they occur 7 7 more or less frequently together than one would expect definition. 8 8 by chance, I would take it that your opinion is that Q. Okay. So is it your opinion that use of the 9 9 the use of a Bair Hugger would have the chance of Bair Hugger is associated with increased infection? 10 10 causing an infection along the same lines as a -- a MR. GORDON: Object to the form of the 11 Rubber Ducky sitting in the OR; is that right? 11 question. 12 MR. GORDON: Object to the form of the 12 A. Not necessarily. 13 13 Q. Okay. So use of the Bair Hugger and an question. 14 14 A. I think there were two elements. One of infection would be by chance as opposed to something 15 them is that there is a chance -- stochastic chance of 15 16 something else. The other one is there are other 16 A. What do you mean "by chance as opposed to 17 moving parts in the scenario. And if you want to say 17 something else?" 18 that everything else is held constant, then yes, only 18 Q. Well, do you believe that the Bair Hugger is 19 chance. 19 associated with any increased risk of infection? 20 Q. Okay. So holding everything else constant, 20 A. I am aware of at least one paper, the 21 having a Bair Hugger in use in the OR would increase 21 McGovern paper, and a subsequent paper which we may 22 your chance of infection to the same extent that a 22 discuss by Augustine, which have alleged that there is 23 Rubber Ducky sitting in the OR on a table would. 23 such an association. I'm not aware of any other data 24 A. I -- I don't know what risk there is to a 2.4 to support that, and I have significant questions 25 Rubber Ducky, so I can't answer your question. 25 about the validity of both of those papers. Page 14 Page 16 1 Q. So it's your opinion that the use of the 1 Q. Well, do you think that a Rubber Ducky would 2 2 Bair Hugger is not associated with an increased risk be associated with an increased risk of infection? 3 of infection. 3 A. I -- I doubt it, but I don't know. 4 A. I believe it has not been associated outside 4 Q. Okay. So assuming that there isn't anything 5 5 of those two papers, which I have concerns about. unusual about the Rubber Ducky, the use of the Bair 6 6 Q. Okay. My question was a little different. Hugger -- presence of the Bair Hugger in use in the 7 7 operation -- or in an operating room would be akin to So you --8 Your opinion is that the use of the Bair 8 having a Rubber Ducky sitting on the table --9 Hugger is not associated with an increased risk of 9 A. I --10 10 infection. Q. -- as it relates to an increased risk of 11 A. I believe there is insufficient evidence to 11 infection. 12 make that statement. I believe that it has been 12 A. I -- I --13 13 Once again, if you would rephrase your associated in two problematic studies. I don't know 14 14 that there is sufficient evidence otherwise. question in a different way. You keep talking about 15 15 Q. Right. So you'd agree that it's your this Rubber Ducky, and it's something I don't know 16 opinion that the Bair Hugger is not associated with an 16 anything about. 17 increased risk of infection based on your review of 17 Q. Well you've seen the little ducks that float 18 the record. 18 around in a bathtub. 19 A. I -- and I am sorry to seem belligerent. 19 A. Oh, I understand conceptually what you're 20 I -- my statement is I don't believe it has been 20 speaking about, but in context I have no knowledge at 21 21 associated in a meaningful way, and I say that because all. I can't answer the question as you pose it. 22 there are these two papers, which I would challenge. 22 23 23 A. Because I don't know what the risks are of a Q. Okay. So setting --2.4 24 Rubber Ducky, and there may be issues that I haven't Because you don't believe those papers are

4 (Pages 13 to 16)

25

accurate, you have seen no evidence to find that the

25

appreciated.

	Page 17		Page 19
1	You might ask Dr. Wenzel, who is an expert	1	ascertaining whether an event or something causes a
2	in nosocomial infections. He may have experience with	2	risk to the general population?
3	Rubber Duckies.	3	A. I'd certainly do research.
4	Q. Okay. Well in any event, your view is use	4	Q. Okay. And as part of that study, I take it
5	of the Bair Hugger during a surgical procedure, such	5	you would attempt, as an epidemiologist, to look at
6	as an orthopedic implant, does not increase the risk	6	all the evidence associated with a particular risk of
7	of infection to a patient; correct?	7	an event to the general population.
8	A. No. My opinion is that I have not seen any	8	A. In principle, that sounds right.
9	evidence that it does, outside of two studies which I	9	(Discussion off the stenographic record.)
10	consider to be problematical.	10	Q. I think you mentioned this, but you're not
11	Q. Okay. And because you're saying those	11	an expert in infectious disease; correct?
12	studies are problematic, it's your opinion that use of	12	A. No, I'm not. Infectious disease is part of
13	the Bair Hugger does not increase the risk of	13	internal medicine, but I am not boarded in in
14	infection for a patient undergoing arthroplastic	14	infectious disease.
15	surgery.	15	Q. Do you have any experience in
16	A. I am not aware of any evidence that it does	16	anesthesiology?
17	so.	17	A. No, not particularly.
18	Q. Okay. Do you consider yourself an	18	Q. How about normothermia or hypothermia?
19	epidemiologist?	19	A. I have treated both, but I don't consider
20	A. I'm a professor of epidemiology. I do a lot	20	myself an expert in either.
21	of work at the interface step of epidemiology and	21	Q. Okay. Do you consider yourself having any
22	toxicology and other such related things, yes.	22	expertise in orthopedic surgery?
23	Q. Okay. So you do hold yourself out as an	23	A. I have not done surgery as a professional
24	epidemiologist.	24	activity after training.
25	A. I am a professor of epidemiology.	25	Q. And do you consider yourself a statistician?
	_ 10		<b>-</b> 00
	Page 18		Page 20
1	Q. Okay. You have a degree in well let's	1	A. I've taken lots of statistics courses, but I
2	Q. Okay. You have a degree in well let's back up.	2	A. I've taken lots of statistics courses, but I am not a statistician.
2	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying	2	<ul><li>A. I've taken lots of statistics courses, but I am not a statistician.</li><li>Q. Okay. Were you the one who suggested</li></ul>
2 3 4	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an	2 3 4	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?
2 3 4 5	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?	2 3 4 5	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave
2 3 4 5 6	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist.	2 3 4 5 6	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr.
2 3 4 5 6 7	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist.  Q. Okay. And you don't have a degree in	2 3 4 5 6 7	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert
2 3 4 5 6 7 8	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?	2 3 4 5 6 7 8	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.
2 3 4 5 6 7 8	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in	2 3 4 5 6 7 8	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel
2 3 4 5 6 7 8 9	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist.  Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology.	2 3 4 5 6 7 8 9	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?
2 3 4 5 6 7 8 9 10	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist.  Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology.  Q. Your degree is in internal medicine?	2 3 4 5 6 7 8 9 10	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he
2 3 4 5 6 7 8 9 10 11	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist.  Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology.  Q. Your degree is in internal medicine?  A. In medicine.	2 3 4 5 6 7 8 9 10 11	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.
2 3 4 5 6 7 8 9 10 11 12	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience	2 3 4 5 6 7 8 9 10 11 12 13	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did
2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience in epidemiology?	2 3 4 5 6 7 8 9 10 11 12 13 14	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did Well you've read Professor Holford's report;
2 3 4 5 6 7 8 9 10 11 12 13 14	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience in epidemiology?  A. I have done epidemiology in the context of	2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did  Well you've read Professor Holford's report; correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience in epidemiology?  A. I have done epidemiology in the context of occupational medical practice for years.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did  Well you've read Professor Holford's report; correct?  A. I have read his report.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience in epidemiology?  A. I have done epidemiology in the context of occupational medical practice for years. Q. Okay. And you would consider that clinical	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did  Well you've read Professor Holford's report; correct?  A. I have read his report.  Q. And do you feel that you, in the absence of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience in epidemiology?  A. I have done epidemiology in the context of occupational medical practice for years. Q. Okay. And you would consider that clinical experience in epidemiology?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did  Well you've read Professor Holford's report; correct?  A. I have read his report.  Q. And do you feel that you, in the absence of him, would have been comfortable writing the numbers
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience in epidemiology?  A. I have done epidemiology in the context of occupational medical practice for years. Q. Okay. And you would consider that clinical experience in epidemiology?  A. I certainly think so.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did  Well you've read Professor Holford's report; correct?  A. I have read his report.  Q. And do you feel that you, in the absence of him, would have been comfortable writing the numbers and doing the statistics that Professor Holford did?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience in epidemiology?  A. I have done epidemiology in the context of occupational medical practice for years. Q. Okay. And you would consider that clinical experience in epidemiology?  A. I certainly think so. Q. Would you agree	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did  Well you've read Professor Holford's report; correct?  A. I have read his report.  Q. And do you feel that you, in the absence of him, would have been comfortable writing the numbers and doing the statistics that Professor Holford did?  A. I probably would not have felt as
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience in epidemiology?  A. I have done epidemiology in the context of occupational medical practice for years. Q. Okay. And you would consider that clinical experience in epidemiology?  A. I certainly think so. Q. Would you agree Well how would you define the field of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did  Well you've read Professor Holford's report; correct?  A. I have read his report.  Q. And do you feel that you, in the absence of him, would have been comfortable writing the numbers and doing the statistics that Professor Holford did?  A. I probably would not have felt as comfortable as he.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience in epidemiology?  A. I have done epidemiology in the context of occupational medical practice for years. Q. Okay. And you would consider that clinical experience in epidemiology?  A. I certainly think so. Q. Would you agree  Well how would you define the field of epidemiology?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did  Well you've read Professor Holford's report; correct?  A. I have read his report.  Q. And do you feel that you, in the absence of him, would have been comfortable writing the numbers and doing the statistics that Professor Holford did?  A. I probably would not have felt as comfortable as he.  Q. Okay. So it's on those issues you're
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience in epidemiology?  A. I have done epidemiology in the context of occupational medical practice for years. Q. Okay. And you would consider that clinical experience in epidemiology?  A. I certainly think so. Q. Would you agree  Well how would you define the field of epidemiology?  A. I think epidemiology is the study of disease	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did  Well you've read Professor Holford's report; correct?  A. I have read his report.  Q. And do you feel that you, in the absence of him, would have been comfortable writing the numbers and doing the statistics that Professor Holford did?  A. I probably would not have felt as comfortable as he.  Q. Okay. So it's on those issues you're deferring to Professor Holford.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. You have a degree in well let's back up.  Are you making a distinction between saying you are a professor of epidemiology and an epidemiologist?  A. I am not a board certified epidemiologist. Q. Okay. And you don't have a degree in epidemiology; correct?  A. I do not have a specific degree in epidemiology. Q. Your degree is in internal medicine? A. In medicine. Q. Okay. Do you have any clinical experience in epidemiology?  A. I have done epidemiology in the context of occupational medical practice for years. Q. Okay. And you would consider that clinical experience in epidemiology?  A. I certainly think so. Q. Would you agree  Well how would you define the field of epidemiology?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I've taken lots of statistics courses, but I am not a statistician.  Q. Okay. Were you the one who suggested Professor Holford get involved in the case?  A. I think I may have been the one who gave Corey his name one day when Corey that is, Mr. Gordon asked me for the names of some expert statisticians.  Q. Okay. And was that because you didn't feel comfortable doing statistics work in the case?  A. I gave the name to Mr. Gordon because he asked me for the name of a world-class statistician.  Q. Okay. Did  Well you've read Professor Holford's report; correct?  A. I have read his report.  Q. And do you feel that you, in the absence of him, would have been comfortable writing the numbers and doing the statistics that Professor Holford did?  A. I probably would not have felt as comfortable as he.  Q. Okay. So it's on those issues you're

	Page 21		Page 23
1	with Professor Holford during the drafting of your	1	Q. Okay. So you knew of his name before you
2	report?	2	met him on May 8th.
3	A. No.	3	A. Yes.
4	Q. Okay. And when did you first see Professor	4	Q. Okay.
5	Holford's expert report?	5	MR. GORDON: Jan, sorry, I'm a little slow
6	A. I'm sorry, I don't remember, but it was	6	on the draw. He he didn't know her, but I had an
7	between	7	associate with me named Micah Hines.
8	It was probably in May, but I don't remember	8	THE WITNESS: I apologize.
9	the date.	9	MS. CONLIN: No offense taken on this side.
10	Q. Okay. And was that in draft form or final	10	THE WITNESS: Thank you.
11	form?	11	Q. So if we can take a look at your report, and
12	A. It may have been in draft form. I'm not	12	I'd like to direct your attention to page two of Borak
13	exactly clear.	13	Exhibit No. 1, paragraph nine
14	Q. Okay. Did you make any comments in terms of	14	A. Yes.
15	edits or suggestions in connection with the report?	15	Q. Okay. In addition to the reference list,
16	A. No.	16	which is contained on pages 24 through 27 of Exhibit
17	Q. Okay.	17	1, your June 2nd report, is this all of the material
18	A. Sorry. Wait, wait. I I I corrected a	18	that you reviewed? In other words, if I take
19	spelling error.	19	paragraph nine and I take your reference list, which
20	Q. Okay. But other than that, you took the	20	is contained on pages 24 through 27, is that the sum
21	report and that was, as we'll go through, incorporated	21	total of the materials that you reviewed in connection
22	in part into some of the things that you have	22	with your opinions in this case?
23	testified to.	23	A. No.
24	A. I am not aware that I suggested to Professor	24	Q. Okay. What else did you review?
25	Holford that he change anything.	25	A. I reviewed a great amount of literature. I
	Dago 22		
	Page 22		Page 24
1	Q. Okay. Setting that aside, my question is:	1	relied upon the references that you see enumerated.
1 2	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating	1 2	relied upon the references that you see enumerated.  Q. Did you review any other depositions,
	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor	2 3	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case
2 3 4	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating	2 3 4	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?
2 3 4 5	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as	2 3 4 5	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this
2 3 4 5 6	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as A. Yes, that's correct.	2 3 4 5 6	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.
2 3 4 5 6 7	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak	2 3 4 5 6 7	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from
2 3 4 5 6 7 8	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as A. Yes, that's correct. Q Borak A. That's correct.	2 3 4 5 6 7 8	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony
2 3 4 5 6 7 8	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1.	2 3 4 5 6 7 8	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?
2 3 4 5 6 7 8 9	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at	2 3 4 5 6 7 8 9	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by
2 3 4 5 6 7 8 9 10	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington?	2 3 4 5 6 7 8 9 10	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft
2 3 4 5 6 7 8 9 10 11	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington? A. We were at a meeting. I'm not sure it was	2 3 4 5 6 7 8 9 10 11	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.
2 3 4 5 6 7 8 9 10 11 12	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington?  A. We were at a meeting. I'm not sure it was May 8th. But yes,	2 3 4 5 6 7 8 9 10 11 12 13	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to
2 3 4 5 6 7 8 9 10 11 12 13 14	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington? A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay.	2 3 4 5 6 7 8 9 10 11 12 13 14	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington?  A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay. A that meeting in Washington.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that have been produced in this case, the sum total of what
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington? A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay. A that meeting in Washington. Q. And who else was present?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that have been produced in this case, the sum total of what you reviewed is set forth in paragraph nine of your
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington? A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay. A that meeting in Washington. Q. And who else was present? A. Mr. Gordon and Dr. Wenzel.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that have been produced in this case, the sum total of what you reviewed is set forth in paragraph nine of your report; correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington?  A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay. A that meeting in Washington. Q. And who else was present? A. Mr. Gordon and Dr. Wenzel. Q. Okay.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that have been produced in this case, the sum total of what you reviewed is set forth in paragraph nine of your report; correct?  A. I think that's correct, yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington? A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay. A that meeting in Washington. Q. And who else was present? A. Mr. Gordon and Dr. Wenzel. Q. Okay. A. I don't think there was anybody else.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that have been produced in this case, the sum total of what you reviewed is set forth in paragraph nine of your report; correct?  A. I think that's correct, yes.  Q. Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington? A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay. A that meeting in Washington. Q. And who else was present? A. Mr. Gordon and Dr. Wenzel. Q. Okay. A. I don't think there was anybody else. Q. Okay. And had you met Dr. Wenzel before?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that have been produced in this case, the sum total of what you reviewed is set forth in paragraph nine of your report; correct?  A. I think that's correct, yes.  Q. Okay.  A. I'm not aware of anything else which might
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington? A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay. A that meeting in Washington. Q. And who else was present? A. Mr. Gordon and Dr. Wenzel. Q. Okay. A. I don't think there was anybody else. Q. Okay. And had you met Dr. Wenzel before? A. No.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that have been produced in this case, the sum total of what you reviewed is set forth in paragraph nine of your report; correct?  A. I think that's correct, yes.  Q. Okay.  A. I'm not aware of anything else which might have been eligible for listing that I have not listed.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington? A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay. A that meeting in Washington. Q. And who else was present? A. Mr. Gordon and Dr. Wenzel. Q. Okay. A. I don't think there was anybody else. Q. Okay. And had you met Dr. Wenzel before? A. No. Q. Okay. Did you know of him or of his work?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that have been produced in this case, the sum total of what you reviewed is set forth in paragraph nine of your report; correct?  A. I think that's correct, yes.  Q. Okay.  A. I'm not aware of anything else which might have been eligible for listing that I have not listed.  Q. Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington? A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay. A that meeting in Washington. Q. And who else was present? A. Mr. Gordon and Dr. Wenzel. Q. Okay. A. I don't think there was anybody else. Q. Okay. And had you met Dr. Wenzel before? A. No. Q. Okay. Did you know of him or of his work? A. I know his name.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that have been produced in this case, the sum total of what you reviewed is set forth in paragraph nine of your report; correct?  A. I think that's correct, yes.  Q. Okay.  A. I'm not aware of anything else which might have been eligible for listing that I have not listed.  Q. Okay.  MR. GORDON: And and Jan, just so you're
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington? A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay. A that meeting in Washington. Q. And who else was present? A. Mr. Gordon and Dr. Wenzel. Q. Okay. A. I don't think there was anybody else. Q. Okay. And had you met Dr. Wenzel before? A. No. Q. Okay. Did you know of him or of his work? A. I know his name. Q. From what?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that have been produced in this case, the sum total of what you reviewed is set forth in paragraph nine of your report; correct?  A. I think that's correct, yes.  Q. Okay.  A. I'm not aware of anything else which might have been eligible for listing that I have not listed.  Q. Okay.  MR. GORDON: And and Jan, just so you're clear, I don't the distinction may be unclear to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. Setting that aside, my question is: You looked at that for the purposes of incorporating portions or reliance on portions of Professor Holford's report in your report that's been marked as  A. Yes, that's correct. Q Borak A. That's correct. Q Deposition Exhibit No. 1. Okay. Now you and Professor Holford were at a May 8th meeting in Washington? A. We were at a meeting. I'm not sure it was May 8th. But yes, Q. Okay. A that meeting in Washington. Q. And who else was present? A. Mr. Gordon and Dr. Wenzel. Q. Okay. A. I don't think there was anybody else. Q. Okay. And had you met Dr. Wenzel before? A. No. Q. Okay. Did you know of him or of his work? A. I know his name.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	relied upon the references that you see enumerated.  Q. Did you review any other depositions, exhibits, or documents that were produced in this case other than what you've listed in paragraph nine?  A. On only as I mentioned earlier this morning.  Q. Okay. And as I recall your testimony from earlier this morning, it wasn't deposition testimony or documents that were produced in the case; correct?  A. I don't know what you mean exactly by "produced in the case," but I looked at a rough draft of much of Dr. Holford's deposition.  Q. Yeah. But other than that, with respect to materials and depositions, exhibits and things that have been produced in this case, the sum total of what you reviewed is set forth in paragraph nine of your report; correct?  A. I think that's correct, yes.  Q. Okay.  A. I'm not aware of anything else which might have been eligible for listing that I have not listed.  Q. Okay.  MR. GORDON: And and Jan, just so you're

6 (Pages 21 to 24)

Page 25 Page 27 1 were documents produced by Ridgeview --1 like to get you involved in this," and that day we 2 MS. CONLIN: Okay. 2 went from being friends to being client and 3 MR. GORDON: -- pursuant to subpoena, not 3 4 pursuant to a deposition. 4 Q. And that was sometime in late April? 5 5 MS. CONLIN: Understood. A. I think so. 6 6 Q. Let me ask it a different way. Prior to the Q. How did you go about compiling the -- you 7 time you rendered your opinions in this case on June 7 said --8 2nd, 2017, does paragraph nine in your report set 8 In paragraph 10 you said, "I also reviewed a 9 forth everything that you reviewed by way of 9 large number of scientific reports related to surgical 10 depositions, transcripts, exhibits and documents 10 warming devices, operating room procedures, surgical 11 produced in the case? 11 complications and infections, and other related 12 A. Yes, I think that is correct. 12 medical and scientific issues." How did you go about 13 Q. Now how did you go about deciding what you 13 gathering that information? 14 were going to review as reflected in paragraph nine? 14 A. I'm trying to reconstruct the history as 15 A. I think most of these were sent to me by Mr. 15 clearly as I can. I -- I assume -- I'm not certain 16 Gordon's office. 16 but I assume that initially, after discussions with 17 Q. Okay. So the documents and transcripts 17 Mr. Gordon, I was provided a packet of materials and 18 reflected in paragraph nine of your report were 18 told that this was background materials, and that 19 selected for you and sent to you by Mr. Gordon; 19 probably would have included the studies from 20 correct? 20 Northumbria and that sort of thing. And I have in my 21 A. They were sent to me by Mr. Gordon. 21 office a full-time librarian who does routinely 22 Q. Okay. Did you ask him for them, or did they 22 extensive literature searches for me using the Yale 23 iust arrive? 23 library and the National Library of Medicine, and we 24 A. It was probably some conversation by phone 24 pick keywords and we search on things, and so sometime 2.5 related to the fact that there were documents and they 25 after I had read those first papers I would have Page 26 Page 28 1 would be sent. I think the one that I requested or 1 identified a series of search strings. I might very 2 2 that came as a consequence of a request was the well have searched on the word -- or phrase "Bair 3 deposition of Dr. Nachtscheim --3 Hugger." I would have looked at literature on 4 Q. Yeah, Nachtscheim. Yeah. 4 orthopedic infections. In addition, from time to time 5 5 Mr. Gordon would send me articles, some of which might A. N-a-c-h-t-s-h-t-e-i-m. 6 6 have been more obscure than not. Some of them were -- and that was a response to a statement 7 7 that was in Dr. Samet's report. I believe, if I from some fairly-out-of-the-way English journals, and 8 8 recall, Dr. Samet referred to an extended series of for some of these I actually had to register with the 9 cases or something of that sort -- I could look it up, 9 journals to be able to access their articles, and I 10 10 did so. but I think you understand what I'm speaking to -- and 11 I said, "What is that?" And I was sent this add --11 Q. Do you have a record of what searches you 12 12 added material because I didn't understand that performed or do you have the documents that you 13 13 pulled, the articles, -statement from this Samet report. 14 Q. Okay. When were you retained in this case? 14 A. The answer --15 A. Probably in late April, but I don't remember 15 Q. -- in your office? 16 specifically. 16 A. The answer to the first one is probably not, 17 Q. So the first time you were retained in this 17 but the answer to the second one is yes. 18 case was in late April after Dr. Samet had issued his 18 MS. CONLIN: Okay. We're going to ask for a 19 19 full list of all the publications that he pulled and 2.0 A. I -- I'm not sure of the chronology 20 reviewed in connection with his opinions in this case. 21 21 Q. Would you agree with me -- I think you did, specifically. 22 2.2 Mr. Gordon was somebody I have known for so I apologize for asking again -- but as a --23 23 some years. We had spoken of this. And I was not When you're investigating an issue with your 2.4 2.4 epidemiologist's hat on, it's important to have all retained or participating, and he was speaking to me 25 as a colleague friend, and one day he said, "I would 25 the information in order to make your decision or

Page 29 Page 31 1 opinion; correct? 1 between the Bair Hugger and a risk of infection? 2 MR. GORDON: Object to the form of the 2 MR. GORDON: Object to the form of the 3 3 question, also misstates his testimony. 4 A. I -- I would say that generalizes to many 4 A. Yeah. I haven't said that there was 5 5 fields, yes. absolutely no association. I said I've seen no 6 6 Q. Okay. And did you ever ask the lawyers for evidence of any association; that was, other than two 7 7 3M for any of the other deposition transcripts or troubled studies. 8 8 documents that have been produced in this case? Q. Okay. So that's why you've opined there is 9 9 A. I -- I -- I'm not aware that I asked for no association between the Bair Hugger and a risk of 10 10 them. infection. 11 Q. Okay. Did you ask for any information 11 A. I have opined that I have seen no evidence 12 12 relating to the Bair Hugger, how it's constructed or that there is an association, except for two troubled 13 13 how it operates? 14 A. I believe I did, and I believe I received 14 Q. Right. And my point is is without 15 15 understanding how the machine operates, is -some information, and I believe I made the point that 16 16 I was not a mechanical engineer and that I was not a Is it just these two studies and that's what 17 ventilation expert, that I was not a filtration 17 you did, and you found those studies to have issues so 18 18 your conclusion is based on that? expert, and that I was not going to render an opinion 19 19 that relied upon such possible expertise. A. I -- I have looked at the literature and 20 20 Q. What materials did you receive related to found no evidence of infections associated with use of 21 21 the Bair Hugger that aren't listed in exhibit nine? the Bair Hugger, which I understand to be a very-22 22 A. I -- I can't recall what I've read. I mean large-volume-used instrument, and the only evidence 23 I've read certainly in depositions and in some of the 23 which I have seen to suggest that it causes infection 24 2.4 exhibits to some of the depositions, but I don't are the two papers that have been linked to Dr. 2.5 specifically recall because it was not a field that I 25 Augustine. Page 30 Page 32 1 1 was looking at specifically. Q. What do you mean "linked to Dr. Augustine?" 2 2 Q. Well don't you think it's important, if Setting aside the new Augustine publication, 3 you're trying to ascertain whether use of the Bair 3 which is self-evident, explain what you mean. 4 Hugger increases a risk of an infection, that you 4 You're -- you're referencing Augustine and 5 5 understand how it operates? McGovern; correct? 6 MR. GORDON: Object to the form of the 6 A. Correct. 7 7 question. Q. Okay. 8 8 A. I thought that the relevant question was A. Well my understanding is that the McGovern 9 whether the Bair Hugger was associated with infection, 9 paper was largely if not entirely funded by Dr. 10 10 and so I really focused on the issue of whether there Augustine, and that the analyses were performed by a 11 11 were infections. member of his staff. 12 12 Q. But in connection with looking at whether Q. Do you think that funding of a study by a 13 13 it's associated with infections, you didn't think it particular party undercuts its scientific validity? 14 was important to understand how the device operates? 14 A. It does not necessarily undercut its 15 15 A. I thought I understood enough in principle scientific validity. 16 16 in how it operated, but I was not going to be opining Q. Okay. So why were you referencing that the 17 upon whether, for example, the motor was too large or 17 McGovern study in your mind was funded by Augustine? 18 too small, or whether the filters were too large or 18 A. I -- I said they were associated with Dr. 19 too small, or -- and -- and so forth, that I was not 19 Augustine and you asked me to clarify what I meant by 2.0 going to be rendering that kind of an opinion and that 20 "associated," and I tried to explain that. 21 21 Q. Why did you think that was important, to that was not my area of expertise. 22 2.2 Q. Well if -- if you don't know how the machine suggest that these two studies had some involvement by 23 23 operates, take into account, for example, the filter Augustine? 24 2.4 A. I-or the -- the efficiency of the filter, how is it that 25 you can opine that there is absolutely no association 25 Q. And by the way, I'm not accepting your

Page 35 Page 33 1 premise, but why -- why did you think that was 1 Reed is a well known orthopedic surgeon. I think Dr. 2 important? 2 McGovern was probably a junior to Dr. Reed. 3 A. I -- I simply used that to describe. But I 3 Q. Okay. Was there a reason why you didn't 4 can take back the description. The description is 4 read Dr. Belani's deposition? 5 5 unimportant. The point I was making is that to the A. I frankly wasn't aware that there was a 6 6 best of my knowledge, having looked at a lot of the deposition of Dr. Belani. 7 7 literature, the only two studies that have proposed an Q. Okay. Well one of the things that you 8 8 association between the use of the Bair Hugger and suggest about the McGovern study is that there was 9 9 infection are the McGovern and the Augustine papers. potentially data manipulation; correct? 10 10 Q. Okay. You would agree with me that funding A. Yes. 11 of a particular study does not suggest on its face 11 O. Okay. 12 that there's a problem with it; correct? 12 A. Potentially. 13 13 A. It always raises suggestions. I deal with Q. All right. When making that accusation, wouldn't it be important to look at the credentials of 14 that every time that I have worked for a funding 14 15 15 the people against whom you're making that accusation? source that might have been regarded as a source of 16 conflict of interest. It's one of the things I'm 16 A. Unfortunately, the credentials are not 17 constantly aware of in my own work, and I'm aware of 17 the -- the assurance of probity. 18 it in others', and I'm aware of it when I sit on an 18 Q. Well you'd have to look and see whether 19 19 editorial board and peer review other people's these were the type of individuals that would 20 submissions. 20 manipulate data; correct? 21 21 Q. And your position is that as a scientist, MR. GORDON: Object to the form of the 22 22 you're -- you're for hire but your opinions are not question, also lack of foundation. 23 for hire; correct? 23 A. I have, as a member of an editorial board. 24 been required to vote for the retraction of an article 24 A. There's something vulgar about the way you 25 say it, but the fact of the matter is that my opinions 25 from authors who have been extraordinarily well Page 34 Page 36 1 are not for sale, only my time. 1 credentialed. I don't think that that is necessarily 2 2 Q. Okay. And you would expect that to be the the assurance. It helps, but it does not assure. 3 case for any legitimate doctor or scientist that's 3 Q. Well which one of these McGothern --4 investigating an issue; correct? 4 McGovern authors are you suggesting engaged in data 5 5 A. One would hope. manipulation? 6 6 Q. Okay. A. I -- I don't know which ones. I have their 7 7 (Discussion off the stenographic record.) depositions. I've cited from their depositions. They 8 8 BY MS. CONLIN: agree, for example, that the published data differed 9 Q. I have handed you, sir, what's been marked 9 from the final data. 10 10 previously as Holford Deposition Exhibit 13, which is If I could look at my notes -- or not my 11 11 the McGovern paper that we've been discussing; notes, but my report, I have citations specifically to 12 12 correct? their depositions, and I was using their words. 13 13 A. Correct. Q. Okay. My question is a little different, so 14 Q. Do you know any of the authors on this 14 try to answer mine. My question is: Which of these 15 15 paper? authors are you suggesting engaged in data 16 16 A. I have read a lot of their work, but I never manipulation? 17 met anv. 17 MR. GORDON: Object to the form of the 18 Q. Okay. Did you --18 question. 19 Do you know who Dr. Belani is, for example? 19 A. I -- I -- I don't have information to tell 2.0 A. I would be unable to describe him. 20 me which ones did. I understand, from the sequence of 21 21 Q. Okay. Do you know where he works? deposition information, that Dr. Reed at some point in 22 22 A. I could look it up, but I don't. his deposition said, "It's clear to me that some of 23 23 Q. Okay. How about Drs. McGovern or Reed? the data on the clinical side are wrong," that Mr. 2.4 24 A. Well I'm familiar with Dr. McGovern and Reed Albrecht says, "It looks like it didn't line up a 25 as part of the Northumberland Health Trust. But Dr. 25 hundred percent. I'm not sure what's going on," Dr.

Page 37 Page 39 1 Reed and Albrecht said, "There are differences." And 1 those two documents. I understand that that has been 2 I don't know --2 done by Dr. Holford, and I rely upon Dr. Holford's 3 You're asking me who is personally and 3 ability to do that. 4 individually responsible. I don't know the answer to 4 Q. Okay. So with respect to the veracity of 5 5 that. McGovern Exhibit 16 or Albrecht Exhibit 10 and what it 6 6 Q. Okay. You -shows or doesn't show, you're relying on Professor 7 7 Did you read the whole depositions? Holford on that. 8 8 A. I did at some point, yes, absolutely. A. In terms of the statistics and the matching 9 9 Q. Okay. How did you decide the quotes that up of the case numbers and those sorts of things, yes, you put in your report? Were those ones that were 10 10 I'm ultimately relying upon Dr. Holford. 11 suggested to you by 3M? 11 (Exhibit 3 was marked for 12 A. No, absolutely not. 12 identification.) 13 13 Q. So they were ones you chose. BY MS. CONLIN: 14 14 Q. I've handed you, sir, what's been marked as 15 Q. Well you know that Dr. Reed testified that 15 Borak Deposition No. 3, which is a page off of your "The data file for the paper was definitely correct. 16 16 company website; correct? 17 I checked it multiple times." Correct? 17 A. Correct. 18 A. I --18 Q. And this was founded in what, 1988? 19 19 He may have said that, but he also said that A. That sounds right. 20 20 there were mistakes and that there was additional Q. Okay. 21 21 A. '86 I think. 22 Q. You're referring to his testimony that he 22 Q. And how many people are employed at Jonathan 23 23 thought maybe there was an additional infection in Borak & Company? each group? 24 A. Currently there are four full time. 24 2.5 A. I believe that's how he testified, correct. 25 Q. Okay. And how much of your time do you Page 38 Page 40 1 Q. Okay. And that was a deposition that was 1 spend as a consultant, under the umbrella of Jonathan 2 2 taken, what, years after the publication; correct? Borak & Company, versus teaching? 3 A. I guess so, but I don't know for sure. 3 A. Probably 85 percent or more. 4 Q. So how did you --4 Q. Is through Jonathan Borak & Company? 5 5 If you think that one or more of these A. That's correct. 6 6 Q. And of that 85 percent of your time, how authors engaged in data manipulation, how did you 7 7 decide what you were going to rely on from their much is in consulting versus litigation? 8 8 depositions and what you were going set aside as being A. I'm sorry. So the distinction you're saying 9 9 is consulting that is not litigation-based. 10 10 A. I can't construct or reconstruct my thought Q. Right. 11 at the time that I read these things, but these 11 A. Let -- let me step back. I --12 12 Just to be clear, many if not all of my statements struck me as being supportive of the fact 13 13 that there were some differences in the data and that clients -- not all, but most of my clients are 14 14 lawyers. Often I am approached by lawyers to do nonthe published data were not the final data. 15 15 Q. Did you do any investigation into the data litigation work or work that is not directly relevant 16 tabulation sets which have been marked as and referred 16 to my being an expert in a litigation. For example, 17 to as McGovern Exhibit 16 or Albrecht Exhibit 10? 17 we recently were involved in doing a vetting of a 18 A. I have -- I have looked at both. If I'm 18 company's website and documentation prior to an 19 correct, the Albrecht Exhibit 10 is a very, very thick 19 acquisition. We did that for an attorney. I have 2.0 document, and I have leafed through it in part trying 2.0 done work in the regulatory area and I'm almost always 21 21 to see if I could locate in there the individual who approached by an attorney. But the answer is I think 22 22 was identified in the McGovern Exhibit 16 as case that I have testified perhaps four or five times in 23 the past four years, and I do a variety of different 23 number 44. If I'm correct, that one is a rather 24 24 small, much more concise document. But I have not kinds of work. I would guess, because it's not 25 25 constant, but I would guess that about 30 percent or made any kind of definitive effort to review either of

Page 41 Page 43 1 so of my income is litigation-related. 1 A. I have done a number of such pieces of work. 2 Q. Thirty percent of your income from the 2 Q. And the issue was whether there was 3 Jonathan Borak & Company. 3 causation presented by the silica. 4 A. I would guess, yes. 4 A. Whether silica was sufficient a causation 5 5 Q. Okay. that it belonged in one pot rather than in the other 6 6 A. And yes, I think that's correct. pot, yes. 7 7 Q. Okay. Now you indicate here that you serve Q. Okay. Have you ever in litigation, just 8 mainly to Fortune 500 companies and their 8 putting on your litigation hat, opined that exposure 9 representatives, government agencies, national labor 9 to an environmental toxin caused harm? 10 unions, and professional societies; is that fair? 10 A. In a litigation context. 11 A. I think so. 11 I've certainly written that it can. I don't 12 Q. Okay. In the past two decades, to the 12 know that I have in a specific litigation context. 13 extent that you've done work in litigation, --13 Q. In fact, in the litigation context every 14 A. Yes. 14 single one of your retentions resulted in you opining 15 Q. -- it's been for the defense; correct? 15 that whatever the exposure to an environmental toxin 16 A. What time period was that? 16 was didn't cause the harm alleged by the injured 17 Q. Last two decades. 17 person; correct? 18 A. At one time I did a lot of plaintiffs' work. 18 A. I -- I think that you misrepresent my 19 Over the recent past it has been predominantly 19 opinions. I've been in a number which have to do with 20 defense, but I do some lit -- plaintiffs' side. 20 concerns about what was known and when was it known 21 Q. Okay. In the last decade, have you done a 21 and whether a particular entity was responsible, and I 22 single case on the plaintiffs' side? 22 don't think any of those opinions suggested that the 23 A. I have not testified on the plaintiffs' 23 claimants were uninjured. There may have been some 24 side, but I have done plaintiffs'-side work. 24 cases where I have said that, but I think that many of 25 Q. What types of cases? 25 my opinions have dealt with questions of the Page 42 Page 44 1 A. Water contamination by perfluorooctanoic 1 adjudication of responsibility. 2 2 acid. Q. My question was a little different. When 3 Q. Anything else? 3 you've opined on causation in the litigation context, 4 A. That was the largest one recently. There 4 there hasn't been a single time where you have found 5 5 that an environmental toxin caused harm in an have been others. Sometimes it's not clear to me who 6 is a plaintiff or a defendant. I know that sounds 6 individual. 7 7 peculiar. But I was involved in a very large MR. GORDON: Object to the form of the 8 situation of a company that had acquired a division 8 question, also asked and answered. 9 from another company that made respirators, and as 9 A. Yeah. I'm -- I'm not sure that I can 10 10 part of the acquisition the seller retained certain remember --11 historical liabilities and the acquirers accepted 11 I mean it may -- it may be that when I 12 12 render such an opinion, people decide to settle their other liabilities, and it became a question of whether 13 13 coal miners' pneumoconiosis could develop in the cases. I don't know. 14 absence of silica. There was no question of damages 14 Q. Can you --15 15 to individuals in the sense that it was not a question As you sit here today, can you think of a 16 of whether somebody was or was not going to get 16 single instance in the last two decades where in the 17 compensation, it was a question of which insurance 17 litigation context you have opined that exposure to a 18 pool was going to pay for it. That -- that is 18 particular environmental toxin or otherwise caused 19 something where it's a litigation-based piece of work, 19 harm in an individual? 20 but I don't see it as being plaintiff and defense as 2.0 A. I -- I can't remember a specific example of 21 21 you raised the question. the other side either, so perhaps you can help me. 22 Q. Yes. It was an issue of retained 22 Q. Okay. Well we'll go through them. But as 23 23 liabilities versus assumed liabilities. you sit here, can you name one? 24 24 A. In that particular case. A. I don't know that I can name one to the 25 25 other side. Most of what I have done has involved --O. And in that case --

Page 45 Page 47 1 Well let me go back. With the exception 1 identification.) 2 of --2 BY MS. CONLIN: 3 Where I have testified. 3 Q. I've handed you, sir, what's been marked as 4 Q. Not where you've testified, where you've 4 Borak Deposition Exhibit No. 4, which is an article 5 rendered an expert opinion in a case, whether it be 5 authored by you and others entitled "Mortality 6 through trial, deposition, or a report --6 Disparities in Appalachia." 7 7 A. Well I think a deposition --A. Yes. 8 8 Okay. Report. I -- I've written reports Q. Okay. And this was a study that you 9 9 and I have never known whatever happened to those authored that was funded entirely by the National 10 10 things. In some cases I felt that there was --Mining Association; correct? 11 Oftentimes, people ask me not to write 11 A. Yes, that's correct. 12 reports when I don't agree with their view, so when 12 Q. And you wouldn't suggest that because the 13 13 defense lawyers ask me whether I think A causes B and National Mining Association funded this study, that that somehow taints this; correct? 14 I say yes, they say thank you, and it never progresses 14 15 15 A. No. They were unhappy with it. beyond that. 16 Q. Can you answer my question? 16 Q. Okay. And in this you conclude that there 17 A. What is your question? 17 hasn't been any solid epidemiological evidence that 18 Q. My question is: As you sit here today, can 18 coal mining increased risks to population health in 19 19 you identify a single instance in which you've the Appalachia region; correct? 20 20 rendered an expert opinion in litigation that exposure A. I think you misspeak it. I -- I think that 21 what we found was "...that coal mining in Appalachia, 21 to an environmental toxin caused harm in an 22 22 individual? an industrial activity associated with rural, MR. GORDON: Object to the form of the 23 23 mountainous areas, is likely to be geographically 24 24 question, asked and answered. associated with a variety of economic and cultural 2.5 A. Most recently I have spent a fair amount of 25 health risk factors. And, for similar reasons, mining Page 46 Page 48 1 time looking at these perfluorooctanoic acid exposures 1 is also likely to be geographically associated with a 2 and I have offered verbal reports but I have not 2 variety of adverse health outcomes. Although our 3 written reports, and the reports were that there was 3 results indicate that mining is not the direct cause 4 causation. 4 of those outcomes, they do not rule out the 5 5 Q. Okay. Can you answer my question though? possibility that mining contributes to the development 6 6 In terms of -of the social environments and cultural practices that 7 7 A. I -- I cannot remember is the answer. adversely impact health." 8 Q. Okay. When did you become a consultant to 8 Q. Right. 9 the National Mining Association? 9 A. My belief was and is that it is not 10 10 A. I don't remember the date. pollution from the coal mines but social pollution 11 Q. Okay. 11 from the industry that has caused these disparities. 12 12 MR. GORDON: Let me interrupt. I'm --Q. Right. That there is no direct link between 13 13 I'm -- I'm -coal mining and adverse health outcomes. 14 The section where he discusses his --14 A. No, no. I think that the coal mining 15 whatever he did with PFOA, I have no idea where that 15 industry and its social context has contributed to 16 is in the litigation process, I'm not involved in it, 16 these adverse effects. 17 but I -- it sounds to me like something that probably 17 Q. Well let's take a look at the last page --18 ought to be marked as confidential. 18 well, second-to-the-last page. I think it's got an 19 MS. CONLIN: I don't have an issue with 19 internal number 154. Direct your attention to the 20 20 right-hand side, first full paragraph starting with 21 Q. You authored a study that was funded by the 21 "Accordingly..." and direct your attention down to the 22 National Mining Association; correct? 22 sentence, "Although our results indicate that mining 23 A. Remind me of the title. 23 is not the direct cause of those outcomes, they do not 2.4 Q. Sure. 24 rule out the possibility that mining contributes to 25 (Exhibit 4 was marked for 25 the development of social environments and cultural

Page 49 Page 51 1 practices that adversely impact health." 1 over a study involving mold; correct? MR. GORDON: Object to the form of the 2 A. That's the sentence I just read to you. 2 3 Q. Okay. And you find that mining is not a 3 4 direct cause of the -- and it's your word, "direct 4 A. There was controversy about a position paper 5 cause" -- of the health -- strike that. 5 that was written by The American College of 6 Let me say you find that mining itself is 6 Occupational Envi -- that was posted by The American 7 7 not a direct cause of illness in a population; College of Occupational Environmental Medicine. I was 8 correct? 8 the chairman of the committee that oversaw the 9 A. Yes, that it was the -- the mining 9 development of the paper. I didn't write it and I had 10 industry's influence on the social environment. 10 little other than the fact that I kept the editorial 11 Q. Right. People are getting black lung 11 process going. 12 disease because they're overweight and poor. 12 Q. All right. And that paper found that there 13 A. The people who were suffering health 13 are no adverse health effects associated with toxic 14 disparities in this community were not miners and they 14 mold: correct? 15 were not getting black lung. 15 A. No, that's not what it found. 16 Now in fact we make mention here that it is 16 Q. What's your understanding of what it found? 17 not because of the miners that there were these health 17 A. What it found was that mold could cause a 18 disparities and that the disparities existed in both 18 number of allergic and irritative disorders, but that 19 males and females, although the females did not work 19 which became known as, quote, unquote, toxic mold 20 in the mines. Black lung is a disease of occupation. 20 syndrome was not; it had not been documented. It was That's not the issue of concern in this paper. 21 21 written by a former deputy director of The National 22 Q. Well you were actually interviewed a bunch 22 Institute of Occupational Safety and Health. I didn't 23 in connection with this article; weren't you? It 23 write it. 24 caused quite a stir; correct? 24 Q. Correct. But you -- you reviewed it as part 2.5 A. I don't know that it caused quite a stir, 25 of your role as director on -- at --Page 50 Page 52 1 1 Do you say -- how do you say it, A-C-O-E-M? but I think I had a couple of interviews. 2 2 Q. And you said the health effects due to coal A. Or ACOEM if you --3 and coal mining is just not known; correct? 3 Q. ACOEM. Okay. 4 A. I'm sorry? 4 And you knew before it was published that 5 Q. You -- you were quoted as saying the health 5 the authors were experts for the defense in mold 6 effects due to coal and coal mining is just not known; 6 litigation; correct? 7 7 A. No. To the contrary, Dr. Hardin told me he 8 A. Regarding people in the community. 8 was not specifically. 9 Q. And in fact you said, quote, "The problem is 9 Q. Okay. But e-mails came to light after that 10 10 that the theory that this is due to coal and coal publication which suggested that you did know before 11 pollution is politically attractive but scientifically 11 12 12 not defensible;" correct? A. Would you read that to me? I'm not aware 13 13 A. That sounds like something I would have that I was aware that Dr. Hardin had been an expert. 14 14 said. To the contrary. 15 15 Q. Okay. And you said, quote, "It may or may O. Okay. A. It also might be useful for the record to 16 not be due to coal mining, I actually don't know, but 16 17 I think it could be, but it's not due to the coal;" 17 note the date that this was: it's about like 15 years 18 correct? 18 19 A. That sounds right. 19 Q. Yeah. It was in 2002; right? 2.0 Q. Okay. And you said while the work was 20 A. Fifteen years ago. 21 21 funded by the National Mining Association, quote, your Q. Yeah. Did you think that there was anything 22 time is for hire, your opinions are not. 22 that was -- undercut it -- undercut the validity of 23 A. Okay. That sounds like something I said to 23 that study because the authors were associated with 2.4 24 you earlier today. the defense? 25 Q. You were also caught up in some controversy 25 A. Dr. Hardin specifically told me that he was

Page 53 Page 55 not, and he gave me a statement of conflict of 1 the College, or at least those concerned enough to 2 interest, and I shared that with the board of ACOEM at 2 voice their views;" correct? 3 3 A. I'm sorry, say that again. 4 Q. My question was a little different. Did --4 Q. There was concerns about the college about 5 5 did you think, when you found out that they publishing this review; correct? 6 6 represented the defense in that litigation, that that A. I was concerned that this particular review 7 7 somehow impugned the veracity of the findings in that was polarizing the college members. 8 8 Q. Right. And you write here though, "Even paper? 9 9 though a great deal of work has gone in, it seems A. When you say "that litigation," I am not 10 10 difficult to satisfy a sufficient spectrum of the sure which litigation you speak to. I understood that 11 College, or at least those concerned enough to voice 11 subsequently Dr. Hardin and his colleagues did opine 12 their views." 12 in litigation for the defense. 13 13 Q. Okay. And do you think, that they did that, A. Correct. 14 that undercuts at all the scientific veracity of the 14 Q. Okay. And then you go on in the next 15 paragraph to suggest that if you officially reject it, 15 paper you reviewed? 16 then you turn Mr. Grove's efforts into garbage; 16 A. I thought the paper was fair. And it was 17 correct? 17 sent to a large, large, large number of peer 18 A. No, this mis --18 reviewers. I did not make the decision as to publish 19 Q. Or to --19 or not. 20 A. It was Dr. --2.0 Q. My question is: Do you think the fact that 21 It was Bryan, Dr. Hardin's efforts. 21 they represented the defense undercuts at all the 22 Q. Okay. So you were concerned if the college 22 scientific veracity of the paper? 23 rejected it, Dr. Hardin's efforts would be turned into 23 A. No. 24 garbage; correct? 2.4 MR. GORDON: Could we take a potty break 25 A. I --25 fairly soon? Page 54 Page 56 MS. CONLIN: Yeah. We can stop here if 1 It sounds right, but show me where the word 1 2 2 you'd like. "garbage" is. I'm sorry. 3 THE REPORTER: Off the record, please. 3 Q. If you look at the last full sentence in the 4 4 second paragraph, "That would be an important (Recess taken.) 5 5 (Exhibit 5 was marked for violation" --6 6 A. Yes. Okay. Fine. I do see it. I just identification.) 7 7 THE WITNESS: Thank you. want to make sure I used that word. 8 BY MS. CONLIN: 8 Q. You write, "That would be an important 9 Q. I've handed you, sir, what's been marked as 9 violation of Bryan -- I have assured him that if we 10 10 do not use it he can freely make whatever other use he Borak Exhibit No. 5, and this is the e-mail that we 11 were talking about just before the break as it relates 11 might want to make. If we 'officially' reject it, 12 12 then we turn his efforts into garbage." Correct? to your role at ACOEM and the publication of an 13 13 A. Correct. article by Dean Grove; is that right? 14 14 Q. And that was the concern, that if the paper A. Yes. He was then president of the college. 15 15 didn't get published and was rejected by the college, Q. Okay. And this related --16 This is dated September 6th, 2002, and this 16 then the paper might not gain traction. 17 relates to the review by ACOEM of the article -- or 17 A. No, that was not the concern. 18 the study that was going to be published on whether --18 Q. What was your concern? 19 A. It was not a study, it was a review. 19 A. My concern was that Bryan was a very 2.0 Q. -- whether a review was going to be 20 respected scientist. I knew that he had interest in 21 21 published; correct? mold because I had seen some of his writings. At that 22 22 time he was not, as I understood it, involved in the A. That's correct. 23 Q. Okay. And in this e-mail you indicated that 23 issue other than as a scientific issue. I asked him 2.4 24 whether he would be willing to prepare this review for "Even though a great deal of work has gone in, it 25 25 purposes of the college and he agreed to do that. He seems difficult to satisfy a sufficient spectrum of

	Page 57		Page 59
1	spent quite a while putting a paper together. He sent	1	talk. I was invited I don't even remember who
2	it to me. I sent it out to my panel of reviewers;	2	invited me, but I was with the Dean of Hastings Law
3	there may have been 20 or 30 or more people in the	3	School.
4	college who reviewed it. They gave me back feedback.	4	Q. I didn't ask you about any of this.
5	And I returned it to Dr. Hardin and I said this is	5	A. Okay.
6	what people think, it's too polarized, it's too this,	6	Q. My question was a simple one. You were a
7	it's too that, it's not enough this, it's not enough	7	faculty member at BRI, which is a defense bar, in a
8	of that, "Are you prepared to change it?" And he said	8	toxic tort seminar; correct?
9	"Yes." And so he then spent quite a bit of time	9	A. Yes. I spoke about peer review in the
10	rewriting, and not different than what happens when I	10	scientific process, I think in March of this year.
11	sit on a journal review and somebody sends a paper in	11	Q. Okay. And that's the only time that you
12	and it goes back with comments from the reviewers	12	think you've done that?
13	which says "Major revision required." And so the	13	A. I'm not aware of having done it other
14	major revision was done and it was sent back. And I	14	It's possible, but I certainly don't
15	returned that to the reviewers and they sent back	15	remember it. And it wasn't recent.
16	comments to me. And I sent those comments back to	16	Q. Okay. Do you agree with me that the
17	Bryan and I said, "It's better, but it's still not	17	Bradford-Hill criteria is an appropriate methodology
18	sufficient for me to put it before the board of	18	for addressing an epidemiological issue?
19	directors because it's too polarizing, and I would	19	MR. GORDON: Object to the form of the
20	like you to address that these are the issues that	20	question.
21	people are raising." And he revised it again and he	21	A. It's been adopted as a methodology. It's
22	sent it back to me. And I sent it out to reviewers	22	not really a methodol a methodology, it's a set of
23	and I said, "Does this answer your concerns?" And	23	viewpoints.
24	there were people who came back with continuing	24	Q. Okay. Would you agree with me that
25	concerns. And so then I had the following problem,	25	observational epidemiological studies can yield data
	Page 58		Page 60
1	Page 58 and that's what is described here.	1	Page 60 that describes associations between environmental
1 2	and that's what is described here.  Q. When did you find out that he was an expert	1 2	
	and that's what is described here.		that describes associations between environmental
2	<ul><li>and that's what is described here.</li><li>Q. When did you find out that he was an expert for the defense in mold litigation?</li><li>A. After publication.</li></ul>	2	that describes associations between environmental factors and health effects?  A. Yes, they can.  Q. You've opined that there is no causal
2	<ul> <li>and that's what is described here.</li> <li>Q. When did you find out that he was an expert for the defense in mold litigation?</li> <li>A. After publication.</li> <li>Q. Did you ever go back and make the</li> </ul>	2 3 4 5	that describes associations between environmental factors and health effects?  A. Yes, they can.
2 3 4	<ul> <li>and that's what is described here.</li> <li>Q. When did you find out that he was an expert for the defense in mold litigation?</li> <li>A. After publication.</li> <li>Q. Did you ever go back and make the correction?</li> </ul>	2 3 4 5 6	that describes associations between environmental factors and health effects?  A. Yes, they can.  Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?
2 3 4 5	<ul> <li>and that's what is described here.</li> <li>Q. When did you find out that he was an expert for the defense in mold litigation?</li> <li>A. After publication.</li> <li>Q. Did you ever go back and make the correction?</li> <li>A. That he was a post-hoc expert?</li> </ul>	2 3 4 5 6 7	that describes associations between environmental factors and health effects?  A. Yes, they can.  Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that.
2 3 4 5 6 7 8	<ul> <li>and that's what is described here.</li> <li>Q. When did you find out that he was an expert for the defense in mold litigation?</li> <li>A. After publication.</li> <li>Q. Did you ever go back and make the correction?</li> <li>A. That he was a post-hoc expert?</li> <li>Q. Yes.</li> </ul>	2 3 4 5 6 7 8	that describes associations between environmental factors and health effects?  A. Yes, they can.  Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that.  Q. Okay. And
2 3 4 5 6 7 8	<ul> <li>and that's what is described here.</li> <li>Q. When did you find out that he was an expert for the defense in mold litigation?</li> <li>A. After publication.</li> <li>Q. Did you ever go back and make the correction?</li> <li>A. That he was a post-hoc expert?</li> <li>Q. Yes.</li> <li>A. No.</li> </ul>	2 3 4 5 6 7 8	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined
2 3 4 5 6 7 8 9	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication.  Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert?  Q. Yes.  A. No.  And so what then happened was	2 3 4 5 6 7 8 9	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask
2 3 4 5 6 7 8 9 10	and that's what is described here. Q. When did you find out that he was an expert for the defense in mold litigation? A. After publication. Q. Did you ever go back and make the correction? A. That he was a post-hoc expert? Q. Yes. A. No. And so what then happened was Q. I didn't ask you what happened next.	2 3 4 5 6 7 8 9 10	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or
2 3 4 5 6 7 8 9 10 11	and that's what is described here. Q. When did you find out that he was an expert for the defense in mold litigation? A. After publication. Q. Did you ever go back and make the correction? A. That he was a post-hoc expert? Q. Yes. A. No. And so what then happened was Q. I didn't ask you what happened next. A. You had asked	2 3 4 5 6 7 8 9 10 11	that describes associations between environmental factors and health effects?  A. Yes, they can.  Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that.  Q. Okay. And  A. I think in that case I opined  Q. I didn't ask  I just wanted to know whether you did or not.
2 3 4 5 6 7 8 9 10 11 12	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication.  Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert?  Q. Yes.  A. No.  And so what then happened was  Q. I didn't ask you what happened next.  A. You had asked  I was answering the earlier question. You	2 3 4 5 6 7 8 9 10 11 12	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to
2 3 4 5 6 7 8 9 10 11 12 13	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication.  Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert?  Q. Yes.  A. No.  And so what then happened was  Q. I didn't ask you what happened next.  A. You had asked  I was answering the earlier question. You don't want it?	2 3 4 5 6 7 8 9 10 11 12 13	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to let him finish his answer.
2 3 4 5 6 7 8 9 10 11 12 13 14	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication.  Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert?  Q. Yes.  A. No.  And so what then happened was  Q. I didn't ask you what happened next.  A. You had asked  I was answering the earlier question. You don't want it?  Q. No. I I don't think your answer was	2 3 4 5 6 7 8 9 10 11 12 13 14	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to let him finish his answer.  MS. CONLIN: I've asked him simply "yes" or
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication.  Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert?  Q. Yes.  A. No.  And so what then happened was  Q. I didn't ask you what happened next.  A. You had asked  I was answering the earlier question. You don't want it?  Q. No. I I don't think your answer was responsive to my question, so we'll move on.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to let him finish his answer.  MS. CONLIN: I've asked him simply "yes" or "no" questions. I'm not going to waste my seven hours
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication.  Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert?  Q. Yes.  A. No.  And so what then happened was  Q. I didn't ask you what happened next.  A. You had asked  I was answering the earlier question. You don't want it?  Q. No. I I don't think your answer was responsive to my question, so we'll move on.  You've you've been a faculty member for	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to let him finish his answer.  MS. CONLIN: I've asked him simply "yes" or "no" questions. I'm not going to waste my seven hours with him giving me speaking testimony in questions I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication. Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert? Q. Yes. A. No.  And so what then happened was Q. I didn't ask you what happened next. A. You had asked I was answering the earlier question. You don't want it?  Q. No. I I don't think your answer was responsive to my question, so we'll move on. You've you've been a faculty member for the defense bar at various toxic tort seminars;	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to let him finish his answer.  MS. CONLIN: I've asked him simply "yes" or "no" questions. I'm not going to waste my seven hours with him giving me speaking testimony in questions I didn't ask. You can you can ask him on followup.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication. Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert? Q. Yes. A. No.  And so what then happened was Q. I didn't ask you what happened next. A. You had asked I was answering the earlier question. You don't want it? Q. No. I I don't think your answer was responsive to my question, so we'll move on. You've you've been a faculty member for the defense bar at various toxic tort seminars; correct?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to let him finish his answer.  MS. CONLIN: I've asked him simply "yes" or "no" questions. I'm not going to waste my seven hours with him giving me speaking testimony in questions I didn't ask. You can you can ask him on followup.  MR. GORDON: Yeah. But it may be a "yes"
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication.  Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert?  Q. Yes.  A. No.  And so what then happened was  Q. I didn't ask you what happened next.  A. You had asked  I was answering the earlier question. You don't want it?  Q. No. I I don't think your answer was responsive to my question, so we'll move on.  You've you've been a faculty member for the defense bar at various toxic tort seminars; correct?  A. Once. I think once.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to let him finish his answer.  MS. CONLIN: I've asked him simply "yes" or "no" questions. I'm not going to waste my seven hours with him giving me speaking testimony in questions I didn't ask. You can you can ask him on followup.  MR. GORDON: Yeah. But it may be a "yes" what you think is a simple "yes" or "no" question, but
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication. Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert? Q. Yes. A. No.  And so what then happened was Q. I didn't ask you what happened next. A. You had asked I was answering the earlier question. You don't want it? Q. No. I I don't think your answer was responsive to my question, so we'll move on. You've you've been a faculty member for the defense bar at various toxic tort seminars; correct?  A. Once. I think once. Q. Just once?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to let him finish his answer.  MS. CONLIN: I've asked him simply "yes" or "no" questions. I'm not going to waste my seven hours with him giving me speaking testimony in questions I didn't ask. You can you can ask him on followup.  MR. GORDON: Yeah. But it may be a "yes" what you think is a simple "yes" or "no" question, but you you don't get to decide that.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication.  Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert?  Q. Yes.  A. No.  And so what then happened was  Q. I didn't ask you what happened next.  A. You had asked  I was answering the earlier question. You don't want it?  Q. No. I I don't think your answer was responsive to my question, so we'll move on.  You've you've been a faculty member for the defense bar at various toxic tort seminars; correct?  A. Once. I think once.  Q. Just once?  A. I gave a talk in March, I think, of this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to let him finish his answer.  MS. CONLIN: I've asked him simply "yes" or "no" questions. I'm not going to waste my seven hours with him giving me speaking testimony in questions I didn't ask. You can you can ask him on followup.  MR. GORDON: Yeah. But it may be a "yes" what you think is a simple "yes" or "no" question, but you you don't get to decide that. Q. And more recently you've opined that there
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication.  Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert?  Q. Yes.  A. No.  And so what then happened was  Q. I didn't ask you what happened next.  A. You had asked  I was answering the earlier question. You don't want it?  Q. No. I I don't think your answer was responsive to my question, so we'll move on.  You've you've been a faculty member for the defense bar at various toxic tort seminars; correct?  A. Once. I think once.  Q. Just once?  A. I gave a talk in March, I think, of this year on the peer-review process in science at a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to let him finish his answer.  MS. CONLIN: I've asked him simply "yes" or "no" questions. I'm not going to waste my seven hours with him giving me speaking testimony in questions I didn't ask. You can you can ask him on followup.  MR. GORDON: Yeah. But it may be a "yes" what you think is a simple "yes" or "no" question, but you you don't get to decide that. Q. And more recently you've opined that there is no specific causation relating to CS teargas or
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	and that's what is described here.  Q. When did you find out that he was an expert for the defense in mold litigation?  A. After publication.  Q. Did you ever go back and make the correction?  A. That he was a post-hoc expert?  Q. Yes.  A. No.  And so what then happened was  Q. I didn't ask you what happened next.  A. You had asked  I was answering the earlier question. You don't want it?  Q. No. I I don't think your answer was responsive to my question, so we'll move on.  You've you've been a faculty member for the defense bar at various toxic tort seminars; correct?  A. Once. I think once.  Q. Just once?  A. I gave a talk in March, I think, of this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	that describes associations between environmental factors and health effects?  A. Yes, they can. Q. You've opined that there is no causal connection between benzine and multiple myeloma; is that right?  A. Yes, I opined on that. Q. Okay. And A. I think in that case I opined Q. I didn't ask I just wanted to know whether you did or not.  MR. GORDON: Well Jan, I think you ought to let him finish his answer.  MS. CONLIN: I've asked him simply "yes" or "no" questions. I'm not going to waste my seven hours with him giving me speaking testimony in questions I didn't ask. You can you can ask him on followup.  MR. GORDON: Yeah. But it may be a "yes" what you think is a simple "yes" or "no" question, but you you don't get to decide that. Q. And more recently you've opined that there

Page 61 Page 63 1 case I said that there was no evidence that the 1 between use of talc and ovarian cancer. 2 2 exposure to the cleaning agents caused the complaints A. I -- I wasn't asked that question. I was 3 of the person who was the claimant, but that the CS 3 asked whether it had been opined and by whom and when, 4 teargas clearly was the cause of symptoms. 4 and I went through the literature, and I opined that 5 5 Q. Did -it had not been said by anybody that it was a cause. 6 If we can take a look at your expert report, 6 Q. Were you --7 and I'd like to talk with you a little bit about -- I 7 So your opinion was strictly that there 8 think it's on page --8 was -- nothing in the literature provided a direct 9 You listed in your report the four times 9 causal link between use of talc and ovarian cancer. 10 that you have testified in the last few years, and for 10 A. I --11 some reason I cannot seem to find that in what I've 11 You're paraphrasing what I said. I -- I 12 12 said that a causal association had not been described 13 A. I think it was in an addendum. I don't 13 in the literature and anywhere other than in court think I listed it specifically --14 14 testimony. 15 Q. Well let's see if I can --15 Q. Okay. Now in --16 A. -- in the report. 16 You also testified in Stults versus American 17 Q. Let's see if I can find it. 17 Popcorn Company in a deposition in 2013; correct? 18 Here, I got it. 18 A. That's correct. 19 (Exhibit 6 was marked for 19 Q. And in that case you concluded that there is 20 identification.) 20 no causal link between diacetyl and what's known as 21 BY MS. CONLIN: 21 popcorn lung; correct? 22 Q. I've handed you, sir, what's been marked as 22 A. No. 23 Borak Exhibit 6. Is this a list of your deposition 23 Q. What was your testimony in that case? 2.4 and trial testimony between January 1st, 2013 and June 24 A. The testimony concerned the likelihood of a 2.5 1st, 2017? 25 lung -- of bronchiolitis obliterans being caused in a Page 62 Page 64 1 A. Yes, that's correct. 1 person who was a consumer of popcorn, and the 2 2 Q. Aside from this deposition today, have you individual himself had a significant underlying 3 had your deposition taken in any other litigation 3 rheumatological disease which was the likely cause of 4 between June 1st of this year and today? 4 his lung disease. 5 5 Q. You found that exposure to diacetyl didn't A. I -- I had a deposition taken on, I think, 6 6 cause the problems in the plaintiff in that case; June 9. 7 7 Q. Okay. What was the name of that case? 8 8 A. I think the caption was Oules, O-u-l-e-s, v A. No, no, I didn't. The -- the problem --9 Johnson & Johnson. 9 Your original question was whether I had 10 10 Q. And what was the subject matter of your opined that diacetyl did not cause the bronchiolitis 11 11 obliterans, and I said no, that's not correct, I was testimony in that case? 12 12 A. The question I was asked to address was not asked that opinion. And it is actually my opinion 13 13 that under some circumstances diacetyl can cause the whether, when, and how it had been opined that talc 14 14 bronchiolitis obliterans. caused ovarian cancer. 15 15 Q. And you represent --Q. But it didn't in this particular plaintiff. 16 16 Or your client in that case is Johnson & A. In this particular case, I don't believe 17 Johnson? 17 that it did. 18 A. No. 18 Q. Okay. And what about In Re: World Trade 19 Q. The plaintiff? 19 Center, what was the subject matter of your testimony 2.0 A. It is -- was a trade organization. 20 21 21 Q. And in that case did you opine that there is A. The subject matter had to do with lung 22 22 no causal connection between talc and ovarian cancer? disease in somebody who had been a cleanup worker in 23 23 A. I -- I testified that the causation had not buildings in the periphery of the World Trade Center. 2.4 24 been proven. Q. Okay. And in that case you found that the 25 Q. That there wasn't a proven causal link 25 exposure by the worker didn't cause the disease;

16 (Pages 61 to 64)

	Page 65		Page 67
1	correct?	1	question.
2	A. It was my opinion that the man's cigarette	2	A. I I don't object to his use of the
3	smoking and long history that predated the World Trade	3	sufficient component cause model. I raise concerns at
4	Center explained his complaints.	4	the end of this section of my report and we could
5	Q. Okay. And what was your subject matter	5	address that specifically. Now it's not only the
6	of your testimony in Cabot Corporation?	6	conclusion, there was something in the method that I
7	A. I I already alluded to that. That had to	7	had a problem with.
8	do with the adjudication in terms of the insurance	8	Q. Okay. But the sufficient component
9	coverage for between two companies.	9	causation methodology is well established and accepted
10	Q. And what was the particular chemical of	10	amongst epidemiologists.
11	concern?	11	A. I I think probably. I I don't
12	A. The issue had to do with if one could get	12	I'm not objecting to that.
13	coal miner's pneumoconiosis in the absence of silica.	13	Q. Okay. And in fact you went through the same
14	Q. And in that case you concluded that the	14	framework in connection with responding to Dr. Samet's
15	that he can't; correct?	15	report; correct?
16	(Discussion off the stenographic record.)	16	A. Well I probably would have done that to be
17	A. Yes. My conclusion was that the absence of	17	responsive to Dr. Samet. I don't know if I would have
18	silica, that no, let me turn it the other way	18	done it otherwise.
19	that the presence of silica contributed to the	19	Q. Okay. But you did in fact use the same
20	formation of pneumoconiosis.	20	framework. You didn't employ a different framework
21	Q. Okay. And how about in the final case,	21	A. No. No.
22	Secretary of Labor (MSHA) versus Klondex Midas, which	22	Q in connection with responding; correct?
23	side were you on in this case?	23	A. Yes, that's correct I think.
24	A. I I was involved with Klondex Midas, and	24	Q. Okay. Would you agree with me that when
25	the case concerned whether medical causes of loss of	25	you're looking at epidemiology, that drawing causal
	Page 66		Page 68
1	consciousness had been addressed and considered by a	1	inferences after finding association requires
2	coroner and others.	2	judgment?
3	Q. And what did you opine in that case?	3	A. Judgment is part of the requirements, yes.
4	A. I agreed with statements from the coroner	4	Q. Okay. Would you agree with me that although
5	that she had not looked for such causes and could not	5	the drawing of causal inferences is informed by
6	render such an opinion.	6	scientific expertise, it is not a determination that
7	Q. Now you talk in your expert report about	7	is made using an objective or algorith algorithmic
8	sufficient component causation; correct?	8	methodology?
9	A. Yes. I think I spoke to it in the context	9	A. It is not necessarily.
10	of Dr. Samet's report.	10	Q. What do you mean by "it is not necessarily."
11	Q. Right. And you'd agree with me that it's a	11	A. Well read me back your question and I'll
12	well accepted methodology in epidemiological studies;	12	answer your second question. You asked me do I agree
13	correct?	13	that it is not, and I my answer was it was not
14	A. I accept the concept.	14	necessarily.
	Q. Yeah. And in fact it was first espoused by	15	Q. Okay. Would you agree, quote, "Although the
15			drawing of a causal in" strike that. Let me start
16	Dr. Rothman; correct?	16	drawing of a causal in strike that. Let the start
	A. I looked at it in Dr. Rothman's writings as	17	over.
16 17 18	A. I looked at it in Dr. Rothman's writings as a result of Dr. Samet citing that, yes.	17 18	over.  Would you agree with me, quote, "Although
16 17	<ul><li>A. I looked at it in Dr. Rothman's writings as a result of Dr. Samet citing that, yes.</li><li>Q. And you'd agree with me Dr. Rothman is one</li></ul>	17 18 19	over.  Would you agree with me, quote, "Although the drawing of causal inferences is informed by
16 17 18	<ul> <li>A. I looked at it in Dr. Rothman's writings as a result of Dr. Samet citing that, yes.</li> <li>Q. And you'd agree with me Dr. Rothman is one of the leading minds in epidemiology.</li> </ul>	17 18 19 20	over.  Would you agree with me, quote, "Although the drawing of causal inferences is informed by scientific expertise, it is not a determination that
16 17 18 19	<ul><li>A. I looked at it in Dr. Rothman's writings as a result of Dr. Samet citing that, yes.</li><li>Q. And you'd agree with me Dr. Rothman is one</li></ul>	17 18 19 20 21	over.  Would you agree with me, quote, "Although the drawing of causal inferences is informed by scientific expertise, it is not a determination that is made using an objective or algorithmic
16 17 18 19 20	<ul> <li>A. I looked at it in Dr. Rothman's writings as a result of Dr. Samet citing that, yes.</li> <li>Q. And you'd agree with me Dr. Rothman is one of the leading minds in epidemiology.</li> <li>A. I think Dr. Rothman is a leading mind in epidemiology.</li> </ul>	17 18 19 20 21 22	over.  Would you agree with me, quote, "Although the drawing of causal inferences is informed by scientific expertise, it is not a determination that is made using an objective or algorithmic methodology," end quote?
16 17 18 19 20 21 22	<ul> <li>A. I looked at it in Dr. Rothman's writings as a result of Dr. Samet citing that, yes.</li> <li>Q. And you'd agree with me Dr. Rothman is one of the leading minds in epidemiology.</li> <li>A. I think Dr. Rothman is a leading mind in epidemiology.</li> <li>Q. So you don't take issue with Dr. Samet's</li> </ul>	17 18 19 20 21 22 23	over.  Would you agree with me, quote, "Although the drawing of causal inferences is informed by scientific expertise, it is not a determination that is made using an objective or algorithmic methodology," end quote?  A. Yes. It is not necessarily based upon such
16 17 18 19 20 21	<ul> <li>A. I looked at it in Dr. Rothman's writings as a result of Dr. Samet citing that, yes.</li> <li>Q. And you'd agree with me Dr. Rothman is one of the leading minds in epidemiology.</li> <li>A. I think Dr. Rothman is a leading mind in epidemiology.</li> </ul>	17 18 19 20 21 22	over.  Would you agree with me, quote, "Although the drawing of causal inferences is informed by scientific expertise, it is not a determination that is made using an objective or algorithmic methodology," end quote?

Page 71 Page 69 1 "Deciding whether associations are causal is not a 1 of SSI." 2 matter of statistics but a matter of good scientific 2 A. Yes, I said that. 3 judgment and the questions that should be asked with 3 Q. Okay. I take it that you think the CDC in 4 respect to the data offered?" 4 terms of --5 5 A. In principle. But there are some terms in You know, let me strike that and ask it a 6 6 that sentence which are difficult to define, such as different way. 7 7 "good." "Good judgment" I think was the word. You relied on the CDC guidelines here in 8 8 Q. Good scientific judgment. connection with your report; correct? 9 9 A. Good scientific judgment. I don't know A. I -- I cited it, yes. 10 10 quite what that means. But I can understand the Q. Okay. And you relied on it. 11 11 A. Well I relied upon it as an example of a 12 Q. Well would you agree with me that The 12 statement from a well-regarded organization, yes. 13 13 Reference Guide on Statistics authored by Drs. Kay and Q. Okay. And you agree the CDC is well-Friedman is an authoritative work? 14 14 regarded; correct? 15 15 A. It's a reference that I refer to. A. Generally, yes. 16 Q. Okay. And you rely on it; right? 16 Q. Okay. In connection with your work over the 17 A. I do. 17 course of your career, your emphasis has been on 18 Q. And you don't take issue with what Drs. Kay 18 exposure to environmental toxins as opposed to 19 19 and Friedman have written in connection with The infectious agents; correct? 20 Reference Guide on Statistics. In fact, you've relied 20 A. For the most part. 21 21 on it; correct? Q. Have you ever opined in a case that involved 22 22 A. That's correct. not an environmental toxin but an infectious agent? 23 Q. I'd like to direct your attention, sir, to 23 A. Years ago, when I ran a trauma center, I was paragraph -- or page three of your expert report in 24 2.4 involved in litigation that involved malpractice kinds 25 this case, Borak Exhibit No. 1. Do you have that in 25 of issues, clinical malpractice issues, and I can Page 70 Page 72 front of you? 1 remember in that context there were questions that 1 2 2 A. I do. arose regarding infections. But that would have been 3 Q. Okay. And I'd like to direct your attention 3 some time ago. 4 to Roman No. II, "The Samet Report." In 11a you talk 4 Q. Well you were a participant. It was part 5 about this notion that there is sufficient evidence 5 of --6 6 I mean you were involved in that case as a that warming surgical patients to prevent hypothermia 7 7 and maintain normothermia reduces the rates of SSI; result of your work; correct? 8 8 correct? A. No, no. I was an expert in that context. 9 A. Correct. 9 O. When was that? 10 10 A. Oh, it --Q. And you cite to the CDC's guideline as one 11 of your references; correct? 11 There were more than one, and it would have 12 12 A. Yes. been before 1990 because before -- in 1990 I 13 13 Q. And the World Health Organization; correct? essentially separated myself from my emergency 14 14 practice, and during the time between 1980 and 1990, A. Yes. 15 15 approximately, I was involved in a fairly large number Q. Okay. Did you investigate what -- what 16 information either the CDC or WHO had in connection 16 of litigation questions, often only from the 17 with their suggestion and determination that warming 17 standpoint of looking at medical records and saying 18 is important? 18 whether I thought there was or was not some kind of a 19 A. Well I -- I've read the documents and I've 19 problem, and in that context, some of those involved 2.0 looked at some of the references. Is that an answer 20 infectious diseases. 21 21 Q. Have you ever been retained, litigation or to your question? 22 Q. Okay. And you say in the next paragraph, 22 non-litigation, to provide an epidemiological opinion "In addition, published findings from two random 23 23 that relates to an infectious organism? 24 24 control trials document that use of Bair Hugger to A. I did some work several years ago at the 25 maintain intraoperative normothermia reduced the risk 25 interface of epidemiology and occupational medicine

Page 75 Page 73 1 and public health, and it was during the Ebola 1 it's important when you're undertaking an 2 outbreak, and it had to do with the development of 2 epidemiologic study, particularly one that relates to 3 occupational protocols for workplaces to minimize the 3 association or causation, to have all the information. 4 risk of spread of that infectious disease. The 4 Did you ask for all the information that might be 5 5 particular issue involved some companies that operated pertinent to your decision? 6 6 mines in the Caribbean who had workers, many of whom MR. GORDON: Object to the form of the 7 7 question. went back and forth to Africa at the time. I recall 8 8 A. I -- I don't know that there even is such as well being involved in the development of 9 9 information to have asked for. influenza-related policies for workplaces, 10 Q. Well did you tell Mr. Gordon, the lawyer for 10 white-collar workplaces, at a time when either SARs or 11 3M, "If I'm going to undertake this, I want to look at 11 influenza was of great concern. So those are two 12 all the evidence that's been accumulated by the 12 examples. 13 13 Q. Okay. My question was a little different. parties in this case?" A. I --14 14 Have you ever undertaken an epidemiologic study that 15 It was understood that I could ask for 15 relates to looking at causation issues of an 16 whatever I thought I needed. I didn't know that there 16 infectious organism? 17 was ever a question of those two articles. They've 17 A. Oh, that's a different question. I think 18 been cited repeatedly. I've never seen them 18 the answer is probably no. 19 retracted. The index of the National Library of 19 Q. Now if we look at the paragraph we were 20 Medicine does not indicate that they have been 2.0 looking at, you say, "In addition, published findings 21 qualified, so it's not my understanding that I was 21 from two random control trials document that use of 22 citing here problematic papers, and I don't think I 22 Bair Hugger to maintain intraoperative normothermia 23 have any reason to know that they were reviewed by 23 reduced the risk of SSI," and you list references 24 anybody as problematic. 2.4 three and four. And if we look at your reference 25 Q. But you didn't ask the question. Did you --25 list, that refers to a paper by Kurz and Sessler as Page 74 Page 76 1 well as Melling; correct? 1 Did you ever say to the lawyers for 3M, "I'd 2 2 A. That's correct. like to know all the depositions that have been taken 3 Q. Okay. Did you look at the depositions that 3 in this case?" 4 were taken by Dr. Kurz and Sessler in this case? 4 A. No. 5 5 Q. Or "I would like to see any evidence that A. I -- I don't think so. Let me --6 6 might exist that undercuts what I'm writing in my Dr. Kurz and Dr. Melling? 7 7 Q. Well one paper was --8 8 A. You -- you asked me about --A. I was writing a -- a report and I thought I 9 Q. -- Kurz and Sessler. My question was: Did 9 had much of the information. If you're telling me 10 10 you look at their depositions in this case? that there's important information that I don't have, 11 A. The answer is no, I don't believe so. I 11 I would be interested to know. 12 12 (Exhibit 7 was marked for don't see them on my list. 13 13 Q. Were you aware or told that Dr. Kurz identification.) 14 disavowed both the study in which she was an author as 14 BY MS. CONLIN: 15 well as the Melling -- Melling study? 15 Q. I've handed you, sir, what's been marked as 16 MR. GORDON: Object to the form of the 16 Borak Deposition Exhibit No. 7, which is the 17 question, completely misstates her testimony. 17 deposition of Andrea Kurz dated January 12th, 2017, 18 A. I -- I'm not aware that either one was 18 and you'll see that on that first page, internal page 19 deposed. 19 four, it lists Mr. Gordon, the lawyer sitting next to 2.0 Q. Don't you think that that would be important 20 you, present at the deposition, as well as a Mr. 21 21 to know when you're relying on things such as these Assaad 22 22 Have you seen this before? 23 23 MR. GORDON: Same objection. A. I don't believe I have. 24 24 Q. Okay. Okay. If you can take a look at page A. I -- I don't have any information about it. 25 Q. Well you testified previously that you think 25 one seven -- internal page 177, which is the last page

	Page 77		Page 79
1	of this document,	1	opinion on whether the use of Bair Hugger increases
2	A. Yes.	2	the number of particulates over a surgical site?
3	Q and they're talking there about the study	3	A. I I don't have such an opinion.
4	which you've listed as reference number three, and she	4	Q. One way or another.
5	says at the top of the page:	5	A. One way or another.
6	"it's a retrospective study and not one	6	Q. Okay. Have you done any investigation into
7	of the best-done either. So you	7	that issue?
8	"Question: Based on in today's standards.	8	A. I I have read a number of papers, but it
9	"Answer: Based on in today's standards.	9	is not my area of expertise, and I read them only
10	"Okay. It might have been good standards	10	because occasionally they've occasionally been
11	back in 1996."	11	cited by some of the others in this case.
12	Then it says, "Okay. And Dr. Sessler has	12	Q. Okay. Do you think that, in connection with
13	mentioned in an e-mail before, in today's standards	13	reaching a conclusion, which you did, that there is no
14	and with respect to reliability of studies, that he	14	association between the use of Bair Hugger and a risk
15	probably wouldn't have published the 1996 Kurz paper.	15	of infection, that it would be important to ascertain
16	Do you agree with him?	16	whether use of the Bair Hugger increases the number of
17	"Absolutely.	17	particulates over the surgical site?
18	"Okay.	18	A. I I rendered my opinion on the basis of
19	"I would not have either."	19	my understanding of evidence linking Bair Hugger and
20	And if you look down at the bottom of page	20	infection, not based upon Bair Hugger and particulates
21	178 with reference to the Melling study, "It was an	21	per se.
22	okay study for"	22	Q. So you haven't done any investigation, for
23	Starting page 178, starting at line 16:	23	example, into the paper published papers by Stocks
24	"Question: Do you think Melling was a good	24	or Darouiche as whether increased particulates over a
25	study?	25	surgical site can increase the risk of infection.
	Page 78		Page 80
1		1	
1 2	"Answer: It was an okay study for the time.	1 2	A. I have read both of those papers. I have no
	"Answer: It was an okay study for the time. "Question: Would you agree with me that it		A. I have read both of those papers. I have no expert opinions about the question you ask.
2	"Answer: It was an okay study for the time. "Question: Would you agree with me that it wouldn't be publishable today?	2	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on
2	"Answer: It was an okay study for the time. "Question: Would you agree with me that it	2	A. I have read both of those papers. I have no expert opinions about the question you ask.
2 3 4	"Answer: It was an okay study for the time. "Question: Would you agree with me that it wouldn't be publishable today? "Answer: I absolutely would agree with	2 3 4	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your
2 3 4 5	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."	2 3 4 5	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained
2 3 4 5 6	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.	2 3 4 5 6	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.
2 3 4 5 6 7	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page	2 3 4 5 6 7	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion
2 3 4 5 6 7 8	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:	2 3 4 5 6 7 8	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger
2 3 4 5 6 7 8	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is	2 3 4 5 6 7 8	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.
2 3 4 5 6 7 8 9	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining	2 3 4 5 6 7 8 9	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an
2 3 4 5 6 7 8 9 10	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.	2 3 4 5 6 7 8 9 10	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you
2 3 4 5 6 7 8 9 10 11	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."	2 3 4 5 6 7 8 9 10 11	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right?
2 3 4 5 6 7 8 9 10 11 12	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."  Were you aware of that testimony before	2 3 4 5 6 7 8 9 10 11 12 13	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right?  There's a concept is called biological plausibility;
2 3 4 5 6 7 8 9 10 11 12 13	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."  Were you aware of that testimony before today?	2 3 4 5 6 7 8 9 10 11 12 13 14	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right?  There's a concept is called biological plausibility; correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."  Were you aware of that testimony before today?  A. No, I was not.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right?  There's a concept is called biological plausibility; correct?  A. Well I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."  Were you aware of that testimony before today?  A. No, I was not.  Q. Did you do any investigation into the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right?  There's a concept is called biological plausibility; correct?  A. Well I  MR. GORDON: Object to the form of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."  Were you aware of that testimony before today?  A. No, I was not.  Q. Did you do any investigation into the Sessler or the Kurz/Sessler and Melling papers as part of your opinions in this case?  A. I did not.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right? There's a concept is called biological plausibility; correct?  A. Well I  MR. GORDON: Object to the form of the question.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."  Were you aware of that testimony before today?  A. No, I was not.  Q. Did you do any investigation into the Sessler or the Kurz/Sessler and Melling papers as part of your opinions in this case?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right? There's a concept is called biological plausibility; correct?  A. Well I  MR. GORDON: Object to the form of the question.  A. I I understand that there is such an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."  Were you aware of that testimony before today?  A. No, I was not.  Q. Did you do any investigation into the Sessler or the Kurz/Sessler and Melling papers as part of your opinions in this case?  A. I did not.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right? There's a concept is called biological plausibility; correct?  A. Well I  MR. GORDON: Object to the form of the question.  A. I I understand that there is such an issue of plausibility and potentiality, yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."  Were you aware of that testimony before today?  A. No, I was not.  Q. Did you do any investigation into the Sessler or the Kurz/Sessler and Melling papers as part of your opinions in this case?  A. I did not.  Q. Do you have an opinion on whether the use of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right?  There's a concept is called biological plausibility; correct?  A. Well I  MR. GORDON: Object to the form of the question.  A. I I understand that there is such an issue of plausibility and potentiality, yes.  Q. Okay. And you didn't think it was important
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."  Were you aware of that testimony before today?  A. No, I was not.  Q. Did you do any investigation into the Sessler or the Kurz/Sessler and Melling papers as part of your opinions in this case?  A. I did not.  Q. Do you have an opinion on whether the use of Bair Hugger increases the number of particulates over a surgical site?  A. I have seen papers that suggest it does and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right?  There's a concept is called biological plausibility; correct?  A. Well I  MR. GORDON: Object to the form of the question.  A. I I understand that there is such an issue of plausibility and potentiality, yes.  Q. Okay. And you didn't think it was important to understand whether, by way of mechanism, the Bair Hugger would increase the number of particulates over the surgical site?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."  Were you aware of that testimony before today?  A. No, I was not.  Q. Did you do any investigation into the Sessler or the Kurz/Sessler and Melling papers as part of your opinions in this case?  A. I did not.  Q. Do you have an opinion on whether the use of Bair Hugger increases the number of particulates over a surgical site?  A. I have seen papers that suggest it does and I have seen papers that suggest it might not.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right?  There's a concept is called biological plausibility; correct?  A. Well I  MR. GORDON: Object to the form of the question.  A. I I understand that there is such an issue of plausibility and potentiality, yes.  Q. Okay. And you didn't think it was important to understand whether, by way of mechanism, the Bair Hugger would increase the number of particulates over the surgical site?  A. I I understood the argument that there
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	"Answer: It was an okay study for the time.  "Question: Would you agree with me that it wouldn't be publishable today?  "Answer: I absolutely would agree with you."  A. You seem to have read it correctly.  Q. Okay. And if you look at the top of page 179, question at line 16:  "In today's scientific standards, there is no reliable evidence that supports that maintaining normothermia reduces the incidence of infection.  "Answer: That is correct."  Were you aware of that testimony before today?  A. No, I was not.  Q. Did you do any investigation into the Sessler or the Kurz/Sessler and Melling papers as part of your opinions in this case?  A. I did not.  Q. Do you have an opinion on whether the use of Bair Hugger increases the number of particulates over a surgical site?  A. I have seen papers that suggest it does and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I have read both of those papers. I have no expert opinions about the question you ask.  Q. Okay. And you don't cite to or rely on Darouiche or Stocks in connection with your conclusions that are rendered in your or contained in your June 2nd expert report.  A. Yes, that is correct. It was my opinion that it was the link between the use of Bair Hugger and the evidence of infection that mattered.  Q. Okay. But you also understand as an epidem as someone studying epidemiology that you have to look at the chain of infection; right?  There's a concept is called biological plausibility; correct?  A. Well I  MR. GORDON: Object to the form of the question.  A. I I understand that there is such an issue of plausibility and potentiality, yes.  Q. Okay. And you didn't think it was important to understand whether, by way of mechanism, the Bair Hugger would increase the number of particulates over the surgical site?

Page 81 Page 83 1 evidence, that there was a link between Bair Hugger 1 would not inform your opinion one way or the other. 2 and infections, not on whether there was some 2 A. It would inform thinking about a 3 intermediary process that might be linked. 3 hypothetical association. In the absence of evidence 4 Q. Well how do you understand how the Bair 4 linking Bair Hugger and surgical infections, the 5 5 Hugger might increase the risk of infection? presence of particulates, as you describe them, would 6 6 A. I understand that there are theoretical be interesting but insufficient to point to causation. 7 7 Q. Okay. I wasn't asking you about causation, mechanisms that might be at play, and I would frankly 8 8 but -defer that to Dr. Wenzel. I was not asked to opine 9 9 Do you have an opinion of whether an about the theoretical mechanisms and I have not opined 10 10 increased number of particles over a surgical site about them. 11 creates an increased risk of infection? 11 Q. So your opinion that there is no association 12 A. I don't have such an opinion. I am not an 12 between Bair Hugger and risk of infection is divorced 13 13 from a concept of whether it increases particulates expert in that domain. I understand the logic of it, 14 14 but it's not an area that I know well enough to opine. over the surgical site. 15 Q. You talk about SSIs or surgical-site 15 MR. GORDON: Object to the form of the 16 infections throughout your report. Could you give me 16 question. 17 a definition of that? 17 A. I -- I -- there --18 A. In the context, I was looking specifically 18 There are two parts of an answer. The first 19 at infections following -- I -- I principally was 19 one is that you misdescribe my opinion, and the second 20 thinking about infections following arthroplastic 20 is that I -- my opinion was not dependent upon whether 21 surgery, and my intent was to speak to deep 21 there was or wasn't a change in the particulate load. 22 infections, but I think in some places I may have used 22 Q. Okay. And so if there was a substantial 23 the term more generally to speak of infections at 23 increase of particulates over the surgical site caused 24 surgical sites. 2.4 by the Bair Hugger, that would not inform your opinion 25 Q. Okay. So where I see "SSI" in your report, 25 one way or another. Page 82 Page 84 1 A. I -- I -- I think I described that in my 1 you really meant deep joint infection? 2 2 report, and I can turn to it if you like. It had to A. If you point to them, I'll try to clarify. 3 do with the end of my discussion of causality, and I 3 Q. Well --4 said that in the absence of evidence --4 A. I may have used it ambiguously. 5 5 I perhaps should look at it so I don't badly Q. Okay. Do you understand the difference 6 6 between a -- what's known to doctors as a deep paraphrase it, if you don't mind. 7 7 Q. Sure. I think you're on page 21, paragraphs incisional infection and a deep joint infection? 8 68 and 69. 8 A. I --9 A. You know it better than I do. I'm 9 MR. GORDON: Object to the form of the 10 impressed. Thank you. If others would read my work 10 question. 11 as well as you do, I would be flattered. 11 A. I think I do, but maybe you will clarify. 12 12 In paragraph 71 I wrote, "In the absence of Q. Okay. What's your understanding? 13 13 valid evidence of a causal association between Bair A. I think that a deep infection of a wound, if 14 14 Hugger and SSI, it can only be said that the we're talking about non-arthroplastic, it's not in the 15 mechanistic studies are coherent with a hypothetical 15 joint, it's not orthopedic, and is in the deeper 16 increase in SSI." And "Hypothetical associations," I 16 tissues of the surgical area; and a joint infection 17 believe, "are not sufficient to sustain an inference 17 seems to be fairly straightforward, it is in the area 18 of causation." 18 of the joint. 19 Q. Okay. 19 Q. Do you know how --2.0 A. I think that's what you were asking me 20 Did you do any investigation as to how deep 21 21 joint infections occur? about. 22 Q. Not necessarily. 22 A. Not per se. 23 23 My question is: And so if there was a Q. Do you have any understanding of bio -- the 2.4 24 term "biofilm" as it relates to infectious organisms substantial increase in the number of particulates 25 over the surgical site caused by the Bair Hugger, that 25 on prosthetic joints?

21 (Pages 81 to 84)

	Page 85		Page 87
1	A. I have read about bio biofilms.	1	Have you met Mr. Van Duren before?
2	Q. Have you done any investigation into whether	2	A. No.
3	or not antibiotics are effective in connection with a	3	Q. Have you met a single individual at 3M in
4	biofilm formed on a prosthetic?	4	connection with your work in this case?
5	A. It is my understanding that biofilms can	5	MR. GORDON: Non-lawyers you mean.
6	make antibiotics less effective.	6	A. Yeah. I met a Mr. Boone when you and I
7	Q. My question was: Did you do any	7	first met about a week ago, and I understood he was
8	investigation into that?	8	in in inside at 3M. But other than that, no, I
9	A. I I read about that.	9	don't think so.
10	Q. Okay. But you didn't undertake an	10	Q. You never talked with any of the folks that
11	exhaustive literature review in connection with that.	11	are involved with Bair Hugger at 3M.
12	A. I I I did not do an exhaustive	12	A. Not that I'm aware of.
13	literature review. My understanding was that Dr.	13	Q. Okay. And certainly not in connection with
14	Wenzel would do that.	14	the opinions you rendered in this case.
15	Q. Okay. Did you meet with Dr. Wenzel other	15	A. I don't think so.
16	than this meeting in DC on May 8th?	16	Q. Okay. If we can take a look on the back
17	A. No, we've never met since then.	17	page of what's been previously marked as Holford
18	Q. Okay. How long did the meeting go?	18	Deposition Exhibit 11, and if you can direct your
19	A. I would guess three or four hours, but I'm	19	attention to the internal page 258, starting on line
20	not sure.	20	five, where the corporate representative for 3M was
21	Q. Have you spoken to him since then?	21	asked the following question:
22	A. I think I spoke to him once.	22	"Okay. Based on the data we have today,
23	Q. What was that in connection with?	23	including the study funded by 3M as well as other
24	A. I think I was asking him a question about a	24	studies, every single study indicates that Bair Hugger
25	definition of surgical infections.	25	increases the particle count over the sterile field.
	Page 86		Page 88
1	Page 86	1	Page 88
1	Q. What did he tell you?	1	"Answer: In absolute numbers, yes.
2	<ul><li>Q. What did he tell you?</li><li>A. I don't recall his answer. I'm sorry.</li></ul>	2	"Answer: In absolute numbers, yes. "Question: Yes. Okay. And you have no
2	<ul><li>Q. What did he tell you?</li><li>A. I don't recall his answer. I'm sorry.</li><li>Q. Did you see his report before it went in?</li></ul>	2 3	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?
2 3 4	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> </ul>	2 3 4	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."
2 3 4 5	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert</li> </ul>	2 3 4 5	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?
2 3 4 5 6	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the</li> </ul>	2 3 4 5 6	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.
2 3 4 5 6 7	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid</li> </ul>	2 3 4 5 6 7	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would
2 3 4 5 6	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?</li> </ul>	2 3 4 5 6	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the
2 3 4 5 6 7 8	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?</li> <li>A. Yes, I have not looked at those reports.</li> </ul>	2 3 4 5 6 7 8	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?
2 3 4 5 6 7 8 9	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?</li> <li>A. Yes, I have not looked at those reports.</li> <li>Q. Okay. Were you aware that corporate</li> </ul>	2 3 4 5 6 7 8	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not
2 3 4 5 6 7 8 9 10	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?</li> <li>A. Yes, I have not looked at those reports.</li> <li>Q. Okay. Were you aware that corporate representatives for 3M have testified in this case</li> </ul>	2 3 4 5 6 7 8 9	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the
2 3 4 5 6 7 8 9	Q. What did he tell you?  A. I don't recall his answer. I'm sorry. Q. Did you see his report before it went in?  A. I think I did, yes. Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?  A. Yes, I have not looked at those reports. Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number	2 3 4 5 6 7 8 9 10	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not
2 3 4 5 6 7 8 9 10 11	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?</li> <li>A. Yes, I have not looked at those reports.</li> <li>Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number of particles over the surgical site?</li> </ul>	2 3 4 5 6 7 8 9 10 11	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the question, assumes facts not evidence.
2 3 4 5 6 7 8 9 10 11 12	Q. What did he tell you?  A. I don't recall his answer. I'm sorry. Q. Did you see his report before it went in?  A. I think I did, yes. Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?  A. Yes, I have not looked at those reports. Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number	2 3 4 5 6 7 8 9 10 11 12	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the question, assumes facts not evidence.  MS. CONLIN: You may answer.
2 3 4 5 6 7 8 9 10 11 12 13 14	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?</li> <li>A. Yes, I have not looked at those reports.</li> <li>Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number of particles over the surgical site?</li> <li>MR. GORDON: Object to the form of the</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the question, assumes facts not evidence.  MS. CONLIN: You may answer.  A. I did not investigate that.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?</li> <li>A. Yes, I have not looked at those reports.</li> <li>Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number of particles over the surgical site?</li> <li>MR. GORDON: Object to the form of the question.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the question, assumes facts not evidence.  MS. CONLIN: You may answer.  A. I did not investigate that.  Q. Okay. I take it it's because you didn't
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?</li> <li>A. Yes, I have not looked at those reports.</li> <li>Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number of particles over the surgical site?</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. I I don't think I'm aware of that. Maybe</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the question, assumes facts not evidence.  MS. CONLIN: You may answer.  A. I did not investigate that.  Q. Okay. I take it it's because you didn't think it was important to the conclusions that you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?</li> <li>A. Yes, I have not looked at those reports.</li> <li>Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number of particles over the surgical site?</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. I I don't think I'm aware of that. Maybe I heard it. I don't know. I haven't read it.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the question, assumes facts not evidence.  MS. CONLIN: You may answer.  A. I did not investigate that.  Q. Okay. I take it it's because you didn't think it was important to the conclusions that you rendered; correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?</li> <li>A. Yes, I have not looked at those reports.</li> <li>Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number of particles over the surgical site? MR. GORDON: Object to the form of the question. A. I I don't think I'm aware of that. Maybe I heard it. I don't know. I haven't read it. MS. CONLIN: If we could pull out Exhibit 11</li></ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the question, assumes facts not evidence.  MS. CONLIN: You may answer.  A. I did not investigate that.  Q. Okay. I take it it's because you didn't think it was important to the conclusions that you rendered; correct?  A. I didn't know that it had been done.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	<ul> <li>Q. What did he tell you?</li> <li>A. I don't recall his answer. I'm sorry.</li> <li>Q. Did you see his report before it went in?</li> <li>A. I think I did, yes.</li> <li>Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?</li> <li>A. Yes, I have not looked at those reports.</li> <li>Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number of particles over the surgical site? MR. GORDON: Object to the form of the question. A. I I don't think I'm aware of that. Maybe I heard it. I don't know. I haven't read it. MS. CONLIN: If we could pull out Exhibit 11 from yesterday, Mr. Stirewalt.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the question, assumes facts not evidence.  MS. CONLIN: You may answer.  A. I did not investigate that.  Q. Okay. I take it it's because you didn't think it was important to the conclusions that you rendered; correct?  A. I didn't know that it had been done.  Q. Well now that you know it had been done, is that information you thought you should have had in connection with your opinions?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. What did he tell you?  A. I don't recall his answer. I'm sorry. Q. Did you see his report before it went in?  A. I think I did, yes. Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?  A. Yes, I have not looked at those reports. Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number of particles over the surgical site?  MR. GORDON: Object to the form of the question.  A. I I don't think I'm aware of that. Maybe I heard it. I don't know. I haven't read it.  MS. CONLIN: If we could pull out Exhibit 11 from yesterday, Mr. Stirewalt.  (Holford Exhibit 11 handed to the witness.)  THE WITNESS: Thank you. Q. I've handed you what was marked during	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the question, assumes facts not evidence.  MS. CONLIN: You may answer.  A. I did not investigate that.  Q. Okay. I take it it's because you didn't think it was important to the conclusions that you rendered; correct?  A. I didn't know that it had been done.  Q. Well now that you know it had been done, is that information you thought you should have had in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. What did he tell you?  A. I don't recall his answer. I'm sorry. Q. Did you see his report before it went in? A. I think I did, yes. Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?  A. Yes, I have not looked at those reports. Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number of particles over the surgical site?  MR. GORDON: Object to the form of the question.  A. I I don't think I'm aware of that. Maybe I heard it. I don't know. I haven't read it.  MS. CONLIN: If we could pull out Exhibit 11 from yesterday, Mr. Stirewalt.  (Holford Exhibit 11 handed to the witness.)  THE WITNESS: Thank you. Q. I've handed you what was marked during Professor Holford's deposition as Exhibit 11, which is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the question, assumes facts not evidence.  MS. CONLIN: You may answer.  A. I did not investigate that.  Q. Okay. I take it it's because you didn't think it was important to the conclusions that you rendered; correct?  A. I didn't know that it had been done.  Q. Well now that you know it had been done, is that information you thought you should have had in connection with your opinions?  A. I had determined early in this process, probably going back to that meeting in May, that I was
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. What did he tell you?  A. I don't recall his answer. I'm sorry. Q. Did you see his report before it went in?  A. I think I did, yes. Q. You haven't looked at any of the expert reports that have been proffered either by 3M or the plaintiffs in connection with computational fluid dynamics?  A. Yes, I have not looked at those reports. Q. Okay. Were you aware that corporate representatives for 3M have testified in this case that the use of the Bair Hugger increases the number of particles over the surgical site?  MR. GORDON: Object to the form of the question.  A. I I don't think I'm aware of that. Maybe I heard it. I don't know. I haven't read it.  MS. CONLIN: If we could pull out Exhibit 11 from yesterday, Mr. Stirewalt.  (Holford Exhibit 11 handed to the witness.)  THE WITNESS: Thank you. Q. I've handed you what was marked during	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	"Answer: In absolute numbers, yes.  "Question: Yes. Okay. And you have no internal studies to refute that?  "No, we don't."  Do you see that?  A. I do see that.  Q. Okay. Did you ever investigate why 3M would be concerned about increased particulates over the sterile surgical site?  A. I did not  MR. GORDON: Object to the form of the question, assumes facts not evidence.  MS. CONLIN: You may answer.  A. I did not investigate that.  Q. Okay. I take it it's because you didn't think it was important to the conclusions that you rendered; correct?  A. I didn't know that it had been done.  Q. Well now that you know it had been done, is that information you thought you should have had in connection with your opinions?  A. I had determined early in this process,

22 (Pages 85 to 88)

Page 89 Page 91 1 Q. And you didn't think that was important to 1 in the air. They are so sensitive to this issue that 2 look at in connection with the opinions that you've 2 they discussed the contribution of talking to 3 rendered: correct? 3 particulates, and to the difference in squames 4 MR. GORDON: Object to the form of the 4 shedding between male and female OR staff. They 5 5 equate particulates with bacteria in the air and cite question. 6 A. Yes. In the absence of evidence that Bair 6 studies (do not have the citations) that support 7 7 Hugger caused joint infections, I did not think that this." Do you see that? 8 8 the particle information mattered. A. I've read that, yes. 9 9 Q. Why didn't it matter? Q. Okay. And did you read this today for the 10 10 A. Because infections were what mattered. first time? 11 Q. Well, do you know whether -- you --11 A. Yes, that's correct. 12 You understand that both Darouiche and 12 Q. This isn't a document that you saw in 13 13 Stocks and others have said that an increase of connection with your expert opinions in this case? particulates equals -- or can equal an increase in the 14 14 A. I've never seen this before. 15 number of infectious organisms; correct? 15 Q. Do you think it would be important if the 16 MR. GORDON: Object to the form of the 16 people who are selling the Bair Hugger are concerned 17 question. 17 that par -- there's an equation of particulates with 18 18 bacteria in the air --A. I -- I have read some who have said that, 19 and I have read others who apparently found no 19 MR. GORDON: Object --20 evidence of either increased particulates or bacteria, 20 Q. -- and that they've cited to studies that 21 and I have read others who found no evidence of 21 support this? 22 bacteria at all. I have not rendered an opinion on 22 MR. GORDON: Object to the form of the 23 that particular body of literature. 23 question, miscon -- misconstrues the document and the 2.4 Q. You have no opinion on whether an increase 24 evidence. 25 in particulates over a surgical site can increase the 25 A. I -- I can understand the concern that this Page 90 Page 92 1 risk of infection. 1 panel would have raised. 2 2 A. I think it would matter greatly what kind of Q. Do you think it would be important if the 3 particulates. There are all kinds of issues there 3 people who are selling the Bair Hugger were concerned 4 that I do not know with sufficient expertise. 4 about it creating an increase of particulates in the 5 5 air over the surgical site? (Exhibit 8 was marked for 6 6 identification.) A. It may have been a very appropriate thing 7 THE WITNESS: Thank you. 7 for them to be concerned about. 8 BY MS. CONLIN: 8 Q. But you didn't know that they were until 9 Q. I have handed you, sir, what's been marked 9 today; correct? 10 as Borak Exhibit 8, which is an e-mail from Michelle 10 MR. GORDON: Object to the form of the 11 Hulse Stevens at 3M to a number of people at 3M. 11 question, it assumes facts not in evidence, mis -- and 12 12 You've never met Dr. Hulse Stevens before? misconstrues the evidence. 13 13 A. No. A. I've never seen this document before. 14 Q. Okay. And you see the subject is "FAW" --14 Q. Okay. In your report you express no opinion on whether the Bair Hugger can create convective 15 which is forced-air warming -- "aerobiology and the 15 16 Orthopedic International Concensus Meeting on 16 turbulence in the OR; correct? 17 Prevention of Prosthetic Joint Infection." Do you see 17 A. I rendered no such opinions. 18 18 Q. Okay. And you haven't looked at any 19 A. I do see that. 19 literature aside from McGovern that addresses that 2.0 Q. Okay. And she starts by saying, "All, 20 specific subject. 21 "I sat in on the group addressing the OR 21 A. I -- I -- I have read articles about it, but I have no opinion about it and I've rendered no 22 environment to this consensus document. There is 22 23 amazing concern about any particulates in the air 23 opinion about it. 24 during joint replacement surgery and almost uniform 24 Q. And I take it you didn't think that that was comment that forced-air warming increases particulates 25 25 important in connection with the opinions that you've

Page 93 Page 95 MR. GORDON: Object to the form of the 1 expressed in your expert report. 1 2 A. As I've explained, I thought that the link 2 question. 3 between Bair Hugger and surgical-site infections was 3 A. I'm accepting that what you've read is 4 the critical issue, and that's what I focused on. 4 correct. I don't see it here, but that doesn't, I 5 5 Q. But you didn't, in connection with that think, matter. 6 6 link, you didn't look at or investigate whether the Q. Well take a look at the last sentence under 7 7 use of the Bair Hugger can create particulates that "SAFETY." Do you see it says --8 can create that link. 8 A. Ah, yes. Okay. There I see it. 9 A. I -- I read that there was literature which 9 Q. -- "The predicate device..." 10 addressed that, and I understood that others were 10 A. Okay. Thank you. 11 going to address that. 11 Q. Okay? 12 Q. So I take it if someone said there was a 12 A. So what you're saying is this is a request 13 risk of airborne contamination with the Bair Hugger, 13 for a subsequent machine to be adopted based upon the 14 you'd disagree with that. 14 history of that predecessor, the predicate. 15 A. No. I don't have enough evidence to say 15 Q. Right. 16 that. I would say that there is no good evidence that 16 A. Okay. 17 use of the Bair Hugger causes surgical-site 17 Q. Okay? And you see on the first page it 18 infections. 18 talks about "Summary of Safety;" correct? 19 Q. Well would you -- if --19 A. Yes. 20 If someone said that there's a risk of 2.0 Q. Okay. And I'd like to direct your attention 21 airborne contamination with the Bair Hugger, would 21 to the back page of this exhibit. Do you see section 22 that be of import to you or not? 22 C. "Other Safety Concerns: 23 A. It's of interest to me. 23 "1. Contamination. Airborne contamination 2.4 Q. Okay. But you haven't seen anything that 2.4 from air blown intraoperatively across the surgical 2.5 says that; right? 25 wound may result in airborne contamination." Page 94 Page 96 1 A. I have seen papers that have indicated that 1 Do you see that? there were increased particulates and I have read 2 2 A. I do. 3 papers that said that there weren't. 3 Q. Okay. Now this was submitted in connection 4 (Discussion off the stenographic record.) 4 with the Bair Hugger model 750. Have you ever seen 5 5 (Exhibit 9 was marked for this before? 6 6 identification.) A. No. 7 BY MS. CONLIN: 7 Q. Okay. Would this be something that you 8 Q. I've handed you, sir, what's been marked as 8 would view as important in connection with the 9 Borak Exhibit 9, which is a 510(k) summary of safety 9 conclusions contained in your expert report in this 10 10 and effectiveness dated January 10th, 1996 involving case? 11 FDA approval of the Bair Hugger 750. 11 A. As I've explained, my expert opinion was 12 12 based upon what I found as evidence linking Bair Do you have any understanding of the 13 13 Hugger with infections. So this is interesting, but differences in designs between, for example, the 500 14 or the 750? 14 this is not evidence of infections. 15 15 A. I've seen reference to it, but I don't know Q. Well you understand that the mechanism of 16 what the differences are. And I don't know what a 16 infections is through airborne contamination; 17 510(k) is. 17 correct. --18 18 Q. 510(k) is when you are seeking abbreviated MR. GORDON: Object --19 approval through the FDA based on a predicate device. 19 O. -- sir? 2.0 2.0 MR. GORDON: Object to the form of the 21 Q. So if you look at the first paragraph here, 21 question, assumes facts not in evidence. 22 it will say, last sentence under "SAFETY," "The 22 A. I understand that that is an area that Dr. 23 predicate device is the Bair Hugger Patient Warming 23 Wenzel is going to be opining about, that I was not 24 24 System, Model 500 Warming Unit." Okay? going to opine about that, and so I have no opinion 25 25 A. I -about that.

Page 99 Page 97 1 Q. Well you understand when --1 infection? 2 When you've opined that there is no 2 A. And the answer was I read articles and 3 association between the use of the Bair Hugger and 3 reports that were relevant to the question, but I did 4 infection, you understand the mechanism by which 4 not render an opinion, and I do not have one to offer 5 5 plaintiffs are alleging the infection occurs is you now as to whether Bair Hugger causes -- and your 6 6 through airborne contamination; correct? phrase was --7 7 Q. Create airborne contamination which can lead A. Well once again you have asked a question 8 8 which has two different parts of it. First of all, I to infection. 9 9 do not accept your description of my opinion. A. Yes. I do not have an opinion as to whether 10 10 it does that because it is my opinion that there is Secondly, I'm not sure what the plaintiffs are 11 alleging. I understand there was discussion of the 11 not sufficient evidence that it causes infection. 12 airborne particulates as being a possible intermediary 12 Q. Well if you didn't look at the issue of 13 13 in the development of infection. I have been looking whether it causes airborne contamination, how could 14 at the infections. 14 you have reached your conclusion that it doesn't cause 15 Q. Okay. And so you did no analysis as to 15 infections? 16 16 whether the Bair Hugger can create airborne A. Because I --17 contamination; correct? 17 MR. GORDON: Object to the form of the 18 A. I think I've explained that I was not asked 18 auestion. 19 19 and agreed that I would not be addressing and did not A. I have looked at the information that I 20 20 do an investigation to determine whether that was so. believe is available. I don't think I'm missing any 21 21 Q. Well how can you find that there is no of the information that has to do with whether the 22 22 association between Bair Hugger and infections if you Bair Hugger causes infection. And other than two 23 23 didn't investigate the mechanism by which those studies, which I believe to be inadequate, I find no 2.4 24 infections can occur? evidence that it causes infection. 2.5 MR. GORDON: Object to the form of the 25 Q. You -- you're -- you're not answering my Page 98 Page 100 1 1 question. question, so --2 2 A. I think we earlier went over the fact that A. I -- I am really trying to answer your 3 I've agreed that the presence of such intermediary 3 question. 4 mechanisms in the absence of infections poses an 4 Q. Okay. 5 5 interesting hypothesis, but that in the absence of A. You're asking the same question, I think, 6 6 infections it is insufficient to show causation. repeatedly, but --7 7 Q. Well am I correct in stating that you didn't Q. No, because you're --8 8 look at the issue, in connection with the conclusion Well if I am, it's because you're not 9 you just stated, as to whether use of the Bair Hugger 9 answering it. My ques --10 10 MR. GORDON: Well move -- move to strike can create airborne contamination which can lead to 11 11 counsel's commentary. 12 12 A. I -- I think I've already answered this but Q. Did you find -- did you find it important at 13 13 all, looking at this document today, to see that the let's try it one more time. I have read a number of 14 14 manufacturer of the Bair Hugger 750 warned in an FDA papers that had to do with the question of whether the 15 15 Bair Hugger did or did not cause increase in airborne document about the risk of airborne contamination 16 particulates, but I have no opinion as to whether that 16 through use of the Bair Hugger? 17 is the cause and whether that causes. My opinion 17 A. I think it's interesting. 18 rests upon whether there is evidence the Bair Hugger 18 Q. Is this something that you wish you would 19 causes infection, and that is the basis of my opinion. 19 have had before you rendered your opinions in this 2.0 Q. Can you answer my question? I'll read it 20 case, or are you saying it's of no import? 21 21 back to you. A. I'm saying that in the absence of evidence 2.2 Am I correct in stating that you didn't look 22 of infections, the fact that this happens doesn't seem at the issue, in connection with the conclusion you 23 23 to me to be central to my opinions. 2.4 24 just stated, as to whether the use of the Bair Hugger Q. Okay. Why would they be warning about 25 can create airborne contamination which can lead to 25 airborne contamination if it wasn't increasing a risk

	Page 101		Page 103
1	of infection?	1	whether airborne contamination could occur over the
2	MR. GORDON: Object to the form of the	2	surgical site if a tape barrier weren't in place?
3	question, it assumes facts not in evidence, lack of	3	A. I did not look at that question
4	foundation.	4	specifically.
5	A. The question is "Why would they have done	5	Q. Okay. And then you see it talks about
6	it?" I think they were required to. And I don't	6	"Additionally, air is filtered through a .2 micron
7	think that there was evidence at that time that this	7	filter." Do you see that?
8	was leading to infections.	8	A. I do see that.
9	Q. Well okay. First of all, you have no idea	9	Q. Do you know why a manufacturer would be
10	because you just told me you don't know what a 510(k)	10	concerned about filtering air before sending it
11	is, so when you state that, you have no idea whether	11	through the Bair Hugger?
12	they're required to do that or not.	12	MR. GORDON: Object to the form of the
13	A. Yes, but	13	question.
14	MR. GORDON: Object to the form of the	14	A. I I can imagine, but it's purely
15	question.	15	conjecture.
16	A your question your question was	16	Q. It wasn't something that you investigated in
17	whether I had an opinion about why they did it. I	17	connection with the opinions that you've rendered;
18	think that was your question.	18	correct, sir?
19	Q. Do you see where it says, "Prevention of	19	A. Yes, that's correct.
20	airborne contamination" underneath the safety	20	Q. And you didn't do any investigation into the
21	concerns, and it says, "Prevention of airborne	21	filter efficiency of the Bair Hugger; correct?
22	contamination: All Bair Hugger Blankets designed for	22	A. No, I specifically did not look at the
23	use in the operating room feature a tape barrier which	23	filter efficiency of the Bair Hugger.
24	prevent air from migrating toward the surgical site."	24	Would would you finish reading that
25	Do you see that?	25	paragraph?
	•		
	Page 102		Page 104
1	Page 102  A. Yes. Point to which line you have just read	1	Page 104  Q. Document speaks for itself.
1 2		1 2	
	A. Yes. Point to which line you have just read		Q. Document speaks for itself.
2	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.	2	<ul><li>Q. Document speaks for itself.</li><li>A. Okay.</li></ul>
2	<ul> <li>A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.</li> <li>Q. Right under "Prevention of airborne contamination." Right?</li> <li>A. Yes, I see that paragraph.</li> </ul>	2	<ul><li>Q. Document speaks for itself.</li><li>A. Okay.</li><li>Q. You haven't looked at it. I'll move on.</li></ul>
2 3 4	<ul> <li>A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.</li> <li>Q. Right under "Prevention of airborne contamination." Right?</li> <li>A. Yes, I see that paragraph.</li> <li>Q. Colon, "All Bair Hugger Blankets designed</li> </ul>	2 3 4	<ul><li>Q. Document speaks for itself.</li><li>A. Okay.</li><li>Q. You haven't looked at it. I'll move on.</li><li>MS. CONLIN: Can you pull out Exhibit 30,</li></ul>
2 3 4 5	<ul> <li>A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.</li> <li>Q. Right under "Prevention of airborne contamination." Right?</li> <li>A. Yes, I see that paragraph.</li> <li>Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier</li> </ul>	2 3 4 5	<ul> <li>Q. Document speaks for itself.</li> <li>A. Okay.</li> <li>Q. You haven't looked at it. I'll move on.</li> <li>MS. CONLIN: Can you pull out Exhibit 30,</li> <li>please, Mr. Stirewalt, from yesterday.</li> </ul>
2 3 4 5 6	<ul> <li>A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.</li> <li>Q. Right under "Prevention of airborne contamination." Right?</li> <li>A. Yes, I see that paragraph.</li> <li>Q. Colon, "All Bair Hugger Blankets designed</li> </ul>	2 3 4 5 6	<ul> <li>Q. Document speaks for itself.</li> <li>A. Okay.</li> <li>Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30,</li> <li>please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.)</li> </ul>
2 3 4 5 6 7 8	<ul> <li>A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.</li> <li>Q. Right under "Prevention of airborne contamination." Right?</li> <li>A. Yes, I see that paragraph.</li> <li>Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."</li> </ul>	2 3 4 5 6 7 8	<ul> <li>Q. Document speaks for itself.</li> <li>A. Okay.</li> <li>Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.)</li> </ul>
2 3 4 5 6 7 8	<ul> <li>A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.</li> <li>Q. Right under "Prevention of airborne contamination." Right?</li> <li>A. Yes, I see that paragraph.</li> <li>Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical</li> </ul>	2 3 4 5 6 7 8	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on.  MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday.  (Holford Exhibit 30 handed to the witness.)  MS. CONLIN: That actually may not be the right one.  (Discussion off the stenographic record.)  BY MS. CONLIN:
2 3 4 5 6 7 8	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph.  Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes.  Q. Okay. Why would the manufacturer of a Bair	2 3 4 5 6 7 8	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as
2 3 4 5 6 7 8 9 10 11	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph.  Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes.  Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from	2 3 4 5 6 7 8 9 10 11	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30.
2 3 4 5 6 7 8 9 10	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph.  Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes.  Q. Okay. Why would the manufacturer of a Bair	2 3 4 5 6 7 8 9 10	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as
2 3 4 5 6 7 8 9 10 11 12 13	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph.  Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes.  Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from migrating toward the surgical site?  MR. GORDON: Objection, lack of foundation.	2 3 4 5 6 7 8 9 10 11 12 13	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30. MS. CONLIN: And perhaps if you could hand him, Mr. Court Reporter, Exhibit 31 as well.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph.  Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes.  Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from migrating toward the surgical site?  MR. GORDON: Objection, lack of foundation.  A. I I'm I'm conjecturing. You	2 3 4 5 6 7 8 9 10 11 12 13 14	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30. MS. CONLIN: And perhaps if you could hand him, Mr. Court Reporter, Exhibit 31 as well. (Holford Exhibit 31 handed to the witness.)
2 3 4 5 6 7 8 9 10 11 12 13	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph.  Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes.  Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from migrating toward the surgical site?  MR. GORDON: Objection, lack of foundation.  A. I I'm I'm conjecturing. You understand I'm not an engineer, I'm not a biomedical	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Document speaks for itself.  A. Okay. Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30. MS. CONLIN: And perhaps if you could hand him, Mr. Court Reporter, Exhibit 31 as well. (Holford Exhibit 31 handed to the witness.) Q. I've handed you, sir, what's been previously
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph.  Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes.  Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from migrating toward the surgical site?  MR. GORDON: Objection, lack of foundation.  A. I I'm I'm conjecturing. You understand I'm not an engineer, I'm not a biomedical expert. I assume they're doing it to keep air from	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30. MS. CONLIN: And perhaps if you could hand him, Mr. Court Reporter, Exhibit 31 as well. (Holford Exhibit 31 handed to the witness.) Q. I've handed you, sir, what's been previously marked as Holford Deposition Exhibits 30 and 31, which
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph.  Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes.  Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from migrating toward the surgical site?  MR. GORDON: Objection, lack of foundation.  A. I I'm I'm conjecturing. You understand I'm not an engineer, I'm not a biomedical expert. I assume they're doing it to keep air from leaving the blanket, but I that's just a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30. MS. CONLIN: And perhaps if you could hand him, Mr. Court Reporter, Exhibit 31 as well. (Holford Exhibit 31 handed to the witness.) Q. I've handed you, sir, what's been previously marked as Holford Deposition Exhibits 30 and 31, which are excerpts from the CDC Department of Health and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph.  Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes.  Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from migrating toward the surgical site?  MR. GORDON: Objection, lack of foundation.  A. I I'm I'm conjecturing. You understand I'm not an engineer, I'm not a biomedical expert. I assume they're doing it to keep air from leaving the blanket, but I that's just a conjecture.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30. MS. CONLIN: And perhaps if you could hand him, Mr. Court Reporter, Exhibit 31 as well. (Holford Exhibit 31 handed to the witness.) Q. I've handed you, sir, what's been previously marked as Holford Deposition Exhibits 30 and 31, which are excerpts from the CDC Department of Health and Human Services, Centers for Disease Control,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph.  Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes.  Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from migrating toward the surgical site?  MR. GORDON: Objection, lack of foundation.  A. I I'm I'm conjecturing. You understand I'm not an engineer, I'm not a biomedical expert. I assume they're doing it to keep air from leaving the blanket, but I that's just a conjecture.  Q. And that would be	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30. MS. CONLIN: And perhaps if you could hand him, Mr. Court Reporter, Exhibit 31 as well. (Holford Exhibit 31 handed to the witness.) Q. I've handed you, sir, what's been previously marked as Holford Deposition Exhibits 30 and 31, which are excerpts from the CDC Department of Health and Human Services, Centers for Disease Control, Healthcare Infection Control Practices Advisory
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph. Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes. Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from migrating toward the surgical site?  MR. GORDON: Objection, lack of foundation.  A. I I'm I'm conjecturing. You understand I'm not an engineer, I'm not a biomedical expert. I assume they're doing it to keep air from leaving the blanket, but I that's just a conjecture.  Q. And that would be And this is, of course, under the section	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30. MS. CONLIN: And perhaps if you could hand him, Mr. Court Reporter, Exhibit 31 as well. (Holford Exhibit 31 handed to the witness.) Q. I've handed you, sir, what's been previously marked as Holford Deposition Exhibits 30 and 31, which are excerpts from the CDC Department of Health and Human Services, Centers for Disease Control, Healthcare Infection Control Practices Advisory Committee. Have you seen
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph. Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes. Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from migrating toward the surgical site?  MR. GORDON: Objection, lack of foundation.  A. I I'm I'm conjecturing. You understand I'm not an engineer, I'm not a biomedical expert. I assume they're doing it to keep air from leaving the blanket, but I that's just a conjecture.  Q. And that would be And this is, of course, under the section where they're talking about concern over airborne	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30. MS. CONLIN: And perhaps if you could hand him, Mr. Court Reporter, Exhibit 31 as well. (Holford Exhibit 31 handed to the witness.) Q. I've handed you, sir, what's been previously marked as Holford Deposition Exhibits 30 and 31, which are excerpts from the CDC Department of Health and Human Services, Centers for Disease Control, Healthcare Infection Control Practices Advisory Committee. Have you seen Had you seen Exhibits 30 or 31 prior to the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph.  Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes.  Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from migrating toward the surgical site?  MR. GORDON: Objection, lack of foundation.  A. I I'm I'm conjecturing. You understand I'm not an engineer, I'm not a biomedical expert. I assume they're doing it to keep air from leaving the blanket, but I that's just a conjecture.  Q. And that would be  And this is, of course, under the section where they're talking about concern over airborne contamination; correct?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30. MS. CONLIN: And perhaps if you could hand him, Mr. Court Reporter, Exhibit 31 as well. (Holford Exhibit 31 handed to the witness.) Q. I've handed you, sir, what's been previously marked as Holford Deposition Exhibits 30 and 31, which are excerpts from the CDC Department of Health and Human Services, Centers for Disease Control, Healthcare Infection Control Practices Advisory Committee. Have you seen Had you seen Exhibits 30 or 31 prior to the time you rendered your expert opinions in this case?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Yes. Point to which line you have just read to me so I'm sure that I am on track here.  Q. Right under "Prevention of airborne contamination." Right?  A. Yes, I see that paragraph. Q. Colon, "All Bair Hugger Blankets designed for use in the operating room feature a tape barrier which prevent air from migrating toward the surgical site."  A. I read that, yes. Q. Okay. Why would the manufacturer of a Bair Hugger have a tape barrier to prevent air from migrating toward the surgical site?  MR. GORDON: Objection, lack of foundation.  A. I I'm I'm conjecturing. You understand I'm not an engineer, I'm not a biomedical expert. I assume they're doing it to keep air from leaving the blanket, but I that's just a conjecture.  Q. And that would be And this is, of course, under the section where they're talking about concern over airborne	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Document speaks for itself.  A. Okay.  Q. You haven't looked at it. I'll move on. MS. CONLIN: Can you pull out Exhibit 30, please, Mr. Stirewalt, from yesterday. (Holford Exhibit 30 handed to the witness.) MS. CONLIN: That actually may not be the right one. (Discussion off the stenographic record.) BY MS. CONLIN: Q. I've handed you, sir, what's been marked as Deposition Exhibit 30, Holford Deposition Exhibit 30. MS. CONLIN: And perhaps if you could hand him, Mr. Court Reporter, Exhibit 31 as well. (Holford Exhibit 31 handed to the witness.) Q. I've handed you, sir, what's been previously marked as Holford Deposition Exhibits 30 and 31, which are excerpts from the CDC Department of Health and Human Services, Centers for Disease Control, Healthcare Infection Control Practices Advisory Committee. Have you seen Had you seen Exhibits 30 or 31 prior to the

26 (Pages 101 to 104)

Page 105 Page 107 1 Mr. -- or after Professor Holford's deposition was 1 and answered. 2 2 A. I think I answered that no, I had not looked 3 A. We may have spoken of it. I -- I may even 3 at this prior to rendering my report. 4 have seen them, but I didn't read them. 4 Q. Do you know whether the CDC would be 5 5 concerned about airborne contamination that could Q. Okay. So at the time you --6 6 And -- and you've, I think, previously infect a patient on an operating table? 7 7 testified you think the CDC is a very reputable A. It would seem reasonable that they might be 8 8 organization; correct? concerned about that. 9 9 Q. But that isn't something that you reviewed A. Yeah. But it's a very big organization, 10 10 which means that it does have components that make prior to yesterday. 11 mistakes. And I have worked for CDC and I have 11 MR. GORDON: Objection, asked and answered. 12 respect for it. 12 A. Yes. 13 13 Q. Okay. And were you aware at the time that Q. Now you don't in your expert report deal at all with the reported issues of culturing of microbes 14 you rendered your expert opinions in this case that 14 15 the CDC Advisory Committee on Healthcare Infection 15 within a Bair Hugger; correct? 16 16 Control Practices had suggested that nothing that A. Correct. 17 blows air should be in an operating room? 17 Q. And I take it you don't think that the 18 MR. GORDON: Object to the form of the 18 presence of microbes within a Bair Hugger can pose a 19 19 question, misstates the evidence, assumes facts not in risk to a patient; correct? 20 evidence. 20 A. No, I didn't say that. 21 21 A. I -- I am aware that they made that Well risk of infection to a patient. 22 22 statement at some time in the past, yes. A. I said that there was, to my knowledge, no 23 Q. Okay. Were you aware of it at the time you 23 good evidence that use of the Bair Hugger caused 24 2.4 rendered your expert opinions in this case? infections. 2.5 A. Not specifically. 25 Q. And my point was: In connection with Page 106 Page 108 1 Q. Okay. Did you do an investigation, once you 1 reaching those opinions, you had to satisfy the issues 2 2 found that out, as to why the CDC was recommending or find them not to be of interest or import that 3 cultures had been taken in many Bair Hugger devices that nothing that blows air should be in an operating 3 4 room, if possible? 4 with infectious microbes. 5 MR. GORDON: Object to the form of the 5 A. I --6 question, misstates the evidence, assumes facts not in 6 MR. GORDON: Object to the form of the 7 7 question. 8 A. My understanding from looking at this and 8 A. I understand that there have been such 9 discussions with Mr. Gordon last night -- or yesterday 9 studies done. I have no evidence that that has led or 10 was that there was a subsequent algorithm or -- or --10 been associated with infections. 11 or structure that addressed that, and that the concern 11 Q. Were you aware that there was an 12 12 the CDC had in -- or HICPAC had at that time concerned Acinetobacter baumannii outbreak that was traced to 13 13 blowers that had interfaces with -- with water the Bair Hugger as well as another surgical unit in a 14 reservoirs that were wet, and I understand the concern 14 hospital? 15 15 was probably related to a cluster of atypical MR. GORDON: Object to the form. Are -- are you saying Acinetobacter? 16 Mycobacterium infections in the cardiothoracic 16 17 surgical area. 17 MS. CONLIN: Yeah. Q. Can you answer my question? 18 18 MR. GORDON: Object to the form of the 19 A. Well ask me your question again then. 19 question, assumes facts not in evidence. 2.0 2.0 A. I -- I don't know that I'm aware of that. 21 Did you do any investigation, prior to the 21 Maybe I have read it. I don't recall. 22 time you rendered your opinion in this case, as to why 22 Q. Okay. So it wasn't anything that informed 2.3 the CDC was recommending that nothing that blows air 23 your opinions. 2.4 should be in an operating room, if possible? 24 A. It did not inform my opinions. 25 MR. GORDON: Same objections, also now asked 25 O. You weren't aware that there was an

27 (Pages 105 to 108)

Page 109 Page 111 1 Acinetobacter outbreak in Kentucky and they were able 1 You agree with me, and I think you did 2 to trace the organism back to the Bair Hugger as well 2 earlier, that association is, at the end of the day, a 3 as another piece of equipment in the OR? 3 matter of scientific judgment; correct? 4 A. I -- I would be happy to look at that if you 4 A. You read me a statement that said that and I 5 5 have information about it. I'm not aware of it off said I didn't disagree with it. 6 6 the top of my head. Q. Right. You agree with it. 7 7 A. It requires judgment. Q. Okay. And it wasn't something that you 8 8 looked at in connection with rendering your expert Q. Right. 9 9 opinions in this case. A. It's not a matter of judgment. 10 10 Q. And in exercising that judgment, you didn't A. No, not specifically. 11 Q. Okay. Do you believe or have an opinion as 11 investigate all the ways in which a Bair Hugger can 12 to whether the presence of infectious microbes being 12 actually increase the risk of infection for a 13 13 plaintiff -- or a patient. harbored in a Bair Hugger unit can create a risk of A. I -- I really apologize. We are banging 14 infection for a pa -- a patient? 14 15 MR. GORDON: Object to the form of the 15 intellectual heads together on this particular issue. 16 16 question. I'm telling you that I read a lot and I am 17 A. It -- it seems reasonable that it could. 17 aware of the hypothetical ways in which Bair Hugger 18 Q. But you didn't look at it. 18 might contribute to infections. I don't have an 19 MR. GORDON: Object to the form of the 19 opinion as to whether any of those hypothetical 20 20 question. mechanisms are in fact causal, and I have said that 21 21 absent evidence that it causes infection, all of those A. I looked to see whether there was evidence 22 22 that use of the Bair Hugger had raised significantly mechanisms are simply hypothetical. So when you ask 23 23 the risk of infection -whether I have considered them, the answer is yes. 24 2.4 Q. Right. But you --Did it contribute to my opinion? No, absent the 25 A. -- in orthopedic surgeries. 25 evidence of infections caused by Bair Hugger. Page 110 Page 112 1 Q. But you didn't investigate all the ways in 1 Q. But still you have to look at the evidence 2 2 which it could cause that increase in infections. to reach the conclusion, sir. A. I -- I --3 A. No, no, no. I thought about them and I read 3 4 about them, but that was not part of my opinion. 4 Q. We just looked at a bunch of documents today 5 5 Q. Well when you found that there wasn't you've never seen. 6 6 sufficient evidence for an association to exist A. I --7 7 between the use of the Bair Hugger and an increased The opinion I render is based on whether or 8 8 risk of infection, is it your opinion that it was just not there is evidence of infection, not whether or not 9 based on your review of McGovern? 9 there is evidence of a hypothetical mechanism. And we 10 10 A. Oh, no, no, it was not limited to my review will not be able to resolve this difference. You 11 11 would like me to say -- I think you would like me to 12 12 Q. Well as an epidemiology analysis, you have say that the hypothetical mechanism is sufficient to 13 13 to look at all of the evidence that might create a reach a causal conclusion, and it is my opinion that 14 risk for a patient; correct? 14 it is not. 15 15 Q. I wasn't asking you that. I'm trying to A. Yes. And we go back to an answer I gave you 16 earlier -- I may not be answering your question, and I 16 get --17 apologize in advance -- but I said that absent valid 17 A. In that case, I withdraw the answer. 18 evidence of a causal association between Bair Hugger 18 Q. I'm trying to get a sense of what you did in 19 and SSI, it can only be said that mechanistic studies 19 connection with reaching your conclusions as expressed 2.0 are coherent with a hypothetical increase, and what 20 in your report, and I've been probing that area, which 21 21 is what I'm asking you about. you're posing to me is a hypothetical increase due to 22 a mechanism, and I agreed with you, it is hypothetical 22 MR. GORDON: And he's told you. Q. So --23 and hypothetically relevant. 23 24

28 (Pages 109 to 112)

I don't know if you answered this or not.

You don't believe there is reason to be concerned

25

2.4

25

Q. But you didn't look at any of the documents

that might -- we'll go -- strike that.

	Page 113		Page 115
1	about pathogens harbored in the Bair Hugger machine	1	of or worried about airborne contamination that
2	itself.	2	might cause an infection in a patient?
3	A. Oh, I don't think it's a good idea to harbor	3	MR. GORDON: Lack
4	pathogens in the Bair Hugger machine.	4	Objection, lack of foundation.
5	Q. Did you look at any of the documents that	5	A. I think they were concerned about how to
6	related to strike that.	6	clean the machine and they removed a filter and threw
7	(Exhibit 10 was marked for	7	it away in the biohazards waste. I'm guessing that
8	identification.)	8	they threw it away because they couldn't clean it, but
9	BY MS. CONLIN:	9	I don't know if that's true.
10	Q. I've handed you, sir, what's been marked as	10	Q. Can you answer my question?
11	Deposition Exhibit No. 10, which is a series of	11	A. I have no knowledge here or no information
12	internal e-mails produced by 3M in the case. I'd like	12	here as to whether this has to do with airborne
13	to direct your attention to the second page at the	13	hazards.
14	bottom.	14	Q. My reading that, do you think they were
15	A. Bear with me. I'm just looking to see	15	worried about airborne contamination that might infect
16	things like dates and so forth. And let me just	16	a patient?
17	Q. Dated March 3rd, 2009.	17	MR. GORDON: Object to the form of the
18	A. Right. Oh, 2009. That's what I was looking	18	question, lack of foundation.
19	at. Yes, please go ahead.	19	A. I I don't know. I assume that would have
20	Q. Okay. So if you can take a look at the last	20	been among the myriad thoughts that might have been,
21	page, please, bottom e-mail from Judy Hodges to Rick	21	but I don't know.
22	Mathieu, "Subject: Bair Hugger," reads, "Rick,	22	Q. Okay. Did you look at any internal
23 24	"We have a model 750 unit, serial number	23 24	documents about from 3M about machines that had were coming out of the field that were testing
25	19137 that has cultured positive for Acinetobacter.  We are looking for directions for proper cleaning/	25	positive for various infectious microbes?
23	we are looking for directions for proper eleming	23	positive for various infectious infectious.
	Page 114		Page 116
1	Page 114 disinfecting this machine, inside and out."	1	Page 116  A. I don't think I did.
1 2		1 2	
2	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al	2	<ul><li>A. I don't think I did.</li><li>Q. Or what 3M did in connection with those reports coming in from the field?</li></ul>
2 3 4	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren	2 3 4	A. I don't think I did.  Q. Or what 3M did in connection with those reports coming in from the field?  MR. GORDON: Object to the form of the
2 3 4 5	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave	2 3 4 5	A. I don't think I did.  Q. Or what 3M did in connection with those reports coming in from the field?  MR. GORDON: Object to the form of the question.
2 3 4 5 6	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.	2 3 4 5 6	<ul> <li>A. I don't think I did.</li> <li>Q. Or what 3M did in connection with those reports coming in from the field?</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. No, I don't think so.</li> </ul>
2 3 4 5 6 7	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by	2 3 4 5 6 7	<ul> <li>A. I don't think I did.</li> <li>Q. Or what 3M did in connection with those reports coming in from the field?</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. No, I don't think so.</li> <li>Q. Okay. And you don't know and didn't do</li> </ul>
2 3 4 5 6 7 8	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?	2 3 4 5 6 7 8	<ul> <li>A. I don't think I did.</li> <li>Q. Or what 3M did in connection with those reports coming in from the field?</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. No, I don't think so.</li> <li>Q. Okay. And you don't know and didn't do investigation whether they were concerned about</li> </ul>
2 3 4 5 6 7 8	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.	2 3 4 5 6 7 8	<ul> <li>A. I don't think I did.</li> <li>Q. Or what 3M did in connection with those reports coming in from the field?</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. No, I don't think so.</li> <li>Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA</li> </ul>
2 3 4 5 6 7 8 9	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit.	2 3 4 5 6 7 8 9	<ul> <li>A. I don't think I did.</li> <li>Q. Or what 3M did in connection with those reports coming in from the field?</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. No, I don't think so.</li> <li>Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier.</li> </ul>
2 3 4 5 6 7 8 9 10	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit. "Remove and discard the filter (in the	2 3 4 5 6 7 8 9 10	<ul> <li>A. I don't think I did.</li> <li>Q. Or what 3M did in connection with those reports coming in from the field?</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. No, I don't think so.</li> <li>Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier.</li> <li>MR. GORDON: Object to the form of the</li> </ul>
2 3 4 5 6 7 8 9 10 11	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit.  "Remove and discard the filter (in the biohazardous waste)."	2 3 4 5 6 7 8 9 10 11	A. I don't think I did. Q. Or what 3M did in connection with those reports coming in from the field?  MR. GORDON: Object to the form of the question.  A. No, I don't think so. Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier.  MR. GORDON: Object to the form of the question.
2 3 4 5 6 7 8 9 10 11 12 13	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No. Q. Okay. And it says, "Do not scrap the unit.  "Remove and discard the filter (in the biohazardous waste)."  Do you see that?	2 3 4 5 6 7 8 9 10 11 12 13	<ul> <li>A. I don't think I did.</li> <li>Q. Or what 3M did in connection with those reports coming in from the field?</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. No, I don't think so.</li> <li>Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier.</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. I I think you have shown me documents</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit.  "Remove and discard the filter (in the biohazardous waste)."  Do you see that?  A. I do.	2 3 4 5 6 7 8 9 10 11 12 13	A. I don't think I did. Q. Or what 3M did in connection with those reports coming in from the field? MR. GORDON: Object to the form of the question. A. No, I don't think so. Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier. MR. GORDON: Object to the form of the question. A. I I think you have shown me documents that suggest that they had concerns, but I don't know.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit.  "Remove and discard the filter (in the biohazardous waste)."  Do you see that?  A. I do.  Q. Why why do you think that representatives	2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. I don't think I did. Q. Or what 3M did in connection with those reports coming in from the field? MR. GORDON: Object to the form of the question. A. No, I don't think so. Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier. MR. GORDON: Object to the form of the question. A. I I think you have shown me documents that suggest that they had concerns, but I don't know. MS. CONLIN: Okay. Why don't we take a
2 3 4 5 6 7 8 9 10 11 12 13	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit. "Remove and discard the filter (in the biohazardous waste)."  Do you see that?  A. I do.  Q. Why why do you think that representatives for 3M would be concerned about changing out a filter	2 3 4 5 6 7 8 9 10 11 12 13	<ul> <li>A. I don't think I did.</li> <li>Q. Or what 3M did in connection with those reports coming in from the field?</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. No, I don't think so.</li> <li>Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier.</li> <li>MR. GORDON: Object to the form of the question.</li> <li>A. I I think you have shown me documents that suggest that they had concerns, but I don't know.</li> <li>MS. CONLIN: Okay. Why don't we take a break there.</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit.  "Remove and discard the filter (in the biohazardous waste)."  Do you see that?  A. I do.  Q. Why why do you think that representatives	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I don't think I did. Q. Or what 3M did in connection with those reports coming in from the field? MR. GORDON: Object to the form of the question. A. No, I don't think so. Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier. MR. GORDON: Object to the form of the question. A. I I think you have shown me documents that suggest that they had concerns, but I don't know. MS. CONLIN: Okay. Why don't we take a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit.  "Remove and discard the filter (in the biohazardous waste)."  Do you see that?  A. I do.  Q. Why why do you think that representatives for 3M would be concerned about changing out a filter when a machine has tested positive for Acinetobacter?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I don't think I did. Q. Or what 3M did in connection with those reports coming in from the field?  MR. GORDON: Object to the form of the question.  A. No, I don't think so. Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier.  MR. GORDON: Object to the form of the question.  A. I I think you have shown me documents that suggest that they had concerns, but I don't know.  MS. CONLIN: Okay. Why don't we take a break there.  THE REPORTER: Off the record, please.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit.  "Remove and discard the filter (in the biohazardous waste)."  Do you see that?  A. I do.  Q. Why why do you think that representatives for 3M would be concerned about changing out a filter when a machine has tested positive for Acinetobacter?  MR. GORDON: Object to the form of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I don't think I did. Q. Or what 3M did in connection with those reports coming in from the field?  MR. GORDON: Object to the form of the question.  A. No, I don't think so. Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier.  MR. GORDON: Object to the form of the question.  A. I I think you have shown me documents that suggest that they had concerns, but I don't know.  MS. CONLIN: Okay. Why don't we take a break there.  THE REPORTER: Off the record, please. (Recess taken.)
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit. "Remove and discard the filter (in the biohazardous waste)."  Do you see that?  A. I do.  Q. Why why do you think that representatives for 3M would be concerned about changing out a filter when a machine has tested positive for Acinetobacter?  MR. GORDON: Object to the form of the question, and lack of foundation.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I don't think I did. Q. Or what 3M did in connection with those reports coming in from the field?  MR. GORDON: Object to the form of the question.  A. No, I don't think so. Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier.  MR. GORDON: Object to the form of the question.  A. I I think you have shown me documents that suggest that they had concerns, but I don't know.  MS. CONLIN: Okay. Why don't we take a break there.  THE REPORTER: Off the record, please. (Recess taken.)  BY MS. CONLIN:
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit. "Remove and discard the filter (in the biohazardous waste)."  Do you see that?  A. I do.  Q. Why why do you think that representatives for 3M would be concerned about changing out a filter when a machine has tested positive for Acinetobacter?  MR. GORDON: Object to the form of the question, and lack of foundation.  A. I I can I can only conjecture. I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I don't think I did. Q. Or what 3M did in connection with those reports coming in from the field?  MR. GORDON: Object to the form of the question.  A. No, I don't think so. Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier.  MR. GORDON: Object to the form of the question.  A. I I think you have shown me documents that suggest that they had concerns, but I don't know.  MS. CONLIN: Okay. Why don't we take a break there.  THE REPORTER: Off the record, please. (Recess taken.)  BY MS. CONLIN: Q. You can direct your attention, sir, to page
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit. "Remove and discard the filter (in the biohazardous waste)."  Do you see that?  A. I do.  Q. Why why do you think that representatives for 3M would be concerned about changing out a filter when a machine has tested positive for Acinetobacter?  MR. GORDON: Object to the form of the question, and lack of foundation.  A. I I can I can only conjecture. I think that if there were bacteria in the machine, then there might be bacteria on the filter, and it's possible that the machine but not the filter can be	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I don't think I did. Q. Or what 3M did in connection with those reports coming in from the field?  MR. GORDON: Object to the form of the question.  A. No, I don't think so. Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier.  MR. GORDON: Object to the form of the question.  A. I I think you have shown me documents that suggest that they had concerns, but I don't know.  MS. CONLIN: Okay. Why don't we take a break there.  THE REPORTER: Off the record, please. (Recess taken.)  BY MS. CONLIN: Q. You can direct your attention, sir, to page four of your expert report, Borak Exhibit 1. In the first full paragraph you say, "But as discussed below, there's insufficient evidence to demonstrate that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	disinfecting this machine, inside and out."  And if we can look, then, there's a series of e-mails. When you look back to the first page, Al Van Duren in the middle of the page, Al Van Duren writes to Mark Scott with a cc to Gary Hansen and Dave Westlin.  Do you know who any of those people are, by the way?  A. No.  Q. Okay. And it says, "Do not scrap the unit. "Remove and discard the filter (in the biohazardous waste)."  Do you see that?  A. I do.  Q. Why why do you think that representatives for 3M would be concerned about changing out a filter when a machine has tested positive for Acinetobacter?  MR. GORDON: Object to the form of the question, and lack of foundation.  A. I I can I can only conjecture. I think that if there were bacteria in the machine, then there might be bacteria on the filter, and it's	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I don't think I did. Q. Or what 3M did in connection with those reports coming in from the field?  MR. GORDON: Object to the form of the question.  A. No, I don't think so. Q. Okay. And you don't know and didn't do investigation whether they were concerned about airborne contamination consistent with the FDA document we looked at earlier.  MR. GORDON: Object to the form of the question.  A. I I think you have shown me documents that suggest that they had concerns, but I don't know.  MS. CONLIN: Okay. Why don't we take a break there.  THE REPORTER: Off the record, please. (Recess taken.)  BY MS. CONLIN: Q. You can direct your attention, sir, to page four of your expert report, Borak Exhibit 1. In the first full paragraph you say, "But as discussed below,

Page 117 Page 119 1 conclusion of the recent CDC Guideline for 1 A. It's possible. 2 Professional -- for Prevention of Surgical Site 2 (Borak Exhibit 11 was marked for 3 Infection." Do you see that? 3 identification.) 4 A. Yes. 4 THE WITNESS: Thank you. 5 Q. And then you say, "Likewise, the nonprofit 5 BY MS. CONLIN: 6 ECRI recently concluded: 6 Q. I have handed you, sir, what's been marked 7 7 "Based on our focused systematic review of as Borak Deposition Exhibit 11, which is an internal 8 8 the published literature, we believe that there is 3M document, timeframe of February 6th and -- 5th, 6th 9 9 insufficient evidence to establish that the use of and 7th, 2011, so this would have been prior to the 10 10 time the ECRI publication came out that you reference forced-air warming systems leads to an increase in 11 SSIs compared to other warming methods." 11 in your report as reference number five. And if you 12 Do you see that? 12 can take a look at the top of it, it's an e-mail from 13 13 Gary Hansen to Dave Westlin, Teri Woodwick-Sides, Jana A. I do. 14 Q. And that was something that you reviewed and 14 Stender and John Rock. 15 relied on in connection with your expert opinion in 15 Do you know who any of those individuals 16 16 this case. are? 17 A. I cited it, yes. 17 A. I do not. 18 Q. By citing it, you relied on it; correct? 18 Q. Okay. Do you know whether they were 19 19 A. That's correct. involved in the ECRI publication that you relied on? 20 20 Q. Okay. Did you ask the attorneys for 3M, Mr. A. I don't recognize the names. 21 21 Q. Were you aware that they were involved in Gordon or otherwise, for information that would show 22 3M's involvement in any of these publications that are 22 the ECRI publication that you relied on? 23 23 A. I am not aware. coming out? 2.4 24 A. No. Q. Okay. You see it says, "I was thinking 25 Q. Did you think that was anything that would 25 about this over the weekend. Our first step with ECRI Page 118 Page 120 1 be important if you're relying on certain studies? 1 should be preventing them from doing their own 2 2 A. I would not have thought of that as an issue testing, but rather to rely on published data." Do 3 with regards to the CDC guideline. 3 you see that? 4 With regards to ECRI, I did some web 4 A. I see that statement. 5 5 Q. Why do you think individuals at 3M didn't searching on it, discovered it was an organization 6 that was perhaps 50 or more years old, that it had a 6 want ECRI to do their own testing with respect to the 7 7 very extensive participation. I looked at its board Bair Hugger? 8 and I think maybe senior staff, whatever. But it 8 MR. GORDON: Objection, lack of foundation. 9 seemed to me to be more than a public-relations 9 A. I -- I don't know. 10 10 effort. I was concerned because it was not a group Q. Would that concern you as an epidemiologist 11 that I normally deal with at great length. 11 if the manufacturer was trying to prevent studies from 12 Q. Was the ECRI publication something that was 12 going on? 13 13 provided to you by the attorneys for 3M? MR. GORDON: Object to the form of the 14 A. It's likely, but I'm not -- I don't remember 14 question. 15 15 A. I -- I don't know whether the motivation specifically. 16 Q. Okay. It's possible that it came from 3M in 16 was -- was financial or otherwise. 17 the packet of materials that you reviewed? 17 Q. Do you --18 18 A. It is possible. Are you aware that outside doctors and 19 Q. Okay. You don't have any independent 19 advisors were suggesting to 3M that they do their own 2.0 recollection of finding it on your own. 20 studies on the Bair Hugger and they refused? 21 A. I -- I don't know whether it came up as a 21 MR. GORDON: Object to the form of the 22 consequence of searching the web on forced-air warmers 22 question, lack of foundation. 23 and Bair Huggers. May have, but I don't remember. 23 A. I'm not aware of that. 2.4 24 Q. Okay. But it's quite possible it came from Q. Well when you say there's insufficient 25 25 evidence, did you ascertain whether the paucity of 3M.

30 (Pages 117 to 120)

	Page 121		Page 123
1	evidence as you've described is due to the fact that	1	relied on the ECRI publication as evidence that
2	3M refused to do their own testing?	2	forced-air warming doesn't increase risk of infection?
3	MR. GORDON: Object to the form of the	3	A. Your your question is whether I would
4	question, assumes facts not in evidence.	4	have wanted to know because I thought that 3M was
5	A. I have no idea.	5	manipulating the document or might have been
6	Q. Were you aware that representatives from 3M	6	manipulating the document, and I don't know whether
7	actually met with ECRI before that publication?	7	that's the case, and I
8	A. I am not aware.	8	Whether it would be interesting to know,
9	Q. Were you aware that ECRI sent that	9	it's interesting.
10	publication to 3M for comment before it was published?	10	Q. I'm just asking you whether it would have
11	A. I am not aware.	11	been something that you would have wanted to know.
12	Q. Would that be something that you would have	12	A. I I don't know. It's all in hindsight.
13	wanted to know?	13	Q. Did you ask 3M for any information related
14	A. I would find it interesting.	14	to this ECRI publication?
15	Q. Why would you find it interesting?	15	A. No.
16	A. Because I didn't know it before and it's an	16	Q. Were you aware that 3M was refusing to do
17	interesting facet.	17	additional studies into the Bair Hugger?
18	I don't know whether 3M rewrote it. Is that	18	MR. GORDON: Object to the form of the
19	the implication of your question? I don't know what	19	question, also assumes facts not in evidence.
20	happened.	20	A. Would you repeat your question?
21	Q. But why would you find it interesting?	21	Q. Sure. Were you aware, prior to the time you
22	A. Because I did not know, prior to five	22	issued your opinions in this case, that 3M was
23	minutes ago, that there was any correlation between 3M	23	refusing to do any additional studies into the Bair
24		24	Hugger?
25	and ECRI.  Q. Would it would it have been of interest	25	MR. GORDON: Same objection.
25	Q. Would it would it have been of interest		
	Page 122		Page 124
1	Page 122 for you to know that 3M representatives met with ECRI	1	Page 124  A. I I don't know whether that was true and
1 2		1 2	
	for you to know that 3M representatives met with ECRI		A. I I don't know whether that was true and
2	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of	2	A. I I don't know whether that was true and I didn't know it.
2	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?	2 3	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for
2 3 4	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether	2 3 4	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)
2 3 4 5	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.	2 3 4 5	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.
2 3 4 5 6	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it	2 3 4 5 6	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you. BY MS. CONLIN:
2 3 4 5 6 7	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?	2 3 4 5 6 7	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as
2 3 4 5 6 7 8	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.	2 3 4 5 6 7 8	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails
2 3 4 5 6 7 8	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. II don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have	2 3 4 5 6 7 8	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.
2 3 4 5 6 7 8 9	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication	2 3 4 5 6 7 8 9	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is?
2 3 4 5 6 7 8 9 10	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase	2 3 4 5 6 7 8 9 10	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is?  (Glass of liquid spills on table.)
2 3 4 5 6 7 8 9 10 11	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?	2 3 4 5 6 7 8 9 10 11	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is? (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.
2 3 4 5 6 7 8 9 10 11 12	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?  A. I read the ECRI document and I looked at the	2 3 4 5 6 7 8 9 10 11 12 13	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is?  (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.  THE REPORTER: Off the record, please.
2 3 4 5 6 7 8 9 10 11 12 13 14	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?  A. I read the ECRI document and I looked at the ECRI website to understand who ECRI was. That was all	2 3 4 5 6 7 8 9 10 11 12 13 14	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is?  (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.  THE REPORTER: Off the record, please.  (Recess taken.)
2 3 4 5 6 7 8 9 10 11 12 13 14 15	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?  A. I read the ECRI document and I looked at the ECRI website to understand who ECRI was. That was all that I knew.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is?  (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.  THE REPORTER: Off the record, please.  (Recess taken.)  THE REPORTER: There's a pending question.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?  A. I read the ECRI document and I looked at the ECRI website to understand who ECRI was. That was all that I knew.  Q. Can you answer my question.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is?  (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.  THE REPORTER: Off the record, please.  (Recess taken.)  THE REPORTER: There's a pending question.  Q. I've handed you, sir, what's been marked as
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. II don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?  A. I read the ECRI document and I looked at the ECRI website to understand who ECRI was. That was all that I knew.  Q. Can you answer my question.  A. You're asking me whether my opinion of their	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is? (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.  THE REPORTER: Off the record, please. (Recess taken.)  THE REPORTER: There's a pending question.  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. II don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?  A. I read the ECRI document and I looked at the ECRI website to understand who ECRI was. That was all that I knew.  Q. Can you answer my question.  A. You're asking me whether my opinion of their document would have been changed by the fact that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is?  (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.  THE REPORTER: Off the record, please.  (Recess taken.)  THE REPORTER: There's a pending question.  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and and Dr. Daniel Sessler.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?  A. I read the ECRI document and I looked at the ECRI website to understand who ECRI was. That was all that I knew.  Q. Can you answer my question.  A. You're asking me whether my opinion of their document would have been changed by the fact that they	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is? (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.  THE REPORTER: Off the record, please. (Recess taken.)  THE REPORTER: There's a pending question.  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and and Dr. Daniel Sessler.  You know who Dr. Sessler is; correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?  A. I read the ECRI document and I looked at the ECRI website to understand who ECRI was. That was all that I knew.  Q. Can you answer my question.  A. You're asking me whether my opinion of their document would have been changed by the fact that they  Q. No.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is? (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.  THE REPORTER: Off the record, please. (Recess taken.)  THE REPORTER: There's a pending question.  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and and Dr. Daniel Sessler.  You know who Dr. Sessler is; correct?  A. I I know the name, yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?  A. I read the ECRI document and I looked at the ECRI website to understand who ECRI was. That was all that I knew.  Q. Can you answer my question.  A. You're asking me whether my opinion of their document would have been changed by the fact that they  Q. No.  A met in Philadelphia confidentially.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is? (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.  THE REPORTER: Off the record, please. (Recess taken.)  THE REPORTER: There's a pending question.  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and and Dr. Daniel Sessler.  You know who Dr. Sessler is; correct?  A. I I know the name, yes.  Q. And you in fact relied on some of his
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?  A. I read the ECRI document and I looked at the ECRI website to understand who ECRI was. That was all that I knew.  Q. Can you answer my question.  A. You're asking me whether my opinion of their document would have been changed by the fact that they  Q. No.  A met in Philadelphia confidentially.  Q. That's not what I asked. It was: Would the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is? (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.  THE REPORTER: Off the record, please. (Recess taken.)  THE REPORTER: There's a pending question.  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and and Dr. Daniel Sessler.  You know who Dr. Sessler is; correct?  A. I I know the name, yes.  Q. And you in fact relied on some of his publications in connection with your opinions in this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	for you to know that 3M representatives met with ECRI officials for an in-person meeting on March 9th of 2011 in Philadelphia?  A. I I don't know enough to tell you whether it's anything of interest.  Q. Were you aware that ECRI assured 3M that it would be a confidential discussion?  A. I have no knowledge of any of this.  Q. Would that be something you would have wanted to know when you relied on the ECRI publication as evidence that forced-air warming doesn't increase risk of infection?  A. I read the ECRI document and I looked at the ECRI website to understand who ECRI was. That was all that I knew.  Q. Can you answer my question.  A. You're asking me whether my opinion of their document would have been changed by the fact that they  Q. No.  A met in Philadelphia confidentially.  Q. That's not what I asked. It was: Would the fact that 3M officials met with ECRI in confidential	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I I don't know whether that was true and I didn't know it.  (Exhibit 12 was marked for identification.)  THE WITNESS: Thank you.  BY MS. CONLIN:  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and Dan Sessler.  Do you know who Mr. Sess Dr. Sessler is? (Glass of liquid spills on table.)  MS. CONLIN: Let's go off the record.  THE REPORTER: Off the record, please. (Recess taken.)  THE REPORTER: There's a pending question.  Q. I've handed you, sir, what's been marked as Deposition Exhibit 12, which is a series of e-mails between Gary Hansen and and Dr. Daniel Sessler.  You know who Dr. Sessler is; correct?  A. I I know the name, yes.  Q. And you in fact relied on some of his publications in connection with your opinions in this case; correct?

31 (Pages 121 to 124)

Page 127 Page 125 1 three, the Kurz and Sessler, that was one of the 1 of time -- and now more to come. Furthermore, this 2 references that you relied on; correct? 2 may damage my reputation; just the fact that a 3 A. That we discussed earlier. 3 complaint was filed already has to some extent." 4 O. Yes. 4 Do you see that? 5 And were you aware that at the time you 5 A. Yes. 6 issued your opinion in this case that Dr. Sessler was 6 Q. Okay. And the next paragraph, it says, 7 7 "This was completely preventable. As I've been saying an outside science advisor/medical doctor to 3M? 8 8 for a year, only a bacterial sampling study will A. I was unaware. 9 9 adequately deal with this issue." Q. So you're hearing that today for the first 10 10 Do you see that? time? 11 A. I think so. 11 A. I see that. 12 12 Q. Okay. And if we take a look at Borak Q. Okay. So you have now seen two separate 13 13 e-mails, separate in time, where Dr. Sessler is urging Exhibit 12, at the bottom it's an e-mail from Dr. 14 Sessler to Gary Hansen at 3M. 14 3M to do a study; correct? 15 15 MR. GORDON: Object to the form of the "Hi Gary, 16 "We were lucky that this was published at 16 question. 17 almost the same time as Scott's paper. We may not 17 A. I -- I'm -- I'm assuming that's what he 18 have -- We may not have warning of his next effort 18 spoke of in the ear -- previous exhibit and his 19 19 though. There is a real possibility that he will do concern is reiterated here, but I don't know that to 20 some sort of bacterial sampling study (the idea is 20 be certain. 21 obvious) and we'll first know of it in the published 21 Q. If it is, you would agree with me that 22 22 paper. If that happens, whatever Scott reports will there's at least evidence that over a period of time 23 be un-opposed for one to two years while we do a 23 Dr. Sessler was urging 3M to do a study. 2.4 24 catch-up study, analysis, and get through the A. Yes. There was apparently evidence that for 25 publication process. Waiting much longer seems like a 25 appar -- that at least twice over a period of Page 126 Page 128 dangerous strategy." 1 something like that, seven months, eight months, that 1 2 2 Do you see that? he had been urging that. 3 A. Yes, that's what you read. 3 Q. Okay. 4 Q. Were you aware that Dan Sessler was urging 4 (Exhibit 14 was marked for 5 5 identification.) 3M for years to do their own bacterial studies? 6 MR. GORDON: Object to the form of the 6 BY MS. CONLIN: 7 7 Q. I've handed you what's been marked as Borak question. 8 8 A. I -- I -- I don't know that, and that's not Deposition Exhibit 14. I'm just going to refer you to 9 put forth here. 9 the top part of this e-mail chain from Mark Morton to 10 10 Scott Waite, cc to Michelle Hulse Stevens, Mark Scott Q. Were you aware that -- were you aware that 11 Dr. Sessler was urging 3M to do their own bacterial 11 and Soria Immaculada, and it says --12 12 studies? And if I could direct your attention in the 13 13 first paragraph where it says "Hi Scott." A. I was not aware. 14 14 A. I see that. (Exhibit 13 was marked for 15 15 identification.) Q. Do you see that? Okay. And it said there 16 BY MS. CONLIN: 16 was an inquiry by Dr. Stefan, to which Mr. Morken is 17 Q. I've handed you, sir, what's been marked as 17 responding: "Also would really need to understand 18 Borak Deposition Exhibit 13, which is an e-mail from 18 what type of study is being proposed. Given the 19 Dan Sessler dated -- looks like approximately a year 19 ongoing legal situation, decisions were previously 2.0 after the e-mail we were just looking at, "Re: 20 made (at a high level) not to pursue clinical research 21 URGENT!!!!" Do you see that? 21 on this topic." 22 A. I see the top, yes. 22 Do you see that? 23 23 Q. Okay. And it says, "Gary, A. Bear with me, I --24 "I'm pretty unhappy. I took this project on 24 25 as a favor and it has ended up costing a huge amount 25 Q. Okay. And the subject is "RE: Message to

32 (Pages 125 to 128)

Page 129 Page 131 1 address safety and efficacy of forced air warming." 1 do you believe that The Reference Guide on 2 Do you see that? 2 Epidemiology by Green, Friedman and Gordis is an 3 A. Yes. 3 authoritative work? 4 Q. Were you aware that decisions were made at a 4 A. I think it's very good work. I reference 5 high level at 3M not to do any clinical research into 5 6 the safety and efficacy of their Bair Huggers? 6 Q. Okay. And you've never taken any issue with 7 7 MR. GORDON: Object to the form of the anything that they've said in connection with that 8 question, mischaracterizes the evidence, --8 reference manual. 9 A. I had no --9 A. Not that I remember. 10 MR. GORDON: -- assumes facts not in 10 Q. Did you do --11 evidence. 11 If we can take a look at page four, footnote 12 A. I had no prior knowledge of that. 12 13 Q. Okay. Was that something that you would 13 MR. GORDON: Of his report? have thought was important for you to know in 14 14 MS. CONLIN: Borak Exhibit 1, his expert 15 connection with your opinion that there's a lack of 15 16 evidence showing that the Bair Hugger increases 16 A. Yes. 17 infection risk? 17 Q. Did you do any investigation into the 18 MR. GORDON: Same objection. 18 efficacy of the Bair Hugger vis-a-vis another type of 19 A. It -- it would be interesting to know. But 19 warming device? 20 as I told you, my opinion rested upon the association 20 MR. GORDON: Object to the form of the 21 between the use of Bair Hugger and infections. 21 question. 22 Q. Right. And you -- and you understand, based 22 A. I -- I thought that I had read the published 23 on looking at that, that 3M refused to do further 23 literature that might have addressed that. I'm not 2.4 research into that topic; correct? 24 sure that there was anything other, at the time that I 25 A. I don't know that that was the topic about 25 did my report, than McGovern, but there may have been Page 130 Page 132 1 which they refused to do research. There is talk here 1 others. I don't remember it. 2 that says that they decided not to pursue clinical 2 Q. My question is a little different. Did 3 research work on this topic; I am not sure what the 3 you --4 topic was. 4 Are you rendering an opinion on the efficacy 5 Q. Well read the subject line. 5 of the Bair Hugger as it relates to maintaining 6 A. "Message to address safety and efficacy of 6 normothermia vis-a-vis any other warming device? 7 forced air warming." I'm sure they were not doing 7 A. Ahh. I'm sorry. I misunderstood your 8 research on the message. And "safety and efficacy" is 8 question. 9 a very broad and vague area. I don't know what the 9 I was not going to render such an opinion. 10 10 clinical research was proposed. My understanding is that the --11 Q. Well are you aware of any other safety and 11 Q. I just want to know if. 12 efficacy issues on the Bair Hugger other than the risk 12 A. Okay. 13 13 of infection through airborne contamination? Q. If you're not rendering an opinion on it, 14 MR. GORDON: Object to the form of the 14 then that's all I need to know and I'll move on. 15 15 question. A. Perfect. Move on. 16 A. I think that safety and efficacy are two 16 Q. And you didn't do any investigation into 17 separate issues and I don't know which aspects of 17 that: correct? 18 either was their concern here. You're asking me to 18 A. I did not do any investigation into that. 19 respond to an e-mail which I find unclear. 19 Q. I'd like to direct your attention to page 2.0 Q. Okay. With respect to the safety of the 20 six, and I'd like to get an understanding --21 21 Well in paragraph 18 under "Confounding" you Bair Hugger, are you aware of any concerns other than 22 the risk of airborne contamination at the time you 22 say, "Confounding is said to occur when the 23 23 rendered your opinion in this case? association between exposure and effect is distorted 2.4 24 A. I am not specifically aware of any, no. by some third variable." Okay? 25 Q. Okay. I may have asked you this before, but 25 Does a confounder have to have association

33 (Pages 129 to 132)

Page 133 Page 135 1 with the effect in order to be a confounder? 1 deep vein thrombosis is associated with the risk of 2 MR. GORDON: Object to the form of the 2 infection, in the Bair Hugger it's not; correct? 3 question. 3 A. I'm sorry, say that again. 4 A. I think that some people have written about 4 Q. Well you said there's an association between 5 the ability of things to influence the relationship 5 antithrombotic drugs and your risk of infection; 6 and to act as an intermediary, but generally I think 6 correct? 7 7 that a confounder should be associated with both the MR. GORDON: Object to the form of the 8 8 exposure and the outcome. question. 9 9 Q. Okay. There has to be an association. A. Yes, ultimately. 10 10 A. I believe so. Q. Okay. So there's an association between 11 Q. Okay. And is that the definition that you 11 that and infection, but not the Bair Hugger and 12 used in connection with your opinions on the 12 infection: correct? 13 13 confounding elements that you set forth in your A. The issue concerns the use of different medications differentially with different warming 14 report? 14 15 15 A. Yes. devices, which led to a mixing and confusion of 16 Q. All right. I'd like to direct your 16 effects. 17 attention to page 14 of your report and first focus 17 Q. Can you answer my question? on, starting on paragraph 41, antithrombotic 18 18 A. But your question can't be answered "yes" or 19 19 prophylaxis. Okay? "no." I don't think it can be. 20 A. Yes. 20 Q. Well you said there's an infec -- there's an 21 21 association between antithrombotic prophylaxis drugs Q. Okay. You found that the change in 22 antithrombotic -- thrombotic -- botic prophylaxis, the 22 and risk of infection; correct? 23 change from trinzaparin to Xarelto, was a confounder; 23 A. Yes. 2.4 is that right? 2.4 Q. Okay. But there isn't an association 2.5 A. I think that the use of different 25 between the use of the Bair Hugger and risk of Page 134 Page 136 1 antithrombotic medications confounded the association 1 infection; correct? 2 2 between warming devices and surgical infections, yes. A. I said I wasn't aware of evidence that there 3 Q. Well you -- you previously testified that 3 was an association. That was way back earlier in the 4 there has to be an association between the potential 4 deposition. 5 5 Q. Well I understand, -confounder and the outcome for it to be a confounder; 6 6 correct? A. Okav. 7 7 A. Yes. Q. -- but I'm just trying to get --8 Q. Okay. So there is an association between 8 So the -- the use of a drug --9 the antithrombotic prophylaxis and the risk of 9 It thins your blood; right? 10 10 infection? A. Correct. 11 A. I believe so. 11 Q. -- can be associated with the risk of 12 12 Q. Okay. And what do you understand an infection; correct? 13 13 A. Yes. antithrombotic drug to do? 14 A. Its purpose is to prevent the formation of 14 Q. But the Bair Hugger is not, based on your 15 deep vein thromboses and pulmonary emboli. It 15 opinion. 16 essentially down-regulates the clotting system. 16 A. The evidence on the antithrom --17 Q. Okay. And that is there's an association 17 I find that you are mingling things and I 18 between which drug you use and your chance of 18 can't respond "yes" or "no." They are separate. I 19 infection; correct? 19 find that there is insufficient evidence that the Bair 2.0 MR. GORDON: Object to the form of the 20 Hugger causes infection. I think that there is 21 21 evidence that the antithrombotic agents can contribute question. 22 A. I believe that there is, probably because of 22 and increase the risk of infection, and I think that the use of the different antithrombotic agents in the 23 the ability of the two drugs to differentially 23 2.4 2.4 influence bleeding in the wound site. context of the McGovern study, in which the two 25 Q. Okay. So what medication you get to avoid 25 warming devices were used differentially with regards

34 (Pages 133 to 136)

	Page 137		Page 139
1	to the thrombotic agents antithrombotic agents, may	1	A. I guess I read them and made judgments based
2	have resulted in the appearance of an association	2	upon what I read.
3	between the warming unit and the risk.	3	Q. Does the use of a thromboprophylactic
4	Q. Well you find that the switch in	4	increase bacteria in a prosthetic joint?
5	antithrombotic agents was a confounder; correct?	5	A. I've
6	A. It's not so much the the switch, but yes,	6	There's evidence that use of different
7	the thrombotic agents were a confounder.	7	antithrombotics can increase the risk of infections in
8	Q. Yes.	8	the joint.
9	A. A different confounder.	9	Q. My question was a little different.
10	Q. And to be a confounder, there has to be an	10	A. I understand. I I told you earlier I
11	association.	11	didn't know that much about the blood flow to the
12	A. Yes.	12	joint, but I know there is evidence to sugg
13	Q. Okay. So how is it that an antithrombotic	13	indicate that there is increased risk of joint
14	drug can increase your risk of infection?	14	infections postoperatively affected by the choice of
15	A. By increasing the risk of bleeding, bleeding	15	antithrombotic.
16	being the blood being a fantastic culture medium	16	Q. Can you answer
17	for bacteria and encourages infection.	17	A. That's all that I can opine to.
18	Q. Okay. Did you do you have any	18	Q. Do you know whether the use of an
19	understanding	19	antithrombotic prophylaxis increases the number of
20	Did you investigate how vascular the joint	20	bacteria on a prosthetic joint?
21	area is in which a knee or hip implant would be going	21	A. I don't know that.
22	in?	22	Q. Okay. That wasn't something that you took
23	A. I I don't think it's necessarily in the	23	into account?
24	joint itself. But I have seen evidence that the use	24	A. I wouldn't have taken that into account.
25	of different medications increases a lot the or it	25	Q. Okay. Do you know whether the use of an
	Dama 130	1	Dama 140
	Page 138		Page 140
1	alters a lot the risk of bleeding into the surgery.	1	antithrombotic prophylaxis increases the number of
1 2		2	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?
	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.	2 3	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.
2 3 4	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.	2 3 4	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic
2 3 4 5	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the	2 3 4 5	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an
2 3 4 5 6	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that	2 3 4 5 6	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?
2 3 4 5 6 7	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic	2 3 4 5 6 7	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered
2 3 4 5 6 7 8	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?	2 3 4 5 6 7 8	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.
2 3 4 5 6 7 8 9	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the	2 3 4 5 6 7 8	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an
2 3 4 5 6 7 8 9	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.	2 3 4 5 6 7 8 9	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular
2 3 4 5 6 7 8 9 10	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they	2 3 4 5 6 7 8 9 10	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.
2 3 4 5 6 7 8 9 10 11	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.	2 3 4 5 6 7 8 9 10 11	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the
2 3 4 5 6 7 8 9 10 11 12	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?	2 3 4 5 6 7 8 9 10 11 12 13	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.
2 3 4 5 6 7 8 9 10 11 12 13	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?  A. I can read.	2 3 4 5 6 7 8 9 10 11 12 13 14	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.  A. I'm not sure what you mean by "an a priori."
2 3 4 5 6 7 8 9 10 11 12 13 14	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?  A. I can read.  Q. I'll pull it out for you.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.  A. I'm not sure what you mean by "an a priori."  Q. Do you know what that means, what that term
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?  A. I can read.  Q. I'll pull it out for you.  A. Both read, -a-d, and -e-d.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.  A. I'm not sure what you mean by "an a priori."  Q. Do you know what that means, what that term means in connection with an epidemiologic undertaking?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?  A. I can read.  Q. I'll pull it out for you.  A. Both read, -a-d, and -e-d.  Q. Well when did you decide that you were going	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.  A. I'm not sure what you mean by "an a priori."  Q. Do you know what that means, what that term means in connection with an epidemiologic undertaking?  A. I I have seen it used. I'm interested to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?  A. I can read.  Q. I'll pull it out for you.  A. Both read, -a-d, and -e-d.  Q. Well when did you decide that you were going to rely on what the McGovern authors said and how did	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.  A. I'm not sure what you mean by "an a priori."  Q. Do you know what that means, what that term means in connection with an epidemiologic undertaking?  A. I I have seen it used. I'm interested to know how you're using it in your question.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?  A. I can read.  Q. I'll pull it out for you.  A. Both read, -a-d, and -e-d.  Q. Well when did you decide that you were going to rely on what the McGovern authors said and how did you go about sorting what you were going to rely upon	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.  A. I'm not sure what you mean by "an a priori."  Q. Do you know what that means, what that term means in connection with an epidemiologic undertaking?  A. I I have seen it used. I'm interested to know how you're using it in your question.  Q. Well how how would
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?  A. I can read.  Q. I'll pull it out for you.  A. Both read, -a-d, and -e-d.  Q. Well when did you decide that you were going to rely on what the McGovern authors said and how did you go about sorting what you were going to rely upon out of their depositions and what you were going to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.  A. I'm not sure what you mean by "an a priori."  Q. Do you know what that means, what that term means in connection with an epidemiologic undertaking?  A. I I have seen it used. I'm interested to know how you're using it in your question.  Q. Well how how would How do you define it?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?  A. I can read.  Q. I'll pull it out for you.  A. Both read, -a-d, and -e-d.  Q. Well when did you decide that you were going to rely on what the McGovern authors said and how did you go about sorting what you were going to set aside as not believing?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.  A. I'm not sure what you mean by "an a priori."  Q. Do you know what that means, what that term means in connection with an epidemiologic undertaking?  A. I I have seen it used. I'm interested to know how you're using it in your question.  Q. Well how how would  How do you define it?  A. As a given.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?  A. I can read.  Q. I'll pull it out for you.  A. Both read, -a-d, and -e-d.  Q. Well when did you decide that you were going to rely on what the McGovern authors said and how did you go about sorting what you were going to rely upon out of their depositions and what you were going to set aside as not believing?  MR. GORDON: I object to the form of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.  A. I'm not sure what you mean by "an a priori."  Q. Do you know what that means, what that term means in connection with an epidemiologic undertaking?  A. I I have seen it used. I'm interested to know how you're using it in your question.  Q. Well how how would  How do you define it?  A. As a given.  Q. Okay. In connection with your opinions
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?  A. I can read.  Q. I'll pull it out for you.  A. Both read, -a-d, and -e-d.  Q. Well when did you decide that you were going to rely on what the McGovern authors said and how did you go about sorting what you were going to rely upon out of their depositions and what you were going to set aside as not believing?  MR. GORDON: I object to the form of the question, assumes facts not in evidence, compound.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.  A. I'm not sure what you mean by "an a priori."  Q. Do you know what that means, what that term means in connection with an epidemiologic undertaking?  A. I I have seen it used. I'm interested to know how you're using it in your question.  Q. Well how how would  How do you define it?  A. As a given.  Q. Okay. In connection with your opinions here, when, for example in paragraph 44
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	alters a lot the risk of bleeding into the surgery.  Q. Okay. And I'm talking about the actual joint.  A. I haven't looked into that.  Q. Okay. You're aware that the authors of the McGovern study looked at this issue and concluded that they didn't view the change in antithrombotic prophylaxis to be a confounder; correct?  MR. GORDON: Object to the form of the question.  A. I I believe they testified that they thought it was a potential confounder.  Q. Do you recall?  A. I can read.  Q. I'll pull it out for you.  A. Both read, -a-d, and -e-d.  Q. Well when did you decide that you were going to rely on what the McGovern authors said and how did you go about sorting what you were going to rely upon out of their depositions and what you were going to set aside as not believing?  MR. GORDON: I object to the form of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	antithrombotic prophylaxis increases the number of particles over a surgical site during operation?  A. I have no knowledge about that.  Q. Do you know when an antithrombotic prophylaxis drug is administered in connection with an orthopedic implant?  A. My understanding is it's first administered postoperatively.  Q. Okay. So it's your opinion that there is an a priori relationship between use of a particular antithrombotic prophylaxis and risk of infection.  MR. GORDON: Object to the form of the question.  A. I'm not sure what you mean by "an a priori."  Q. Do you know what that means, what that term means in connection with an epidemiologic undertaking?  A. I I have seen it used. I'm interested to know how you're using it in your question.  Q. Well how how would  How do you define it?  A. As a given.  Q. Okay. In connection with your opinions

35 (Pages 137 to 140)

#### Page 141 Page 143 1 In connection with your conclusions that 1 based on the results of that study, that, quote, "We 2 there is an association between what antithrombotic 2 can now exclude Xarelto as a confounding factor for 3 prophylaxis drug is used and your risk of infection, 3 infection rate." You're aware of that; correct? 4 were you specifically focused on deep joint infection 4 A. I'm sorry, I don't remember the statement. 5 5 or SSIs in general? Q. Okay. Was that something that would be 6 A. I was specifically focused on the McGovern 6 important to you, that the author of the McGovern 7 7 and the Jensen re -- and -- reports, which I study did further work into the -- the use of Xarelto 8 8 understood to be deep joint infections. as an antithrombotic prophylaxis and found that -- he 9 9 Q. Okay. Were you the one that suggested that said that it could be excluded as a confounding factor 10 10 Dr. Holford should reanalyze the McGovern data set for infection rates? 11 using the Jensen report? 11 A. I -- I would certainly want to see it before 12 A. I thought it was very clever but -- and I'd 12 I rendered any opinion about it. 13 13 love to take credit for it, but I don't think I was. Q. Are you aware that Professor Nachtscheim Q. Okay. And you didn't -- you didn't look at 14 14 said the same thing? 15 those numbers and see whether they were accurate and 15 A. I don't remember that particularly. 16 you didn't express an opinion on whether that's 16 Q. And you didn't even cite that article in 17 something that's appropriate to do or not; correct? 17 your report; did you, sir? 18 MR. GORDON: Object to the form of the 18 A. I don't think I did, no. 19 19 Q. Okay. So how is it that --A. I -- I think when I first read it --20 20 MR. GORDON: What -- what article are you 21 21 You're asking me whether I suggested it. referring to? 22 I'm not sure that I suggested it. I know that I 22 MS. CONLIN: The Reed article on Xarelto. 23 remarked to myself and to no one else that the Jensen 23 MR. GORDON: Is he the first -- first --24 2.4 report had a shorter followup and that the Q. What do you -- what do --2.5 postoperative joint infections could be delayed and 25 MR. GORDON: Is he the first author? Page 142 Page 144 1 1 Q. What do you -therefore the Jensen report might have undercounted 2 2 infections. I did not look to see the numbers of Explain to me the mechanism by which the use 3 cases which suggest that the Jensen report included 3 of Xarelto increases your infection risk over other kinds of cases other than those included in 4 4 trinzaparin. 5 5 McGovern. A. My understanding is it increases bleeding 6 6 Q. You didn't express an opinion on whether into the wound, and that the blood in the wound is a 7 7 what Professor Holford did in connection with his great culture medium and accelerates and enhances 8 remix or reanalyzation of the McGovern data set taking 8 infection. 9 into account Jensen was appropriate; correct? 9 O. Well both are antithrombotic; correct? 10 10 A. Did I express an opinion? A. Correct, but by different mechanisms. 11 11 Q. Yes. 12 12 A. In my writing I think I -- I accepted Dr. A. And my understanding is that there is a 13 Holford's reanalysis. 13 differential in the rate of postoperative bleeds when 14 (Discussion off the stenographic record.) 14 rivaroxaban was used. 15 Q. Okay. Now you un --15 Q. Well rivaroxaban is Xarelto; correct? 16 You understand that after McGovern, Dr. Reed 16 A. Correct. 17 published another study analyzing wound complications 17 Q. Okay. And what's that based on? 18 following the use of Xarelto. 18 A. The literature that I have reviewed. It's 19 A. I -- I -- I'm not surprised when you say it, 19 clearly in the Jensen paper, it's probably in others, 20 but I can't think of it right off the top. Can you 20 but I -- I can't make this a memory test and I 21 21 give me a title? apologize. But Jensen certainly indicates increased 22 Q. Not right now, but I -- I'll pull it out for 22 risks with rivaroxaban. 23 23 you in a second. Q. We'll get to Jensen in a second. I'm just asking you if you understand the mechanism by which 24 24 A. Okay. 25 O. You're aware that Dr. Reed testified that, 25 you think that use of trinzaparin creates a lower risk

36 (Pages 141 to 144)

	Page 145		Page 147
1	for infection than Xarelto.	1	MR. GORDON: Object to the form of the
2	A. I understand that tinza tinzap	2	question.
3	trinzaparin I don't know how to say it, but I	3	Q. You haven't done an investigation beyond
4	believe it's trinzaparin I believe that it is	4	what you what you've read; correct?
5	associated with less wound bleeding postoperatively.	5	A. I have not directly studied the use of
6	Q. We'll just go there. Hold on.	6	Xarox Xarelto.
7	(Exhibit 15 was marked for	7	Q. Okay. What investigation did you do other
8	identification.)	8	than read the couple of articles that are cited in
9	THE WITNESS: Thank you.	9	your report?
10	BY MS. CONLIN:	10	A. Well I've read a lot of articles. Only
11	Q. I've handed you what's been marked as Borak	11	those cited are the ones I specifically was relying
12	Deposition Exhibit 15, which is an article entitled	12	upon. I don't want to diminish the effort that was
13	"Return to the surgery following total hip and knee	13	put into it, but I read the literature.
14	replacement, before and after the introduction of	14	Q. Okay. With respect to this issue of Xarelto
15	rivaroxaban." Do you see that?	15	being a potential confounder
16	A. I do.	16	A. Yes.
17	Q. And the rivaroxaban is Xarelto; correct?	17	Q for the risk of infection in knee and hip
18	A. I believe so.	18	surgeries, what other articles do you have in mind
19	Q. Okay. And is this the study that you're	19	other than those that you cited in your report?
20	referencing?	20	A. I think at the moment those are the ones
21	A. I believe it is. I've looked at it in a	21	specifically that I would name.
22	different format, so it's	22	Q. And to the extent that Dr. Reed, an author
23	It was a pdf, printed in a different format,	23	of this study, said that this study proves that
24	but I think it's correct.	24	Xarelto is not a confounder in knee and hip surgery,
25	Q. Okay. Do you see the third author listed	25	you would disagree with him.
	Page 146		Page 148
1	Page 146 there?	1	Page 148  A. Did he say that here?
1 2		1 2	
	there?		A. Did he say that here?
2	there?  A. Is it Partington?	2	<ul><li>A. Did he say that here?</li><li>Q. He said it in his deposition. I'm</li></ul>
2	there?  A. Is it Partington?  Q. No, that would be the well do you see	2 3	<ul><li>A. Did he say that here?</li><li>Q. He said it in his deposition. I'm representing that to you.</li></ul>
2 3 4	there?  A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you	2 3 4	<ul><li>A. Did he say that here?</li><li>Q. He said it in his deposition. I'm representing that to you.</li><li>A. I I don't think that this study</li></ul>
2 3 4 5	there?  A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?	2 3 4 5	<ul> <li>A. Did he say that here?</li> <li>Q. He said it in his deposition. I'm representing that to you.</li> <li>A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan</li> </ul>
2 3 4 5 6	there?  A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.	2 3 4 5 6	<ul> <li>A. Did he say that here?</li> <li>Q. He said it in his deposition. I'm representing that to you.</li> <li>A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.</li> </ul>
2 3 4 5 6 7	there?  A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.  Q. Okay. Are you aware that Dr. Reed testified	2 3 4 5 6 7	<ul> <li>A. Did he say that here?</li> <li>Q. He said it in his deposition. I'm representing that to you.</li> <li>A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.</li> <li>Q. Okay. Based on what is my question.</li> </ul>
2 3 4 5 6 7 8	there?  A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.  Q. Okay. Are you aware that Dr. Reed testified that this study showed no	2 3 4 5 6 7 8	<ul> <li>A. Did he say that here?</li> <li>Q. He said it in his deposition. I'm representing that to you.</li> <li>A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.</li> <li>Q. Okay. Based on what is my question.</li> <li>A. Based on the fact that there was a</li> </ul>
2 3 4 5 6 7 8	there?  A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.  Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different	2 3 4 5 6 7 8	<ul> <li>A. Did he say that here?</li> <li>Q. He said it in his deposition. I'm representing that to you.</li> <li>A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.</li> <li>Q. Okay. Based on what is my question.</li> <li>A. Based on the fact that there was a significant increase there was a large increase, I</li> </ul>
2 3 4 5 6 7 8 9	there?  A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.  Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way.	2 3 4 5 6 7 8 9	A. Did he say that here? Q. He said it in his deposition. I'm representing that to you. A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study. Q. Okay. Based on what is my question. A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I
2 3 4 5 6 7 8 9 10	A. Is it Partington? Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there? A. Dr. Reed. Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way. Are you aware that Dr. Reed testified that	2 3 4 5 6 7 8 9 10	A. Did he say that here? Q. He said it in his deposition. I'm representing that to you. A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study. Q. Okay. Based on what is my question. A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it
2 3 4 5 6 7 8 9 10 11	A. Is it Partington? Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there? A. Dr. Reed. Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way. Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for	2 3 4 5 6 7 8 9 10 11	A. Did he say that here? Q. He said it in his deposition. I'm representing that to you. A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study. Q. Okay. Based on what is my question. A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup.
2 3 4 5 6 7 8 9 10 11 12 13	there?  A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.  Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way.  Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for infection risks in knee and hip surgeries?	2 3 4 5 6 7 8 9 10 11 12 13	A. Did he say that here?  Q. He said it in his deposition. I'm representing that to you.  A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.  Q. Okay. Based on what is my question.  A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup.  Q. Well so you relied on it but you didn't rely
2 3 4 5 6 7 8 9 10 11 12 13 14	A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.  Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way.  Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for infection risks in knee and hip surgeries?  MR. GORDON: Object to the form of the	2 3 4 5 6 7 8 9 10 11 12 13 14	A. Did he say that here?  Q. He said it in his deposition. I'm representing that to you.  A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.  Q. Okay. Based on what is my question.  A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup.  Q. Well so you relied on it but you didn't rely on it?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	there?  A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.  Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way.  Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for infection risks in knee and hip surgeries?  MR. GORDON: Object to the form of the question.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. Did he say that here?  Q. He said it in his deposition. I'm representing that to you.  A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.  Q. Okay. Based on what is my question.  A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup.  Q. Well so you relied on it but you didn't rely on it?  A. No, no, no, no, no, no. I didn't rely upon it.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	there?  A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.  Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way.  Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for infection risks in knee and hip surgeries?  MR. GORDON: Object to the form of the question.  A. I'm	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Did he say that here?  Q. He said it in his deposition. I'm representing that to you.  A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.  Q. Okay. Based on what is my question.  A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup.  Q. Well so you relied on it but you didn't rely on it?  A. No, no, no, no, no. I didn't rely upon it. I said I think it did not prove that it was not a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Is it Partington? Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there? A. Dr. Reed. Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way. Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for infection risks in knee and hip surgeries? MR. GORDON: Object to the form of the question. A. I'm I don't remember that he said that, but I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Did he say that here? Q. He said it in his deposition. I'm representing that to you. A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study. Q. Okay. Based on what is my question. A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup. Q. Well so you relied on it but you didn't rely on it? A. No, no, no, no, no. I didn't rely upon it. I said I think it did not prove that it was not a confounder. Moreover, a confounder whether
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Is it Partington? Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there? A. Dr. Reed. Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way. Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for infection risks in knee and hip surgeries? MR. GORDON: Object to the form of the question. A. I'm I don't remember that he said that, but I think it's wrong.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Did he say that here?  Q. He said it in his deposition. I'm representing that to you.  A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.  Q. Okay. Based on what is my question.  A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup.  Q. Well so you relied on it but you didn't rely on it?  A. No, no, no, no, no. I didn't rely upon it. I said I think it did not prove that it was not a confounder. Moreover, a confounder whether something is or is not a confounder is not dependent
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Is it Partington? Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there? A. Dr. Reed. Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way. Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for infection risks in knee and hip surgeries? MR. GORDON: Object to the form of the question. A. I'm I don't remember that he said that, but I think it's wrong. Q. Okay. So you don't remember reading it, but	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. Did he say that here?  Q. He said it in his deposition. I'm representing that to you.  A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.  Q. Okay. Based on what is my question.  A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup.  Q. Well so you relied on it but you didn't rely on it?  A. No, no, no, no, no. I didn't rely upon it. I said I think it did not prove that it was not a confounder. Moreover, a confounder whether something is or is not a confounder is not dependent on whether it is, on a univariate level, statistically
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.  Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way.  Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for infection risks in knee and hip surgeries?  MR. GORDON: Object to the form of the question.  A. I'm I don't remember that he said that, but I think it's wrong.  Q. Okay. So you don't remember reading it, but if he said it, he's wrong.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Did he say that here?  Q. He said it in his deposition. I'm representing that to you.  A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.  Q. Okay. Based on what is my question.  A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup.  Q. Well so you relied on it but you didn't rely on it?  A. No, no, no, no, no. I didn't rely upon it. I said I think it did not prove that it was not a confounder. Moreover, a confounder whether something is or is not a confounder is not dependent on whether it is, on a univariate level, statistically significantly associated with the outcome or whether
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Is it Partington? Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there? A. Dr. Reed. Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way. Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for infection risks in knee and hip surgeries? MR. GORDON: Object to the form of the question. A. I'm I don't remember that he said that, but I think it's wrong. Q. Okay. So you don't remember reading it, but if he said it, he's wrong. A. I believe it does not eliminate it. Yes,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Did he say that here?  Q. He said it in his deposition. I'm representing that to you.  A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.  Q. Okay. Based on what is my question.  A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup.  Q. Well so you relied on it but you didn't rely on it?  A. No, no, no, no, no. I didn't rely upon it. I said I think it did not prove that it was not a confounder. Moreover, a confounder whether something is or is not a confounder is not dependent on whether it is, on a univariate level, statistically significantly associated with the outcome or whether it significantly influences the relationship that it
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.  Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way.  Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for infection risks in knee and hip surgeries?  MR. GORDON: Object to the form of the question.  A. I'm I don't remember that he said that, but I think it's wrong.  Q. Okay. So you don't remember reading it, but if he said it, he's wrong.  A. I believe it does not eliminate it. Yes, that's correct.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Did he say that here?  Q. He said it in his deposition. I'm representing that to you.  A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.  Q. Okay. Based on what is my question.  A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup.  Q. Well so you relied on it but you didn't rely on it?  A. No, no, no, no, no. I didn't rely upon it. I said I think it did not prove that it was not a confounder. Moreover, a confounder whether something is or is not a confounder is not dependent on whether it is, on a univariate level, statistically significantly associated with the outcome or whether it significantly influences the relationship that it confounds.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	there?  A. Is it Partington?  Q. No, that would be the well do you see I guess it would be the fourth then. Do you see the fourth author there?  A. Dr. Reed.  Q. Okay. Are you aware that Dr. Reed testified that this study showed no Well strike it. Let me ask it a different way.  Are you aware that Dr. Reed testified that this study eliminates Xarelto as a confounder for infection risks in knee and hip surgeries?  MR. GORDON: Object to the form of the question.  A. I'm I don't remember that he said that, but I think it's wrong.  Q. Okay. So you don't remember reading it, but if he said it, he's wrong.  A. I believe it does not eliminate it. Yes, that's correct.  Q. Okay. And he's somebody who has	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Did he say that here?  Q. He said it in his deposition. I'm representing that to you.  A. I I don't think that this study eliminates rivaroxaban as a confounder in the McGowan study.  Q. Okay. Based on what is my question.  A. Based on the fact that there was a significant increase there was a large increase, I think 2.5-to-one increase in infection rates, and I think this study under-ascertained cases because it only had a 30-day followup.  Q. Well so you relied on it but you didn't rely on it?  A. No, no, no, no, no. I didn't rely upon it. I said I think it did not prove that it was not a confounder. Moreover, a confounder whether something is or is not a confounder is not dependent on whether it is, on a univariate level, statistically significantly associated with the outcome or whether it significantly influences the relationship that it confounds.  Q. It has to have an association.

37 (Pages 145 to 148)

	Page 149		Page 151
1	out, Mr. Stirewalt, what was marked yesterday as	1	that?
2	Exhibit 19, because I think that is probably the pdf	2	A. I'm sorry, let me try and read it more
3	that he's used to seeing in connection with this	3	clearly. I'm not seeing it well enough in this print.
4	study.	4	Yes. Okay, I see that.
5	A. Maybe that one.	5	Q. Okay. And do you see the p-value of .7?
6	(Holford Exhibit 19 handed to the witness.)	6	A7 had to do with the probability that there
7	Q. I've handed you what's previously been	7	was a difference in the rate of deep versus
8	marked as Holford Exhibit 19, which is, I believe, the	8	superficial infections.
9	same study in a different format. Is this the format	9	Q. My question is: Do you see the p-value of
10	that you're used to seeing this study?	10	.7?
11	A. Yes, that's correct.	11	A. Yes, I see it.
12	Q. Okay. And did you understand this study to	12	Q. Is that statistically significant?
13	be breaking down wound complications such as surgical	13	A. No.
14	wound infections versus deep joint infections?	14	Q. Okay. Then it says, "The overall rate of
15	MR. GORDON: Object to the form of the	15	deep infection in group 1 was 1 percent (95) compared
16	question.	16	with 2.5 percent in group 2," p-value of .102, do you
17	A. You're asking me whether it specifically	17	see that?
18	differentiated different kinds of wound infections?	18	A. I do.
19	Q. Deep joint versus a superficial wound	19	Q. Is that statistically significant?
20	infection or the like. Did you have that in mind when	20	A. It is not.
21	you reviewed this?	21	Q. Did you take that into account in connection
22	A. I don't recall having that particular	22	with your conclusions in this case that Xarelto is a
23	question in mind,	23	confounding factor for risk of infection?
24	Q. Okay.	24	MR. GORDON: Object to the form of the
25	A but I will would again if you'd like	25	question.
	Page 150		Page 152
1	Page 150 me to.	1	Page 152  A. It's discussed in paragraph 42 and following
1 2		1 2	
	me to.		<ul><li>A. It's discussed in paragraph 42 and following in my report.</li><li>Q. My question is a little different. Did you</li></ul>
2	me to.  Q. Did you have it in mind when you rendered	2	A. It's discussed in paragraph 42 and following in my report.
2	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?	2 3	<ul><li>A. It's discussed in paragraph 42 and following in my report.</li><li>Q. My question is a little different. Did you</li></ul>
2 3 4	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether	2 3 4	<ul> <li>A. It's discussed in paragraph 42 and following in my report.</li> <li>Q. My question is a little different. Did you take that into account in connection with your</li> </ul>
2 3 4 5	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of	2 3 4 5	<ul> <li>A. It's discussed in paragraph 42 and following in my report.</li> <li>Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?</li> </ul>
2 3 4 5 6	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is	2 3 4 5 6	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.
2 3 4 5 6 7	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to	2 3 4 5 6 7 8	<ul> <li>A. It's discussed in paragraph 42 and following in my report.</li> <li>Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?</li> <li>A. And I'm showing you, yes, I took it into account</li> </ul>
2 3 4 5 6 7 8	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.	2 3 4 5 6 7 8	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account  Q. Okay.  A in paragraphs 42 and following in my report.
2 3 4 5 6 7 8	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to	2 3 4 5 6 7 8	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account  Q. Okay.  A in paragraphs 42 and following in my
2 3 4 5 6 7 8 9 10 11	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you	2 3 4 5 6 7 8 9 10 11	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't
2 3 4 5 6 7 8 9 10	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I	2 3 4 5 6 7 8 9 10	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account  Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't  You didn't actually look at the mathematical
2 3 4 5 6 7 8 9 10 11	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I don't remember whether it was relevant, that question,	2 3 4 5 6 7 8 9 10 11 12 13 14	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account  Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't  You didn't actually look at the mathematical work Professor Holford did in reanalyzing the McGovern
2 3 4 5 6 7 8 9 10 11 12 13	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I	2 3 4 5 6 7 8 9 10 11 12 13	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account  Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't  You didn't actually look at the mathematical
2 3 4 5 6 7 8 9 10 11 12 13 14	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I don't remember whether it was relevant, that question, to this article.  Q. Okay. Why don't you take a look at	2 3 4 5 6 7 8 9 10 11 12 13 14	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't You didn't actually look at the mathematical work Professor Holford did in reanalyzing the McGovern data with Jensen; correct?  MR. GORDON: Objection.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I don't remember whether it was relevant, that question, to this article.  Q. Okay. Why don't you take a look at intern page 523, which is the third page of this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't You didn't actually look at the mathematical work Professor Holford did in reanalyzing the McGovern data with Jensen; correct?  MR. GORDON: Objection.  A. Yes, I did not.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I don't remember whether it was relevant, that question, to this article.  Q. Okay. Why don't you take a look at intern page 523, which is the third page of this study, under "Results," and I'd like to direct your	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't You didn't actually look at the mathematical work Professor Holford did in reanalyzing the McGovern data with Jensen; correct?  MR. GORDON: Objection.  A. Yes, I did not. Q. Okay. And to the extent that he used either
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I don't remember whether it was relevant, that question, to this article.  Q. Okay. Why don't you take a look at intern page 523, which is the third page of this study, under "Results," and I'd like to direct your attention down to the third paragraph starting with	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't You didn't actually look at the mathematical work Professor Holford did in reanalyzing the McGovern data with Jensen; correct?  MR. GORDON: Objection.  A. Yes, I did not. Q. Okay. And to the extent that he used either data from Albrecht Exhibit 10 or McGovern Exhibit 16,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I don't remember whether it was relevant, that question, to this article.  Q. Okay. Why don't you take a look at intern page 523, which is the third page of this study, under "Results," and I'd like to direct your attention down to the third paragraph starting with "Of those patients who returned to theatre,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't You didn't actually look at the mathematical work Professor Holford did in reanalyzing the McGovern data with Jensen; correct?  MR. GORDON: Objection.  A. Yes, I did not. Q. Okay. And to the extent that he used either
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I don't remember whether it was relevant, that question, to this article.  Q. Okay. Why don't you take a look at intern page 523, which is the third page of this study, under "Results," and I'd like to direct your attention down to the third paragraph starting with "Of those patients who returned to theatre, microbiology results showed that five of the nine	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't You didn't actually look at the mathematical work Professor Holford did in reanalyzing the McGovern data with Jensen; correct?  MR. GORDON: Objection.  A. Yes, I did not. Q. Okay. And to the extent that he used either data from Albrecht Exhibit 10 or McGovern Exhibit 16,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I don't remember whether it was relevant, that question, to this article.  Q. Okay. Why don't you take a look at intern page 523, which is the third page of this study, under "Results," and I'd like to direct your attention down to the third paragraph starting with "Of those patients who returned to theatre, microbiology results showed that five of the nine (55.5 percent) in group 1 had a deep infection,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't You didn't actually look at the mathematical work Professor Holford did in reanalyzing the McGovern data with Jensen; correct?  MR. GORDON: Objection.  A. Yes, I did not. Q. Okay. And to the extent that he used either data from Albrecht Exhibit 10 or McGovern Exhibit 16, you would be deferring to him as to the appropriateness of that; correct?  A. Yes, I would.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I don't remember whether it was relevant, that question, to this article.  Q. Okay. Why don't you take a look at intern page 523, which is the third page of this study, under "Results," and I'd like to direct your attention down to the third paragraph starting with "Of those patients who returned to theatre, microbiology results showed that five of the nine	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't You didn't actually look at the mathematical work Professor Holford did in reanalyzing the McGovern data with Jensen; correct?  MR. GORDON: Objection.  A. Yes, I did not. Q. Okay. And to the extent that he used either data from Albrecht Exhibit 10 or McGovern Exhibit 16, you would be deferring to him as to the appropriateness of that; correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I don't remember whether it was relevant, that question, to this article.  Q. Okay. Why don't you take a look at intern page 523, which is the third page of this study, under "Results," and I'd like to direct your attention down to the third paragraph starting with "Of those patients who returned to theatre, microbiology results showed that five of the nine (55.5 percent) in group 1 had a deep infection, compared with 14 of 22 (63.6 percent) in group 2."  A. Okay.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't You didn't actually look at the mathematical work Professor Holford did in reanalyzing the McGovern data with Jensen; correct?  MR. GORDON: Objection.  A. Yes, I did not. Q. Okay. And to the extent that he used either data from Albrecht Exhibit 10 or McGovern Exhibit 16, you would be deferring to him as to the appropriateness of that; correct?  A. Yes, I would. Q. Now I'd like to talk to you a little bit about the Hawthorne effect and which is contained
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	me to.  Q. Did you have it in mind when you rendered your opinions in this case on June 2nd?  A. Whether  The differentiation between the types of wound infections?  Q. Correct.  A. I I'm sorry, and I'm just backing up. Is that raised in this document? It would help me to reconstruct and answer your question.  Q. Well I'm just asking if you had it in mind when you  A. I'm sure I had it somewhere in mind, but I don't remember whether it was relevant, that question, to this article.  Q. Okay. Why don't you take a look at intern page 523, which is the third page of this study, under "Results," and I'd like to direct your attention down to the third paragraph starting with "Of those patients who returned to theatre, microbiology results showed that five of the nine (55.5 percent) in group 1 had a deep infection, compared with 14 of 22 (63.6 percent) in group 2."	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. It's discussed in paragraph 42 and following in my report.  Q. My question is a little different. Did you take that into account in connection with your conclusions in this case?  A. And I'm showing you, yes, I took it into account Q. Okay.  A in paragraphs 42 and following in my report.  Q. I think I asked you this before, but in connection you didn't You didn't actually look at the mathematical work Professor Holford did in reanalyzing the McGovern data with Jensen; correct?  MR. GORDON: Objection.  A. Yes, I did not. Q. Okay. And to the extent that he used either data from Albrecht Exhibit 10 or McGovern Exhibit 16, you would be deferring to him as to the appropriateness of that; correct?  A. Yes, I would. Q. Now I'd like to talk to you a little bit

38 (Pages 149 to 152)

Page 155 Page 153 1 Well first of all, wouldn't the Hawthorne 1 Q. -- which is the Jameson study entitled 2 effect exist in any observational study? 2 "Wound Complications Following Rivaroxaban 3 A. I think it depends upon whether the subjects 3 Administration." This is one of the documents that 4 are aware of the observation and how intensively the 4 you referenced and opined on in your report; correct? 5 5 observation impacts the daily life of those A. That's correct. 6 6 individuals. Q. Okay. In connection with your review, did 7 7 Q. Well do you know whether any of the you have in mind a difference or -- between a deep 8 8 participants in the Reed and McGovern study were joint infection and a superficial or deep tissue 9 9 infection? involved, that there was a study going on? 10 10 A. I don't think it was defined clearly in this A. I -- I understand from the statements that 11 paper, and so I don't think that I made a decision. 11 were made in the citation which I cited -- "citation 12 12 which I cited" sounds like a redundancy -- there was But --13 13 an award given to Northumbria, and in the context of Q. Okay. Would it be important in connection 14 14 with making decisions that a change to Xarelto that they cited the efforts that had gone into it. 15 postoperatively as an antithrombotic prophylaxis 15 There's also description of the change in the 16 increases the risk of a deep joint infection? 16 sensibility that was engendered as described by 17 A. I'm sorry, repeat that. 17 Gillson and Lowdon or something, and my understanding 18 Q. Sure. Would it be important in connection 18 is that there was a full-court press to try to change 19 with making decisions in this case that a change in 19 the behavior of the people, which included changing 20 Xarelto postoperatively -- postoperatively as an 2.0 clothes and changing the manner in which the clothes 21 antithrombotic prophylaxis increases the risk of a were stored and changing shoes, and a variety of other 21 22 deep joint infection as opposed to another kind of 22 things were done, and I think that everybody there was 23 wound infection? 23 very aware that there was a problem with infections. 2.4 A. Would it matter to me? Yes, I would 2.4 Q. My question was a little different. 25 consider that. I --25 A. Okay. I'm sorry. Page 154 Page 156 1 Q. My question was: Do you believe that any of 1 Would you point to what you are talking 2 2 the participants' employees understood or were aware about in the paper so I understand the context of your 3 that there was going to be an observational study 3 question? 4 conducted and published regarding infections in knee 4 Q. Well I'm just under --5 5 I'm trying to understand your opinion, sir, and hip arthroplasty? 6 A. I -- I have --6 when you say that the change in -- from rivar -- or 7 MR. GORDON: Object to the form of the 7 from trinzaparin to Xarelto creates an increased risk 8 8 of a deep joint infection, that you had paid attention 9 A. I have no idea if anybody at the time knew 9 in the papers that you were citing as to differences 10 10 because the study was post hoc. between, for example, a superficial wound or a deep 11 (Discussion off the stenographic record.) 11 wound infection and a deep joint infection. 12 A. I'm sorry, I -- I cited this paper for a 12 (Exhibit 16 was marked for 13 13 different reason, not to suggest what you are asking. identification.) 14 THE WITNESS: Thank you. 14 I cited it because Dr. Samet had cited it, and Dr. 15 15 BY MS. CONLIN: Samet had cited it as evidence that it did not create 16 Q. I have handed you, sir, what's been marked 16 a difference. 17 as Borak Deposition Exhibit 16, which is -- not what I 17 Q. My question was: When you opine that a 18 wanted to give you. Hold on. You can set that aside, 18 change from trinzaparin to Xarelto creates an 19 I'll get back to that. 19 increased risk of deep joint infection, did you pay 20 (Exhibit 17 was marked for 20 attention in the papers that you were citing as to the 21 identification.) 21 differences between, for example, superficial wound or 22 BY MS. CONLIN: 22 deep wound or a deep joint infection? 23 23 Q. I have handed you, sir, what's been marked A. Let me answer, yes, I was aware of the 24 24 as Borak Deposition Exhibit 17, -difference. 25 25 Q. Do you think that you can extrapolate from A. Yes.

39 (Pages 153 to 156)

	Page 157		Page 159
1	papers regarding superficial wound infections to a	1	increase in infectious microbes in the air can affect
2	deep joint infection?	2	your ability to get a deep joint infection; correct?
3	A. I am not a nosocomial infection expert. I	3	A. I said I don't I don't have an opinion
4	was looking at a very specific paper, not generalizing	4	about that.
5	from it. It was a paper that was cited for a	5	Q. Okay.
6	particular purpose. I was responding to that.	6	A. That's correct.
7	Q. Can you answer my question?	7	Q. So if it's on the skin, you have an opinion
8	A. Ask the question again.	8	about it, if it's in the air, you don't; correct?
9	Q. Sure. Do you think that you can extrapolate	9	A. The answer is yes, because the available
10	from papers regarding superficial wound infections to	10	data are different.
11	deep joint infections in connection with what might be	11	MS. CONLIN: Okay. All right. Why don't we
12	a confounder or not?	12	stop here for lunch.
13	A. I I didn't. I'm not sure that I did that	13	THE REPORTER: Off the record, please.
14	and I'm not sure that you can do that.	14	(Luncheon recess taken.)
15	Q. Okay. You'd agree with me that there's a	15	,
16	difference between a a a superficial surgical-	16	
17	site infection and a deep joint infection; correct?	17	
18	A. I understand that there is a difference.	18	
19	Q. Okay. Changing the dressings or a change in	19	
20	protocol on changing the dressings might affect a	20	
21	superficial surgical-site infection but not	21	
22	necessarily impact a deep joint infection.	22	
23	A. Or might affect both, yes.	23	
24	Q. Do you know whether it could affect both?	24	
25	A. I thought I had seen comments by Dr. Reed	25	
	Page 158		Page 160
1	Page 158 indicating that a change in dressing affected that	1	Page 160 AFTERNOON SESSION
1 2		1 2	
	indicating that a change in dressing affected that		AFTERNOON SESSION
2	indicating that a change in dressing affected that outcome, but I can't point to where it was other than	2	AFTERNOON SESSION BY MS. CONLIN:
2	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.	2 3	AFTERNOON SESSION BY MS. CONLIN: Q. If the change in antithrombotic prophylaxis
2 3 4	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed	2 3 4	AFTERNOON SESSION BY MS. CONLIN: Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's
2 3 4 5	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol	2 3 4 5	AFTERNOON SESSION BY MS. CONLIN: Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a
2 3 4 5 6	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?	2 3 4 5 6	AFTERNOON SESSION BY MS. CONLIN: Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would
2 3 4 5 6 7	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may	2 3 4 5 6 7	AFTERNOON SESSION BY MS. CONLIN: Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?
2 3 4 5 6 7 8	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.	2 3 4 5 6 7 8	AFTERNOON SESSION BY MS. CONLIN: Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the
2 3 4 5 6 7 8	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the	2 3 4 5 6 7 8	AFTERNOON SESSION BY MS. CONLIN: Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.
2 3 4 5 6 7 8 9	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?	2 3 4 5 6 7 8 9	AFTERNOON SESSION BY MS. CONLIN: Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if
2 3 4 5 6 7 8 9 10	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.	2 3 4 5 6 7 8 9 10	AFTERNOON SESSION BY MS. CONLIN: Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none.
2 3 4 5 6 7 8 9 10 11	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?	2 3 4 5 6 7 8 9 10 11	AFTERNOON SESSION BY MS. CONLIN: Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right? MR. GORDON: Object to the form of the question. A. You asked me first a hypothetical, saying if there were none. Q. Yup.
2 3 4 5 6 7 8 9 10 11 12 13	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?  A. Yes.	2 3 4 5 6 7 8 9 10 11 12 13	AFTERNOON SESSION BY MS. CONLIN:  Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none.  Q. Yup.  A. Okay. And then when you say the remix, are
2 3 4 5 6 7 8 9 10 11 12 13 14	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?  A. Yes.  Q. Okay. Do you think that a change in skin	2 3 4 5 6 7 8 9 10 11 12 13 14	AFTERNOON SESSION BY MS. CONLIN:  Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none.  Q. Yup.  A. Okay. And then when you say the remix, are you referring to what Professor Holford did?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?  A. Yes.  Q. Okay. Do you think that a change in skin preparation can have an impact on a deep joint	2 3 4 5 6 7 8 9 10 11 12 13 14 15	AFTERNOON SESSION BY MS. CONLIN:  Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none. Q. Yup.  A. Okay. And then when you say the remix, are you referring to what Professor Holford did? Q. Correct.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?  A. Yes.  Q. Okay. Do you think that a change in skin preparation can have an impact on a deep joint infection?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	AFTERNOON SESSION BY MS. CONLIN:  Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none. Q. Yup.  A. Okay. And then when you say the remix, are you referring to what Professor Holford did? Q. Correct.  A. I think that it would still have merit given
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?  A. Yes.  Q. Okay. Do you think that a change in skin preparation can have an impact on a deep joint infection?  A. Absolutely.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	AFTERNOON SESSION BY MS. CONLIN:  Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none. Q. Yup. A. Okay. And then when you say the remix, are you referring to what Professor Holford did? Q. Correct. A. I think that it would still have merit given the fact that the followup period in the Jensen study
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?  A. Yes.  Q. Okay. Do you think that a change in skin preparation can have an impact on a deep joint infection?  A. Absolutely.  Q. Okay. How so?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	AFTERNOON SESSION BY MS. CONLIN:  Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none. Q. Yup. A. Okay. And then when you say the remix, are you referring to what Professor Holford did? Q. Correct. A. I think that it would still have merit given the fact that the followup period in the Jensen study was probably too short because of the well-recognized
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?  A. Yes.  Q. Okay. Do you think that a change in skin preparation can have an impact on a deep joint infection?  A. Absolutely.  Q. Okay. How so?  A. Reducing the number of bacteria on the skin	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	AFTERNOON SESSION BY MS. CONLIN:  Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none. Q. Yup.  A. Okay. And then when you say the remix, are you referring to what Professor Holford did? Q. Correct.  A. I think that it would still have merit given the fact that the followup period in the Jensen study was probably too short because of the well-recognized delay in the manifestation of infections.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?  A. Yes.  Q. Okay. Do you think that a change in skin preparation can have an impact on a deep joint infection?  A. Absolutely.  Q. Okay. How so?  A. Reducing the number of bacteria on the skin reduces the likelihood of followup of of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	AFTERNOON SESSION BY MS. CONLIN:  Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none. Q. Yup.  A. Okay. And then when you say the remix, are you referring to what Professor Holford did? Q. Correct.  A. I think that it would still have merit given the fact that the followup period in the Jensen study was probably too short because of the well-recognized delay in the manifestation of infections. Q. The hypothetical is is that the change in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?  A. Yes.  Q. Okay. Do you think that a change in skin preparation can have an impact on a deep joint infection?  A. Absolutely.  Q. Okay. How so?  A. Reducing the number of bacteria on the skin reduces the likelihood of followup of of infection postoperatively.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	AFTERNOON SESSION BY MS. CONLIN:  Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none. Q. Yup.  A. Okay. And then when you say the remix, are you referring to what Professor Holford did? Q. Correct.  A. I think that it would still have merit given the fact that the followup period in the Jensen study was probably too short because of the well-recognized delay in the manifestation of infections.  Q. The hypothetical is is that the change in there's no association between a change in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?  A. Yes.  Q. Okay. Do you think that a change in skin preparation can have an impact on a deep joint infection?  A. Absolutely.  Q. Okay. How so?  A. Reducing the number of bacteria on the skin reduces the likelihood of followup of of infection postoperatively.  Q. Okay. So having less bacteria on your skin	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	AFTERNOON SESSION BY MS. CONLIN:  Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none. Q. Yup.  A. Okay. And then when you say the remix, are you referring to what Professor Holford did? Q. Correct.  A. I think that it would still have merit given the fact that the followup period in the Jensen study was probably too short because of the well-recognized delay in the manifestation of infections.  Q. The hypothetical is is that the change in there's no association between a change in antithrombotic prophylaxis and infection. If that's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	indicating that a change in dressing affected that outcome, but I can't point to where it was other than maybe a deposition.  Q. So it's your understanding that Dr. Reed said that a change in dressing or change in protocol in dressings could affect a deep joint infection?  A. I believe that is my remembrance, but it may not be correct. I didn't focus on it.  Q. Well you talked about changes in the protocol; right?  A. Yes.  Q. And skin preparation; right?  A. Yes.  Q. Okay. Do you think that a change in skin preparation can have an impact on a deep joint infection?  A. Absolutely.  Q. Okay. How so?  A. Reducing the number of bacteria on the skin reduces the likelihood of followup of of infection postoperatively.  Q. Okay. So having less bacteria on your skin can lower your risk of a deep joint infection.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	AFTERNOON SESSION BY MS. CONLIN:  Q. If the change in antithrombotic prophylaxis is not a confounder, in other words, meaning there's no association as as you've described it, doing a remix of the Jensen data and the McGovern data would not make sense in that case; right?  MR. GORDON: Object to the form of the question.  A. You asked me first a hypothetical, saying if there were none. Q. Yup.  A. Okay. And then when you say the remix, are you referring to what Professor Holford did? Q. Correct.  A. I think that it would still have merit given the fact that the followup period in the Jensen study was probably too short because of the well-recognized delay in the manifestation of infections.  Q. The hypothetical is is that the change in there's no association between a change in antithrombotic prophylaxis and infection. If that's the case, there would be no reason for Dr. Holford to

40 (Pages 157 to 160)

Page 161 Page 163 1 assumption was correct or incorrect. 1 looking at the date of the McGovern paper, that we can 2 (Exhibit 18 was marked for 2 exclude xarelto as a confounding factor for infection 3 identification.) 3 rates?" 4 BY MS. CONLIN: 4 MS. CONLIN: He's not an author on that, Mr. 5 Q. I've handed you what's been marked as Borak 5 Gordon. 6 Exhibit 18, which was -- is an excerpt from the 6 THE WITNESS: Mr. -- Dr. Reed is. 7 7 deposition of Dr. Reed, and I'd like to direct your MS. CONLIN: On the Jameson paper? 8 8 attention to internal page 215 of this exhibit. And MR. GORDON: Yes. 9 9 this is relating to the Reed study, I'll represent to THE WITNESS: He's the last author. 10 10 you, the Reed study on Xarelto that we just looked at MS. CONLIN: Okay. 11 and was marked as Exhibit 19. If we can take a look 11 MR. GORDON: He's a senior author. 12 12 Q. Okay. So let me start over. With reference at page 215 --13 13 Let me -- let me just make sure I gave you to the Jameson paper, the testimony went as follows: 14 the right exhibit number. Yeah, that's it. 14 "So would you agree with me that based on 15 15 A. Can -- can we, just for avoiding confusion, this study, that you are an author of, that looking at 16 16 agree that what you were referring to as the Reed the date of the McGovern paper, that we can now 17 study is the Jensen study? 17 exclude xarelto as a confounding factor for infection 18 Q. Sure. And I apologize for that. 18 rates? 19 19 A. No, no, no, no. I -- I'm not trying to "Answer: I think that's what this paper 20 says." 20 make it harder, --21 21 Do you see that? Q. All right. 22 22 A. -- I'm trying to make it clearer. A. I do see that. 23 23 Q. So with regard to this testimony on page Q. And you disagree with Dr. Reed, the author 24 215, internal page 215 of Exhibit 18, they're 24 of the Jameson -- one of the authors of the Jameson 25 referencing the Jensen study, and I'd like to direct 25 study; correct? Page 162 Page 164 1 1 A. Yes. your attention down to line --2 2 MR. GORDON: Jan, I -- I -- I can't believe Q. And you disagree with his conclusions as it 3 you're trying to sandbag him with that. He's not 3 relates to the Jensen study, of which he is also an 4 talking about the Jensen study here. And I -- I --4 author: correct? 5 I'm assuming you don't know. He's talking about the 5 A. We -- I --6 6 Jameson study. I think so, but I'm not sure which 7 7 MS. CONLIN: Oh, okay. I stand corrected. conclusion you're referring to. 8 As you know me, Mr. Gordon, I wouldn't do that to a 8 Q. That Xarelto was not a confounding factor in 9 witness, so --9 connection with the McGovern study. 10 10 MR. GORDON: And that's why I said it that A. It's two separate issues. I agree with you 11 11 on both of those. I disagree with Dr. Reed. way. 12 12 MS. CONLIN: All right. Thank you. Yeah. Q. Okay. 13 13 Okay. A. You're not interested in why? 14 Q. Do you see the testimony on 215, starting at 14 Q. Actually, I am. Go ahead and tell me why 15 line 14 --15 you disagree. 16 And I stand corrected. It is in connection 16 A. Well I think that in the Jensen study the 17 with the Jameson study which is -- we also marked this 17 2.5-to-one ratio of deep infection increase is 18 18 morning as Exhibit 17. indication of confounding. The only conclusion that 19 MR. GORDON: Seventeen. 19 supports that it's not important is that it's 2.0 Q. Okay? And do you see it says: 20 statistically not significant, and when re-evaluated 21 "So based on this study of 12,000 patients, 21 it was statistically significant. That is Dr. 22 I would say that there was no effect on return to 22 Holford's re-evaluation. 23 23 surgery from infection. The Jameson study provides a totally 24 24 "Question: So would you agree with me that different thing. It contains contradictory internal 25 based on this study, that you are an author of, and 25 information that I believe it is not useful, and part

41 (Pages 161 to 164)

#### Page 165 Page 167 1 of it is that while it does at one place say that the 1 of your report, --2 combined data did not have a statistically significant 2 A. Yes. 3 increase -- and that's in a table on page 1556 --3 Q. -- and I'd like to talk to you about your 4 however, there were these other difficulties. One of 4 section entitled "...Skin Preparation." 5 5 them is that the numbers don't add up. It -- it does A. Yes. 6 6 not make sense, the paper, the data do not make sense. Q. Okay. And it's your opinion that the --7 7 Is it your opinion that the change in skin And the other is that the authors clearly state that 8 8 they were unable to differentiate from this pooled preparation protocol during the McGovern study period 9 9 was a confounder? data set between return to theater for infection 10 10 versus return for other wound complications, and they A. It probably was. There's no evidence to say 11 just pooled them. 11 "yes" or "no," but it is one that should have been 12 Now the point I made in my report -- and I 12 considered. I think it was likely to be. 13 just point out so you understand -- I'm -- what I'm 13 Q. Okay. So without evidence, you're okay 14 14 saying is the Jameson study isn't usable, and I point saying there is an association between the change in 15 to the fact that in Table 2 on what you refer to as 15 skin protocol and the risk of infection, is that 16 16 internal 1556, there is a count of total wound right, at least as it relates to skin preparation? 17 17 complications and underneath that there is a list of A. My sen -- my --18 18 those that were managed non-operatively and those that My statement was to the extent that use of 19 19 chlorhexidine reduced infections would be -- only returned to surgery for infection, and when you add 2.0 them up, it does not square. There are too many 20 reduce the rate in the non-FAW cases, thereby wrongly 21 21 cases. The numbers are not correct. suggesting a benefit. In that case, it would have 22 Q. Okay. So that's based on your view that you 22 been a confounder. 23 couldn't understand what was going on in that study, 23 Q. My -- my question was -- okay. 2.4 2.4 but you don't agree with the author of the study who My question was: So you're saying that 25 says in his mind this created a conclusion that 25 there's an association between the change in skin Page 166 Page 168 1 Xarelto was not a confounding factor in McGovern. 1 protocol and the risk of infection, at least as it 2 2 A. Yes, I believe these data did not support relates to skin preparation; correct? 3 that conclusion. 3 A. I -- I think that that is correct. 4 Q. Now you mentioned in that last answer that 4 Q. Okay. And in connection with this you cite 5 5 Dr. Reed's testimony; right? Quote, "If your surgeon you thought the authors didn't discriminate between 6 6 re -- repeat surgical-wound irrigation for infection is still using iodine plus alcohol then there is a 7 7 and surgery for hematoma; correct? very robust study that shows they could do better;" 8 A. Yes. 8 correct? 9 Q. That -- that involves the procedure, not the 9 A. Correct, I did cite that. 10 10 detection of a DJI; correct? Q. So in connection with this you're relying on 11 A. They group them together. 11 Dr. Reed; correct? 12 12 Q. Well no. It just --A. I'm pointing to Dr. Reed agreeing with me, 13 They grouped them together for the purposes 13 yes. 14 of the surgery, not whether there were infections. 14 Q. Right. You're relying on it. 15 15 A. I don't know that I specifically relied upon A. Yes, yes, yes. 16 Q. Okay. 16 it, but I cited it. 17 A. And there's no data to conclude about 17 Q. Well you said earlier in your report that if 18 infections because they were grouped together. They 18 you cited it, you relied on it. 19 do not have a separate list. To the contrary, what 19 A. No, no. I appreciate what you're saying. I 20 they say was -- if I can find it --20 would have reached the same conclusion without Dr. 21 21 I'm sorry, let me -- I have it in my report. Reed's opinion. 22 If I find it, it will save rather than looking in --22 Q. Okay. But you took the time to put Dr. 23 23 Reed's testimony in on this; correct? Q. I read it in your report. Let's move on. 24 24 A. Okay. A. I did. 25 Q. If we can direct your attention to page 14 25 Q. Okay. And then you say, "Use of

42 (Pages 165 to 168)

	Page 169		Page 171
1	chlorhexidine alcohol has been reported to reduce SSI	1	A. I do.
2	by up to 40 percent compared to po poviodone-	2	Q. It says:
3	iodine"	3	"but not against organ-space infections."
4	Did I say that right?	4	Do you see that?
5	A. No, but it's close enough.	5	A. I do.
6	Q. How do you say that?	6	Q. 4.4 percent to 4.5 percent; correct?
7	A. Poviodine.	7	A. Correct.
8	Q. Poviodine-iodine.	8	Q. Okay. So how is it that this study supports
9	A. Poviodone.	9	your conclusion that the change in skin preparation
10	Q. Poviodone.	10	during the McGovern period was a confounder?
11	A. I actually normally put a incorrectly put	11	A. I think it provides evidence of decreased
12	an "r" in the word. That's okay, I will take however	12	wound infections, and I believe wound infections lead
13	you say it.	13	to, mechanistically, deep infections and conceivably
14	Q "povidone-iodine and it reduced	14	joint infections.
15	infections related to vascular catheters by 49	15	Q. How did you rely on this study when the
16	percent." Correct?	16	authors found virtually no change in deep joint
17	A. Correct.	17	infections
18	Q. That didn't involve deep joint infections,	18	MR. GORDON: Object to the form
19	correct,	19	Q between the two protocols?
20	A. No, it did not.	20	MR. GORDON: Object to the form,
21	Q in arthroplastic or hip hip and knee	21	mischaracterizes the evidence.
22	replacements; correct?	22	A. It provides evidence of decreased deep wound
23	A. Correct.	23	infections. I believe that is a risk for the joint
24	Q. And you also cite in that sentence to	24	infections.
25	reference 33, which is a Darouiche reference; correct?	2.5	Q. I'm sorry, can you say what you said again?
1	Page 170	1	Page 172
1	A. Correct.	1	A. I said it decreases deep infections, and I
2	Q. Let me pull that out for you.	2	believe that's a risk for joint infections. But I
3	(Exhibit 19 was marked for	3	would defer on that opinion probably to Dr. Wenzel.
4	identification.)	4	Q. How how does a microbe from the skin get
5	THE WITNESS: Thank you.	5	onto an implant?
6 7	BY MS. CONLIN:	6	A. It depends on the circumstance. I think
8	Q. I've handed you, sir, what's been marked as	8	that, for example, it can swim through the tissues.  Q. So it starts on the skin and decides it
	Deposition Exhibit 19, which is an article entitled		•
9 10	"Chlorhexidine-Alcohol versus Povidone-Iodine for	9	wants to land on the implant and it swims down?  A. I don't know whether it makes a conscious
11	Surgical-Site Antisepsis." Do you see that?	11	
12	<ul><li>A. I do.</li><li>Q. And the lead author on this is Dr.</li></ul>	12	decision, but I think that there is a spread that can
13	Q. And the lead author on this is Dr.  Darouiche;	13	O Okay But you don't think that it can be
14	A. Correct.	14	Q. Okay. But you don't think that it can be floating in the air and drop down, it's got to swim
15	Q correct? And I'd like	15	through the tissue?
16	And this was something you relied on to say	16	A. I don't know that. I've said only that I
17	that the change in skin preparation during the	17	see no evidence that the air dispersion results in
18	McGovern period was a confounder; correct?	18	increased infections.
19	A. Correct.	19	Q. Okay. And in your mind there is that
20	Q. So let's take a look at the results section	20	if that if something decreases a deep tissue
21	on this. It says about midway down, "Chlorhexidine-	21	infection, it should also decrease the risk of a deep
22	alcohol was significantly more protective than	22	joint infection?
23	povidone-iodine against both superficial incisional	23	A. I think it's reasonable to me, but it's not
	infections and deep incisional infections"	2.4	my area of expertise and it's not an expert opinion
24 25	infections and deep incisional infections" Do you see that?	24 25	my area of expertise and it's not an expert opinion that I'm rendering.

43 (Pages 169 to 172)

Page 175 Page 173 1 Q. Okay. Well you'd agree with me that looking 1 "There is also evidence that the combination of MSSA 2 at the Darouiche article suggests that there is no 2 screening and chlorhexidine was complementary, 3 difference for deep joint infections between these two 3 resulting in a five-fold reduction in deep SSI 4 4 compared -- compared to the placebo." Do you see 5 5 that? MR. GORDON: Jan, again I'm going to assume 6 you're -- you're -- you're not doing this 6 A. Yes. 7 7 intentionally. Darouiche says nothing about joint Q. Okay. And let me pull that out for you. 8 8 infections. (Exhibit 20 was marked for 9 9 Q. What do you understand -identification.) 10 10 MR. GORDON: It was clean contaminated BY MS. CONLIN: 11 11 Q. I have handed you what's been marked as surgery. 12 Q. What do -- what do you think organ-space 12 Borak Exhibit 20, which is the Bode reference which 13 13 infections is? supports your statement in your report that there's A. I would have assumed it was things like also evidence that a combination of MSSA screening and 14 14 intrapleural infections or peritoneal infections. But 15 15 chlorhexidine was complementary, resulting in a 16 your point is well taken. I can't define that term 16 five-fold reduction in deep SSI compared to placebo; 17 right now. 17 correct? 18 Q. Okay. Now what was the change in skin 18 A. Yes. 19 Q. Okay. Now what was the placebo that was 19 preparation protocol during McGovern? 20 A. The adoption of chlorhexidine as opposed to 20 used in this study? A. I would have to look back. 21 21 poviodine-iodine, which was effected in October of 22 22 They describe it as "placebo," which I 23 Q. You reference here that the "CDC found 23 assume would -- may have been inactive, but I do not 2.4 24 know. I don't see a description of --'high-quality evidence suggested a benefit of CHG-25 alcohol [chlorohex -- chlorhexidine gluconate-alcohol] 25 MR. GORDON: It's on page 11, the Page 174 Page 176 1 as compared with aqueous iodophor." Do you see that? 1 randomization. 2 2 A. I do. MS. CONLIN: You don't need to help him. 3 Q. Okay. There was no point in time during the 3 I'm trying to get his understanding, Mr. Gordon, of 4 McGovern period where aqueous iodophor was being used. 4 what he had in mind when he --5 A. I believe that's the povidone-iodine analog. 5 MR. GORDON: Jan, we can --6 Q. But it wasn't the same. 6 If you -- if you want to know what was in 7 7 A. It may not have been exactly the same. one of the dozens of articles he cited, you can either 8 There were several variants of the iodine that was 8 take the time and he'll read through it all, or I --9 9 You know, sorry, I won't point him to it. 10 10 Q. Okay. And you think that a -- that even But just so I understand, next time he'll -- he'll --11 though there -- well let me strike that and ask it a 11 he'll read it in its entirety. 12 12 different way. A. Okay. So it's the "Placebo soap and 13 13 If it wasn't aqueous iodophor that was ever ointment were identical to the active treatment except 14 used for McGovern, what relevance if any does the CDC 14 for the active ingredients," so it was inactive. 15 15 Q. So the placebo didn't have any antimicrobial findings that you've stated here have? 16 A. This statement that chlorhexidine, in the 16 effect; correct? 17 views of CDC, was preferable to what was then the most 17 A. That's my understanding. 18 used iodine for skin treatment was meaningful to me. 18 Q. Okay. So do you think it's appropriate to 19 Q. So if something is slightly different, you 19 rely on a placebo study for your conclusion that the 2.0 still think it's okay to use it and extrapolate to 20 change in skin preparation during the McGovern study 21 21 that in connection with your conclusions in this case? was a confounder? 22 A. I thought that there was high-quality 22 A. I think it reflects the fact that the two 23 evidence that this chlorhexidine was useful. But I 23 were interactive and complementary; that is, the 2.4 24 understand your question about the direct comparison. mech -- the chlorhexidine and the screening. But I do 25 Q. Then you also cite here -- or you state, 25 understand that this is a comparison against placebo.

44 (Pages 173 to 176)

	Page 177		Page 179
1	Q. Right. And so did you see anything that had	1	Stirewalt.
2	a comparison that showed a statistical difference	2	(Holford Exhibit 9 handed to the witness.)
3	between the skin preparation used at the beginning of	3	THE WITNESS: Thank you.
4	the McGovern study and the skin preparation that was	4	Q. I've handed you what was marked as Holford
5	implemented in October 2010?	5	Deposition Exhibit 9, which is the Darouiche study
6	A. The iodophor is the only head-to-head that I	6	entitled "Association of Airborne Microorganisms in
7	can point to here at this moment.	7	the Operating Room With Implant Infections: A
8	Q. Okay. And you know that wasn't the exact	8	Randomized Controlled Trial." Do you see that?
9	one; correct?	9	A. Yes, I do.
10	A. I think it was not exact. I could look it	10	Q. And do you do you agree with me that an
11	up again. I know I looked at it at one time.	11	RCT is, in terms of the pecking order of evidence that
12	Q. Do you have any evidence as you sit there	12	you rely on in an epidemiologic study, a step above
13	A. As I sit here today	13	observational studies?
14	Q of a pub of a published study that	14	A. Generally, if it's well done.
15	suggests a material difference between the two skin-	15	Q. Okay. And you see it says the objective is
16	preparation protocols and a risk of a deep joint	16	"To evaluate the association"
17	infection?	17	By the way, do you know if this this is
18	A. I don't know that I can point to one now,	18	the same Dr. Darouiche that you relied on in
19	but this again is something to which I will defer to	19	connection with your opinions regarding skin
20	Dr. Wenzel.	20	preparation;
21	Q. Okay. But without evidence, you're still	21	A. I'm aware.
22	comfortable opining that there is an association, at	22	Q correct?
23	least as it relates to skin preparation; correct?	23	MR. GORDON: Dick, your
24	A. I think I was carefully nuanced in my	24	It (referring to realtime screens) stopped.
25	statement, which was "To the extent that use of	25	I don't I don't care for myself, but I just want
	Page 178		Page 180
1	Page 178 chlorhexidine reduced infections, it would be a	1	Page 180 you to if that means your computer screwed up, I
1 2		1 2	
	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the		you to if that means your computer screwed up, I
2	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do	2	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please.
2	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me	2	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.)
2 3 4 5 6	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin	2 3 4 5 6	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN:
2 3 4 5 6 7	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me	2 3 4 5 6 7	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some
2 3 4 5 6 7 8	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was	2 3 4 5 6 7 8	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine
2 3 4 5 6 7 8	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison	2 3 4 5 6 7 8	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right?
2 3 4 5 6 7 8 9	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right.	2 3 4 5 6 7 8 9	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right?  A. Correct.
2 3 4 5 6 7 8 9 10	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right. A to offer you today.	2 3 4 5 6 7 8 9 10	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right?  A. Correct. Q. And that's something that you've learned
2 3 4 5 6 7 8 9 10 11 12	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right. A to offer you today. Q. Right. But you're still comfortable saying	2 3 4 5 6 7 8 9 10 11	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right?  A. Correct. Q. And that's something that you've learned since you've been sitting here?
2 3 4 5 6 7 8 9 10 11 12 13	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right.  A to offer you today.  Q. Right. But you're still comfortable saying there's an association.	2 3 4 5 6 7 8 9 10 11 12	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I
2 3 4 5 6 7 8 9 10 11 12 13	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right.  A to offer you today.  Q. Right. But you're still comfortable saying there's an association.  A. I think that there might be.	2 3 4 5 6 7 8 9 10 11 12 13 14	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I was sitting here after your you took a break.
2 3 4 5 6 7 8 9 10 11 12 13 14	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right. A to offer you today. Q. Right. But you're still comfortable saying there's an association.  A. I think that there might be. Q. Okay. There might be?	2 3 4 5 6 7 8 9 10 11 12 13 14	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I was sitting here after your you took a break. Q. Yeah. Go ahead.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right. A to offer you today. Q. Right. But you're still comfortable saying there's an association.  A. I think that there might be. Q. Okay. There might be? A. I don't have any evidence to ful complete	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I was sitting here after your you took a break. Q. Yeah. Go ahead. A. Yeah. It's the same thing as povidone-
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right. A to offer you today. Q. Right. But you're still comfortable saying there's an association.  A. I think that there might be. Q. Okay. There might be? A. I don't have any evidence to ful complete the last sentence, which I gave you before, which was	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I was sitting here after your you took a break. Q. Yeah. Go ahead. A. Yeah. It's the same thing as povidone- iodine.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right. A to offer you today. Q. Right. But you're still comfortable saying there's an association.  A. I think that there might be. Q. Okay. There might be? A. I don't have any evidence to ful complete the last sentence, which I gave you before, which was that if there was a reduction from the chlorhexidine,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I was sitting here after your you took a break. Q. Yeah. Go ahead. A. Yeah. It's the same thing as povidone- iodine. Q. And in connection with your CDC statement
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right.  A to offer you today.  Q. Right. But you're still comfortable saying there's an association.  A. I think that there might be.  Q. Okay. There might be?  A. I don't have any evidence to ful complete the last sentence, which I gave you before, which was that if there was a reduction from the chlorhexidine, it would be a confounder, and I don't have any field	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I was sitting here after your you took a break. Q. Yeah. Go ahead. A. Yeah. It's the same thing as povidone- iodine. Q. And in connection with your CDC statement there, do you know whether the CDC was referencing
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right.  A to offer you today.  Q. Right. But you're still comfortable saying there's an association.  A. I think that there might be.  Q. Okay. There might be?  A. I don't have any evidence to ful complete the last sentence, which I gave you before, which was that if there was a reduction from the chlorhexidine, it would be a confounder, and I don't have any field data in the McGovern study showing that it wasn't.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I was sitting here after your you took a break. Q. Yeah. Go ahead. A. Yeah. It's the same thing as povidone- iodine. Q. And in connection with your CDC statement there, do you know whether the CDC was referencing wound infections generally versus deep joint
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right.  A to offer you today.  Q. Right. But you're still comfortable saying there's an association.  A. I think that there might be.  Q. Okay. There might be?  A. I don't have any evidence to ful complete the last sentence, which I gave you before, which was that if there was a reduction from the chlorhexidine, it would be a confounder, and I don't have any field data in the McGovern study showing that it wasn't.  Q. All right. I'd like to go to your next	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I was sitting here after your you took a break. Q. Yeah. Go ahead. A. Yeah. It's the same thing as povidone- iodine. Q. And in connection with your CDC statement there, do you know whether the CDC was referencing wound infections generally versus deep joint infections?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right.  A to offer you today.  Q. Right. But you're still comfortable saying there's an association.  A. I think that there might be.  Q. Okay. There might be?  A. I don't have any evidence to ful complete the last sentence, which I gave you before, which was that if there was a reduction from the chlorhexidine, it would be a confounder, and I don't have any field data in the McGovern study showing that it wasn't.  Q. All right. I'd like to go to your next section	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I was sitting here after your you took a break. Q. Yeah. Go ahead. A. Yeah. It's the same thing as povidone- iodine. Q. And in connection with your CDC statement there, do you know whether the CDC was referencing wound infections? A. I can't tell you that right now.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right. A to offer you today. Q. Right. But you're still comfortable saying there's an association. A. I think that there might be. Q. Okay. There might be? A. I don't have any evidence to ful complete the last sentence, which I gave you before, which was that if there was a reduction from the chlorhexidine, it would be a confounder, and I don't have any field data in the McGovern study showing that it wasn't. Q. All right. I'd like to go to your next section Actually, let's go back to page 12.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I was sitting here after your you took a break. Q. Yeah. Go ahead. A. Yeah. It's the same thing as povidone- iodine. Q. And in connection with your CDC statement there, do you know whether the CDC was referencing wound infections generally versus deep joint infections? A. I can't tell you that right now. Q. Okay. So back to the point before the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	chlorhexidine reduced infections, it would be a confounder."  Q. But my point is is you you said at the beginning of this module that we started that you do believe it's a confounder, but you'll agree with me that you don't have any evidence that the skin change in skin preparation during the McGovern period was  A. I do not have a direct comparison Q. Right.  A to offer you today.  Q. Right. But you're still comfortable saying there's an association.  A. I think that there might be.  Q. Okay. There might be?  A. I don't have any evidence to ful complete the last sentence, which I gave you before, which was that if there was a reduction from the chlorhexidine, it would be a confounder, and I don't have any field data in the McGovern study showing that it wasn't.  Q. All right. I'd like to go to your next section	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	you to if that means your computer screwed up, I don't want to THE REPORTER: Let's go off the record, please. (Discussion off the record.) BY MS. CONLIN: Q. So I take it during the break you did some internet searching in connection with your iodine aqueous iodophor; is that right? A. Correct. Q. And that's something that you've learned since you've been sitting here? A. It's something I affirmed in my mind since I was sitting here after your you took a break. Q. Yeah. Go ahead. A. Yeah. It's the same thing as povidone- iodine. Q. And in connection with your CDC statement there, do you know whether the CDC was referencing wound infections? A. I can't tell you that right now.

	D 101		D 102
	Page 181		Page 183
1	in skin preparation during the McGovern period	1	Q. Right. And you hadn't seen the fact that
2	creates or is a confounder associated with risk of	2	the manufacturer of the Bair Hugger warned at the FDA
3	infection; correct?	3	of the risk of airborne contamination; correct?
4	A. I cannot tell you whether article 33	4	MR. GORDON: Object to the form of the
5	specifically looked at that, no, not now as we are	5	question.
6	sitting here.	6	A. I if you'll
7	Q. Now if we can turn to Holford Deposition	7	I think you're referring to that five oh
8	Exhibit 9, the article entitled "Association of	8	512(k) or something?
9	Airborne Micronis Microorganisms in the Operating	9	Q. 510(k), yes.
10	Room With Implant Infections," you see I think	10	A. I think there was a statement there that
11	we talked about this before the break that Dr.	11	there was no evidence of infections resulting
12	Darouiche is the same doctor who you cited in	12	therefrom.
13	connection his study in connection with your skin-	13	Q. I didn't ask you about that. Can you answer
14	preparation section of your report; correct?	14	my question?
15	A. That's correct.	15	A. Ask the question again.
16	Q. And the objective of this article is "To	16	Q. Sure.
17	evaluate the association of airborne colony-forming	17	MS. CONLIN: Could you read it back, Mr.
18	units (CFU) at incision sites during implantation of	18	Court Reporter.
19	prostheses with incidence of either incisional or	19	(Record read by the court reporter.)
20	prosthesis-related surgical site infections;" correct?	20	A. I guess that was a statement in that paper.
21	A. Yes.	21	Q. I'd like to turn back now to page 12 of your
22	Q. Okay. And if we can take a look at the last	22	report, the prophylactic antibiotics. And you
23	page of this, the "In conclusion," Drs. Darouiche	23	understand that during the McGovern period there was a
24	and the other study authors of this randomized	24	change in Gentamicin to Gentamicin plus Teicoplanin?
25	clinical trial write, quote, "In conclusion, our	25	A. Yes.
	Page 182		Page 184
1	Page 182		Page 184
1	results indicate that CFU contamination of air at the	1	Q. Okay. Can I refer to the Gentamicin period
2	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not	2	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?
2	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related	2 3	<ul><li>Q. Okay. Can I refer to the Gentamicin period</li><li>as Gen and the Gentamicin plus Teicoplanin as GenTeic?</li><li>A. Sure.</li></ul>
2 3 4	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision	2 3 4	<ul> <li>Q. Okay. Can I refer to the Gentamicin period</li> <li>as Gen and the Gentamicin plus Teicoplanin as GenTeic?</li> <li>A. Sure.</li> <li>Q. Okay. And you'll understand what I'm</li> </ul>
2 3 4 5	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a	2 3 4 5	<ul> <li>Q. Okay. Can I refer to the Gentamicin period</li> <li>as Gen and the Gentamicin plus Teicoplanin as GenTeic?</li> <li>A. Sure.</li> <li>Q. Okay. And you'll understand what I'm referring to.</li> </ul>
2 3 4 5 6	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating	2 3 4 5 6	<ul> <li>Q. Okay. Can I refer to the Gentamicin period</li> <li>as Gen and the Gentamicin plus Teicoplanin as GenTeic?</li> <li>A. Sure.</li> <li>Q. Okay. And you'll understand what I'm referring to.</li> <li>A. I think so.</li> </ul>
2 3 4 5 6 7	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the	2 3 4 5 6 7	<ul> <li>Q. Okay. Can I refer to the Gentamicin period</li> <li>as Gen and the Gentamicin plus Teicoplanin as GenTeic?</li> <li>A. Sure.</li> <li>Q. Okay. And you'll understand what I'm referring to.</li> <li>A. I think so.</li> <li>Q. And I take it that you found the change in</li> </ul>
2 3 4 5 6 7 8	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant	2 3 4 5 6 7 8	<ul> <li>Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?</li> <li>A. Sure.</li> <li>Q. Okay. And you'll understand what I'm referring to.</li> <li>A. I think so.</li> <li>Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I</li> </ul>
2 3 4 5 6 7 8	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?	2 3 4 5 6 7 8	<ul> <li>Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?</li> <li>A. Sure.</li> <li>Q. Okay. And you'll understand what I'm referring to.</li> <li>A. I think so.</li> <li>Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?</li> </ul>
2 3 4 5 6 7 8 9	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.	2 3 4 5 6 7 8 9	<ul> <li>Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?</li> <li>A. Sure.</li> <li>Q. Okay. And you'll understand what I'm referring to.</li> <li>A. I think so.</li> <li>Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?</li> <li>A. It appeared to confound, yes.</li> </ul>
2 3 4 5 6 7 8 9 10	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular	2 3 4 5 6 7 8 9 10	<ul> <li>Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?</li> <li>A. Sure.</li> <li>Q. Okay. And you'll understand what I'm referring to.</li> <li>A. I think so.</li> <li>Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?</li> <li>A. It appeared to confound, yes.</li> <li>Q. Okay. Meaning that there is an association</li> </ul>
2 3 4 5 6 7 8 9 10 11	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is	2 3 4 5 6 7 8 9 10 11	<ul> <li>Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?</li> <li>A. Sure.</li> <li>Q. Okay. And you'll understand what I'm referring to.</li> <li>A. I think so.</li> <li>Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?</li> <li>A. It appeared to confound, yes.</li> <li>Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic</li> </ul>
2 3 4 5 6 7 8 9 10 11 12	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is described in Holford Deposition Exhibit 9; correct?	2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?  A. Sure. Q. Okay. And you'll understand what I'm referring to.  A. I think so. Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?  A. It appeared to confound, yes. Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic and risk of infection; correct?
2 3 4 5 6 7 8 9 10 11 12 13	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is described in Holford Deposition Exhibit 9; correct?  A. This paper? Yes, I did not. This paper	2 3 4 5 6 7 8 9 10 11 12 13 14	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?  A. Sure. Q. Okay. And you'll understand what I'm referring to.  A. I think so. Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?  A. It appeared to confound, yes. Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic and risk of infection; correct?  A. Yes. And they were differentially the
2 3 4 5 6 7 8 9 10 11 12	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is described in Holford Deposition Exhibit 9; correct?	2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?  A. Sure. Q. Okay. And you'll understand what I'm referring to.  A. I think so. Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?  A. It appeared to confound, yes. Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic and risk of infection; correct?  A. Yes. And they were differentially the antibiotics were differentially associated with the
2 3 4 5 6 7 8 9 10 11 12 13 14 15	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is described in Holford Deposition Exhibit 9; correct?  A. This paper? Yes, I did not. This paper does not deal with Bair Hugger.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?  A. Sure. Q. Okay. And you'll understand what I'm referring to.  A. I think so. Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?  A. It appeared to confound, yes. Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic and risk of infection; correct?  A. Yes. And they were differentially the
2 3 4 5 6 7 8 9 10 11 12 13 14 15	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is described in Holford Deposition Exhibit 9; correct?  A. This paper? Yes, I did not. This paper does not deal with Bair Hugger.  Q. Well it deals with CFUs in the air near the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?  A. Sure. Q. Okay. And you'll understand what I'm referring to.  A. I think so. Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?  A. It appeared to confound, yes. Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic and risk of infection; correct?  A. Yes. And they were differentially the antibiotics were differentially associated with the two different warming units.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is described in Holford Deposition Exhibit 9; correct?  A. This paper? Yes, I did not. This paper does not deal with Bair Hugger.  Q. Well it deals with CFUs in the air near the implant; correct?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?  A. Sure. Q. Okay. And you'll understand what I'm referring to.  A. I think so. Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?  A. It appeared to confound, yes. Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic and risk of infection; correct?  A. Yes. And they were differentially the antibiotics were differentially associated with the two different warming units. Q. What do you mean by "warming units?"
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is described in Holford Deposition Exhibit 9; correct?  A. This paper? Yes, I did not. This paper does not deal with Bair Hugger.  Q. Well it deals with CFUs in the air near the implant; correct?  A. Yes. Yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?  A. Sure. Q. Okay. And you'll understand what I'm referring to.  A. I think so. Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?  A. It appeared to confound, yes. Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic and risk of infection; correct?  A. Yes. And they were differentially the antibiotics were differentially associated with the two different warming units. Q. What do you mean by "warming units?"  A. Bair Hugger versus Hot Dog.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is described in Holford Deposition Exhibit 9; correct?  A. This paper? Yes, I did not. This paper does not deal with Bair Hugger.  Q. Well it deals with CFUs in the air near the implant; correct?  A. Yes. Yes.  Q. Okay. And you've already stated you don't	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?  A. Sure. Q. Okay. And you'll understand what I'm referring to.  A. I think so. Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?  A. It appeared to confound, yes. Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic and risk of infection; correct?  A. Yes. And they were differentially the antibiotics were differentially associated with the two different warming units. Q. What do you mean by "warming units?"  A. Bair Hugger versus Hot Dog. Q. Oh, okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is described in Holford Deposition Exhibit 9; correct?  A. This paper? Yes, I did not. This paper does not deal with Bair Hugger.  Q. Well it deals with CFUs in the air near the implant; correct?  A. Yes. Yes.  Q. Okay. And you've already stated you don't have an opinion whether Bair Hugger increases CFUs in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?  A. Sure. Q. Okay. And you'll understand what I'm referring to.  A. I think so. Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?  A. It appeared to confound, yes. Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic and risk of infection; correct?  A. Yes. And they were differentially the antibiotics were differentially associated with the two different warming units. Q. What do you mean by "warming units?"  A. Bair Hugger versus Hot Dog. Q. Oh, okay. What investigation did you do to ascertain
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is described in Holford Deposition Exhibit 9; correct?  A. This paper? Yes, I did not. This paper does not deal with Bair Hugger.  Q. Well it deals with CFUs in the air near the implant; correct?  A. Yes. Yes.  Q. Okay. And you've already stated you don't have an opinion whether Bair Hugger increases CFUs in the air at the incisional site; correct?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?  A. Sure. Q. Okay. And you'll understand what I'm referring to. A. I think so. Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right? A. It appeared to confound, yes. Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic and risk of infection; correct? A. Yes. And they were differentially the antibiotics were differentially associated with the two different warming units. Q. What do you mean by "warming units?" A. Bair Hugger versus Hot Dog. Q. Oh, okay. What investigation did you do to ascertain that, with respect to prosthetic joint infections
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	results indicate that CFU contamination of air at the incision site is a risk factor for implant but not incisional infections. CFU contamination is related to the particulate density in the air at the incision site, and both CFU and particulate density are a function of the number of people in the operating room. Limiting airborne CFU contamination at the incision site can be expected to lower implant infection risk." Do you see that?  A. I see that.  Q. And you didn't opine on this particular article or challenge the validity of the RCT that is described in Holford Deposition Exhibit 9; correct?  A. This paper? Yes, I did not. This paper does not deal with Bair Hugger.  Q. Well it deals with CFUs in the air near the implant; correct?  A. Yes. Yes.  Q. Okay. And you've already stated you don't have an opinion whether Bair Hugger increases CFUs in the air at the incisional site; correct?  MR. GORDON: Objection, mischaracterizes his	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. Can I refer to the Gentamicin period as Gen and the Gentamicin plus Teicoplanin as GenTeic?  A. Sure. Q. Okay. And you'll understand what I'm referring to.  A. I think so. Q. And I take it that you found the change in prophylactic antibiotics to be a confounder; am I right?  A. It appeared to confound, yes. Q. Okay. Meaning that there is an association between the change in the in from Gen to GenTeic and risk of infection; correct?  A. Yes. And they were differentially the antibiotics were differentially associated with the two different warming units. Q. What do you mean by "warming units?"  A. Bair Hugger versus Hot Dog. Q. Oh, okay.  What investigation did you do to ascertain that, with respect to prosthetic joint infections not just infections in general but prosthetic joint

46 (Pages 181 to 184)

	Page 185		Page 187
1	A. Well I read a lot of literature and I	1	describe it, but yes, I think in effect that's what
2	evaluated, as I could, the papers that were put in	2	happens.
3	front of me by my search on McGowan McGovern, and I	3	Q. And you can't deliver that much antibiotic
4	looked at statements from Dr. Reed and others that	4	to a patient that can penetrate that, and that's one
5	seemed to be that there was evidence that there was an	5	of the reasons why deep joint infections take a while
6	increase in infections when Gentamicin was used alone	6	to show up; correct?
7	and a decrease when Teicoplanin was added.	7	MR. GORDON: Same objection.
8	Q. Well if anything, then, GenTeic would	8	A. I don't think I don't think that's why it
9	increase the risk of deep joint infections in Hot Dog;	9	takes a while for them to show up, but
10	correct?	10	Q. Have you seen articles that have concluded
11	A. Why would that be?	11	that the benefits of prophylactic antibiotics in
12	Q. Well did you did you analyze whether	12	reducing infection rates after clean surgeries are
13	there was an increase or decrease in infections	13	unclear?
14	related to the Gen versus GenTeic period, or did you	14	MR. GORDON: Object to the form of the
15	rely on Professor Holford for that analysis?	15	question.
16	A. I I didn't independently review any	16	A. I don't know that I've seen that.
17	arithmetic calculations, if that's your question.	17	Q. Okay. That wasn't something you came
18	Q. Okay. Well you understand that during the	18	across?
19	Hot Dog period GenTeic was used; correct?	19	A. I don't remember it.
20	A. Correct.	20	Q. Well how did you go about making the
21	Q. Exclusively. All right.	21	decision that the change in prophylactic antibiotics
22	Did you understand that, based on Professor	22	would have a material effect on risk of infection in a
23	Holford's analysis, patients who received Gen had a	23	prosthetic joint?
24	deep joint infection rate of 1.92 while patients who	24	MR. GORDON: Object to the form of the
25	received GenTeic had a 3.13 percent infection rate?	25	question.
	Page 186		Page 188
1	Page 186  A. Would you point me to where those numbers	1	Page 188  A. There was a series. One of them was the
1 2		1 2	
	A. Would you point me to where those numbers		A. There was a series. One of them was the
2	A. Would you point me to where those numbers are found?	2	A. There was a series. One of them was the differential capacity of the antibiotics to act upon
2	<ul><li>A. Would you point me to where those numbers are found?</li><li>Q. I'm just asking if you know.</li></ul>	2	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with
2 3 4	<ul><li>A. Would you point me to where those numbers are found?</li><li>Q. I'm just asking if you know.</li><li>A. I</li></ul>	2 3 4	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the
2 3 4 5	<ul> <li>A. Would you point me to where those numbers are found?</li> <li>Q. I'm just asking if you know.</li> <li>A. I Off the top of my head, I don't remember the</li> </ul>	2 3 4 5	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that
2 3 4 5 6	<ul> <li>A. Would you point me to where those numbers are found?</li> <li>Q. I'm just asking if you know.</li> <li>A. I Off the top of my head, I don't remember the numbers.</li> </ul>	2 3 4 5 6	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to
2 3 4 5 6 7	<ul> <li>A. Would you point me to where those numbers are found?</li> <li>Q. I'm just asking if you know.</li> <li>A. I Off the top of my head, I don't remember the numbers.</li> <li>Q. Okay. So how can you determine that</li> </ul>	2 3 4 5 6 7	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others
2 3 4 5 6 7 8	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?	2 3 4 5 6 7 8	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have
2 3 4 5 6 7 8 9	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr.	2 3 4 5 6 7 8 9 10	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.
2 3 4 5 6 7 8 9	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.	2 3 4 5 6 7 8 9 10 11	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the
2 3 4 5 6 7 8 9 10	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr.	2 3 4 5 6 7 8 9 10 11 12 13	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the effectiveness, how can you opine that it's a
2 3 4 5 6 7 8 9 10 11	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.	2 3 4 5 6 7 8 9 10 11 12 13 14	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the
2 3 4 5 6 7 8 9 10 11 12	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.  Q. Well, are you aware of any evidence showing	2 3 4 5 6 7 8 9 10 11 12 13	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the effectiveness, how can you opine that it's a
2 3 4 5 6 7 8 9 10 11 12 13 14	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.  Q. Well, are you aware of any evidence showing that antibiotics are of limited value in warding off	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the effectiveness, how can you opine that it's a confounder?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.  Q. Well, are you aware of any evidence showing that antibiotics are of limited value in warding off or preventing deep joint infections?  MR. GORDON: Object to the form of the question.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the effectiveness, how can you opine that it's a confounder?  A. I have a statement from Dr. Reed from this operating room who said that the infection rate went up significantly when they used Gentamicin, and we
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.  Q. Well, are you aware of any evidence showing that antibiotics are of limited value in warding off or preventing deep joint infections?  MR. GORDON: Object to the form of the question.  A. I I have read, as you asked me earlier,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics.  But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the effectiveness, how can you opine that it's a confounder?  A. I have a statement from Dr. Reed from this operating room who said that the infection rate went up significantly when they used Gentamicin, and we have evidence that the infectious rate infection
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.  Q. Well, are you aware of any evidence showing that antibiotics are of limited value in warding off or preventing deep joint infections?  MR. GORDON: Object to the form of the question.  A. I I have read, as you asked me earlier, that biofilm can reduce the effectiveness of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics.  But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the effectiveness, how can you opine that it's a confounder?  A. I have a statement from Dr. Reed from this operating room who said that the infection rate went up significantly when they used Gentamicin, and we have evidence that the infectious rate infection rate declined after the adoption of Teicoplanin.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.  Q. Well, are you aware of any evidence showing that antibiotics are of limited value in warding off or preventing deep joint infections?  MR. GORDON: Object to the form of the question.  A. I I have read, as you asked me earlier, that biofilm can reduce the effectiveness of antibiotics, if that was your question.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the effectiveness, how can you opine that it's a confounder?  A. I have a statement from Dr. Reed from this operating room who said that the infection rate went up significantly when they used Gentamicin, and we have evidence that the infectious rate infection rate declined after the adoption of Teicoplanin.  Q. I thought you just said you didn't do that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.  Q. Well, are you aware of any evidence showing that antibiotics are of limited value in warding off or preventing deep joint infections?  MR. GORDON: Object to the form of the question.  A. I I have read, as you asked me earlier, that biofilm can reduce the effectiveness of antibiotics, if that was your question.  Q. Right. And it it basically creates a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the effectiveness, how can you opine that it's a confounder?  A. I have a statement from Dr. Reed from this operating room who said that the infection rate went up significantly when they used Gentamicin, and we have evidence that the infectious rate infection rate declined after the adoption of Teicoplanin.  Q. I thought you just said you didn't do that analysis.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.  Q. Well, are you aware of any evidence showing that antibiotics are of limited value in warding off or preventing deep joint infections?  MR. GORDON: Object to the form of the question.  A. I I have read, as you asked me earlier, that biofilm can reduce the effectiveness of antibiotics, if that was your question.  Q. Right. And it it basically creates a slime or a a a film over the infection and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the effectiveness, how can you opine that it's a confounder?  A. I have a statement from Dr. Reed from this operating room who said that the infection rate went up significantly when they used Gentamicin, and we have evidence that the infectious rate infection rate declined after the adoption of Teicoplanin.  Q. I thought you just said you didn't do that analysis.  A. I I was looking at just the the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.  Q. Well, are you aware of any evidence showing that antibiotics are of limited value in warding off or preventing deep joint infections?  MR. GORDON: Object to the form of the question.  A. I I have read, as you asked me earlier, that biofilm can reduce the effectiveness of antibiotics, if that was your question.  Q. Right. And it it basically creates a slime or a a a film over the infection and antibiotics can't get at it; correct?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the effectiveness, how can you opine that it's a confounder?  A. I have a statement from Dr. Reed from this operating room who said that the infection rate went up significantly when they used Gentamicin, and we have evidence that the infectious rate infection rate declined after the adoption of Teicoplanin.  Q. I thought you just said you didn't do that analysis.  A. I I was looking at just the the the crude numbers. I didn't do the analysis, I looked at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Would you point me to where those numbers are found?  Q. I'm just asking if you know.  A. I  Off the top of my head, I don't remember the numbers.  Q. Okay. So how can you determine that something is a confounder if you didn't even look at that issue as it relates to the infection rates between the two?  A. On the numerical thing, I relied upon Dr. Holford's mathematical analysis.  Q. Well, are you aware of any evidence showing that antibiotics are of limited value in warding off or preventing deep joint infections?  MR. GORDON: Object to the form of the question.  A. I I have read, as you asked me earlier, that biofilm can reduce the effectiveness of antibiotics, if that was your question.  Q. Right. And it it basically creates a slime or a a a film over the infection and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. There was a series. One of them was the differential capacity of the antibiotics to act upon the bacteria that were most commonly associated with the infections, a second I thought interesting was the comment which I've quoted from Dr. Reed who said that "Our infection rate doubled when we went to Gentamicin," and I am sure that I there were others at the moment I can't think of by name which have shown the effectiveness of prophylactic antibiotics. But in large part I would defer that, in terms of the effectiveness, to Dr. Wenzel.  Q. Well if you don't have an opinion on the effectiveness, how can you opine that it's a confounder?  A. I have a statement from Dr. Reed from this operating room who said that the infection rate went up significantly when they used Gentamicin, and we have evidence that the infectious rate infection rate declined after the adoption of Teicoplanin.  Q. I thought you just said you didn't do that analysis.  A. I I was looking at just the the

47 (Pages 185 to 188)

	Page 189	Page	191
1	statement that the infection rate doubled when we went	1 references that you relied upon in connection wit	h
2	to Gentamicin; correct?	2 your opinions; correct? For example, reference n	
3	A. That was his statement, yes.	four on your list of documents relied upon.	
4	Q. Okay. And and that was a statement that,	4 A. Yes. I skipped it somehow. Thanks.	
5	when you read that, you said, "Okay, I'm going to rely	5 Q. All right. So this is	
6	on Dr. Reed for that." Right?	6 This author of Exhibit 21 is the same doctor	or
7	A. I thought that was an interesting statement.	as one of the other references that you relied upon	
8	Q. And you said, "I'm going to rely on that;"	8 connection with your expert opinions in this case	
9	right?	9 correct?	,
10	A. Yes.	10 A. Presumably. And this may even be the	same
11	Q. And then when Dr. Reed said things you	paper.	
12	didn't agree with, you just set those aside; isn't	12 Q. Okay.	
13	that right?	13 A. How do you like that?	
14	A. To some extent that's correct.	Q. All right. So if we can take a look under	
15	Q. Okay. Cherry-picking, isn't that what it's	15 "Introduction," one, two, three four paragraphs	3
16	called?	down, it says, "Many factors have been shown to	
17	A. No, no, no, no. I can explain how I got	the incidence of surgical wound infection, most of	
18	there, so that's not cherry-picking.	which are now part of best practice. The value o	
19	Q. Okay. Do you know whether Dr. Reed was	prophylactic antibiotics in clean-contaminated ar	
20	talking about deep joint infections versus superficial	contaminated surgery is not contentious but the	
21	wound infections?	benefits of prophylactic antibiotics in reducing w	ound
22	A. Not without looking back at the document.	infection rates after clean surgery remain unclear	
23	Q. Okay. Do you know whether antibiotics are	23 Although it has been suggested that antibiotics ar	
24	better and perhaps more efficacious when it relates to	beneficial this idea has not been supported by oth	
25	wound infections as opposed to deep joint infections?	25 studies." Do you see that?	
		•	
	Page 190	Page	192
1	Page 190  A. I I don't know for sure.	Page 1 A. I see that.	192
1 2			9 192
	A. I I don't know for sure.	1 A. I see that.	192
2	<ul><li>A. I I don't know for sure.</li><li>Q. That wasn't something you investigated when</li></ul>	<ol> <li>A. I see that.</li> <li>Q. Okay. So this</li> </ol>	192
2	<ul><li>A. I I don't know for sure.</li><li>Q. That wasn't something you investigated when you reached your conclusion that the change in</li></ul>	<ol> <li>A. I see that.</li> <li>Q. Okay. So this</li> <li>I take it you had read this before you</li> </ol>	
2 3 4	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep	1 A. I see that. 2 Q. Okay. So this 3 I take it you had read this before you 4 rendered your opinions in this case; correct?	
2 3 4 5	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?	1 A. I see that. 2 Q. Okay. So this 3 I take it you had read this before you 4 rendered your opinions in this case; correct? 5 A. I'm sure I'd read this before I rendered	red my
2 3 4 5 6	<ul> <li>A. I I don't know for sure.</li> <li>Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?</li> <li>A. I did not independently investigate that question.</li> <li>Q. Do you believe that the that any changes</li> </ul>	A. I see that.  Q. Okay. So this  I take it you had read this before you rendered your opinions in this case; correct?  A. I'm sure I'd read this before I rende opinions.  Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be	red my ided tween
2 3 4 5 6 7	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.	1 A. I see that. 2 Q. Okay. So this 3 I take it you had read this before you 4 rendered your opinions in this case; correct? 5 A. I'm sure I'd read this before I rende 6 opinions. 7 Q. Okay. And one of the reasons you dec	red my ided tween
2 3 4 5 6 7 8	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?	A. I see that.  Q. Okay. So this  I take it you had read this before you rendered your opinions in this case; correct?  A. I'm sure I'd read this before I rende opinions.  Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be	red my ided tween ction is
2 3 4 5 6 7 8	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the	1 A. I see that. 2 Q. Okay. So this 3 I take it you had read this before you 4 rendered your opinions in this case; correct? 5 A. I'm sure I'd read this before I rende 6 opinions. 7 Q. Okay. And one of the reasons you dec 8 that there wasn't evidence of an association be 9 the Bair Hugger and the increased risk of infer 10 because there were studies on both sides; right 11 talked about that this morning.	red my ided tween ction is
2 3 4 5 6 7 8 9	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infer because there were studies on both sides; right talked about that this morning.  A. I think that's right.	red my ided tween ction is t? We
2 3 4 5 6 7 8 9 10 11 12	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infect because there were studies on both sides; right talked about that this morning.  A. I think that's right. Q. Okay. And this is an article that's sayi	red my ided tween ction is t? We
2 3 4 5 6 7 8 9 10 11	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.  (Exhibit 21 was marked for	A. I see that.  Q. Okay. So this  I take it you had read this before you rendered your opinions in this case; correct?  A. I'm sure I'd read this before I rendered opinions.  Q. Okay. And one of the reasons you decreated that there wasn't evidence of an association beto the Bair Hugger and the increased risk of inference of the property of the because there were studies on both sides; right talked about that this morning.  A. I think that's right.  Q. Okay. And this is an article that's saying that there's sort of studies on both sides on when the property of the p	red my ided tween ction is ? We
2 3 4 5 6 7 8 9 10 11 12	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infect because there were studies on both sides; right talked about that this morning.  A. I think that's right. Q. Okay. And this is an article that's sayi that there's sort of studies on both sides on wh even administering any antibiotic or prophy	red my ided tween etion is t? We
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.  (Exhibit 21 was marked for	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infect because there were studies on both sides; right talked about that this morning. A. I think that's right. Q. Okay. And this is an article that's sayi that there's sort of studies on both sides on wh even administering any antibiotic or prophy antibiotic after a clean surgery is unclear; corr	red my ided tween etion is t? We
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.  (Exhibit 21 was marked for identification.)  BY MS. CONLIN:  Q. I've handed you what's been marked as	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infect because there were studies on both sides; right talked about that this morning. A. I think that's right. Q. Okay. And this is an article that's sayi that there's sort of studies on both sides on wh that there's sort of studies on both sides on wh that there's sort of studies on both sides on wh that there's sort of studies on both sides on wh That was the starting premise, yes.	ided tween ction is t? We ng ether lactic rect?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.  (Exhibit 21 was marked for identification.)  BY MS. CONLIN:  Q. I've handed you what's been marked as Deposition Exhibit 21, which is an article by Dr.	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infer because there were studies on both sides; right talked about that this morning. A. I think that's right. Q. Okay. And this is an article that's sayi that there's sort of studies on both sides on wh even administering any antibiotic or prophy antibiotic after a clean surgery is unclear; corr A. That was the starting premise, yes. Q. Okay. But you've decided that the cha	ided of tween oction is 1? We of the rection is 1. The rection is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.  (Exhibit 21 was marked for identification.)  BY MS. CONLIN:  Q. I've handed you what's been marked as Deposition Exhibit 21, which is an article by Dr. Melling et al, quote, "Effects of preoperative warming	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infer because there were studies on both sides; right talked about that this morning. A. I think that's right. Q. Okay. And this is an article that's sayi that there's sort of studies on both sides on wh even administering any antibiotic or prophy antibiotic after a clean surgery is unclear; corr A. That was the starting premise, yes. Q. Okay. But you've decided that the cha antibiotics was a confounder in connection wi	ided of tween oction is 1? We of the rection is 1. The rection is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.  (Exhibit 21 was marked for identification.)  BY MS. CONLIN:  Q. I've handed you what's been marked as Deposition Exhibit 21, which is an article by Dr. Melling et al, quote, "Effects of preoperative warming on the incidence of wound infection after clean	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infer because there were studies on both sides; right talked about that this morning. A. I think that's right. Q. Okay. And this is an article that's sayi that there's sort of studies on both sides on wh even administering any antibiotic or prophy antibiotic after a clean surgery is unclear; corr A. That was the starting premise, yes. Q. Okay. But you've decided that the cha antibiotics was a confounder in connection wi McGovern; correct?	ided of tween oction is 1? We of the rection is 1. The rection is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.  (Exhibit 21 was marked for identification.)  BY MS. CONLIN:  Q. I've handed you what's been marked as Deposition Exhibit 21, which is an article by Dr. Melling et al, quote, "Effects of preoperative warming on the incidence of wound infection after clean surgery: a randomized controlled trial." Do you see	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infer because there were studies on both sides; right talked about that this morning.  A. I think that's right. Q. Okay. And this is an article that's sayi that there's sort of studies on both sides on wh even administering any antibiotic or prophy antibiotic after a clean surgery is unclear; corr A. That was the starting premise, yes. Q. Okay. But you've decided that the cha antibiotics was a confounder in connection wi McGovern; correct?  A. Based on the McGovern data, yes.	red my ided tween ction is t? We  ng ether lactic ect?  nge in th
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.  (Exhibit 21 was marked for identification.)  BY MS. CONLIN:  Q. I've handed you what's been marked as Deposition Exhibit 21, which is an article by Dr. Melling et al, quote, "Effects of preoperative warming on the incidence of wound infection after clean surgery: a randomized controlled trial." Do you see that?	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infect because there were studies on both sides; right talked about that this morning. A. I think that's right. Q. Okay. And this is an article that's sayi that there's sort of studies on both sides on wh even administering any antibiotic or prophy antibiotic after a clean surgery is unclear; corr A. That was the starting premise, yes. Q. Okay. But you've decided that the cha antibiotics was a confounder in connection wi McGovern; correct?  A. Based on the McGovern data, yes. Q. You know the authors said that it wasn	red my ided tween ction is t? We  ng ether lactic ect?  nge in th
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.  (Exhibit 21 was marked for identification.)  BY MS. CONLIN:  Q. I've handed you what's been marked as Deposition Exhibit 21, which is an article by Dr. Melling et al, quote, "Effects of preoperative warming on the incidence of wound infection after clean surgery: a randomized controlled trial." Do you see that?  A. I do.	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infect because there were studies on both sides; right talked about that this morning. A. I think that's right. Q. Okay. And this is an article that's sayi that there's sort of studies on both sides on wh even administering any antibiotic or prophy antibiotic after a clean surgery is unclear; corr A. That was the starting premise, yes. Q. Okay. But you've decided that the cha antibiotics was a confounder in connection wi McGovern; correct?  A. Based on the McGovern data, yes. Q. You know the authors said that it wasn confounder in their mind; correct?	ided atween ction is t? We ang ether lactic ect?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I I don't know for sure.  Q. That wasn't something you investigated when you reached your conclusion that the change in antibiotics was a confounder as it related to deep joint infections during the McGovern period; correct?  A. I did not independently investigate that question.  Q. Do you believe that the that any changes in wound dressing post surgery during the McGovern period is a confounder?  A. I believe they changed dressings after the end of the McGovern study.  Q. Okay.  (Exhibit 21 was marked for identification.)  BY MS. CONLIN:  Q. I've handed you what's been marked as Deposition Exhibit 21, which is an article by Dr. Melling et al, quote, "Effects of preoperative warming on the incidence of wound infection after clean surgery: a randomized controlled trial." Do you see that?	A. I see that. Q. Okay. So this I take it you had read this before you rendered your opinions in this case; correct? A. I'm sure I'd read this before I rende opinions. Q. Okay. And one of the reasons you dec that there wasn't evidence of an association be the Bair Hugger and the increased risk of infec because there were studies on both sides; right talked about that this morning. A. I think that's right. Q. Okay. And this is an article that's sayi that there's sort of studies on both sides on wh even administering any antibiotic or prophy antibiotic after a clean surgery is unclear; corr A. That was the starting premise, yes. Q. Okay. But you've decided that the cha antibiotics was a confounder in connection wi McGovern; correct? A. Based on the McGovern data, yes. Q. You know the authors said that it wasn	ided atween ction is t? We ang ether lactic ect?

48 (Pages 189 to 192)

Page 193 Page 195 1 (Exhibit 22 was marked for 1 A. I would have to look it up. And I think it 2 identification.) 2 was muc -- mupirocin that was used, but I could look 3 BY MS. CONLIN: 3 4 Q. I've handed you, sir, what's been marked as 4 Probably it was in Gillson, but I'm not 5 5 Deposition Exhibit 22, which is a study entitled sure. 6 "Prophylactic antibiotics in elective hip and knee 6 Q. Okay. In connection with --7 7 arthroplasty," authored by Dr. Hickson among others. MS. CONLIN: Well I'll dig that out. Why 8 8 Do you see that? don't we just take a quick break here; we've been 9 9 A. I do. going about an hour anyway. 10 10 Q. You see that Dr. Reed is also an author on THE REPORTER: Off the record, please. 11 this? 11 (Recess taken.) 12 A. I do. 12 (Exhibit 23 was marked for 13 13 Q. Okay. If we can take a look at page 186 of identification.) 14 this. 14 BY MS. CONLIN: 15 15 A. May I just look at the abstract first, Q. I've handed you, sir, what's been marked as 16 make --16 Deposition -- Borak Deposition Exhibit 23, which is 17 Q. Sure. 17 entitled "Implementing effective SSI surveillance" by 18 A. Okay. Thank you. 18 Julie Gillson and Gail Lowdon. 19 19 Q. Can you direct your attention to page 186 of Is this what you were referencing before the 20 this, and direct your attention to the second 20 break in connection with your understanding that once 21 21 paragraph down starting with "Although..." It says, MSSA screening was undertaken in January of 2010, 22 "Although there is a large body of evidence for the 22 there was decolonization with a topical antibiotic? 23 use of prophylactic antibiotics in primary hip and 23 A. This is the article I was referring to. 24 knee arthroplasty, there is no clear benefit to using 24 Q. Okay. And then I'd just ask you to point 25 one particular agent/regimen." Do you see that? 25 out for me where in the article the actual Page 194 Page 196 1 A. I do. 1 decolonization procedure is outlined. I'll just 2 2 Q. Okay. Do you have any reason to dispute the represent to you I -- I couldn't find it, so --3 statements by Drs. Reed and Hickson as reported in 3 MR. GORDON: I'll save you both time. It's 4 this --4 not in there. 5 A. I --5 A. I -- I --6 6 Q. -- article? At the moment I don't see it. I'm not sure 7 7 A. I don't. if it's in the table, which I can't see. 8 Q. Okay. So I'd like to direct your attention 8 Q. I'll represent to you that I blew that up 9 to page 13 of your report regarding the MSSA 9 and it doesn't say it there either, so I'm just 10 10 screening. curious --11 11 MR. GORDON: I'll -- I'll stipulate to that. 12 12 Q. And I take it you also find that there is an MS. CONLIN: Okay. 13 13 association between MSSA screening and an increased Q. So where -- where did you get this notion 14 risk of a prosthetic joint infection; correct? 14 that the screening was followed by a decolonization 15 15 with a topical antibiotic mupir --A. I believe that's correct, yes. 16 Q. Okay. And you said that there was screening 16 A. Mupirocin. implemented for MSSA, or methicillin sensitive 17 17 Q. -- mupirocin? 18 Streptococcus aureus, correct, in January of 2010? 18 A. I think that I --19 A. Yes, I did say that. 19 If I didn't find it in here and if I did not 2.0 Q. Okay. And is it -- and you also say that 20 see it in Dr. Reed's testimony, then I presume I 21 21 there -assumed that it would be the only purpose for doing 22 Well, do you know if there was 22 the MSSA screening; that is, to detect and then to 23 23 decolonization after that? respond to it. 24 24 A. That's my understanding. Q. Well I guess my point is is how do you know 25 Q. And what was the decolonization protocol? 25 it was that particular topical antibiotic versus

49 (Pages 193 to 196)

1 MR. GORDON: Dotted green or blue? 2 A. That is the one that has been used almost 3 universally, so I I am reasonably certain that I 4 I would have expected that. And I thought I knew 5 that, but at the moment sitting here I can't point to 6 a place where I found that specific detail. 7 Q. And you again, in connection with this MSSA 8 screening, rely on statements by Dr. Reed; correct? 9 A. Well I pointed to Dr. Reed's statement. 10 Q. Well you relied on it; correct? 11 A. Yes. 12 Q. Okay. 13 A. Oh, okay. There. Okay. So it is Dr. Reed 1 MR. GORDON: Dotted green or blue? 2 MS. CONLIN: Well whatever. It's the dotted line with the circle. 4 Q. Do you see that? 5 A. Yes. 6 MS. CONLIN: Okay. And yeah, it doe blue, Mr. Gordon. Thank you. We'll refer to the dotted blue line. 9 Q. You'll see that there's a reference poin there of September 2008. 11 Right here. 12 Q. Okay. 13 Q. Okay. And then if you look, based on	one es look it as
A. That is the one that has been used almost universally, so I I am reasonably certain that I I would have expected that. And I thought I knew that, but at the moment sitting here I can't point to a place where I found that specific detail.  Q. And you again, in connection with this MSSA screening, rely on statements by Dr. Reed; correct? A. Well I pointed to Dr. Reed's statement.  Q. Well you relied on it; correct?  A. Yes.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  A. Yes.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.  MS. CONLIN: Well whatever. It's the dotted line with the circle.	one es look it as
3 universally, so I I am reasonably certain that I 4 I would have expected that. And I thought I knew 5 that, but at the moment sitting here I can't point to 6 a place where I found that specific detail. 7 Q. And you again, in connection with this MSSA 8 screening, rely on statements by Dr. Reed; correct? 9 A. Well I pointed to Dr. Reed's statement. 10 Q. Well you relied on it; correct? 10 there of September 2008. 11 A. Yes. 12 Q. Okay. 3 dotted line with the circle. 4 Q. Do you see that? 5 A. Yes. 6 MS. CONLIN: Okay. And yeah, it doe blue, Mr. Gordon. Thank you. We'll refer to the dotted blue line. 9 Q. You'll see that there's a reference poin there of September 2008. 11 Right here. 12 A. Yes.	es look it as
4 I would have expected that. And I thought I knew 5 that, but at the moment sitting here I can't point to 6 a place where I found that specific detail. 7 Q. And you again, in connection with this MSSA 8 screening, rely on statements by Dr. Reed; correct? 9 A. Well I pointed to Dr. Reed's statement. 10 Q. Well you relied on it; correct? 11 A. Yes. 12 Q. Okay. 4 Q. Do you see that?  A. Yes. 5 A. Yes. 6 MS. CONLIN: Okay. And yeah, it doe blue, Mr. Gordon. Thank you. We'll refer to the dotted blue line. 9 Q. You'll see that there's a reference poin there of September 2008. 11 Right here. 12 A. Yes.	it as
that, but at the moment sitting here I can't point to a place where I found that specific detail.  Q. And you again, in connection with this MSSA screening, rely on statements by Dr. Reed; correct?  A. Well I pointed to Dr. Reed's statement.  Q. Well you relied on it; correct?  A. Yes.  10 there of September 2008.  11 Right here.  12 Q. Okay.  5 A. Yes.  6 MS. CONLIN: Okay. And yeah, it does blue, Mr. Gordon. Thank you. We'll refer to the dotted blue line.  9 Q. You'll see that there's a reference point there of September 2008.  11 Right here.  12 A. Yes.	it as
6a place where I found that specific detail.6MS. CONLIN: Okay. And yeah, it doe7Q. And you again, in connection with this MSSA7blue, Mr. Gordon. Thank you. We'll refer to8screening, rely on statements by Dr. Reed; correct?8the dotted blue line.9A. Well I pointed to Dr. Reed's statement.9Q. You'll see that there's a reference poin10Q. Well you relied on it; correct?10there of September 2008.11A. Yes.11Right here.12Q. Okay.12A. Yes.	it as
7 Q. And you again, in connection with this MSSA 8 screening, rely on statements by Dr. Reed; correct? 9 A. Well I pointed to Dr. Reed's statement. 10 Q. Well you relied on it; correct? 11 A. Yes. 12 Q. Okay. 17 blue, Mr. Gordon. Thank you. We'll refer to the dotted blue line. 18 Q. You'll see that there's a reference poin there of September 2008. 19 Right here. 10 A. Yes.	it as
8 screening, rely on statements by Dr. Reed; correct? 9 A. Well I pointed to Dr. Reed's statement. 10 Q. Well you relied on it; correct? 11 A. Yes. 12 Q. Okay. 18 the dotted blue line. 9 Q. You'll see that there's a reference poin there of September 2008. 11 Right here. 12 A. Yes.	
10       Q. Well you relied on it; correct?       10 there of September 2008.         11       A. Yes.       11 Right here.         12       Q. Okay.       12 A. Yes.	f
10       Q. Well you relied on it; correct?       10 there of September 2008.         11       A. Yes.       11 Right here.         12       Q. Okay.       12 A. Yes.	
12 Q. Okay. 12 <b>A. Yes.</b>	
•	
13 A. Oh, okay, There, Okay, So it is Dr. Reed 13 O Okay, And then if you look, based on	
2. Only, The dien if you look, based on	this
who literally there said, "After MSSA screening, a 14 graph, MSSA infections went down between	September
decolonization was introduced," and I took for granted 15 2008 and October 2009; correct?	
that that was referring to this time in this study of 16 A. It seems to be.	
concern that we have with McGovern. 17 Q. Okay. And then after October 2009 to	)
Q. Okay. Did you do any analysis as to whether 18 November 2011, you'll see there's an uptick;	correct?
19 MSSA infections went up after MSSA screening and 19 A. I do see that.	
20 decolonization was implemented in January 2010? 20 Q. Okay. Is that something that you	
A. I understand from conversations I did not 21 investigated in connection with your view that	
look at the raw data that there were none reported 22 MSSA screening renders the McGov is a co	onfounder to
23 <b>after the introduction of that process.</b> 23 the McGovern report?	
Q. So you would disagree that there was an 24 MR. GORDON: Object to the form of	the
25 uptick in infections after MSSA screening was 25 question.	
Page 198	age 200
1 implemented? 1 A. I would not have looked at this since	this
2 A. I thought that there were no MSSA 2 is a composite of all of the hospitals in Engl.	
3 infections. 3 think it is all of them and it is all forms of	
4 (Exhibit 24 was marked for 4 surgery, and so I'm not quite sure what one	e could have
5 identification.) 5 drawn from this or what it would have told	
6 BY MS. CONLIN: 6 than the fact that there was heterogeneity in	n the
7 Q. I've handed you, sir, what's been marked as 7 <b>operating room procedures in the NHS hos</b>	pitals.
8 Borak Deposition Exhibit 24, which is a document 8 Q. Do you know which hospitals were inc	luded in
9 entitled "Surveillance of surgical site infections in 9 this?	
NHS hospitals in England." Do you see that?  10  A. I'm happy to look at the beginning.	
11 <b>A. I do.</b> 11 Q. Well you just said it includes all the	
12 Q. Okay. And is this something you've seen 12 hospitals. I'm wondering if you know that or y	ou're
13 before? 13 just assuming that.	
14 A. I have seen documents that look like this. 14 A. I am assuming it based upon what I	
15 I don't know if this is the one I saw. 15 quick look at the document, but I'm happy	
16 Q. Okay. If we can direct your attention to 16 <b>further.</b> "Since July 2008 hospitals were re	-
	k for
17 page 30, 17 I mean I'm happy to take time to look	
18 A. Yes. 18 the number, but	
18 <b>A. Yes.</b> 18 <b>the number, but</b> 19 Q Figure 11, "Trends in micro-organisms 19 Q. No. I I was just curious, when you s	
18 A. Yes. 19 Q Figure 11, "Trends in micro-organisms 20 reported as causing inpatient SSIs, proportions with 18 the number, but 19 Q. No. I I was just curious, when you s 20 that it included more hospitals than the three at	t
18 A. Yes.  19 Q Figure 11, "Trends in micro-organisms 20 reported as causing inpatient SSIs, proportions with 21 lower and upper 95 percent confidence, all surgical  18 the number, but  Q. No. I I was just curious, when you s that it included more hospitals than the three are issue in McGovern, whether you knew that or	t
18 A. Yes.  19 Q Figure 11, "Trends in micro-organisms 20 reported as causing inpatient SSIs, proportions with 21 lower and upper 95 percent confidence, all surgical 22 categories, NHS hospitals, England." Do you see that?  18 the number, but  19 Q. No. I I was just curious, when you s that it included more hospitals than the three a issue in McGovern, whether you knew that or just speculating.	t you were
18 A. Yes. 19 Q Figure 11, "Trends in micro-organisms 20 reported as causing inpatient SSIs, proportions with 21 lower and upper 95 percent confidence, all surgical 22 categories, NHS hospitals, England." Do you see that? 23 A. I do.  18 the number, but Q. No. I I was just curious, when you see that it included more hospitals than the three a issue in McGovern, whether you knew that or just speculating. 22 A. Oh, no, no, no, I'm not speculating, I was provided in the number, but Q. No. I I was just curious, when you see that it included more hospitals than the three and issue in McGovern, whether you knew that or just speculating. 23 A. Oh, no, no, no, no, I'm not speculating, I was just curious, when you see that it included more hospitals than the three and issue in McGovern, whether you knew that or just speculating.	t you were
18 A. Yes.  19 Q Figure 11, "Trends in micro-organisms 20 reported as causing inpatient SSIs, proportions with 21 lower and upper 95 percent confidence, all surgical 22 categories, NHS hospitals, England." Do you see that?  18 the number, but  19 Q. No. I I was just curious, when you s that it included more hospitals than the three a issue in McGovern, whether you knew that or just speculating.	t you were

50 (Pages 197 to 200)

Page 203 Page 201 1 A. This is a composite of the NHS system. We 1 (Exhibit 25 was marked for 2 are looking at, in McGovern, one hospital. 2 identification.) 3 Q. Okay. But you --3 BY MS. CONLIN: 4 Your view is that because the MSSA data on 4 Q. I've handed you, sir, what's been marked as 5 that chart we just looked at isn't specific to deep 5 Borak Exhibit 25, which I think is your reference --6 joint infections, it wouldn't be a fair comparison; is 6 A. I think it's number 30. 7 7 that right? Q. -- your reference number 30; correct? 8 8 A. No. It wouldn't be a fair comparison A. I believe that's correct. 9 9 because it's looking at, I believe, most if not all of Q. Thank you. Okay. And this was one of the 10 the NHS hospitals in England. I don't know about 10 things that you relied on to suggest that 11 their implementation of procedures and protocols. I 11 decolonization with a topical antibiotic, mupirocin, 12 believe I saw something here about a lack of 12 has been shown to significantly reduce risk of post-13 13 consistency in the applications of protocols. I think surgical infections, including hip and knee 14 there are a variety of other considerations. So I 14 replacements; correct? 15 15 wouldn't use this to inform my thinking about A. Yes. 16 16 Northumbria. Q. Okay. I'd like to direct your attention to 17 Q. And one of the reasons that you just stated 17 the third paragraph of this article. 18 that you didn't think it would be a fair comparison is 18 A. After the introduction or in the abstract? 19 because it's including other surgeries, not just deep 19 Q. Internal page 2385. Got a chart at the top. 20 joint infections; correct? 20 A. Third page. I thought you said paragraph. 21 21 A. Yes. Okay. 22 Q. Other types of infections. 22 Q. In the paragraph about "Of the 19 23 23 studies..." A. Yes. Q. And you don't think it would be fair to 24 2.4 A. "Of the 19 studies..." Yes. 25 extrapolate from one type of infection in one part of 25 Q. On the right-hand side, midway down, it Page 202 Page 204 1 the body to a deep joint infection even if it's MSSA; 1 says, "The majority of studies detected S. aureus 2 2 correct? colonization using cultures, most SSIs were defined by 3 A. I -- I --3 CDC criteria, the majority of studies did not Yes. I think this would raise the question 4 4 differentiate between superfer -- superficial versus 5 5 deep infections, and most of the patients who whether this added or altered my thinking, and I 6 referred ultimately to a comment which came literally 6 underwent decolonization were positive for S. aureus 7 from Dr. Reed who said that "In the fight against 7 on nasal screens." Do you see that? 8 PJI" -- prosthetic joint infections -- "after MSSA 8 A. I do. 9 screening and decolonization was introduced, one NHS 9 Q. In connection with your discussion of MSSA 10 10 joint replacement unit, the MSSA infection was reduced screening, you bundled infections regardless of 11 from .84 to .26." I believe that is speaking about 11 whether they were deep joint infections; correct? 12 12 Wansbeck, though in looking at the document I couldn't MR. GORDON: Object to the form of the 13 13 tell which of the three hospitals it was, but I question. 14 presume it is because it's where there was the data. 14 A. I cited a paper which I think may have 15 MS. CONLIN: Move to strike as non-15 bundled it. 16 responsive. 16 Q. In -- in support of your belief that the 17 Can you read my question back? 17 implementation of MSSA screening and decolonization is a confounding factor in McGovern; correct? 18 (Record read by the court reporter.) 18 19 A. I -- I have difficulty extrapolating from 19 A. Yes. Correct. 2.0 this document. I might also have --2.0 (Exhibit 26 was marked for 21 Q. I didn't ask you that. I asked you a 21 identification.) 22 straight-up question. 22 THE WITNESS: Thank you. 23 MS. CONLIN: Could you read it back again. 23 BY MS. CONLIN: 24 2.4 (Record read by the court reporter.) Q. I've handed you what's been marked as Borak 25 A. It might not be fair. 25 Exhibit 26, which is a JAMA survey entitled "Centers

51 (Pages 201 to 204)

	Page 205		Page 207
1	for Disease Control and Preven Prevention Guideline	1	basically a low-molecular-weight heparin similar to
2	for the Prevention of Surgical Site Infection, 2017;"	2	trinzaparin, compared to Xarelto, which
3	correct?	3	A. I know that it
4	A. Correct.	4	MR. GORDON: Object to the form of the
5	Q. And this was something that you relied on in	5	question.
6	connection with your opinions in this case; correct?	6	A. They they reviewed a number of studies,
7	A. Correct.	7	none of which compared trinzaparin.
8	Q. Okay. I'd like to direct	8	Q. So you were aware of that.
9	Now by the way, you understand that this	9	A. Yes.
10	particular recommendation didn't advocate one type of	10	Q. And your point is is you can't rely on that
11	patient warming over another; correct?	11	because enoxaparin is even though it's another type
12	A. I don't remember that.	12	of low-molecular-weight heparin, it's not the same as
13	Q. Okay. That they said keep patients warm,	13	trinzaparin; correct?
14	but they didn't advocate a specific	14	A. Well that was one, and the second is that
15	A. Okay. That is probably correct. I don't	15	the papers they reference don't actually define
16	specifically remember.	16	surgical infection.
17	Q. And you're not suggesting that there's	17	Q. So with respect
18	something special about the Bair Hugger that keeps a	18	Well fair point. You'd agree with me that
19	patient warmer; correct?	19	you got to know whether it's a deep joint infection or
20	A. I understood that the Bair Hugger warmed	20	some other type of infection.
21 22	more quickly, but I can't tell you where I know that from.	22	A. I I I didn't I didn't know what
23	Q. Okay. Now if we can take a look at E4,	23	they were looking at. I tried. It was cited only In each of the four papers they reference
24	under "Normothermia," do you see that	24	there, it is only cited in a table with a footnote,
25	A. Yes.	25	and the footnote doesn't lead is a is a
23			and the roothote doesn't read is a is a is a
	Page 206		Page 208
1	Page 206  Q in the left-hand side underneath	1	Page 208 blind path.
1 2		1 2	<b>blind path.</b> Q. Okay. And you set aside the
	<ul><li>Q in the left-hand side underneath</li><li>"Glycemic Control?"</li><li>A. Yes.</li></ul>		<b>blind path.</b> Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a
2 3 4	<ul> <li>Q in the left-hand side underneath</li> <li>"Glycemic Control?"</li> <li>A. Yes.</li> <li>Q. At the end of it it says, "Other</li> </ul>	2 3 4	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto
2 3 4 5	<ul> <li>Q in the left-hand side underneath</li> <li>"Glycemic Control?"</li> <li>A. Yes.</li> <li>Q. At the end of it it says, "Other</li> <li>Guidelines section of the narrative summary for this</li> </ul>	2 3 4 5	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?
2 3 4 5 6	Q in the left-hand side underneath "Glycemic Control?"  A. Yes.  Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you	2 3 4 5 6	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.
2 3 4 5 6 7	Q in the left-hand side underneath "Glycemic Control?"  A. Yes.  Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?	2 3 4 5 6 7	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate
2 3 4 5 6 7 8	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes.	2 3 4 5 6 7 8	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's
2 3 4 5 6 7 8	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to	2 3 4 5 6 7 8	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that
2 3 4 5 6 7 8 9	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did.	2 3 4 5 6 7 8 9	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?
2 3 4 5 6 7 8 9 10	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that	2 3 4 5 6 7 8 9 10	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.
2 3 4 5 6 7 8 9 10 11	Q in the left-hand side underneath "Glycemic Control?"  A. Yes.  Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes.  Q. Okay. Did you look at that supplement to A. I believe I did.  Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG-	2 3 4 5 6 7 8 9 10 11	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.  Q. And that's one of the reasons you set it
2 3 4 5 6 7 8 9 10 11 12	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG-alcohol compared to iodophor alcohol; correct?	2 3 4 5 6 7 8 9 10 11 12	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.  Q. And that's one of the reasons you set it aside; correct?
2 3 4 5 6 7 8 9 10 11 12 13 14	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG- alcohol compared to iodophor alcohol; correct?  A. I actually don't recall that.	2 3 4 5 6 7 8 9 10 11 12 13	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.  Q. And that's one of the reasons you set it aside; correct?  A. Correct.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG- alcohol compared to iodophor alcohol; correct?  A. I actually don't recall that. Q. Okay. Are you aware that the CDC found no	2 3 4 5 6 7 8 9 10 11 12 13 14	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.  Q. And that's one of the reasons you set it aside; correct?  A. Correct.  Q. Now I'd like to direct your attention to
2 3 4 5 6 7 8 9 10 11 12 13 14	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG- alcohol compared to iodophor alcohol; correct?  A. I actually don't recall that.	2 3 4 5 6 7 8 9 10 11 12 13	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.  Q. And that's one of the reasons you set it aside; correct?  A. Correct.  Q. Now I'd like to direct your attention to page nine of your expert report, Borak Exhibit 1, "The
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG- alcohol compared to iodophor alcohol; correct?  A. I actually don't recall that. Q. Okay. Are you aware that the CDC found no benefit to CHG versus povidone-iodine?  A. I don't recall that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.  Q. And that's one of the reasons you set it aside; correct?  A. Correct.  Q. Now I'd like to direct your attention to page nine of your expert report, Borak Exhibit 1, "The McGovern Study: Background." Are you there?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG- alcohol compared to iodophor alcohol; correct?  A. I actually don't recall that. Q. Okay. Are you aware that the CDC found no benefit to CHG versus povidone-iodine?  A. I don't recall that. Q. Okay. Would that be something that would be	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	blind path. Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison. Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different. Q. And that's one of the reasons you set it aside; correct? A. Correct. Q. Now I'd like to direct your attention to page nine of your expert report, Borak Exhibit 1, "The McGovern Study: Background." Are you there?  A. I am.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG- alcohol compared to iodophor alcohol; correct?  A. I actually don't recall that. Q. Okay. Are you aware that the CDC found no benefit to CHG versus povidone-iodine?  A. I don't recall that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.  Q. And that's one of the reasons you set it aside; correct?  A. Correct.  Q. Now I'd like to direct your attention to page nine of your expert report, Borak Exhibit 1, "The McGovern Study: Background." Are you there?  A. I am.  Q. Okay. And in paragraph 22 you say, "The
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG- alcohol compared to iodophor alcohol; correct?  A. I actually don't recall that. Q. Okay. Are you aware that the CDC found no benefit to CHG versus povidone-iodine?  A. I don't recall that. Q. Okay. Would that be something that would be important in connection with your view that the change	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	blind path. Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison. Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different. Q. And that's one of the reasons you set it aside; correct? A. Correct. Q. Now I'd like to direct your attention to page nine of your expert report, Borak Exhibit 1, "The McGovern Study: Background." Are you there?  A. I am.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG- alcohol compared to iodophor alcohol; correct?  A. I actually don't recall that. Q. Okay. Are you aware that the CDC found no benefit to CHG versus povidone-iodine?  A. I don't recall that. Q. Okay. Would that be something that would be important in connection with your view that the change in skin preparation is a confounder that undercuts the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.  Q. And that's one of the reasons you set it aside; correct?  A. Correct.  Q. Now I'd like to direct your attention to page nine of your expert report, Borak Exhibit 1, "The McGovern Study: Background." Are you there?  A. I am.  Q. Okay. And in paragraph 22 you say, "The report report by McGovern is the only published
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG- alcohol compared to iodophor alcohol; correct?  A. I actually don't recall that. Q. Okay. Are you aware that the CDC found no benefit to CHG versus povidone-iodine?  A. I don't recall that. Q. Okay. Would that be something that would be important in connection with your view that the change in skin preparation is a confounder that undercuts the validity of McGovern?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.  Q. And that's one of the reasons you set it aside; correct?  A. Correct.  Q. Now I'd like to direct your attention to page nine of your expert report, Borak Exhibit 1, "The McGovern Study: Background." Are you there?  A. I am.  Q. Okay. And in paragraph 22 you say, "The report report by McGovern is the only published study that purports to show an increased risk of SSI
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG- alcohol compared to iodophor alcohol; correct?  A. I actually don't recall that. Q. Okay. Are you aware that the CDC found no benefit to CHG versus povidone-iodine?  A. I don't recall that. Q. Okay. Would that be something that would be important in connection with your view that the change in skin preparation is a confounder that undercuts the validity of McGovern?  A. I would probably go back and look at it	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.  Q. And that's one of the reasons you set it aside; correct?  A. Correct.  Q. Now I'd like to direct your attention to page nine of your expert report, Borak Exhibit 1, "The McGovern Study: Background." Are you there?  A. I am.  Q. Okay. And in paragraph 22 you say, "The report report by McGovern is the only published study that purports to show an increased risk of SSI associated with the use of the Bair Hugger."
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q in the left-hand side underneath "Glycemic Control?"  A. Yes. Q. At the end of it it says, "Other Guidelines section of the narrative summary for this question (eAppendix 1 one of the Supplement)." Do you see that?  A. Yes. Q. Okay. Did you look at that supplement to A. I believe I did. Q. Okay. So you're aware that in that supplement the CDC found no benefit to using CHG- alcohol compared to iodophor alcohol; correct?  A. I actually don't recall that. Q. Okay. Are you aware that the CDC found no benefit to CHG versus povidone-iodine?  A. I don't recall that. Q. Okay. Would that be something that would be important in connection with your view that the change in skin preparation is a confounder that undercuts the validity of McGovern?  A. I would probably go back and look at it again, and I may do so tonight.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	blind path.  Q. Okay. And you set aside the thromboprophylaxis discussion because you didn't see a comparison between between trinzaparin and Xarelto directly; correct?  A. I did not see such a comparison.  Q. And you felt like it would be inappropriate to use the reference to enoxaparin even though it's similar to trinzaparin because it's different; is that right?  A. It's different.  Q. And that's one of the reasons you set it aside; correct?  A. Correct.  Q. Now I'd like to direct your attention to page nine of your expert report, Borak Exhibit 1, "The McGovern Study: Background." Are you there?  A. I am.  Q. Okay. And in paragraph 22 you say, "The report report by McGovern is the only published study that purports to show an increased risk of SSI associated with the use of the Bair Hugger."  A. I did say that.

52 (Pages 205 to 208)

	Page 209		Page 211
1	paper that's been published; correct?	1	sure.
2	A. Correct.	2	A. For the moment. It's possible something
3	Q. And I take it that doesn't change your	3	else will occur to me, but I haven't pulled out my
4	views.	4	notes.
5	A. No. I think little of the Augustine paper.	5	Q. Okay. If the McGovern study is valid, would
6	Q. You think little of the Aug	6	you agree with me that there is a substantial increase
7	Why is that?	7	in the risk of infection through use of the Bair
8	A. It doesn't seem to follow its protocol. It	8	Hugger?
9	seems to have cherry-picked data.	9	MR. GORDON: Object to the form of the
10	Q. What kind of cherry-picking?	10	question.
11	A. Hmm. There are data from Ridgeview Medical	11	A. Hypothetically, if there were no problems
12	Center, that were apparently provided under whatever	12	with the McGovern paper, then its conclusions could be
13	process legally, which shows a compilation of knee and	13	relied upon.
14	hip surgeries and infectious rates for four years,	14	Q. Okay. And it would show a substantial
15	2006, 2007, 2008, 2009. Looking at the recent	15	increased risk of a deep joint infection
16	Augustine paper, it appears that he only dealt with	16	A. Hypothetically, if it were different
17	the knees, not the hips nor the two combined, that he	17	Q through use of Bair Hugger.
18	compared 2006 knees to 2008 and 2009 knees, which was	18	A. Hypothetically, if there were no problems
19	not at all what he said would be the protocol, which	19	with the McGovern paper and if the results as
20	was a two-month or three-month washout period, and	20	presented were correct, then it would show a 3.8-fold
21	that he selectickly selectively excluded the 2007	21	increased risk with the Bair Hugger that was
22	data. And so it doesn't look to me as though the	22	statistically significant.
23	Augustine paper is based upon legitimate data, it	23	Q. Okay. And if
24	looks as though well "legitimate" real but	24	One of the things that Professor Holford did
25	selected in a way to influence the appearance of an	25	is say, well, there Dr. Reed testified he thought
	Page 210		Page 212
1	outcome.	1	there was one more infection in each group, then
2	Q. How about the other two centers?	2	running those numbers is a 2.76 increased risk of
3	A. I don't have any data on them.	3	infection. Would you consider that substantial?
4	Q. Now in paragraph 24	4	MR. GORDON: It's actually 2.86.
5	Oh, by the way, is there anything else that	5	MS. CONLIN: 2.86. Thank you for that
6	you want to say about why you think very little of the	6	correction.
7	Augustine paper?	7	A. The word "substantial" is awfully
8	A. Well it's clear that he doesn't provide	8	subjective. I don't I don't think I used it, but
9	enough information about the cases, and his statement,	9	maybe I would. I would not use it necessarily for
10	which is that nothing else changed, is contradicted by	10	2.76.
11	statements from that Ridgeview Medical Center itself,	11	Q. But for 3.8, you would call that a
12	so my sense of it is that the data are not what he	12	significantly increased odds ratio.
13	presents or that he misrepresents the data, and that	13	A. I I think it was significantly increased.
14	he excluded a year's worth of data which would not	14	I think that's what the arithmetics showed.
15	have enhanced the comparison, that he deviated from	15	Q. Well you used the term "significantly
16	the protocol, and that he excluded the hip data.	16	increased odds ratio"
	Q. Excluded the what? I'm sorry.	17	A. Yes.
17	•	18	Q for SSI during the Bair Hugger period
17 18	A. Excluded the hip data	1	A. Yes.
17 18 19	A. Excluded the hip data Q. Oh "hip." Okay. Yeah.	19	
17 18 19 20	<ul><li>A. Excluded the hip data</li><li>Q. Oh "hip." Okay. Yeah.</li><li>A and did not present the paper properly.</li></ul>	19 20	Q if the McGovern data is accurate;
17 18 19 20 21	<ul> <li>A. Excluded the hip data</li> <li>Q. Oh "hip." Okay. Yeah.</li> <li>A and did not present the paper properly.</li> <li>He says that he did a replica or something I'm</li> </ul>	19 20 21	Q if the McGovern data is accurate; correct?
17 18 19 20 21 22	<ul> <li>A. Excluded the hip data</li> <li>Q. Oh "hip." Okay. Yeah.</li> <li>A and did not present the paper properly.</li> <li>He says that he did a replica or something I'm paraphrasing of the McGovern study, but of course</li> </ul>	19 20 21 22	<ul><li>Q if the McGovern data is accurate; correct?</li><li>A. Yes.</li></ul>
17 18 19 20 21 22 23	A. Excluded the hip data Q. Oh "hip." Okay. Yeah. A and did not present the paper properly. He says that he did a replica or something I'm paraphrasing of the McGovern study, but of course he clearly did not.	19 20 21 22 23	<ul> <li>Q if the McGovern data is accurate;</li> <li>correct?</li> <li>A. Yes.</li> <li>Q. Okay. Now in paragraph 24 you say, "The</li> </ul>
17 18 19 20 21 22	<ul> <li>A. Excluded the hip data</li> <li>Q. Oh "hip." Okay. Yeah.</li> <li>A and did not present the paper properly.</li> <li>He says that he did a replica or something I'm paraphrasing of the McGovern study, but of course</li> </ul>	19 20 21 22	<ul><li>Q if the McGovern data is accurate; correct?</li><li>A. Yes.</li></ul>

53 (Pages 209 to 212)

	Page 213		Page 215
1	antibiotic regimen and two changes in their	1	correct, by both Drs. Reed and McGovern?
2	thromboprophylaxis regimen." Do you see that?	2	A. I certainly quoted from them, yes.
3	A. Ido.	3	(Discussion off the stenographic record.)
4	Q. Where does that quote "unfortunately" come	4	(Exhibit 27 was marked for
5	from?	5	identification.)
6	A. I'd have to look and see whether it's in	6	BY MS. CONLIN:
7	McGovern or in some of the depositions.	7	Q. I've handed you a portion of Dr. McGovern's
8	Q. Okay. So you weren't suggesting an	8	deposition.
9	attribution to the article itself.	9	By the way, did you get both days of Dr.
10	A. I don't know. I can look and see. I don't	10	McGovern's deposition?
11	remember.	11	A. Yes, I did.
12	Q. Okay. And you write in 25 that "The authors	12	Q. Okay.
13	concluded that their study did not establish a causal	13	A. But forgive me, I thought you were asking me
14	basis for an association between Bair Hugger and risk	14	a question a moment ago about Dr. Reed.
15	of SSI;" correct?	15	Q. No, I asked you about one of the authors.
16	A. Yes, that's correct.	16	A. Oh. And I thought you said it was Dr. Reed.
17	Q. Okay. Now you read the depositions of at	17	Maybe I'm wrong. Maybe I misheard.
18	least some of the authors; correct?	18	Q. And if you take a look at the bottom of page
19	A. Yes.	19	114 where Mr. Gordon was questioning him:
20	Q. Okay. And you understand that they hadn't	20	"Question: Based on the evidence, you
21	done a full epidemiological study at the time the	21	believe it would have been reasonable to imply there
22	McGovern paper was published; correct?	22	was a causation?"
23	A. I'm not sure what you mean by "a full	23	Mr. Gordon, quote or
24	epidemiological study," but perhaps you can refer to	24	"Question: Based on the evidence, you
25	the statement that you're referring to.	25	believe it would have been reasonable for your paper
	Page 214		Page 216
1	Page 214  Q. Well you understand that they hadn't gone	1	Page 216 to imply a causal connection?
1 2		1 2	
	Q. Well you understand that they hadn't gone		to imply a causal connection?
2	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the	2	to imply a causal connection?  "Answer: If properly qualified, yes."
2	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they	2	to imply a causal connection?  "Answer: If properly qualified, yes."  Do you see that?
2 3 4	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?	2 3 4	to imply a causal connection?  "Answer: If properly qualified, yes."  Do you see that?  A. I'm sorry, direct me to which page.
2 3 4 5	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said	2 3 4 5	to imply a causal connection?  "Answer: If properly qualified, yes."  Do you see that?  A. I'm sorry, direct me to which page.  Q. Page one internal page 115. Bottom of
2 3 4 5 6	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.	2 3 4 5 6	to imply a causal connection?  "Answer: If properly qualified, yes."  Do you see that?  A. I'm sorry, direct me to which page.  Q. Page one — internal page 115. Bottom of 114, top of 115. Do you see that?
2 3 4 5 6 7	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't	2 3 4 5 6 7	to imply a causal connection?  "Answer: If properly qualified, yes."  Do you see that?  A. I'm sorry, direct me to which page.  Q. Page one — internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which
2 3 4 5 6 7 8	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper;	2 3 4 5 6 7 8	to imply a causal connection?  "Answer: If properly qualified, yes."  Do you see that?  A. I'm sorry, direct me to which page.  Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?"
2 3 4 5 6 7 8	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?	2 3 4 5 6 7 8	to imply a causal connection?  "Answer: If properly qualified, yes."  Do you see that?  A. I'm sorry, direct me to which page.  Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?"  I see what you've read.
2 3 4 5 6 7 8 9	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I	2 3 4 5 6 7 8 9	to imply a causal connection?  "Answer: If properly qualified, yes."  Do you see that?  A. I'm sorry, direct me to which page.  Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?"  I see what you've read.  Q. Okay. And it's your opinion that not only
2 3 4 5 6 7 8 9 10	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.	2 3 4 5 6 7 8 9 10	to imply a causal connection?  "Answer: If properly qualified, yes."  Do you see that?  A. I'm sorry, direct me to which page.  Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?"  I see what you've read.  Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review
2 3 4 5 6 7 8 9 10 11	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.  Q. Okay. And you're aware that at least one of	2 3 4 5 6 7 8 9 10 11	to imply a causal connection?  "Answer: If properly qualified, yes."  Do you see that?  A. I'm sorry, direct me to which page.  Q. Page one — internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?"  I see what you've read.  Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review of all the evidence, but you can't even suggest an
2 3 4 5 6 7 8 9 10 11 12 13	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.  Q. Okay. And you're aware that at least one of the authors testified under oath, under penalty of	2 3 4 5 6 7 8 9 10 11 12 13	to imply a causal connection?  "Answer: If properly qualified, yes." Do you see that?  A. I'm sorry, direct me to which page. Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?" I see what you've read. Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review of all the evidence, but you can't even suggest an association between the Bair Hugger and an increased
2 3 4 5 6 7 8 9 10 11 12 13	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.  Q. Okay. And you're aware that at least one of the authors testified under oath, under penalty of perjury, that a causal connection if properly	2 3 4 5 6 7 8 9 10 11 12 13 14	to imply a causal connection?  "Answer: If properly qualified, yes."  Do you see that?  A. I'm sorry, direct me to which page.  Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?"  I see what you've read.  Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review of all the evidence, but you can't even suggest an association between the Bair Hugger and an increased risk of infection; isn't that right?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.  Q. Okay. And you're aware that at least one of the authors testified under oath, under penalty of perjury, that a causal connection if properly qualified could be made; correct?  MR. GORDON: Object to the form of the question, mischaracterizes the testimony.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	"Answer: If properly qualified, yes." Do you see that?  A. I'm sorry, direct me to which page. Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?" I see what you've read. Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review of all the evidence, but you can't even suggest an association between the Bair Hugger and an increased risk of infection; isn't that right?  A. No. There's clearly an association that's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.  Q. Okay. And you're aware that at least one of the authors testified under oath, under penalty of perjury, that a causal connection if properly qualified could be made; correct?  MR. GORDON: Object to the form of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	"Answer: If properly qualified, yes." Do you see that?  A. I'm sorry, direct me to which page. Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?" I see what you've read. Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review of all the evidence, but you can't even suggest an association between the Bair Hugger and an increased risk of infection; isn't that right?  A. No. There's clearly an association that's been made by the McGovern paper. What I've said is I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.  Q. Okay. And you're aware that at least one of the authors testified under oath, under penalty of perjury, that a causal connection if properly qualified could be made; correct?  MR. GORDON: Object to the form of the question, mischaracterizes the testimony.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	"Answer: If properly qualified, yes." Do you see that?  A. I'm sorry, direct me to which page. Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?" I see what you've read. Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review of all the evidence, but you can't even suggest an association between the Bair Hugger and an increased risk of infection; isn't that right?  A. No. There's clearly an association that's been made by the McGovern paper. What I've said is I find no evidence to indicate that there is a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.  Q. Okay. And you're aware that at least one of the authors testified under oath, under penalty of perjury, that a causal connection if properly qualified could be made; correct?  MR. GORDON: Object to the form of the question, mischaracterizes the testimony.  A. I I don't recall that. Which expert was	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	"Answer: If properly qualified, yes." Do you see that?  A. I'm sorry, direct me to which page. Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?" I see what you've read. Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review of all the evidence, but you can't even suggest an association between the Bair Hugger and an increased risk of infection; isn't that right?  A. No. There's clearly an association that's been made by the McGovern paper. What I've said is I find no evidence to indicate that there is a causation.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.  Q. Okay. And you're aware that at least one of the authors testified under oath, under penalty of perjury, that a causal connection if properly qualified could be made; correct?  MR. GORDON: Object to the form of the question, mischaracterizes the testimony.  A. I I don't recall that. Which expert was that or which author?  Q. I think it was Dr. Reed. I can dig it out. Do you recall reading that?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	"Answer: If properly qualified, yes." Do you see that?  A. I'm sorry, direct me to which page. Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?" I see what you've read. Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review of all the evidence, but you can't even suggest an association between the Bair Hugger and an increased risk of infection; isn't that right?  A. No. There's clearly an association that's been made by the McGovern paper. What I've said is I find no evidence to indicate that there is a causation. Q. Well let's take a look. I thought we went
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.  Q. Okay. And you're aware that at least one of the authors testified under oath, under penalty of perjury, that a causal connection if properly qualified could be made; correct?  MR. GORDON: Object to the form of the question, mischaracterizes the testimony.  A. I I don't recall that. Which expert was that or which author?  Q. I think it was Dr. Reed. I can dig it out.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	"Answer: If properly qualified, yes." Do you see that?  A. I'm sorry, direct me to which page. Q. Page one — internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?" I see what you've read. Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review of all the evidence, but you can't even suggest an association between the Bair Hugger and an increased risk of infection; isn't that right?  A. No. There's clearly an association that's been made by the McGovern paper. What I've said is I find no evidence to indicate that there is a causation.  Q. Well let's take a look. I thought we went over this this morning. It took us a while to establish it. You write in paragraph 74c, "The McGovern
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.  Q. Okay. And you're aware that at least one of the authors testified under oath, under penalty of perjury, that a causal connection if properly qualified could be made; correct?  MR. GORDON: Object to the form of the question, mischaracterizes the testimony.  A. I I don't recall that. Which expert was that or which author?  Q. I think it was Dr. Reed. I can dig it out. Do you recall reading that?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	"Answer: If properly qualified, yes." Do you see that?  A. I'm sorry, direct me to which page. Q. Page one internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?" I see what you've read. Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review of all the evidence, but you can't even suggest an association between the Bair Hugger and an increased risk of infection; isn't that right?  A. No. There's clearly an association that's been made by the McGovern paper. What I've said is I find no evidence to indicate that there is a causation.  Q. Well let's take a look. I thought we went over this this morning. It took us a while to establish it.  You write in paragraph 74c, "The McGovern report relied on truncated and incorrect
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Well you understand that they hadn't gone out and done a bunch of research beyond what the McGovern paper itself. I mean they they they were reporting on work they did; correct?  A. They were reporting the data that they said they had collected at this hospital.  Q. Okay. And, for example, they don't reference the Stocks paper or the Darouiche paper; correct?  A. They did not refer to that, but I Yes, I don't think they did.  Q. Okay. And you're aware that at least one of the authors testified under oath, under penalty of perjury, that a causal connection if properly qualified could be made; correct?  MR. GORDON: Object to the form of the question, mischaracterizes the testimony.  A. I I don't recall that. Which expert was that or which author?  Q. I think it was Dr. Reed. I can dig it out. Do you recall reading that?  A. I don't specifically. I've cited something	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	"Answer: If properly qualified, yes." Do you see that?  A. I'm sorry, direct me to which page. Q. Page one — internal page 115. Bottom of 114, top of 115. Do you see that?  A. I'm looking at the next interaction, which is "What would the proper qualifications be?" I see what you've read. Q. Okay. And it's your opinion that not only can you not draw a causal connection based on a review of all the evidence, but you can't even suggest an association between the Bair Hugger and an increased risk of infection; isn't that right?  A. No. There's clearly an association that's been made by the McGovern paper. What I've said is I find no evidence to indicate that there is a causation.  Q. Well let's take a look. I thought we went over this this morning. It took us a while to establish it. You write in paragraph 74c, "The McGovern

54 (Pages 213 to 216)

	Page 217		Page 219
1	evidence that the Bair Hugger is associated with a	1	And what is your view of the importance of
2	significant increase in SSI;" correct?	2	establishing a p-value in connection with an
3	A. The operative word there is "a significant	3	epidemiological undertaking?
4	increase," and once those data errors are corrected,	4	A. I think it is a useful guiding datum. It
5	the association becomes non-significant.	5	gives you some sense of what is going on, but it also
6	Q. Well you know that the study authors, in	6	has a certain quality of subjectiveness.
7	addition to saying they checked the numbers three	7	Q. Okay. So if something falls just below or
8	times before they went in the final report, Dr. Reed,	8	just above the known p-value of .05, that's not the
9	for example, said that if you added one infection on	9	end of the inquiry is your is your view.
10	each side, it would change the odds ratio very very	10	A. I believe that that is not the end of one's
11	slightly; right?	11	inquiry.
12	A. I I saw such a statement.	12	Q. Okay. So something can have a causal
13	Q. Okay. And you you disagree with that,	13	connection even though the p-value is less than .05;
14	too; don't you?	14	correct?
15	A. I relied upon Dr. Holford's calculations	15	A. You mean more than.
16	based on that,	16	Q. I'm sorry, more than .05.
17	Q. Okay.	17	A. Yes. And something can be a confounder even
18	A both in his paper and in in his report	18	when its association on a univariate level is greater
19	and in footnote one of his report.	19	than p equals .05.
20	Q. But you would disagree with Dr. Reed that it	20	Q. Okay. What if it's one?
21	would change the odds ratio very slightly; correct?	21	A. What if it's p equals one?
22	A. I don't know what he meant by "very	22	Q. Uh-huh. Can it be a confounder?
23	slightly." But yes, I don't agree that it would have	23	A. I don't have an answer to that question.
24	retained significance.	24	Probably not, but I don't know.
25	Q. Even if it had at p-value of under .05?	25	Q. Okay. You don't have an opinion on that one
		_	
	Page 218		Page 220
1	Page 218  A. I would have to see that.	1	
1 2	A. I would have to see that.	1 2	Page 220 way or another.  A. Not on a univariate.
	<ul><li>A. I would have to see that.</li><li>Q. Okay. Do you think if</li></ul>		way or another.
2	A. I would have to see that.	2	way or another.  A. Not on a univariate.
2	<ul><li>A. I would have to see that.</li><li>Q. Okay. Do you think if</li><li>Well, let me ask you this: Do you do</li></ul>	2 3	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in
2 3 4	A. I would have to see that.  Q. Okay. Do you think if Well, let me ask you this: Do you do you	2 3 4	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder
2 3 4 5	A. I would have to see that.  Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether	2 3 4 5	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?
2 3 4 5 6	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate	2 3 4 5 6	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?
2 3 4 5 6 7	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct?	2 3 4 5 6 7	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added
2 3 4 5 6 7 8	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct? A. Well I could tell you what	2 3 4 5 6 7 8	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.
2 3 4 5 6 7 8 9	<ul> <li>A. I would have to see that.</li> <li>Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct?</li> <li>A. Well I could tell you what Q. In the McGovern study. And I'm just asking</li> </ul>	2 3 4 5 6 7 8 9 10	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.
2 3 4 5 6 7 8 9 10 11	<ul> <li>A. I would have to see that.</li> <li>Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct?</li> <li>A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the</li> </ul>	2 3 4 5 6 7 8 9	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's
2 3 4 5 6 7 8 9 10	<ul> <li>A. I would have to see that.</li> <li>Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct?</li> <li>A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.
2 3 4 5 6 7 8 9 10 11 12 13 14	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct? A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the appropriateness A. I do not o	2 3 4 5 6 7 8 9 10 11 12 13	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.  Q. Okay. You didn't, in connection with
2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. I would have to see that.  Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct?  A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the appropriateness A. I do not o Q of using chi-squared	2 3 4 5 6 7 8 9 10 11 12 13 14	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.  Q. Okay. You didn't, in connection with deciding whether something was a confounder, take into
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct? A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the appropriateness A. I do not o	2 3 4 5 6 7 8 9 10 11 12 13 14 15	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.  Q. Okay. You didn't, in connection with deciding whether something was a confounder, take into account the strength of association or the p-value;
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct? A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the appropriateness A. I do not o Q of using chi-squared A. I have not opined upon exact test versus chi-square.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.  Q. Okay. You didn't, in connection with deciding whether something was a confounder, take into account the strength of association or the p-value; correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I would have to see that.  Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct?  A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the appropriateness A. I do not o Q of using chi-squared A. I have not opined upon exact test versus chi-square. Q. Okay. And you express no opinion on the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.  Q. Okay. You didn't, in connection with deciding whether something was a confounder, take into account the strength of association or the p-value; correct?  A. Did I?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct? A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the appropriateness A. I do not o Q of using chi-squared A. I have not opined upon exact test versus chi-square. Q. Okay. And you express no opinion on the appropriateness of the use of chi-squared in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.  Q. Okay. You didn't, in connection with deciding whether something was a confounder, take into account the strength of association or the p-value; correct?  A. Did I?  Q. Yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct? A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the appropriateness A. I do not o Q of using chi-squared A. I have not opined upon exact test versus chi-square. Q. Okay. And you express no opinion on the appropriateness of the use of chi-squared in connection with McGovern.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.  Q. Okay. You didn't, in connection with deciding whether something was a confounder, take into account the strength of association or the p-value; correct?  A. Did I?  Q. Yes.  A. I was not looking at p-values. I think I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct? A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the appropriateness A. I do not o Q of using chi-squared A. I have not opined upon exact test versus chi-square. Q. Okay. And you express no opinion on the appropriateness of the use of chi-squared in connection with McGovern. A. I did not opine in my report.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.  Q. Okay. You didn't, in connection with deciding whether something was a confounder, take into account the strength of association or the p-value; correct?  A. Did I?  Q. Yes.  A. I was not looking at p-values. I think I was not looking at p-values. I was largely looking at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct? A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the appropriateness A. I do not o Q of using chi-squared A. I have not opined upon exact test versus chi-square. Q. Okay. And you express no opinion on the appropriateness of the use of chi-squared in connection with McGovern. A. I did not opine in my report. Q. You got to wait until I'm finished	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.  Q. Okay. You didn't, in connection with deciding whether something was a confounder, take into account the strength of association or the p-value; correct?  A. Did I?  Q. Yes.  A. I was not looking at p-values. I think I was not looking at p-values. I was largely looking at the evidence indicating that there were associations.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct? A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the appropriateness A. I do not o Q of using chi-squared A. I have not opined upon exact test versus chi-square. Q. Okay. And you express no opinion on the appropriateness of the use of chi-squared in connection with McGovern. A. I did not opine in my report. Q. You got to wait until I'm finished A. I'm sorry.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.  Q. Okay. You didn't, in connection with deciding whether something was a confounder, take into account the strength of association or the p-value; correct?  A. Did I?  Q. Yes.  A. I was not looking at p-values. I think I was not looking at p-values. I was largely looking at the evidence indicating that there were associations.  Q. Right. You were using
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I would have to see that. Q. Okay. Do you think if Well, let me ask you this: Do you do you You don't have an opinion on whether chi-squared or Fisher's exact is the appropriate methodology for deriving a p-value; correct? A. Well I could tell you what Q. In the McGovern study. And I'm just asking you about your report, I'm not interested in your thoughts on it. In your report you don't opine on the appropriateness A. I do not o Q of using chi-squared A. I have not opined upon exact test versus chi-square. Q. Okay. And you express no opinion on the appropriateness of the use of chi-squared in connection with McGovern. A. I did not opine in my report. Q. You got to wait until I'm finished	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	way or another.  A. Not on a univariate.  Q. And you didn't take that into account in conjunction with your opinions on what is a confounder in connection with McGovern and what's not; correct?  A. I didn't take what into account?  Q. Whether any of these changes, if you added them up, had a p-value of one.  A. That's not what we're talking about.  It's  I'm sorry, forgive me. Your statement is a misstatement. Perhaps you should ask your question again.  Q. Okay. You didn't, in connection with deciding whether something was a confounder, take into account the strength of association or the p-value; correct?  A. Did I?  Q. Yes.  A. I was not looking at p-values. I think I was not looking at p-values. I was largely looking at the evidence indicating that there were associations.

55 (Pages 217 to 220)

Page 223 Page 221 1 A. And my knowledge, yes. 1 A. I didn't have any evidence of that. 2 Q. Okay. Because, as we talked about earlier 2 Q. Okay. Did you do any investigation as to 3 in the day, there's an element of epidemiology that 3 whether there was underreporting going on by other 4 involves scientific judgment; correct? 4 hospitals in the U.K.? 5 A. I think scientific judgment is an important 5 A. I only know that -- that this hospital was 6 6 reporting much higher than the national rates. I've thing, yes. 7 7 Q. Okay. And that's what you did here in looked at some data on that. 8 8 conjunction with deciding what you thought was a Q. Okay. Did you do an investigation --9 confounder and what you thought wasn't a confounder; 9 Can you answer my question? Did you do an 10 10 investigation as to whether Dr. Reed was correct in correct? 11 A. It was part of what I did. 11 his statement that there was underreporting going on 12 Q. I'd like to direct your attention to page 11 12 at other hospitals during this time period? 13 of your report starting under the heading "The 13 A. I did no such investigation. McGovern Study: Sources of Confounding and Systematic 14 14 Q. You also -- I take it paragraph 28 is --15 Bias." 15 You're relying on Dr. Holford for the 16 A. Correct. 16 statements and conclusions in paragraph 28 in your 17 Q. Okay. And in paragraph 27 you talk about 17 18 Gillson and Lowdon, that "...the Northumbria 18 A. Yes, that's correct. 19 19 Healthcare Trust was regularly informed by the Health Q. Okay. And if he's wrong, you're wrong; 20 Protection Agency during 2008 and 2009 that it was 'a 20 right? high outlier for SSI." Do you see that? 21 21 A. If he's wrong, I'd have to revisit it. Yes. 22 22 A. I do. Q. Okay. And then in paragraph 29 you say, 23 Q. Do you know whether it was a high outlier 23 "The analysis by Dr. Holford raises another concern, for deep joint infections? 24 24 the possibility that the data included in the McGovern 2.5 A. I understood that to be what they were 25 study had been 'cherry-picked'." Do you see that? Page 222 Page 224 1 talking about. 1 A. I did. 2 2 Q. Based on what? Q. And you say, "As noted above, appropriate 3 A. The focus of the Gillson and Lowdon paper. 3 SSI data were available for 9 months from October '07 4 But maybe I overstate it. I'm happy to look again. 4 to June '08, but they were excluded from the McGovern 5 5 report." Do you see that? It's clearly within the orthopedic 6 6 A. Yes. department. I don't know whether they specifically 7 7 Q. Okay. You're aware that it wasn't until note -- they say that there was a certain criteria 8 8 which included --July of 2008 that there was a robust surveillance and 9 Well my initial read here does not 9 reporting of infections at Wansbeck; correct? 10 MR. GORDON: Object to the form of the 10 specifically differentiate the types of infections. 11 Q. Okay. You don't know whether the 11 12 12 Northumbria Healthcare Trust was a high outlier for A. I -- I have seen conflicting information 13 13 deep joint infections; do you, sir? about when --14 14 I've seen information from Dr. Reed's A. No, not specifically. I guess I do not. Q. Okay. And you say, "This was confirmed by 15 depositions and I've seen stuff from the Gillson 15 Dr. Reed in his deposition." So you relied on Dr. 16 16 paper, and I don't know what date it started. I think 17 Reed for support for that statement about Northumbria 17 I understand that much of the data that comprise the 18 being a high outlier for SSI; correct? 18 McGovern 16/Albrecht 10 were compiled -- some of it 19 A. I guess I did, yes. 19 was compiled ongoing and some of it was retrospective, 2.0 Q. Okay. You also know that Dr. Reed testified 2.0 and I don't know which was which, so I don't know when 21 21 the evaluations really began. that he felt that other hospitals in the trust were 22 22 Q. Okay. Without having evidence to know underreporting. 23 23 A. I read that. whether Dr. Reed was correct that there wasn't 24 24 Q. Okay. But you didn't rely on that; did you, complete data reporting until July 2008, you still 25 25 felt comfortable opining in this case that there was sir?

56 (Pages 221 to 224)

	Page 225		Page 227
1	cherry-picking and manipulation with respect to the	1	September, and so I think that there was some ability
2	start date; correct, sir?	2	to alter the starting date. That's the first piece.
3	MR. GORDON: Object to the form of	3	The second piece, it may be entirely coincidental, but
4	A. I I didn't say	4	I think that the Holford analysis of statistical
5	MR. GORDON: the question.	5	significant starting dates is very interesting because
6	A that there was cherry-picking, I said	6	had it started September instead of July, then the
7	that the possibility is there based upon the fact that	7	effect of switching from Bair Hugger to Hot Dog would
8	there were these data for nine months. And I believe	8	not have been statistically significant; July was
9	I have seen from some deposition exhibits	9	statistically significant; June and August were not.
10	prepublication figures, graphs, which suggest a number	10	It's
11	of different start dates for this series of cases, one	11	It may be just coincidence, I don't know,
12	which began in September rather than in July, which	12	that's why I say it raises the possibility.
13	makes me think that the start date was subject to some	13	Q. Well don't you think you need some evidence
14	manipulation or option.	14	if you're going to accuse the authors of the McGovern
15	Q. Well those were start dates with respect to	15	study of scientific fraud?
16	the SS SSI bundle. I'm talking about robust	16	MR. GORDON: Object to the form of the
17	reporting with respect to deep joint infections in	17	question.
18	knees and hips. You have no you have no evidence	18	A. I I was being very careful not to accuse
19	to suggest that Dr. Reed was lying when he said that	19	anybody.
20	the reason they started in July of '08 was because	20	Q. Okay. Then
21	that was when they felt there was full and robust	21	A. I said
22	reporting available.	22	Q accuse them of data manipulation.
23	MR. GORDON: Object to the	23	A. I said it raises the concerns of that.
24	Q. Is that right?	24	Q. Do you know who Mark Albrecht is, what his
25	MR. GORDON: Object to the form of the	25	credentials are?
	Page 226		Page 228
1	question, move to strike counsel's preamble, and	1	
1 2	question, move to strike counsel's preamble, and misstates and mischaracterizes the evidence.	1 2	A. I think that he has a master's degree from the University of Minnesota in statistics.
	•		A. I think that he has a master's degree from
2	misstates and mischaracterizes the evidence.	2	A. I think that he has a master's degree from the University of Minnesota in statistics.
2	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.	2 3	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?
2 3 4	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.	2 3 4	<ul><li>A. I think that he has a master's degree from the University of Minnesota in statistics.</li><li>Q. And he's a professor there?</li><li>A. I didn't know that.</li></ul>
2 3 4 5	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.	2 3 4 5	<ul> <li>A. I think that he has a master's degree from the University of Minnesota in statistics.</li> <li>Q. And he's a professor there?</li> <li>A. I didn't know that.</li> <li>MR. GORDON: Object to the form of the</li> </ul>
2 3 4 5 6	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with	2 3 4 5 6	<ul> <li>A. I think that he has a master's degree from the University of Minnesota in statistics.</li> <li>Q. And he's a professor there?</li> <li>A. I didn't know that.</li> <li>MR. GORDON: Object to the form of the question, assumes facts not in evidence.</li> </ul>
2 3 4 5 6 7	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data	2 3 4 5 6 7	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are
2 3 4 5 6 7 8 9	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors	2 3 4 5 6 7 8 9	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.
2 3 4 5 6 7 8 9 10	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?	2 3 4 5 6 7 8 9 10	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the
2 3 4 5 6 7 8 9 10 11	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.	2 3 4 5 6 7 8 9 10 11	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.
2 3 4 5 6 7 8 9 10 11 12 13	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not	2 3 4 5 6 7 8 9 10 11 12 13	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we	2 3 4 5 6 7 8 9 10 11 12 13 14	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we started in July of '08 was because that's when we had	2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.  Q. All right. Was it Dr. Reed, Dr
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we started in July of '08 was because that's when we had full reporting, what is the data manipulation that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.  Q. All right. Was it Dr. Reed, Dr  How about Dr. Belani?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we started in July of '08 was because that's when we had full reporting, what is the data manipulation that you're referencing there?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.  Q. All right. Was it Dr. Reed, Dr  How about Dr. Belani?  MR. GORDON: Same objection.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we started in July of '08 was because that's when we had full reporting, what is the data manipulation that you're referencing there?  MR. GORDON: Object to the form of the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.  Q. All right. Was it Dr. Reed, Dr  How about Dr. Belani?  MR. GORDON: Same objection.  A. I don't know.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we started in July of '08 was because that's when we had full reporting, what is the data manipulation that you're referencing there?  MR. GORDON: Object to the form of the question, incomplete hypothetical, assumes facts not	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.  Q. All right. Was it Dr. Reed, Dr  How about Dr. Belani?  MR. GORDON: Same objection.  A. I don't know.  Q. Okay. But as you sit here, you don't have
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we started in July of '08 was because that's when we had full reporting, what is the data manipulation that you're referencing there?  MR. GORDON: Object to the form of the question, incomplete hypothetical, assumes facts not in evidence.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.  Q. All right. Was it Dr. Reed, Dr  How about Dr. Belani?  MR. GORDON: Same objection.  A. I don't know.  Q. Okay. But as you sit here, you don't have any evidence to refute Dr. Reed's sworn testimony that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we started in July of '08 was because that's when we had full reporting, what is the data manipulation that you're referencing there?  MR. GORDON: Object to the form of the question, incomplete hypothetical, assumes facts not in evidence.  A. I I I have seen some earlier work that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.  Q. All right. Was it Dr. Reed, Dr  How about Dr. Belani?  MR. GORDON: Same objection.  A. I don't know.  Q. Okay. But as you sit here, you don't have any evidence to refute Dr. Reed's sworn testimony that the reason they started in July of '08 was because
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we started in July of '08 was because that's when we had full reporting, what is the data manipulation that you're referencing there?  MR. GORDON: Object to the form of the question, incomplete hypothetical, assumes facts not in evidence.  A. I I I have seen some earlier work that I think came from Mr. Albrecht, but I'm not certain,	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.  Q. All right. Was it Dr. Reed, Dr  How about Dr. Belani?  MR. GORDON: Same objection.  A. I don't know.  Q. Okay. But as you sit here, you don't have any evidence to refute Dr. Reed's sworn testimony that the reason they started in July of '08 was because that was the first time they felt like they had full
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we started in July of '08 was because that's when we had full reporting, what is the data manipulation that you're referencing there?  MR. GORDON: Object to the form of the question, incomplete hypothetical, assumes facts not in evidence.  A. I I I have seen some earlier work that I think came from Mr. Albrecht, but I'm not certain, which suggested a different starting date for the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.  Q. All right. Was it Dr. Reed, Dr  How about Dr. Belani?  MR. GORDON: Same objection.  A. I don't know.  Q. Okay. But as you sit here, you don't have any evidence to refute Dr. Reed's sworn testimony that the reason they started in July of '08 was because that was the first time they felt like they had full implementation of surveillance and reporting of DJIs
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we started in July of '08 was because that's when we had full reporting, what is the data manipulation that you're referencing there?  MR. GORDON: Object to the form of the question, incomplete hypothetical, assumes facts not in evidence.  A. I I I have seen some earlier work that I think came from Mr. Albrecht, but I'm not certain, which suggested a different starting date for the analysis which comprises the McGovern study, and it	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.  Q. All right. Was it Dr. Reed, Dr  How about Dr. Belani?  MR. GORDON: Same objection.  A. I don't know.  Q. Okay. But as you sit here, you don't have any evidence to refute Dr. Reed's sworn testimony that the reason they started in July of '08 was because that was the first time they felt like they had full implementation of surveillance and reporting of DJIs in knees and hips.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	misstates and mischaracterizes the evidence.  MS. CONLIN: You may answer.  A. I I have no reason to believe that Dr.  Reed was lying.  Q. Okay. And you say, in connection with paragraph 29, it suggests the possibility of data manipulation.  A. Uh-huh. Yes.  Q. And again, data manipulation by the authors of the McGovern study?  A. Ultimately, yes.  Q. Okay. So assuming that Dr. Reed was not lying under oath when he said the reason why we started in July of '08 was because that's when we had full reporting, what is the data manipulation that you're referencing there?  MR. GORDON: Object to the form of the question, incomplete hypothetical, assumes facts not in evidence.  A. I I I have seen some earlier work that I think came from Mr. Albrecht, but I'm not certain, which suggested a different starting date for the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I think that he has a master's degree from the University of Minnesota in statistics.  Q. And he's a professor there?  A. I didn't know that.  MR. GORDON: Object to the form of the question, assumes facts not in evidence.  Q. Are you are you are  Is it Mark Albrecht who engaged in data manipulation? You referenced him.  A. I don't know.  MR. GORDON: Object to the form of the question.  Q. Okay.  A. I don't know.  Q. All right. Was it Dr. Reed, Dr  How about Dr. Belani?  MR. GORDON: Same objection.  A. I don't know.  Q. Okay. But as you sit here, you don't have any evidence to refute Dr. Reed's sworn testimony that the reason they started in July of '08 was because that was the first time they felt like they had full implementation of surveillance and reporting of DJIs

57 (Pages 225 to 228)

Page 231 Page 229 1 question. 1 standard adhesive addressing to a jubilee dressing 2 A. I -- I earlier said that there were earlier 2 that would statistically significantly alter infection 3 efforts at the analysis which started on different 3 rates among arthroplasties? 4 dates. The information about when the surveillance 4 A. That was the question that was posed. 5 5 began I assume didn't change over time, and so it Q. Yes. 6 suggests that the analysis was changed over time. 6 A. Yes. And you're asking do I have --7 7 And his answer was "I am not aware of any That's all I'm saying. 8 8 Q. And -- and can you answer my question now? such paper." 9 MS. CONLIN: Can you read it back, Mr. Court 9 Q. Are you aware of any? 10 10 A. I have not, in depth, read about the jubilee Reporter. 11 (Record read by the court reporter.) 11 12 MS. CONLIN: You may answer. 12 Q. Okay. If you look on page 409 and at line 13 13 MR. GORDON: Same objection. four: 14 A. I have no basis to refute his statement, but 14 "Question: Are you aware of any evidence 15 15 that is statistically significant that suggests the I have reason to question it. 16 Q. Okay. And that's the same individual that 16 use of MSSA screening significantly impacts the rate 17 you relied on repeatedly throughout your expert 17 of deep joint infections among patients? 18 report; correct? 18 "Answer: I'm not aware of any such papers." 19 MR. GORDON: Object to the form of the 19 Do you see that? question. 20 20 A. I do. 21 21 A. I quoted him a number of times, yes. Q. Are you aware of any such papers? 22 Q. Thank you. 22 A. I thought I was. Perhaps I'm not. I had MS. CONLIN: Why don't we take a break here. 23 23 Dr. Reed's statement which I had referred to, I think, THE REPORTER: Off the record, please. 24 2.4 specifically. I don't remember whether I have one 25 25 that specifically addresses joint infection. (Recess taken.) Page 230 Page 232 1 (Exhibit 28 was marked for 1 Q. Okay. Directing your attention back to your 2 2 identification.) report, page 21, did you find -- based on your review 3 BY MS. CONLIN: 3 of the record, did you find consistency among the 4 Q. I've handed you, sir, what's been marked as 4 bubble and particle studies as it relates to use of 5 5 the Bair Hugger increasing particulates or bubbles Borak Exhibit 28, which is another excerpt out of day 6 two of the deposition of Dr. McGovern. You can take a 6 over the surgical site? 7 7 A. I thought there was inconsistency, but I did look on the back page of this excerpt exhibit and 8 8 direct your attention down to page 408. At line 17 it not do a systematic review and I did not offer an 9 9 opinion on that. 10 10 "Are you aware of any paper that is Q. Okay. So you don't know. 11 adequately powered that shows a change from a standard 11 We looked at, for example, the corporate 12 12 adhesive dressing to a jubilee dressing would representative Al Van Duren's testimony this morning 13 13 statistically significant -- significantly alter that said that every single study out there shows an 14 infection rates among arthroplasties?" Do you see 14 increase in absolute numbers of particles when Bair 15 15 that? Hugger is in use. You don't have any reason to 16 A. I do. 16 dispute that; do you? 17 Q. And he says, "I am not aware of any such 17 A. I -- I have read other papers, I think 18 paper." Do you see that? 18 there's one by somebody named Oguz, who found no 19 A. I do. 19 evidence of increase. I -- I'm --2.0 Q. Do you have any reason to dispute that? 20 But it's not an area that I have 21 MR. GORDON: To dispute what? 21 particularly taken on for myself, and I don't have 22 A. That he said that? 22 expertise in that area. 23 23 Q. I'll rephrase it. Q. Okay. So you don't have any reason to 24 24 Are you aware of any paper that is dispute at least Al Van Duren's testimony as a 25 25 adequately powered that shows a change from the corporate representative for 3M.

58 (Pages 229 to 232)

Page 235 Page 233 1 A. I would have no basis to dispute the 1 Q. Okay. But they --2 corporate representative's opinion. 2 Even those who said there might have been 3 Q. Now I'd like to direct your attention to --3 one more infection said there would still be a 4 You understand that each of the authors of 4 significant odds risk ratio; correct? 5 5 the McGovern study continue to stand behind the A. I don't think --6 6 conclusions in that study; right, sir? MR. GORDON: Same objections. 7 7 MR. GORDON: Object to the form of the Q. Well let me ask it a different way. 8 8 Did you see any of them in their depositions 9 9 A. I'm not sure which conclusions. What? under oath say that the findings that they reached in 10 10 McGovern that use of the Bair Hugger is associated Q. That the study is valid and that there's a 11 significant increased risk of a deep joint infection 11 with an increased risk of deep joint infection was 12 by use of the Bair Hugger. 12 wrong? MR. GORDON: Object to the form of the 13 13 A. I saw some of them say that the numbers 14 question and mis --14 included in the publications --15 15 A. I think each of them --Q. I'm not asking about that. 16 MR. GORDON: Let me finish my objection. 16 A. -- were wrong. 17 THE WITNESS: Sorry. 17 Q. I'm asking about the conclusions in the 18 MR. GORDON: -- assumes facts not in 18 paper. Can you answer my question? 19 evidence, mischaracterizes the evidence. 19 A. Well, but if the conclusion is, as you 20 MS. CONLIN: You may answer. 20 suggested before, an odds ratio of 3.8 --21 21 A. I believe each of the authors has said that Q. That's not what I asked. 22 this shows an association, not a causation, so it 22 MS. CONLIN: Mr. Stirewalt, can you read it 23 23 agreed with what you just said in your question. back, please. Q. Okay. You would agree that each of the (Record read by the court reporter.) 24 24 25 authors, when questioned under oath, stand by the A. I did not see any of them withdraw the 25 Page 234 Page 236 1 veracity and the validity of the findings as expressed 1 conclusion in the paper. 2 2 MS. CONLIN: Thank you. Mark this, please. in the McGovern paper; correct? 3 A. I think that they indicated that the numbers 3 (Exhibit 29 was marked for 4 were not correct. Now when you say "veracity and 4 identification.) 5 validity," I'm not sure how to deal with that if the 5 BY MS. CONLIN: 6 6 Q. I've handed you what's been marked as numbers are not correct. 7 7 Q. Okay. Let me state it a different way Deposition Exhibit 29, Borak Deposition Exhibit 29 --8 because I don't want to drag you through all the 8 MR. GORDON: Is that 29 or 30? Oh, you used 9 9 a premarked. I'm sorry. Go ahead. 10 10 Doesn't this deal with Nachtscheim? You'd agree with me that each of the authors 11 testified under oath that they stand by the 11 MS. CONLIN: Yeah. 12 12 conclusions in the McGovern paper that they found a Q. Let me start over again. 13 13 3.8 increased risk of infection when the Bair Hugger You've been handed, sir, what's been marked 14 was used over the Hot Dog; correct? 14 as Borak Deposition Exhibit 29, which is an excerpt 15 15 A. My impress -out of the Professor Nachtscheim deposition, one of MR. GORDON: Object to form -- object to --16 16 the depositions that you relied on; correct? 17 Well same objections as the last one. 17 A. Yes. 18 A. Just for the record, I apologize to 18 Q. Do you know whether Professor --19 everybody for stepping on you. It's late in the day 19 Do you have any reason to dispute the 2.0 and I'm losing my control. 2.0 honesty and scientific credibility of Professor 21 21 My understanding was that one or more of the Nachtscheim? 22 authors agreed that the numbers were not correct, and 22 A. I have no particular reason to do that. 23 23 if the numbers were changed according to what was Q. Okay. And if you look at internal page 350 2.4 talked about in the depositions, then the 3.8 number 24 of this exhibit --25 would not be correct. That's my understanding. 25 Do you have it there?

59 (Pages 233 to 236)

	Page 237		Page 239
1	A. I see it.	1	Augustine publication or both are scientifically
2	Q the question is:	2	valid, then your opinion as expressed in 74e of your
3	"Question: And do you And you continue	3	report also wouldn't hold up; correct?
4	to stand by the results of the observational	4	A. If
5	studies	5	Yes.
6	"Yes.	6	Q. Okay. And same with respect to your final
7	"in the McGovern publication?	7	conclusion, 74f, "Because there is insufficient
8	"I do."	8	evidence that there's a significant association
9	Do you see that?	9	between the Bair Hugger and deep joint infections,
10	A. I do see that.	10	Bair Hugger does not represent a substantial
11	Q. Okay. Do you have any reason to suspect	11	contributing cause of deep joint infections."
12	that Professor Nachtscheim engaged in data	12	Correct?
13	manipulation?	13	A. Yes.
14	A. I have no reason to suggest that he did	14	MS. CONLIN: Okay. Let me check my notes.
15	that.	15	I think we're done.
16	Q. Okay. And have you seen anything that would	16	THE REPORTER: Off the record, please.
17	suggest that Professor Nachtscheim would allow	17	(Recess taken.)
18	somebody to manipulate data in connection with a study	18	(Exhibit 30 was marked for
19	that he was on?	19	identification.)
20	A. I I have no ability to comment on that.	20	BY MS. CONLIN:
21	Q. Finally, if we can look, sir, at your	21	Q. I've handed you, sir, what's been
22	summary, which is contained on page 22.	22	A. Can I first
23	A. Yes.	23	Yes. Please go ahead. I'm sorry.
24	Q. And you've got a summary, "Following is a	24	Q what's been marked as Borak Exhibit 30,
25	list of my opinions, all to a reasonable degree of	25	which is the Bradford-Hill article entitled "The
	Page 238		Page 240
1	medical and scientific certainty." Do you see that?	1	Environment and Disease: Association or Causation?"
2	A. Yes.		Correct?
		1 2	Correct/
	O Okay You'd agree with me that each of your	2 3	
3	Q. Okay. You'd agree with me that each of your conclusions stated there rely on a finding that the	3	A. Correct.
3 4	conclusions stated there rely on a finding that the	3 4	<ul><li>A. Correct.</li><li>Q. And you've actually cited this publication</li></ul>
3	conclusions stated there rely on a finding that the McGovern study is not valid; correct?	3	<ul><li>A. Correct.</li><li>Q. And you've actually cited this publication in connection with your work; correct?</li></ul>
3 4 5	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the	3 4 5	<ul><li>A. Correct.</li><li>Q. And you've actually cited this publication in connection with your work; correct?</li><li>A. Correct.</li></ul>
3 4 5 6	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.	3 4 5 6 7	<ul> <li>A. Correct.</li> <li>Q. And you've actually cited this publication in connection with your work; correct?</li> <li>A. Correct.</li> <li>Q. I'd like to direct your attention to the</li> </ul>
3 4 5 6 7 8	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same	3 4 5 6 7 8	<ul> <li>A. Correct.</li> <li>Q. And you've actually cited this publication in connection with your work; correct?</li> <li>A. Correct.</li> <li>Q. I'd like to direct your attention to the last page, page 12.</li> </ul>
3 4 5 6 7	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.	3 4 5 6 7 8	<ul> <li>A. Correct.</li> <li>Q. And you've actually cited this publication in connection with your work; correct?</li> <li>A. Correct.</li> <li>Q. I'd like to direct your attention to the last page, page 12.</li> <li>A. Yes.</li> </ul>
3 4 5 6 7 8	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the	3 4 5 6 7 8	<ul> <li>A. Correct.</li> <li>Q. And you've actually cited this publication in connection with your work; correct?</li> <li>A. Correct.</li> <li>Q. I'd like to direct your attention to the last page, page 12.</li> <li>A. Yes.</li> <li>Q. Second-to-last paragraph, "All scientific</li> </ul>
3 4 5 6 7 8 9	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there	3 4 5 6 7 8 9	<ul> <li>A. Correct.</li> <li>Q. And you've actually cited this publication in connection with your work; correct?</li> <li>A. Correct.</li> <li>Q. I'd like to direct your attention to the last page, page 12.</li> <li>A. Yes.</li> <li>Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or</li> </ul>
3 4 5 6 7 8 9 10	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there are correct, then none of your opinions as expressed	3 4 5 6 7 8 9 10	<ul> <li>A. Correct.</li> <li>Q. And you've actually cited this publication in connection with your work; correct?</li> <li>A. Correct.</li> <li>Q. I'd like to direct your attention to the last page, page 12.</li> <li>A. Yes.</li> <li>Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be</li> </ul>
3 4 5 6 7 8 9 10 11	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there	3 4 5 6 7 8 9 10 11	<ul> <li>A. Correct.</li> <li>Q. And you've actually cited this publication in connection with your work; correct?</li> <li>A. Correct.</li> <li>Q. I'd like to direct your attention to the last page, page 12.</li> <li>A. Yes.</li> <li>Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does</li> </ul>
3 4 5 6 7 8 9 10 11 12 13	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there are correct, then none of your opinions as expressed in your summary have merit; correct?  MR. GORDON: Object to the form of the	3 4 5 6 7 8 9 10 11 12 13	A. Correct. Q. And you've actually cited this publication in connection with your work; correct? A. Correct. Q. I'd like to direct your attention to the last page, page 12. A. Yes. Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge
3 4 5 6 7 8 9 10 11 12 13 14	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there are correct, then none of your opinions as expressed in your summary have merit; correct?	3 4 5 6 7 8 9 10 11 12 13 14	A. Correct. Q. And you've actually cited this publication in connection with your work; correct? A. Correct. Q. I'd like to direct your attention to the last page, page 12. A. Yes. Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it
3 4 5 6 7 8 9 10 11 12 13 14	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there are correct, then none of your opinions as expressed in your summary have merit; correct?  MR. GORDON: Object to the form of the question.  A. The first four are probably a through d	3 4 5 6 7 8 9 10 11 12 13 14 15	A. Correct. Q. And you've actually cited this publication in connection with your work; correct? A. Correct. Q. I'd like to direct your attention to the last page, page 12. A. Yes. Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time." Do you see that?
3 4 5 6 7 8 9 10 11 12 13 14 15	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there are correct, then none of your opinions as expressed in your summary have merit; correct?  MR. GORDON: Object to the form of the question.  A. The first four are probably a through d probably follow from the point that you've just made.	3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Correct. Q. And you've actually cited this publication in connection with your work; correct? A. Correct. Q. I'd like to direct your attention to the last page, page 12. A. Yes. Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time." Do you see that? A. I do.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there are correct, then none of your opinions as expressed in your summary have merit; correct?  MR. GORDON: Object to the form of the question.  A. The first four are probably a through d probably follow from the point that you've just made. The issue is whether the McGovern paper is or is not a	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Correct. Q. And you've actually cited this publication in connection with your work; correct? A. Correct. Q. I'd like to direct your attention to the last page, page 12. A. Yes. Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time." Do you see that? A. I do. Q. Do you agree with that statement?
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there are correct, then none of your opinions as expressed in your summary have merit; correct?  MR. GORDON: Object to the form of the question.  A. The first four are probably a through d probably follow from the point that you've just made. The issue is whether the McGovern paper is or is not a legitimate basis of evidence.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Correct. Q. And you've actually cited this publication in connection with your work; correct? A. Correct. Q. I'd like to direct your attention to the last page, page 12. A. Yes. Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time." Do you see that? A. I do. Q. Do you agree with that statement? A. I think it's very reasonable.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there are correct, then none of your opinions as expressed in your summary have merit; correct?  MR. GORDON: Object to the form of the question.  A. The first four are probably a through d probably follow from the point that you've just made. The issue is whether the McGovern paper is or is not a legitimate basis of evidence.  Q. Well e relies your conclusion in e also	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. Correct.  Q. And you've actually cited this publication in connection with your work; correct?  A. Correct.  Q. I'd like to direct your attention to the last page, page 12.  A. Yes.  Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time." Do you see that?  A. I do.  Q. Do you agree with that statement?  A. I think it's very reasonable.  MS. CONLIN: Okay. No further questions.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there are correct, then none of your opinions as expressed in your summary have merit; correct?  MR. GORDON: Object to the form of the question.  A. The first four are probably a through d probably follow from the point that you've just made. The issue is whether the McGovern paper is or is not a legitimate basis of evidence.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Correct. Q. And you've actually cited this publication in connection with your work; correct? A. Correct. Q. I'd like to direct your attention to the last page, page 12. A. Yes. Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time." Do you see that? A. I do. Q. Do you agree with that statement? A. I think it's very reasonable.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there are correct, then none of your opinions as expressed in your summary have merit; correct?  MR. GORDON: Object to the form of the question.  A. The first four are probably a through d probably follow from the point that you've just made. The issue is whether the McGovern paper is or is not a legitimate basis of evidence.  Q. Well e relies your conclusion in e also require relies on McGovern being invalid; correct?	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Correct.  Q. And you've actually cited this publication in connection with your work; correct?  A. Correct.  Q. I'd like to direct your attention to the last page, page 12.  A. Yes.  Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time." Do you see that?  A. I do.  Q. Do you agree with that statement?  A. I think it's very reasonable.  MS. CONLIN: Okay. No further questions.  THE REPORTER: Let's go off the record a
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	conclusions stated there rely on a finding that the McGovern study is not valid; correct?  MR. GORDON: Object to the form of the question.  A. Not valid or wrong. Perhaps that's the same thing.  Q. Okay. But you'd agree with me if if the McGovern paper is legitimate, if the findings in there are correct, then none of your opinions as expressed in your summary have merit; correct?  MR. GORDON: Object to the form of the question.  A. The first four are probably a through d probably follow from the point that you've just made. The issue is whether the McGovern paper is or is not a legitimate basis of evidence.  Q. Well e relies your conclusion in e also require relies on McGovern being invalid; correct?  A. No, no, it's also on the current Augustine	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Correct. Q. And you've actually cited this publication in connection with your work; correct? A. Correct. Q. I'd like to direct your attention to the last page, page 12. A. Yes. Q. Second-to-last paragraph, "All scientific work is incomplete whether it be observational or experimental. All scientific work is liable to be upset or modified by advancing knowledge. That does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand at a given time." Do you see that? A. I do. Q. Do you agree with that statement? A. I think it's very reasonable.  MS. CONLIN: Okay. No further questions. THE REPORTER: Let's go off the record a moment, please.

60 (Pages 237 to 240)

Page 243 Page 241 1 out Exhibit 27. 1 benefit to using one particular agent/regimen." 2 MS. CONLIN: Which exhibit is that, Mr. 2 A. Yes. 3 3 Q. Do you see that? 4 MR. GORDON: It is a piece of testimony from 4 Okay. And on the same page does it discuss 5 5 specifically the regimen of Gentamicin only? the first day of Dr. McGovern. 6 6 A. It reads, "There is no evidence for the use A. Yes, sir. 7 7 Q. And if you want to turn to page 115, of systematic -- systemic gentamicin as prophylaxis in 8 8 transcript page 115. primary elective total hip arthroplasty and total knee 9 9 A. Yes, sir. arthroplasty surgery." 10 10 Q. And that -- the first question and answer Q. Okay. And do you have any reason to 11 that -- the question and answer that Ms. Conlin asked 11 disagree with Dr. Reed's conclusion that there was no 12 12 evidence for the use of system -- systemic Gentamicin you about. 13 13 A. "...do you believe it would have been as prophylaxis in primary elective THA and TKA 14 reasonable" --14 surgery? 15 Yes, I see that. 15 A. I -- I have no reason to disagree. 16 Q. Okay. And you said you also read the --16 Q. And what was the antibiotic prophylaxis that 17 You were reading to yourself the -- the 17 was being used at the beginning of the Bair Hugger-18 second question. Could you read that -- the question 18 only period? 19 19 and answer that you read to yourself. A. Gentamicin only. Q. Okay. And does it say anything about the 20 A. The paragraph that starts "We -- if we have 20 21 21 said that we believe, or think" --Teicoplanin? 22 Q. Yeah. In fact, you know what? For context, 22 A. It reads, "Four randomised controlled trials 23 would you mind just reading both questions and 23 provide strong evidence for the use of a single dose 24 24 answers, the one that Ms. Conlin asked you and then of 400 milligrams of teicoplanin at induction. 25 25 Although there is no evidence to suggest that higher the -- then the next one. Page 242 Page 244 1 A. The question is: 1 doses or prolonged courses of treatment result in 2 2 "Based on the evidence that you had, do you fewer SSIs, studies have shown that this dose may be 3 believe it would have been reasonable for your paper 3 inadequate for patients weighing over 70 kilograms." 4 to imply a causal connection? 4 Q. Okay. Do you have any disagree -- reason to 5 5 "Answer: If properly qualified, yes. disagree with Dr. Reed's statements about the efficacy 6 "Question: What would the proper 6 of Teicoplanin? 7 7 A. I have no reason to disagree with that. qualifications be? 8 "Answer: We -- if we had said that we 8 Q. And what was the antibiotic that was added 9 believe, or think, that there is evidence that 9 to the prophylactic antibiotic regimen prior to the 10 10 suggests that forced-air warming has an influence on switchover to the Hot Dog in the McGovern paper? 11 infection, but that we recognize there are confounding 11 A. Teicoplanin was added to a reduced 12 12 factors, then that implication is tempered with the Gentamicin dose. 13 13 recognition that there are other effects that could be Q. Okay. Do you recall any discussion in Mr. 14 at play." 14 Albrecht's testimony about the statistical comparison 15 15 between a time period during the Bair Hugger-only Q. Okay. You can put that -- thank you, you 16 can put that aside. 16 cohort where the same antibiotics and same 17 And then I just want to pull -- have you 17 thromboprophylaxis was used as was used in the Hot Dog 18 pull out Exhibit 22, I think, the Hickson paper, and I 18 period? 19 will direct you to the same page Ms. Conlin read from, 19 A. I recall that there was such a discussion. 2.0 page 186, in that second full paragraph there which 20 Q. And do you recall whether -- what -- what 21 21 is -- that's -- that's the one she read from where Mr. Albrecht had to say about what -- about whether 22 she -- where it said -- where this paper -- Dr. Reed 22 there was or was not any statistically significant 23 is one of the authors, "Although there is a large body 23 difference in the infection rate in -- in those two 2.4 24 of evidence for the use of prophylactic antibiotics in periods? 25 primary hip and knee arthroplasty, there is no clear 25 MS. CONLIN: Objection, misstates the record

61 (Pages 241 to 244)

	Page 245		Page 247
1	and assumes facts not in evidence.	1	antibiotics in primary hip and knee arthroplasty,
2	A. I I believe he reported that there was no	2	there is no clear benefit to using one particular
3	significant difference.	3	agent/regimen."
4	Q. And did you read any testimony from Dr. Reed	4	Could you read the next sentence in that
5	about that same comparison; in other words, the the	5	paragraph.
6	period during the Bair Hugger-only cohort when it was	6	A. "This is unsurprising, given that prosthetic
7	the same antibiotics and same thromboprophylaxis as	7	joint infection is a rare event and that a randomised
8	the Hot Dog period?	8	study would need over 3000 patients per group in order
9	A. I think I do remember it.	9	to demonstrate a reduction in the rate of infection
10	Q. Do you recall what Dr. Reed testified	10	from 2 percent to 1 percent, with a power of 90
11	about	11	percent at the 95 percent confidence interval."
12	A. I'm sorry.	12	Q. Do you know what "PJI" refers to there?
13	Q in that comparison?	13	A. Prosthetic joint infection.
14	A. I I I, by now, cannot distinguish	14	Q. Okay.
15	between the two, al but I I	15	A. That would lead me to correct my response
16	I don't remember specifically. I'm sorry.	16	earlier. This suggests that this was specifically
17	Q. By by "the two," do you mean Reed and	17	concerned with prosthetic joint infections.
18	Albrecht or Reed and McGovern?	18	MR. GORDON: Thank you. Nothing further.
19	A. Yes, Reed and McGovern.	19	RE-RECROSS EXAMINATION
20	MR. GORDON: Okay. No further question.	20	BY MS. CONLIN:
21	MS. CONLIN: One followup.	21	Q. Can you go back to the language that Mr.
22	RECROSS EXAMINATION	22	Gordon quoted you during his first examination of you
23	BY MS. CONLIN:	23	and read that back into the record.
24	Q. With respect to the Hickson study and the	24	A. Are you speaking to me?
25	statements from that study that you just read, those	25	Q. Yes.
	Daga 246		Page 248
1	Page 246 were for SSIs, not necessarily deep joint infections;	1	A. You want me to go back to what?
2	correct?	2	Q. Read the statement that Mr. Gordon read you
3	MR. GORDON: Object to the form of the	3	out of the Hickson paper.
4	question. Ask you to read the the whole paper if	4	A. Out of the Hickson paper.
5	she if you want to go there.	5	Q. Yes, prior to the time he just showed you
6	MS. CONLIN: No. I'm asking him with	6	that one.
7	respect to the specific statement that you just had	7	A. I I'm getting confused and it's late.
8	him read into the record.	8	Would you point to which paragraph you would like me
9	Q. It was directed to SSIs and not specifically	9	to look at.
10	deep joint infections; correct?	10	MS. CONLIN: Which page and paragraph was
11	A. It was specifically hip and knee	11	it, Mr. Gordon?
12	arthroplasty, but I do not see a distinction of joint	12	MR. GORDON: One fif
13	versus other infections.	13	One eighty-six, second full paragraph.
14	Q. Right. And the language that Mr. Gordon	14	MS. CONLIN: No, the first time you went
15	just had you read related to SSIs; correct?	15	over it with him.
16	A. Yes, I think so.	16	MR. GORDON: Oh, earlier?
17	MS. CONLIN: No further questions.	17	MS. CONLIN: Yes. That was early
18	RE-REDIRECT EXAMINATION	18	MR. GORDON: Same page, same page, and it
19	BY MR. GORDON:	19	was on the other side of the there was
20	Q. Unfortunately, we're going to have to go	20	A. Oh, the Gentamicin and the Teicoplanin
21	back to the Hickson paper then, Exhibit 22. Go	21	questions?
22	back to the frickson paper then, Exhibit 22. Go back go back to page 186 and the statement that	22	Q. Yes.
23	We'll go back to the original statement that	23	A. And what is the question you would like me
24	Ms. Conlin read from that. "Although there is a large	24	to respond to?
25	body of evidence for the use of prophylactic	25	Q. You know what? Let's just let the record
			· · · · · · · · · · · · · · · · · · ·

62 (Pages 245 to 248)

# CASE 0:15-md-02666-JNE-DTS Doc. 784-2 Filed 09/12/17 Page 64 of 104

### CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

	Page 249		Page 251
1	_	1	CERTIFICATE
2	speak for itself. We'll be done.  MS. CONLIN: I have no further questions.	2	I, JONATHAN BORAK, hereby certify that I
3	THE REPORTER: Off the record, please.	3	have carefully read the foregoing transcript, and that
4	(Deposition concluded.)	4	the same is a true and complete, full and correct
5	(Deposition concluded.)	5	transcription of my deposition, except:
6		6	PAGE/LINE CHANGE REASON
7		7	
8		8	
9		9	
10		10	
11		11	
12		12	
13		13	
14		14	
15		15	
16		16	IONATHAN DODAY
17		17	JONATHAN BORAK
18 19		18 19	Deponent
20		20	Signed and sworn to before me this day of
21		21	August, 2017.
22		22	114gust, 2017.
23		23	
24		24	Notary Public
25		25	·
	Page 250		
1	CERTIFICATE		
2	I, Richard G. Stirewalt, hereby certify that		
3	I am qualified as a verbatim shorthand reporter, that		
4	I took in stenographic shorthand the deposition of		
5	JONATHAN BORAK at the time and place aforesaid, and		
6	that the foregoing transcript is a true and correct,		
7	full and complete transcription of said shorthand		
8	notes, to the best of my ability.		
9	Dated at Deerwood, Minnesota, this 26th day		
10	of July, 2017.		
11			
12 13			
14			
15			
16			
17	RICHARD G. STIREWALT		
18	Registered Professional Reporter		
19	Notary Public		
20			
21			
22			
23			
24			
25			

63 (Pages 249 to 251)

	14:25 141:15	93:10 106:11	AFTERNOON	95:24 101:24
A	212:20	131:23	160:1	102:8,12,17
A-C-O-E-M	accusation	addresses 92:19	agencies 41:9	102:6,12,17
52:1	35:13,15	231:25	<b>Agency</b> 221:20	105:17 106:3
<b>a-d</b> 138:16	accuse 227:14	addressing	agent 71:22	106:23 129:1
a.m 1:22	227:18,22	59:18 90:21	agent/regimen	130:7 159:1,8
abbreviated	acid 42:2 46:1	97:19 231:1	193:25 243:1	172:14,17
94:18	Acinetobacter	adequately	247:3	182:1,4,16,21
ability 39:3	108:12,16	127:9 230:11	agents 61:2	airborne 93:13
133:5 134:23	109:1 113:24	230:25	71:19 136:21	93:21 95:23,25
159:2 227:1	114:17	adhesive 230:12	136:23 137:1,1	96:16 97:6,12
237:20 250:8	<b>ACOEM</b> 52:2,3	231:1	137:5,7	97:16 98:10,15
able 28:9 109:1	53:2 54:12,17	adjudication	ago 52:18,20	98:25 99:7,13
112:10	acquired 42:8	44:1 65:8	71:23 72:3,24	100:15,25
absence 20:17	acquirers 42:11	administered	87:7 121:23	101:20,21
42:14 65:13,17	acquirers 42.11	140:5,7	215:14	101:20,21
82:4,12 83:3	40:19 42:10	administering	agree 13:1 14:15	107:5 115:1,12
89:6 98:4,5	act 133:6 188:2	192:15	18:20 28:21	115:15 116:9
100:21	action 240:15	Administra- 4:8	33:10 36:8	130:13,22
absent 110:17	<b>Actions</b> 1:9	Administration	45:12 59:16,24	179:6 181:9,17
111:21,24	active 176:13,14	155:3	66:11,19 67:24	182:7 183:3
absolute 88:1	activity 19:24	adopted 59:21	68:4,12,15,18	akin 16:7
232:14	47:22	95:13	68:25 69:12	<b>al</b> 3:9 4:3,9,15
<b>absolutely</b> 30:25	actual 138:2	<b>adoption</b> 173:20	71:13 77:16	4:19,24 5:2,5
31:5 37:8,12	195:25	188:19	78:2,4 111:1,6	5:13 86:24
77:17 78:4	add 26:11 165:5	<b>advance</b> 110:17	127:21 157:15	114:3,4 190:19
158:17	165:19	advancing	161:16 162:24	232:12,24
<b>abstract</b> 193:15	added 26:12	240:13	163:14 164:10	245:15
203:18	185:7 202:5	adverse 7:6 48:2	165:24 173:1	<b>Albrecht</b> 36:24
accelerates 144:7	217:9 220:7	48:13,16 51:13	178:5 179:10	37:1 38:17,19
	244:8,11	adversely 48:7	189:12 207:18	39:5 152:19
<b>accept</b> 66:14 97:9	addendum	49:1	211:6 217:23	226:22 227:24
accepted 42:11	61:13	advisor/medical	233:24 234:10	228:8 244:21
66:12 67:9	addition 23:15	125:7	238:3,10	245:18
142:12	28:4 70:23	advisors 120:19	240:18	Albrecht's
accepting 32:25	73:20 217:7	Advisory 104:20	agreed 56:25	244:14
95:3	additional 10:17	105:15	66:4 97:19	alcohol 168:6
access 28:9	37:20,23	advocate 205:10	98:3 110:22	169:1 170:22
account 30:23	123:17,23	205:14	233:23 234:22	173:25 206:13
139:23,24	Additionally	aerobiology	agreeing 168:12	206:13
142:9 151:21	103:6	90:15	<b>Ah</b> 95:8	algorith 68:7
152:4,7 220:3	additions 8:23	affect 157:20,23	ahead 113:19	algorithm
220:6,16	address 57:20	157:24 158:6	164:14 180:15	106:10
accumulated	62:12 67:5	159:1	236:9 239:23	algorithmic 68:7
75:12	93:11 129:1	affirmed 180:13	<b>Ahh</b> 132:7	68:21,24
accurate 8:25	130:6	aforesaid 250:5	air 1:5 90:23	alleged 13:22
	addressed 66:1	Africa 73:7	91:1,5,18 92:5	43:16
	l	l	l	l

				3
<b>alleging</b> 97:5,11	150:10 156:23	137:1,5,13	141:17 142:9	181:4,8,16
allergic 51:18	150.10 150.25	138:7 139:15	176:18 218:6	182:12 190:18
allow 237:17	163:19 166:4	139:19 140:1,4	224:2	192:13 194:6
alluded 65:7	183:13 216:2	140:11 141:2		195:23,25
alter 227:2	219:23 223:9	143:8 144:9	appropriateness 152:21 218:13	203:17 213:9
230:13 231:2	226:3 229:8,12	155:15,21	218:19	239:25
altered 202:5	231:7,18	,		
alters 138:1	233:20 235:18	160:3,22 antithrombotics	<b>approval</b> 94:11 94:19	articles 10:18,22
amazing 90:23	241:10,11,19	139:7		28:5,9,13 75:17 92:21
amazing 90:23	, ,		approximately 1:22 72:15	99:2 146:25
84:4	242:5,8	anybody 22:19 63:5 75:24	126:19	
	answered 44:8	154:9 227:19		147:8,10,18 176:7 187:10
<b>American</b> 51:5,6	45:24 98:12		<b>April</b> 26:15,18	
63:16	107:1,2,11	anyway 195:9	27:4	ascertain 30:3
amount 23:25	112:24 135:18	<b>apologize</b> 23:8	aqueous 174:1,4	79:15 120:25
45:25 126:25	<b>answering</b> 58:13	28:22 110:17	174:13 180:9	184:20
analog 174:5	99:25 100:9	111:14 144:21	area 30:21 40:20	ascertaining
analyses 32:10	110:16	161:18 234:18	79:9 83:14	19:1
analysis 97:15	answers 241:24	Appalachia 3:9	84:16,17 96:22	aside 22:1 32:2
110:12 125:24	antibiotic 187:3	47:6,19,21	106:17 112:20	38:8 62:2
185:15,23	192:15,16	appar 127:25	130:9 137:21	92:19 138:21
186:12 188:21	195:22 196:15	apparent 12:22	172:24 232:20	154:18 189:12
188:23 197:18	196:25 203:11	apparently	232:22	208:2,13
223:23 226:24	213:1 243:16	89:19 127:24	areas 47:23	242:16
227:4 229:3,6	244:8,9	209:12	argument 80:24	asked 20:7,12
analyze 185:12	antibiotics 4:25	appearance	arithmetic	29:9 32:19
analyzing	85:3,6 183:22	137:2 209:25	185:17	44:8 45:24
142:17	184:8,15	APPEARAN	arithmetics	56:23 58:12
Andrea 76:17	186:14,20,23	2:1	212:14	60:15 62:12
anesthesiology	187:11,21	appeared	arose 10:23 72:2	63:2,3 64:12
19:16	188:2,9 189:23	184:10	arrive 25:23	68:12 69:3
answer 10:11	190:4 191:19	APPEARING	arthroplastic	74:8 75:9 81:8
15:25 16:21	191:21,23	2:9	17:14 83:20	87:21 97:7,18
28:14,16,17	192:19 193:6	appears 209:16	169:21	106:25 107:11
36:14 37:4	193:23 242:24	240:16	arthroplasties	122:22 130:25
40:21 45:16	244:16 245:7	appendix	230:14 231:3	152:11 160:10
46:5,7 57:23	247:1	206:24	arthroplasty 5:2	186:18 202:21
58:15 60:14	antimicrobial	applications	154:5 193:7,24	215:15 235:21
68:12,13 70:20	176:15	201:13	242:25 243:8,9	241:11,24
73:18 74:11	Antisepsis 4:14	appreciate	246:12 247:1	asking 28:22
77:9 78:1,4,12	170:10	168:19	article 3:8,24	37:3 82:20
81:18 86:2	antithrom	appreciated	4:4,7,12,16,20	83:7 85:24
88:1,13 98:20	136:16	16:25	4:25 5:3,6,9,24	100:5 112:15
99:2 100:2	antithrombotic	approach 68:24	35:24 47:4	112:21 122:17
106:18 110:15	133:18,22	approached	49:23 54:13,17	123:10 130:18
111:23 112:17	134:1,9,13	40:14,21	143:16,20,22	141:21 144:24
115:10 122:16	135:5,21	appropriate	145:12 150:15	149:17 150:11
135:17 139:16	136:21,23	59:17 92:6	170:8 173:2	156:13 186:3
	130.21,23	33.17 32.0	170.0 173.2	150.15 100.5

				1490 251
215:13 218:9	219:18 220:16	221:12 230:8	213:18 214:13	<b>B</b> 3:11 45:13
231:6 235:15	233:22 239:8	232:1 233:3	215:15 217:6	B-e-n-j-a-m-i-n
235:17 246:6	240:1	240:7	226:10 227:14	7:17
aspects 130:17	associations	attorney 40:19	233:4,21,25	<b>B-o-r-a-k</b> 7:17
<b>Assaad</b> 76:21	60:1 69:1	40:21	234:10,22	back 9:3 10:16
associate 23:7	82:16 220:22	attorneys	242:23	12:2 18:2 33:4
associated 9:16	assume 10:7	117:20 118:13	available 99:20	40:11 45:1
12:4,5,10,13	27:15,16	attractive 50:11	159:9 224:3	57:4,12,14,15
12:16,20 13:3	102:17 115:19	attribution	225:22	57:16,22,24
13:9,19 14:2,4	173:5 175:23	213:9	avoid 134:25	58:5 68:11
14:9,13,16,21	229:5	atypical 106:15	avoiding 161:15	73:7 77:11
15:1,6 16:2	assumed 42:23	Aug 209:6	award 153:13	87:16 88:23
19:6 30:9,13	173:14 196:21	August 227:9	aware 11:16	95:21 98:21
31:20 32:18,20	assumes 88:12	251:21	13:20,23 17:16	109:2 110:15
47:22,24 48:1	92:11 96:21	Augustine 10:4	21:24 24:20	114:3 136:3
51:13 52:23	101:3 105:19	10:8 11:14	29:9 33:17,17	140:24 154:19
108:10 133:7	106:6 108:19	13:22 31:25	33:18 35:5	175:21 178:23
135:1 136:11	121:4 123:19	32:1,2,4,10,17	52:12,13 59:13	180:23 183:17
145:5 148:20	129:10 138:23	32:19,23 33:9	74:13,18 78:13	183:21 189:22
181:2 184:15	226:19 228:6	208:25 209:5	86:10,16 87:12	202:17,23
188:3 208:22	233:18 245:1	209:16,23	105:13,21,23	206:22 229:9
217:1 235:10	assuming 16:4	210:7 238:22	108:11,20,25	230:7 232:1
association 5:25	127:17 162:5	239:1	109:5 111:17	235:23 246:21
12:8,15,21	200:13,14	aureus 4:19 5:9	119:21,23	246:22,22,23
13:2,23 30:25	226:13	194:18 204:1,6	120:18,23	247:21,23
31:5,6,9,12	assumption	author 74:14	121:6,8,9,11	248:1
33:8 46:9,22	161:1	143:6,25	122:6 123:16	background
47:10,13 50:21	assurance 35:17	145:25 146:5	123:21 125:5	27:18 208:17
63:12 68:1	36:2	147:22 162:25	126:4,10,10,13	backing 150:8
75:3 79:14	assure 36:2	163:4,9,11,15	129:4 130:11	bacteria 89:20
81:11 82:13	assured 56:9	163:23 164:4	130:21,24	89:22 91:5,18
83:3 97:3,22	122:6	165:24 170:12	136:2 138:5	114:21,22
110:6,18 111:2	attempt 19:5	190:25 191:6	142:25 143:3	137:17 139:4
129:20 132:23	160:24	193:10 214:19	143:13 146:7	139:20 158:19
132:25 133:9	attention 9:2,5,9	authored 46:21	146:11 153:4	158:22 188:3
134:1,4,8,17	12:2 23:12	47:5,9 69:13	153:23 154:2	bacterial 125:20
135:4,10,21,24	48:19,21 69:23	193:7	156:23 179:21	126:5,11 127:8
136:3 137:2,11	70:3 87:19	authoritative	186:13 206:11	<b>badly</b> 82:5
141:2 148:23	95:20 113:13	69:14 131:3	206:15,24	<b>Bair</b> 1:5 9:15
160:5,21	116:20 128:12	authors 34:14	207:8 214:12	12:3 13:9,13
167:14,25	132:19 133:17	35:25 36:4,15	224:7 230:10	13:18 14:2,8
177:22 178:13	150:19 156:8	38:6 52:5,23	230:17,24	14:16 15:1,9
179:6,16 181:8	156:20 161:8	138:5,18	231:7,9,14,18	15:21 16:5,6
181:17 184:11	162:1 166:25	163:24 165:7	231:21	17:5,13 28:2
192:8 194:13	193:19,20	166:5 171:16	awfully 212:7	29:12,21 30:3
213:14 216:13	194:8 198:16	181:24 192:22		30:9 31:1,9,21
216:15 217:5	203:16 208:15	212:24 213:12	B	33:8 70:24
	<u> </u>	I .	<u> </u>	ı

73:22 78:21	102:7,12 103:2	29:14,14,15	<b>Bias</b> 221:15	242:23 246:25
79:1,14,16,19	based 10:23	37:25 64:16	<b>big</b> 105:9	<b>Boone</b> 87:6
79:20 80:8,21	14:17 31:18	74:11 76:23	<b>bio</b> 84:23 85:1	<b>Borak</b> 1:13,19
81:1,4,12,24	68:23 77:8,9	82:17 99:20,23	biofilm 84:24	3:4,5,6,9 6:5
82:13,25 83:4	79:20 80:25	109:11 112:25	85:4 186:19	7:3,8,9,9,17,22
86:12 87:11,24	87:22 94:19	117:8 131:1	biofilms 85:1,5	8:3,10,11 9:5
89:6 91:16	95:13 96:12	133:10 134:11	biohazardous	22:7 23:12
92:3,15 93:3,7	110:9 112:7	134:22 138:11	114:12	24:25 39:15,23
93:13,17,21	117:7 129:22	145:4,4,18,21	biohazards	40:2,4 41:3
94:11,23 96:4	136:14 139:1	146:21 149:8	115:7	47:4 54:10
96:12 97:3,16	143:1 144:17	154:1 158:7	biological 80:13	61:23 69:25
97:22 98:9,15	148:7,8 162:21	162:2 164:25	biomedical	76:16 90:10
98:18,24 99:5	162:25 163:14	166:2 171:12	102:16	94:9 116:21
99:22 100:14	165:22 185:22	171:23 172:2	<b>bit</b> 57:9 61:7	119:2,7 125:12
100:16 101:22	192:21 199:13	174:5 178:5	152:23	126:18 128:7
102:6,11	200:14 209:23	190:8,11	<b>black</b> 49:11,15	131:14 145:11
103:11,21,23	215:20,24	194:15 201:9	49:20	154:17,24
107:15,18,23	216:11 217:16	201:12 202:11	BLACKWELL	161:5 175:12
108:3,13 109:2	222:2 225:7	203:8 206:10	2:7	195:16 198:8
109:13,22	232:2 242:2	215:21,25	<b>blanket</b> 102:18	203:5 204:24
110:7,18	basically 186:21	219:10 225:8	Blankets 101:22	208:16 230:5
111:11,17,25	207:1	226:4 233:21	102:6	236:7,14
113:1,4,22	<b>basis</b> 79:18	241:13,21	bleeding 134:24	239:24 240:25
118:23 120:7	98:19 213:14	242:3,9 245:2	137:15,15	250:5 251:2,17
120:20 123:17	229:14 233:1	believing 138:21	138:1 144:5	<b>Borak's</b> 3:11
123:23 129:6	238:19	belligerent	145:5	<b>botic</b> 133:22
129:16,21	Bates 11:19	14:19	bleeds 144:13	<b>bottom</b> 77:20
130:12,21	bathtub 16:18	belonged 43:5	blew 196:8	113:14,21
131:18 132:5	baumannii	beneficial	<b>blind</b> 208:1	125:13 215:18
135:2,11,25	108:12	191:24	<b>blood</b> 136:9	216:5
136:14,19	Bear 113:15	benefit 167:21	137:16 139:11	Boulevard 1:21
182:15,20	128:23	173:24 193:24	144:6	Bradford-Hill
183:2 184:18	began 224:21	206:12,16,25	<b>blowers</b> 106:13	59:17 239:25
192:9 205:18	225:12 229:5	243:1 247:2	blown 95:24	break 53:24
205:20 208:22	<b>beginning</b> 177:3	benefits 187:11	blows 105:17	54:11 116:16
211:7,17,21	178:4 200:10	191:21	106:3,23	180:7,14,24
212:18 213:14	243:17	Benjamin 7:16	<b>blue</b> 199:1,7,8	181:11 195:8
216:13 217:1	Behalf 2:2,5	<b>benzine</b> 60:5	board 18:6	195:20 229:23
227:7 232:5,14	<b>behavior</b> 153:19	best 8:24 33:6	33:19 35:23	breaking 149:13
233:12 234:13	<b>Belani</b> 34:19	191:18 250:8 <b>best-done</b> 77:7	53:2 57:18	BRI 59:7
235:10 239:9 239:10 243:17	35:6 228:16 <b>Belani's</b> 35:4	better 57:17	118:7 <b>boarded</b> 19:13	broad 130:9 bronchiolitis
244:15 245:6	<b>belief</b> 48:9	82:9 168:7	<b>boards</b> 11:6	63:25 64:10,14
<b>banging</b> 111:14	204:16	189:24	<b>Bode</b> 4:19	Bryan 55:21
bar 58:18,25	believe 13:18	beyond 45:15	175:12	56:9,19 57:17
59:7	14:4,11,12,20	147:3 214:2	body 89:23	<b>bubble</b> 232:4
<b>barrier</b> 101:23	14:24 26:7	BH 9:15	193:22 202:1	<b>bubbles</b> 232:5
Julie 101.23	11.2120.7	<b>211</b> 7.13	173.22 202.1	5455ics 252.5

buildings 64:23	71:21 72:6	83:6,7 98:6	certain 27:15	229:5 230:11
<b>bunch</b> 49:22	74:4,10 75:13	215:22 216:18	42:10 118:1	230:25 251:6
112:4 214:2	76:3 78:18	233:22 240:1	127:20 197:3	changed 122:18
<b>bundle</b> 225:16	79:11 86:11	cause 43:16 48:3	219:6 222:7	190:11 210:10
<b>bundled</b> 204:10	87:4,14 91:13	48:23 49:4,5,7	226:22	229:6 234:23
204:15	96:10 100:20	51:17 61:4	certainly 10:16	changes 158:9
<b>BURKE</b> 2:7	104:23 105:14	63:5 64:3,6,10	18:19 19:3	190:8 213:1
	105:24 106:22	64:13,25 67:3	29:23 43:11	220:7
C	109:9 112:17	98:15,17 99:14	59:14 87:13	changing 114:16
<b>C</b> 7:1 95:22	113:12 117:16	110:2 115:2	143:11 144:21	153:19,20,21
250:1,1 251:1	123:7,22	239:11	215:2	157:19,20
251:1	124:23 125:6	<b>caused</b> 43:9 44:5	certainty 238:1	<b>chart</b> 201:5
Cabot 65:6	130:23 150:3	44:18 45:21	certified 18:6	203:19
calculations	151:22 152:5	48:11 49:24,25	certify 250:2	check 239:14
185:17 217:15	155:19 160:7	61:2 62:14	251:2	checked 37:17
call 212:11	160:23 167:21	63:25 81:23	<b>CFU</b> 181:18	217:7
called 7:4 80:13	174:21 191:8	82:25 89:7	182:1,3,5,7	chemical 65:10
189:16	192:4 205:6	107:23 111:25	<b>CFUs</b> 182:16,20	chemicals 60:24
cancer 62:14,22	224:25	causes 19:1	<b>chain</b> 80:12	<b>Chen</b> 5:13
63:1,9	cases 26:9 37:21	31:23 45:13	128:9	cherry-picked
capacity 188:2	41:25 43:24	65:25 66:5	chairman 51:8	209:9
<b>caption</b> 62:8 102:24	44:13 45:10	93:17 98:17,19	challenge 14:22	cherry-picked'
- '	142:3,4 148:11	99:5,11,13,22	182:12	223:25
cardiothoracic 106:16	165:21 167:20	99:24 111:21	<b>chance</b> 13:5,14	cherry-picking
care 179:25	210:9 225:11	136:20	13:16 15:8,9	189:15,18
care 179.23 career 71:17	<b>catch-up</b> 125:24	causing 15:10	15:15,15,19,22	209:10 225:1,6
careful 227:18	categories	198:20	134:18	<b>CHG</b> 206:16
carefully 177:24	198:22	cc 114:5 128:10	change 21:25	<b>CHG-</b> 173:24
251:3	<b>catheters</b> 169:15	<b>CDC</b> 70:16 71:3	57:8 81:21	206:12
Caribbean 73:6	caught 50:25	71:7,13 104:18	133:21,23	chi-square 218:17
Carriers 4:18	causal 60:4	105:7,11,15	138:7 153:15	
case 8:4 9:3	62:22,25 63:9	106:2,12,23	153:18 155:14	chi-squared
11:25 20:4,10	63:12,20 67:25	107:4 117:1 118:3 173:23	155:19 156:6 156:18 157:19	218:6,15,19 chlorhexidine
23:22 24:3,9	68:5,16,19 69:1 82:13	174:14,17	158:1,5,5,14	167:19 169:1
24:11,15 25:7	110:18 111:20	180:18,19	160:3,20,21	173:20,25
25:11 26:14,18	112:13 213:13	204:3 206:12	167:7,14,25	173.20,23
28:20 29:8	214:14 216:1	204:3 200:12	170:17 171:9	174.10,23
34:3 38:22	216:11 219:12	CDC's 70:10	171:16 173:18	176:24 178:1
39:9 41:22	242:4	center 10:9	176:20 178:7	178:18
42:24,25 45:5	causality 82:3	11:17 64:19,23	180:25,25	Chlorhexidine-
60:9,25 61:1	causation 6:1	65:4 71:23	183:24 184:7	170:21
62:7,11,16,21	43:3,4 44:3	209:12 210:11	184:12,24	Chlorhexidine
63:19,23 64:6	46:4 60:23,24	centers 5:14	187:21 190:3	4:12 170:9
64:16,24 65:14	62:23 66:8	104:19 204:25	192:18 206:19	chlorohex
65:21,23,25	67:9 73:15	210:2	209:3 212:25	173:25
66:3 69:25	75:3 82:18	<b>central</b> 100:23	217:10,21	<b>choice</b> 139:14
	<u> </u>		·	

				1496 257
<b>chose</b> 37:13	cleaning/113:25	colonization	comparison	90:16
chronology	cleanup 64:22	204:2	174:24 176:25	concept 66:14
26:20	clear 21:13	colony-forming	177:2 178:9	80:13 81:13
cigarette 65:2	24:24 36:22	181:17	201:6,8,18	conceptually
circle 199:3	40:12 42:5	Columbus 1:21	208:4,6 210:15	16:19
circumstance	193:24 210:8	combination	244:14 245:5	concern 49:21
172:6	242:25 247:2	175:1,14	245:13	56:14,17,18,19
circumstances	clearer 161:22	combined 165:2	compensation	65:11 73:11
64:13	clearly 27:15	209:17	42:17	90:23 91:25
CIRESI 2:3	61:4 144:19	<b>come</b> 10:18	compilation	102:22 106:11
citation 153:11	151:3 155:10	127:1 213:4	209:13	106:14 120:10
153:11	165:7 210:23	comfortable	compiled 224:18	127:19 130:18
citations 36:11	216:15 222:5	7:10 20:10,18	224:19	197:17 223:23
91:6	<b>clever</b> 141:12	20:21 177:22	compiling 27:6	concerned 55:1
cite 70:10 80:3	<b>client</b> 27:2 62:16	178:12 224:25	complaint 127:3	55:6,11,22
91:5 143:16	<b>clients</b> 40:13,13	<b>coming</b> 115:24	complaints 61:2	63:24 65:25
168:4,9 169:24	<b>clinical</b> 18:13,17	116:3 117:23	65:4	88:8 91:16
174:25 214:24	36:23 71:25	commencing	complementary	92:3,7 103:10
cited 36:7 71:9	128:20 129:5	1:21	175:2,15	106:12 107:5,8
75:18 79:11	130:2,10	comment 90:25	176:23	112:25 114:16
91:20 117:17	181:25	121:10 188:5	complete 178:16	115:5 116:8
124:24 147:8	<b>close</b> 169:5	202:6 237:20	224:24 250:7	118:10 247:17
147:11,19	<b>clothes</b> 153:20	commentary	251:4	concerns 14:5
153:11,12,14	153:20	100:11	completely	43:20 55:4
156:12,14,14	<b>clotting</b> 134:16	comments 21:14	74:17 127:7	57:23,25 67:3
156:15 157:5	<b>cluster</b> 106:15	57:12,16,16	complications	95:22 101:21
168:16,18	<b>coal</b> 42:13 47:18	157:25	4:7 27:11	116:14 130:21
176:7 181:12	47:21 48:10,13	committee 51:8	142:17 149:13	135:13 227:23
204:14 207:22	48:14 50:2,3,6	104:21 105:15	155:2 165:10	concise 38:24
207:24 214:22	50:6,10,10,16	common 11:8	165:17	conclude 47:16
240:4	50:17 65:13	commonly 188:3	component 66:8	166:17
<b>citing</b> 66:18	coherent 82:15	community	67:3,8	concluded 63:19
75:22 117:18	110:20	49:14 50:8	components	65:14 117:6
156:9,20	<b>cohort</b> 244:16	companies 41:8	105:10	138:6 187:10
claimant 61:3	245:6	65:9 73:5	composite 200:2	213:13 249:4
claimants 43:23	coincidence	company 3:6	201:1	conclusion
clarify 32:19	227:11	39:16,23 40:2	compound	31:18 65:17
84:2,11	coincidental	40:4 41:3 42:8	138:23	67:6 79:13
clean 4:22 115:6	227:3	42:9 63:17	comprise 224:17	98:8,23 99:14
115:8 173:10	colleague 26:25	company's	comprises	112:2,13 117:1
187:12 190:20	colleagues 53:11	40:18	226:24	164:7,18
191:22 192:16	collected 214:6	compared	computational	165:25 166:3
clean-contami	<b>college</b> 51:5,7	117:11 150:23	86:7	168:20 171:9
191:19	54:14 55:1,4,7	151:15 169:2	computer 180:1	176:19 181:23
cleaned 114:24	55:11,22 56:15	174:1 175:4,4	conceivably	181:25 190:3
cleaning 60:24	56:25 57:4	175:16 206:13	171:13	235:19 236:1
61:2	<b>Colon</b> 102:6	207:2,7 209:18	Concensus	238:20 239:7
	•	•	•	•

	_	_	_	1 490 250
243:11	220:15 221:9,9	195:7,14	180:8,18	173:10 191:20
conclusions	confounding	196:12 198:6	181:13,13	contamination
66:24 80:5	132:21,22	199:2,6 202:15	191:1,8 192:19	42:1 93:13,21
88:16 96:9	133:13 143:2,9	202:23 203:3	195:6,20 197:7	95:23,23,25
112:19 141:1	151:23 163:2	204:23 212:5	199:21 204:9	96:16 97:6,17
151:22 152:5	163:17 164:8	215:6 226:3	205:6 206:19	98:10,25 99:7
164:2 174:21	164:18 166:1	229:9,12,23	214:14 216:1	99:13 100:15
211:12 223:16	204:18 221:14	230:3 233:20	216:11 218:20	100:25 101:20
233:6,9 234:12	242:11	235:22 236:2,5	219:2,13 220:5	101:22 102:4
235:17 238:4	confounds	236:11 239:14	220:14 226:6	102:23 103:1
conducted 154:4	148:22	239:20 240:20	237:18 240:5	107:5 115:1,15
<b>confer</b> 240:14	confused 248:7	241:2,11,24	242:4	116:9 130:13
confidence	confusion	242:19 244:25	conscious	130:22 182:1,3
198:21 247:11	135:15 161:15	245:21,23	172:10	182:7 183:3
confidential	conjecture	246:6,17,24	consciousness	contentious
46:18 122:7,23	102:19 103:15	247:20 248:10	66:1	191:20
confidentially	114:20	248:14,17	consensus 90:22	context 12:13
122:21	conjecturing	249:2	consequence	16:20 18:15
confirmed	102:15	Connecticut	26:2 118:22	43:10,12,13
222:15	conjunction	1:21	consider 17:10	44:3,17 48:15
conflict 33:16	220:4 221:8	connection	17:18 18:17	66:9 72:1,8,19
53:1	<b>Conlin</b> 2:3,3 6:5	12:19 21:15	19:19,21,25	83:18 136:24
conflicting	6:7,9 7:7,18,22	23:21 28:20	155:25 212:3	153:13 156:2
224:12	8:1,9 11:23	30:12 49:23	considerations	241:22
confound	23:9 25:2,5	60:5 62:22	201:14	continue 233:5
184:10	28:18 34:8	67:14,22 69:19	considered 66:1	237:3
confounded	39:13 46:19	70:16 71:8,16	111:23 167:12	continuing
134:1	47:2 54:1,8	79:12 80:4	consistency	57:24
confounder	60:15 61:21	85:3,11,23	201:13 232:3	contradicted
132:25 133:1,7	76:14 86:18	86:7 87:4,13	consistent 116:9	210:10
133:23 134:5,5	88:13 90:8	88:21 89:2	constant 15:18	contradictory
137:5,7,9,10	94:7 104:4,7	91:13 92:25	15:20 40:25	164:24
138:8,12	104:10,13	93:5 96:3,8	constantly 33:17	contrary 52:7
146:12 147:15	108:17 113:9	98:8,23 103:17	construct 38:10	52:14 166:19
147:24 148:5	116:15,19	107:25 109:8	constructed	contribute
148:17,17,18	119:5 124:6,12	112:19 116:2	29:12	111:18,24
157:12 160:4	126:16 128:6	117:15 124:22	consultant 27:3	136:21
167:9,22	131:14 143:22	129:15 131:7	40:1 46:8	contributed
170:18 171:10	145:10 148:25	133:12 140:5	consulting 40:7	48:15 65:19
176:21 178:2,5	154:15,22	140:16,22	40:9	contributes 48:5
178:19 181:2	159:11 160:2	141:1 142:7	consumer 64:1	48:24
184:8,25 186:8	161:4 162:7,12	149:3 151:21	contained 23:16	contributing
188:14 190:4	163:4,7,10	152:4,12 155:6	23:20 80:5	239:11
190:10 192:19	170:6 175:10	155:13,18	96:9 152:24	contribution
192:23 199:22	176:2 178:24	157:11 162:16	237:22	91:2
206:20 219:17	180:6 183:17	164:9 168:4,10	contains 164:24	control 5:14
219:22 220:4	190:16 193:3	174:21 179:19	contaminated	70:24 73:21
	<u> </u>	<u> </u>	<u> </u>	

				rage 257
104:19,20	66:13,16,24	181:3,14,15,20	121:23	144:7
105:16 205:1	67:15,22,23	182:13,17,21	<b>costing</b> 126:25	cultured 113:24
206:2 234:20	69:21,22 70:8	183:3 184:13	counsel's 100:11	cultures 108:3
controlled 4:23	70:9,11,13	185:10,19,20	226:1	204:2
179:8 190:21	71:8,14,19	186:23 187:6	count 87:25	culturing 107:14
243:22	72:7 74:1,2	189:2,14 190:5	165:16	curious 196:10
controversy	78:12 80:7,14	191:2,9 192:4	couple 50:1	200:19
50:25 51:4	88:17 89:3,15	192:16,20,23	147:8	current 238:22
convective 92:15	91:11 92:9,16	194:14,15,18	course 10:17	Currently 39:24
conversation	95:4,18 96:17	197:8,10	71:17 102:21	curriculum 3:5
25:24	97:6,17 98:7	198:25 199:15	210:22	CV 8:12,14
conversations	98:22 102:23	199:18 201:20	courses 20:1	,
197:21	103:18,19,21	202:2 203:7,8	244:1	<b>D</b>
<b>copy</b> 7:19 8:2,12	105:8 107:15	203:14 204:11	<b>court</b> 1:1 63:13	<b>d</b> 3:1 7:1 238:16
8:14	107:16,19	204:18,19	104:14 183:18	<b>daily</b> 153:5
Corey 2:6 20:6,6	110:14 111:3	205:3,4,6,7,11	183:19 202:18	damage 127:2
<b>coroner</b> 66:2,4	117:18,19	205:15,19	202:24 229:9	damages 42:14
corporate 86:10	124:19,23	206:13 207:13	229:11 235:24	<b>Dan</b> 124:9 126:4
87:20 232:11	125:2 127:14	208:5,13,14	coverage 65:9	126:19
232:25 233:2	129:24 132:17	209:1,2 211:20	create 92:15	dangerous 126:1
Corporation	134:6,19 135:2	212:21 213:15	93:7,8 97:16	<b>Daniel</b> 124:18
65:6	135:6,12,22	213:16,18,22	98:10,25 99:7	Darouiche 4:15
<b>correct</b> 8:5,24	136:1,10,12	214:4,9,15	109:13 110:13	79:24 80:4
9:18 12:16,17	137:5 138:8	215:1 217:2,21	156:15	89:12 169:25
17:7 18:8	141:17 142:9	218:7 219:14	created 165:25	170:13 173:2,7
19:11 20:15	143:3 144:9,10	220:5,17,25	creates 83:11	179:5,18
22:6,8 24:9,17	144:15,16	221:4,10,16	144:25 156:7	181:12,23
24:18 25:12,20	145:17,24	222:18 223:10	156:18 181:2	214:8
29:1 32:5,6	146:22,25	223:18 224:9	186:21	data 9:13,15
33:12,23 34:4	147:4 149:11	224:23 225:2	creating 92:4	13:23 35:9,20
34:12,13 35:9	150:7 152:15	229:18 234:2,4	credentialed	36:4,8,9,15,23
35:20 37:16,17	152:21 155:4,5	234:6,14,22,25	36:1	37:16 38:6,13
37:25 38:2,19	157:17 158:8	235:4 236:16	credentials	38:14,14,15
38:23 39:16,17	159:2,6,8	238:5,12,13,21	35:14,16	59:25 69:4
40:5 41:6,15	160:15,24,25	239:3,12 240:2	227:25	87:22 120:2
43:17 46:22	161:1 163:25	240:3,5,6	credibility	141:10 142:8
47:10,11,14,19	164:4 165:21	246:2,10,15	236:20	152:15,19
49:8,24 50:3,7	166:7,10 168:2	247:15 250:6	credit 141:13	159:10 160:6,6
50:12,18 51:1	168:3,8,9,11	251:4	criteria 59:17	160:24 165:2,6
51:14,24 52:6	168:23 169:16	corrected 9:14	204:3 222:7	165:9 166:2,17
54:21,22 55:2	169:17,19,22	21:18 162:7,16	critical 8:21	178:20 192:21
55:5,13,17,24	169:23,25	216:25 217:4	93:4	197:22 201:4
56:12,13 58:19	170:1,14,15,18	correction 58:6	crude 188:23	202:14 209:9
59:8 60:24	170:19 171:6,7	212:6	CS 60:23 61:3	209:11,22,23
62:1 63:17,18	175:17 176:16	correctly 9:19	cultural 47:24	210:3,12,13,14
63:21 64:7,11	177:9,23	78:6	48:6,25	210:16,18 212:20 214:5
65:1,15 66:8	179:22 180:10	correlation	culture 137:16	212.20 214.J
		•	•	•

	_	_	_	. Tage 200
216:24,25	192:7,18	190:4 201:5,19	148:18	236:16
217:4 223:7,24	decides 172:8	202:1 204:5,11	depends 153:3	depth 231:10
224:3,17,24	deciding 25:13	207:19 211:15	172:6	deputy 51:21
225:8 226:7,10	69:1 220:15	221:24 222:13	Deponent	deriving 218:7
226:16 227:22	221:8	225:17 231:17	251:18	describe 33:3
228:8 237:12	decision 28:25	233:11 235:11	deposed 74:19	34:20 83:5
237:18	53:18 75:5	239:9,11 246:1	deposition 1:13	175:22 187:1
date 21:9 46:10	155:11 172:11	246:10	1:18,19 3:13	described 58:1
52:17 163:1,16	187:21	deeper 84:15	4:10 5:18,20	63:12 82:1
224:16 225:2	decisions 128:19	Deerwood 250:9	5:22 8:3,11	121:1 153:16
225:13 226:23	129:4 155:14	defendant 42:6	10:15 11:13,15	160:5 182:13
227:2	155:19	<b>Defendants</b> 2:5	22:9 24:8,12	describes 60:1
dated 9:3 54:16	declined 188:19	defended 10:25	25:4 26:3 29:7	describing 88:25
76:17 94:10	decolonization	<b>defense</b> 41:15,20	34:10 35:4,6	description 3:2
113:17 126:19	5:10 194:23,25	42:20 45:13	36:21,22 38:1	33:4,4 97:9
250:9	195:22 196:1	52:5,24 53:6	39:15 45:6,7	153:15 175:24
dates 113:16	196:14 197:15	53:12,21 58:3	47:4 61:23	designed 101:22
225:11,15	197:20 202:9	58:18,25 59:7	62:2,3,5 63:17	102:6
227:5 229:4	203:11 204:6	defensible 50:12	76:16,17,20	designs 94:13
datum 219:4	204:17	defer 81:8 172:3	86:23,24 87:18	<b>detail</b> 197:6
<b>Dave</b> 114:5	decrease 172:21	177:19 188:10	104:12,12,17	detect 196:22
119:13	185:7,13	deferring 20:23	105:1 113:11	detected 204:1
day 20:6 26:25	decreased	152:20	119:7 124:8,17	detection 166:10
27:1 111:2	171:11,22	<b>define</b> 12:5,10	126:18 128:8	determination
221:3 230:5	decreases 172:1	18:21 69:6	136:4 145:12	68:6,20 70:17
234:19 241:5	172:20	140:20 173:16	148:2 154:17	determine 97:20
250:9 251:20	deep 83:21 84:1	207:15	154:24 158:3	186:7
days 215:9	84:6,7,13,20	<b>defined</b> 155:10	161:7 170:8	determined
<b>DC</b> 85:16	116:24 134:15	204:2	179:5 181:7	88:22
<b>deal</b> 33:13 54:24	135:1 141:4,8	definitely 37:16	182:13 190:18	develop 42:13
55:9 107:13	149:14,19	definition 13:7	193:5 195:16	development
118:11 127:9	150:22 151:7	83:17 85:25	195:16 198:8	48:5,25 51:9
182:15 234:5	151:15 155:7,8	133:11	214:23 215:8	73:2,8 97:13
236:10	155:16,22	definitive 38:25	215:10 222:16	deviated 210:15
dealing 88:24	156:8,10,11,19	<b>degree</b> 18:1,7,9	225:9 230:6	device 30:14
<b>deals</b> 182:16	156:22,22	18:11 228:1	236:7,7,14,15	94:19,23 95:9
dealt 43:25	157:2,11,17,22	237:25	249:4 250:4	131:19 132:6
209:16	158:6,15,23	<b>delay</b> 160:19	251:5	devices 4:4
<b>Dean</b> 54:13 59:2	159:2 164:17	delayed 141:25	depositions 10:7	27:10 108:3
decade 41:21	169:18 170:24	deliver 187:3	24:2,14 25:10	134:2 135:15
decades 41:12	171:13,16,22	<b>demand</b> 240:16	29:23,24 36:7	136:25
41:17 44:16	172:1,20,21	demonstrate	36:7,12 37:7	diacetyl 63:20
December 4:11	173:3 175:3,16	116:23 247:9	38:8 74:3,10	64:5,10,13
decide 37:9 38:7	177:16 180:20	<b>density</b> 182:4,5	76:2 138:20	Dick 179:23
44:12 60:21	185:9,24	department	192:24 213:7	differed 36:8
138:17,24	186:15 187:5	104:18 222:6	213:17 224:15	difference 84:5
decided 130:2	189:20,25	dependent 81:20	234:24 235:8	91:3 112:10
				•

	•	-	•	
151:7 155:7	difficulty 202:19	243:4	<b>DJI</b> 166:10	199:1,3,8
156:16,24	dig 195:7 214:20	discussed 91:2	<b>DJIs</b> 228:23	doubled 188:6
157:16,18	diminish 147:12	116:22 125:3	<b>doctor</b> 7:11,13	189:1
173:3 177:2,15	direct 9:2,5,9	152:1	34:3 125:7	<b>doubt</b> 16:3
244:23 245:3	23:12 48:3,12	discusses 46:14	181:12 191:6	down-regulates
differences 37:1	48:19,21,23	discussing 34:11	doctors 84:6	134:16
38:13 94:13,16	49:4,4,7 63:8	discussion 11:2	120:18	download 3:7
156:9,21	69:23 70:3	19:9 34:7	document 1:8	Downtown 1:20
different 12:9	87:18 95:20	65:16 82:3	38:20,24 70:24	dozens 176:7
14:6 16:14	113:13 116:20	94:4 97:11	73:21 77:1	<b>Dr</b> 7:9 8:10 9:5
25:6 36:13	128:12 132:19	104:9 122:7	90:22 91:12,23	10:3,15,25
40:23 44:2	133:16 150:18	142:14 154:11	92:13 100:13	11:14 17:1
53:4 57:10	161:7,25	180:5 204:9	100:15 104:1	22:17,20 24:12
67:20 71:6	166:25 174:24	208:3 215:3	116:10 119:8	24:25 26:3,7,8
73:13,17 78:25	178:9 193:19	244:13,19	122:13,18	26:18 31:24
97:8 132:2	193:20 194:8	discussions	123:5,6 150:9	32:1,9,18
133:25 135:13	198:16 203:16	20:25 27:16	189:22 198:8	34:19,24,25
135:14 136:23	205:8 208:15	106:9 122:24	200:15 202:12	35:1,2,4,6
137:9,25 139:6	216:4 221:12	<b>disease</b> 5:14,25	202:20	36:21,25 37:15
139:9 144:10	230:8 233:3	18:23 19:11,12	documentation	39:2,2,10 52:7
145:22,23	240:7 242:19	19:14 49:12,20	40:18	52:13,25 53:11
146:9 149:9,18	directed 246:9	64:3,4,22,25	documented	55:20,21,23
152:3 153:24	Directing 12:2	73:4 104:19	51:20	57:5 66:10,16
156:13 159:10	232:1	205:1 240:1	documents	66:17,18,19,21
164:24 174:12	directions	diseases 72:20	11:18,24 24:3	66:23 67:14,17
174:19 184:16	113:25	disinfecting	24:9,25 25:1	74:4,6,6,13
208:9,11	directly 40:15	114:1	25:10,17,25	77:12 81:8
211:16 225:11	147:5 208:5	disorders 51:18	28:12 29:8	85:13,15 90:12
226:23 229:3	<b>director</b> 51:21	disparities 3:8	39:1 70:19	96:22 124:10
234:7 235:7	51:25	47:6 48:11	110:24 112:4	124:18,19
differential	directors 57:19	49:14,18,18	113:5 115:23	125:6,13
144:13 188:2	<b>disagree</b> 93:14	dispersion 172:17	116:13 155:3 191:3 198:14	126:11 127:13 127:23 128:16
differentially 134:23 135:14	111:5 147:25 163:23 164:2	dispute 194:2		141:10 142:12
136:25 184:14	164:11,15	230:20,21	<b>Dog</b> 184:18 185:9,19 227:7	141.10 142.12
184:15	197:24 217:13	230.20,21	234:14 244:10	146:6,7,11
differentiate	217:20 243:11	233:1 236:19	244:17 245:8	147:22 156:14
165:8 204:4	243:15 244:4,5	distinction 18:3	doing 20:10,19	156:14 157:25
222:10	244:7	24:24 40:8	40:17 102:17	158:4 160:23
differentiated	disavowed	246:12	120:1 130:7	161:7 163:6,23
149:18	74:14	distinguish	160:5 173:6	164:11,21
differentiation	discard 114:11	245:14	196:21	168:5,11,12,20
150:5	discovered	distorted 132:23	domain 83:13	168:22 170:12
difficult 54:25	118:5	DISTRICT 1:1	dose 243:23	172:3 177:20
55:10 69:6	discriminate	1:2	244:2,12	179:18 181:11
difficulties	166:5	division 42:8	doses 244:1	185:4 186:11
165:4	discuss 13:22	divorced 81:12	<b>dotted</b> 198:24	188:5,11,15,24
L	I		I	

	ı	1	1	ı
188:25 189:6	<b>Ducky</b> 15:11,23	economic 47:24	<b>either</b> 11:19	47:9 227:3
189:11,19	15:25 16:1,5,8	<b>ECRI</b> 117:6	19:20 38:25	entirety 176:11
190:18,24	16:15,24	118:4,12	44:21 70:16	entitled 47:5
193:7,10	<b>due</b> 50:2,6,10,16	119:10,19,22	73:10 74:18	145:12 155:1
196:20 197:8,9	50:17 110:21	119:25 120:6	77:7,19 86:6	167:4 170:8
197:13 202:7	121:1	121:7,9,24	89:20 116:25	179:6 181:8
211:25 214:20	<b>duly</b> 7:4	122:1,6,10,13	130:18 152:18	193:5 195:17
214:23 215:7,9	<b>Duren</b> 86:25	122:14,14,23	176:7 181:19	198:9 204:25
215:14,16	87:1 114:4,4	123:1,14	196:9 238:25	239:25
217:8,15,20	<b>Duren's</b> 232:12	editorial 11:6	elective 5:1	<b>entity</b> 43:21
222:16,16,20	232:24	33:19 35:23	193:6 243:8,13	enumerated
223:10,15,23	dynamics 86:8	51:10	element 221:3	24:1
224:14,23		<b>edits</b> 21:15	elemental 8:20	<b>Envi</b> 51:6
225:19 226:4	E	<b>effect</b> 132:23	elements 15:14	environment
226:13 228:15	e 3:1 7:1,1	133:1 152:24	133:13	5:24 49:10
228:15,16,20	238:20,20	153:2 162:22	eligible 24:21	90:22 240:1
230:6 231:23	250:1,1 251:1	176:16 187:1	eliminate 146:21	environmental
240:25 241:5	251:1	187:22 227:7	eliminates	43:9,15 44:5
242:22 243:11	<b>e-d</b> 138:16	effected 173:21	146:12 148:5	44:18 45:21
244:5 245:4,10	<b>e-mail</b> 3:10,15	effective 5:3	<b>emboli</b> 134:15	51:7 60:1
<b>draft</b> 10:15	3:19,20,21,22	85:3,6 195:17	emergency	71:18,22
21:10,12 24:11	3:23 54:10,23	effectiveness	72:13	environments
drafting 21:1	77:13 90:10	3:17 94:10	emphasis 71:17	48:6,25
<b>drag</b> 234:8	113:21 119:12	186:19 188:9	<b>employ</b> 67:20	<b>epidem</b> 80:11
draw 23:6	125:13 126:18	188:11,13	employed 39:22	epidemiologic
216:11	126:20 128:9	effects 4:20	employees 154:2	12:18 73:14
drawing 67:25	130:19	48:16 50:2,6	encourages	75:2 140:16
68:5,16,19	e-mails 52:9	51:13 60:2	137:17	179:12
drawn 200:5	113:12 114:3	135:16 190:19	<b>ended</b> 126:25	epidemiological
dressing 158:1,5	124:8,17	242:13	<b>engaged</b> 36:4,15	12:16 47:17
190:9 230:12	127:13	efficacious	38:6 228:8	59:18,25 66:12
230:12 231:1	<b>E4</b> 205:23	189:24	237:12	72:22 213:21
231:11	eAppendix	<b>efficacy</b> 129:1,6	engendered	213:24 219:3
dressings 157:19	206:6	130:6,8,12,16	153:16	epidemiologist
157:20 158:6	ear 127:18	131:18 132:4	engineer 29:16	17:19,24 18:5
190:11	earlier 24:5,8	244:5	102:16	18:6 19:5
<b>drop</b> 172:14	50:24 58:13	efficiency 30:24	England 5:8	120:10
<b>Drs</b> 34:23 69:13	98:2 110:16	103:21,23	198:10,22	epidemiologist's
69:18 181:23	111:2 116:10	<b>effort</b> 38:25	200:2 201:10	28:24
194:3 215:1	125:3 136:3	118:10 125:18	English 28:7	epidemiologists
<b>drug</b> 134:13,18	139:10 168:17	147:12	enhanced	13:2 15:5
136:8 137:14	186:18 221:2	<b>efforts</b> 55:16,21	210:15	67:10
140:5 141:3	226:21 229:2,2	55:23 56:12	enhances 144:7	epidemiology
<b>drugs</b> 134:23	247:16 248:16	153:14 229:3	enoxaparin	12:17 17:20,21
135:5,21	early 88:22	<b>eight</b> 128:1	206:25 207:11	17:25 18:4,8
Duckies 17:3	248:17	eighty-six	208:8	18:10,14,15,18
ducks 16:17	<b>Ebola</b> 73:1	248:13	entirely 32:9	18:22,23 66:20
	<u> </u>	<u> </u>	I	I

				1490 200
66:22 67:25	93:16 96:12,14	exactly 21:13	76:12,16 86:18	18:13,18 19:15
72:25 80:11	96:21 98:18	24:10 174:7	86:20,23 87:18	experimental
110:12 131:2	99:11,24	examination 6:4	90:5,10 94:5,9	240:12
221:3	100:21 101:3,7	7:6 240:23	95:21 104:4,6	expert 3:3,11
equal 89:14	105:19,20	245:22 246:18	104:12,12,14	8:4 9:3 17:1
equals 89:14	106:6,7 107:23	247:19,22	104:15 113:7	19:11,20 20:7
219:19,21	108:9,19	examined 7:5	113:11 116:21	21:5 29:17,18
equate 91:5	109:21 110:6	example 30:17	119:2,7 124:3	40:16 45:5,20
equation 91:17	110:13,18	30:23 34:19	124:8,17	52:13 58:2,7
equipment	111:21,25	36:8 40:16	125:13 126:14	61:6 66:7
109:3	112:1,8,9	44:20 71:11	126:18 127:18	69:24 72:8
<b>error</b> 21:19	116:23 117:9	79:23 94:13	128:4,8 131:14	80:2,6 83:13
errors 217:4	120:25 121:1,4	124:25 140:23	145:7,12 149:2	86:5 91:13
espoused 66:15	122:11 123:1	156:10,21	149:6,8 152:19	93:1 96:9,11
essentially 72:13	123:19 127:22	172:7 191:2	152:19 154:12	102:17 104:23
134:16	127:24 129:8	214:7 217:9	154:17,20,24	105:14,24
establish 117:9	129:11,16	232:11	161:2,6,8,11	107:13 109:8
213:13 216:21	136:2,16,19,21	examples 73:12	161:14,24	116:21 117:15
established 67:9	137:24 138:23	exception 45:1	162:18 170:3,8	131:14 157:3
establishing	139:6,12	excerpt 3:13	175:8,12	172:24 182:24
219:2	156:15 158:24	5:18,20,22	178:25 179:2,5	191:8 208:16
et 3:9 4:3,9,15	167:10,13	86:24 161:6	181:8 182:13	214:18 229:17
4:19,24 5:2,5	171:11,21,22	230:5,7 236:14	190:14,18	expertise 19:22
5:13 190:19	172:17 173:24	excerpts 104:18	191:6 193:1,5	29:19 30:21
evaluate 179:16	174:23 175:1	exclude 143:2	195:12,16	68:6,20 79:9
181:17	175:14 177:12	163:2,17	198:4,8 203:1	90:4 172:24
evaluated 185:2	177:21 178:6	excluded 143:9	203:5 204:20	232:22
evaluations	178:16 179:11	209:21 210:14	204:25 208:16	experts 52:5
224:21	183:11 185:5	210:16,17,18	215:4 230:1,5	<b>explain</b> 32:3,20
<b>event</b> 17:4 19:1	186:13 188:18	224:4	230:7 236:3,7	144:2 189:17
19:7 247:7	192:8 193:22	Excluding 15:3	236:7,14,24	explained 65:4
events 13:3 15:6	215:20,24	Exclusively	239:18,24	93:2 96:11
everybody	216:12,17	185:21	241:1,2 242:18	97:18
153:22 234:19	217:1 220:22	exercising	246:21	exposure 8:20
evidence 9:15	223:1 224:22	111:10	<b>exhibits</b> 3:2 10:6	43:8,15 44:17
14:11,14,25	225:18 226:2	exhaustive	11:19 24:3,14	45:20 61:2
15:4 17:9,16	226:20 227:13	85:11,12	25:10 29:24	64:5,25 71:18
19:6 31:6,11	228:6,20	exhibit 3:11	104:17,22	132:23 133:8
31:20,22 47:17	231:14 232:19	7:23,24 8:3,7	225:9	exposures 46:1
61:1 70:5	233:19,19	8:11,24 9:4	exist 76:6 110:6	express 92:14
75:12 76:5	238:19 239:8	22:9 23:13,16	153:2	141:16 142:6
78:10 79:19	242:2,9,24	29:21 34:10	existed 49:18	142:10 218:18
80:9 81:1 82:4	243:6,12,23,25	38:17,17,19,22	expect 13:4 15:7	expressed 93:1
82:13 83:3	245:1 246:25	39:5,5,11	34:2	112:19 234:1
88:12 89:6,20	Ex 3:3	46:25 47:4	expected 182:8	238:12 239:2
89:21 91:24	exact 177:8,10	54:5,10 61:19	197:4	extended 26:8
92:11,12 93:15	218:6,16	61:23 69:25	experience 17:2	extensive 27:22
	•	•	•	•

				1490 201
118:7	233:18 245:1	<b>film</b> 186:22	128:13 133:17	forced-air 90:15
extent 12:21	faculty 58:17	<b>filter</b> 30:23,24	140:7 141:20	90:25 116:24
15:22 41:13	59:7	103:7,21,23	143:23,23,25	117:10 118:22
127:3 147:22	fair 41:10 45:25	114:11,16,22	153:1 160:10	122:11 123:2
152:18 167:18	53:16 201:6,8	114:23 115:6	193:15 227:2	242:10
177:25 189:14	201:18,24	filtered 103:6	228:22 238:16	foregoing 250:6
extraordinarily	202:25 207:18	filtering 103:10	239:22 241:5	251:3
35:25	238:24	<b>filters</b> 30:18	241:10 247:22	<b>forgive</b> 215:13
extrapolate	<b>fairly</b> 53:25	filtration 29:17	248:14	220:11
156:25 157:9	72:15 84:17	<b>final</b> 21:10 36:9	<b>Fisher's</b> 218:6	<b>form</b> 13:10
174:20 201:25	fairly-out-of-t	38:14 65:21	<b>five</b> 40:22 87:20	15:12 21:10,11
extrapolating	28:7	217:8 239:6	119:11 121:22	21:12 29:2
202:19	<b>falls</b> 219:7	<b>Finally</b> 237:21	150:21 183:7	30:6 31:2
	<b>false</b> 38:9	financial 120:16	<b>five-fold</b> 175:3	35:21 36:17
<b>F</b>	familiar 34:24	<b>find</b> 14:25 49:3	175:16	44:7 45:23
<b>F</b> 250:1 251:1	fantastic 137:16	49:6 58:2	flattered 82:11	51:2 59:19
<b>face</b> 33:11	<b>favor</b> 126:25	61:11,17 97:21	<b>float</b> 16:17	66:25 74:16
facet 121:17	<b>FAW</b> 90:14	99:23 100:12	floating 172:14	75:6 80:16
fact 25:25 33:25	<b>FDA</b> 94:11,19	100:12 108:2	<b>flow</b> 139:11	81:15 84:9
38:12 43:13	100:14 116:9	121:14,15,21	<b>fluid</b> 86:7	86:14 88:11
49:16 50:9	183:2	130:19 136:17	<b>focus</b> 133:17	89:4,16 91:22
51:10 53:20	feature 101:23	136:19 137:4	158:8 222:3	92:10 95:1
66:15 67:13,19	102:7	166:20,22	focused 30:10	96:20 97:25
69:20 98:2	February 119:8	194:12 196:2	93:4 117:7	99:17 101:2,14
100:22 111:20	feedback 57:4	196:19 216:17	141:4,6	103:12 105:18
121:1 122:18	<b>feel</b> 20:9,17	232:2,3	<b>folks</b> 87:10	106:5 108:6,15
122:23 124:21	<b>felt</b> 20:20 45:10	<b>finding</b> 68:1	<b>follow</b> 209:8	108:18 109:15
127:2 148:8	208:7 222:21	118:20 238:4	238:17	109:19 114:18
160:17 165:15	224:25 225:21	findings 53:7	<b>followed</b> 196:14	115:17 116:4
176:22 183:1	228:22	70:23 73:20	following 1:18	116:11 120:13
200:6 225:7	female 91:4	174:15 234:1	3:25 4:8 57:25	120:21 121:3
241:22	<b>females</b> 49:19	235:9 238:11	83:19,20 87:21	123:18 126:6
<b>factor</b> 143:2,9	49:19	<b>Fine</b> 56:6	142:18 145:13	127:15 129:7
151:23 163:2	fewer 244:2	<b>finish</b> 60:14	152:1,9 155:2	130:14 131:20
163:17 164:8	<b>field</b> 18:21 29:25	103:24 148:24	226:25 237:24	133:2 134:20
166:1 182:2	87:25 115:24	233:16	follows 7:5	135:7 138:9,22
204:18	116:3 178:19	finished 218:22	163:13	140:12 141:18
factors 47:25	fields 29:5	first 7:4 21:4	followup 60:18	146:14 147:1
60:2 191:16	<b>fif</b> 248:12	26:17 27:25	141:24 148:12	149:15 151:24
242:12	Fifteen 52:20	28:16 48:20	158:20 160:17	154:7 160:8
facts 88:12	<b>fight</b> 202:7	66:15 76:18	245:21	171:18,20
92:11 96:21	<b>Figure</b> 198:19	81:18 87:7	footnote 131:11	183:4 186:16
101:3 105:19	<b>figures</b> 225:10	91:10 94:21	207:24,25	187:14,24
106:6 108:19	<b>file</b> 37:16	95:17 97:8	217:19	199:24 204:12
121:4 123:19	<b>filed</b> 127:3	101:9 114:3	Force-Air 4:5	207:4 211:9
129:10 138:23	<b>files</b> 10:16	116:22 119:25	<b>forced</b> 1:5 129:1	214:16 224:10
226:19 228:6	filing 9:25	125:9,21	130:7	225:3,25
	<u> </u>	<u> </u>	ı	<u> </u>

226:18 227:16 228:5,11,25 229:19 233:7 freedom 240:14 233:13 234:16 238:6,14 246:3 freedom 240:14 69:19 13:2 145:23 149:9,9 format 145:22 145:23 149:9,9 format 65:20 134:14 freedom 26:25 friends 27:2 formed 85:4 formed 85:4 forms 20:2 formed 85:4 forms 20:3 forth 24:16 25:9 30:19 73:7 full 7:15 28:19 30:19 73:7 full 7:15 28:19 30:19 73:7 full 7:15 28:19 133:13 56:3 116:22 133:13 56:3 116:22 133:13 56:3 116:22 133:12 133:14 47:21 125:15 126:23 130:19 145:25 130:19 145:21 130:10 147:21 130:10 147:21 130:10 147:21 130:10 147:21 130:10 147:21 130:10 147:21 130:10 147:21 130:10 147:21 130:10 147:21 130:10 147:21 130:10 147:21 130:10 147:21 130:10 147:21 140:21 145:21 140					1490 200
228:5,11,25 229:19 233:7 239:19 233:7 238:6,14 246:3 freedom 240:14 freedom 240:15 from 240:14 freedom 240:14 f	226:18 227:16	81.7	125:15 126:23	110:15 25	53.24 59.19
229:19 233:7   233:13 234:16   238:14 246:3   185:14,23   185:14,23   187:20 206:22   145:23 149:9.9   Friedman 69:14   6romation 65:20   6romed 85:4   164:24 178:21   187:20 206:22   187:30 185:3   140:25 179:14   188:20   246:23 247:21   100:10 101:2   133:13   185:3   148:22   188:31.3   233:13   238:16 243:22   248:13 250:7   248:13 250:14   183:24:24   183:14:28   106:5.92:3   133:21   143:8   171:16 173:23   143:8   171:16 173:23   143:8   171:16 173:23   143:8   171:16 173:23   143:8   171:16 173:23   143:8   171:16 173:23   143:8   171:16 173:23   143:8   171:16 173:23   143:8   171:16 173:23   143:8   171:16 173:23   143:8   171:16 173:23   143:8   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   171:16 173:23   143:18   145:5 18   145:6   143:17   143				, and the second	
233:13 234:16 238:6,14 246:3 frequently 13:4 format 145:22 145:23 149:9,9 formation 65:20 134:14 69:19 131:2 friends 27:2 friends 27:2 former 51:21 forms 200:3 forth 24:16 25:9 forth 24:25 forth 24:2					,
238.6,14 246.3   frequently 13:4   15:7 format 145:22   134:14   friend 26:25   fromed 85:4   friends 27:2   157:4   246:20,212.29   59:196:18.20   157:4   246:20,212.29   59:196:18.20   157:4   246:20,212.29   59:196:18.20   236:19   39:24 48:20   183:24   248:20   248:1   25:14   288:19   249:20   248:1   25:14   288:19   249:20   248:1   25:14   288:19   25:14   288:19   25:14   288:19   25:14   288:19   25:14   288:19   26:15   25:14   288:22   242:20   248:1   25:14   288:19   25:14   288:19   25:14   288:19   25:14   288:19   26:15   25:14   288:19   27:15   288:19   27:15   288:19   288:22   242:20   288:19   29:18   30:16,20   29:18   30:16,			, ,		*
Table 2015		_	,		
145:23 149:9,9	The state of the s		_	′	
formation 65:20 134:14         69:19 131:2 friend 26:25         generalizing friend 26:25         236:9 239:23         89:4,16 91:19 91:22 92:10           formed 85:4 former 51:21 forms 20:3         friend 26:25 friends 27:2         generally 71:15 246:20 212-22         246:20 247:21         97:25 99:17           forth 24:16 25:9 forth 24:16 25:9 133:13         full 78:16 series         full 78:16 series         sa3:23 133:6         246:23 247:21 22         97:25 99:17           Fortune 41:8 cord 31:17,20 44:4 47:20         39:24 48:20 25:21 226:16 221:22,23         188:24,24 24         25:14 28:18 20:10:11 100:10 10:12 going 10:11 100:10 10:12 going 10:11 100:15 100:18           51:12,15,16,17 53:5 44; 21:1,215,16,17 53:5 64:5,24 89:19,21 96:12 106:21 105:3         228:22 242:20 242:20 244:12 248:20 24				, and the second	
134:14			O		
formed 85:4 forms 20:3 forms 20:3 forms 20:3 forth 24:16 25:9 30:19 73:7 113:16 126:9 39:24 48:20 133:13         friends 27:2 full 78:16 180:20 gentamicin 183:24,24 24:18 100:10 101:2 going 10:11 103:12 105:18 183:24,24 25:14 28:18 106:5.9.25 184:1,2 185:6 29:18 30:16,20 107:11 108:6 100:15,925 184:1,2 185:6 29:18 30:16,20 107:11 108:6 100:15,925 184:1,2 185:6 29:18 30:16,20 107:11 108:6 100:15,925 184:1,2 185:6 29:18 30:16,20 107:11 108:6 100:15,925 184:1,2 185:6 29:18 30:16,20 107:11 108:6 100:15,925 184:1,2 185:6 29:18 30:16,20 107:11 108:6 100:15,925 184:1,2 185:6 29:18 30:16,20 107:11 108:6 100:15,925 184:1,2 185:6 29:18 30:16,20 107:11 108:6 100:15,925 184:1,2 185:6 29:18 30:16,20 107:11 108:6 100:15,925 184:1,2 185:6 29:18 30:16,20 107:11 108:6 100:15,925 184:1,2 185:6 45,24 184:12 248:10 24:16,18 51:11 109:15,19 244:12 248:20 241:12 248:20 241:12 248:20 241:12 248:12 184:12,24 184:12,24 184:12,24 184:12,24 185:8,14,19,25 120:12 128:8 120:8,13,21 133:21 143:8 1141:ime 27:21 46:21 47:9,13 13:21 143:8 133:21 143:8 133:21 143:8 133:21 143:8 133:21 143:8 133:21 143:8 133:21 143:8 133:21 143:8 133:21 143:19 13:13 13:10,14 13:13 13:10,14 13:13 13:10,14 13:13 13:14 14:15 15:14 14			0		*
former 51:21 forms 200:3 forth 24:16 25:9 and 29:17 forms 200:3 forth 24:16 25:9 and 29:18 and 29:19 an					
forms 200:3 forth 24:16 25:9 30:19 73:7         ful 178:16 full 7:15 28:19 39:24 48:20 133:13         140:25 179:14 180:20 gentamicin gentamicin gentamicin 25:14 28:18 106:5,9,25 133:13         130:19 73:7 56:3 116:22 184:1,2 185:6 29:18 30:16,20 107:11 108:6 107:11			-	, ,	
forth 24:16 25:9 30:19 73:7 113:16 126:9 133:13         full 17:15 28:19 39:24 48:20 213:21,23 188:24,24 184:12,185:6 229:18 30:16,20 107:11 108:6 105:19,25         101:14 102:14 103:12 105:18 106:5,9,25 107:11 108:6 107:11 108:11 109:15,19 110:11 109:15,19 110:11 103:11 109:15,19 110:11 109:15,19 110:11 109:15,19 110:11 109:11 109:15,19 110:11 109:15,19 110:11 109:15,19 1109:15,19 110:10 1					
30:19 73:7   13:16 126:9   39:24 48:20   183:24,24   25:14 28:18   106:5,9,25   133:13   56:3 116:22   184:1,2 185:6   29:18 30:16,20   107:11 108:6   107:11 108:6   106:5,9,25   133:13   225:21 226:16   243:5,7,12,19   42:16,18 51:11   109:15,19   44:4 47:21   228:22 242:20   244:12 248:20   54:18,20 60:16   112:22 114:18   106:2 106:2 110:5   153:18					
13:16 126:9   39:24 48:20   183:24,24   25:14 28:18   106:5,9,25     133:13				C	
Table   Tabl			0	0 0	
Fortune 41:8 found 31:17,20         213:21,23         188:7,17 189:2 243:5,7,12,19         36:25 38:7,8 4:16,18 51:11         108:15,18 109:15,19           44:4 47:21         228:22 242:20         244:12 248:20         54:18,20 60:16         112:22 114:18           51:12,15,16,17 53:5 64:5,24         248:13 250:7 248:13 250:7         GenTeic 184:2 75:11 88:23,24         75:11 88:23,24         116:11 117:21           89:19,21 96:12 106:2 110:5 133:18 133:21 143:8 123:14 143:8 123:14 143:8 144:1 153:18 133:21 143:8 143:1 153:18 133:21 143:8 143:1 153:18 133:21 143:8 143:1 153:18 133:21 143:8 143:1 153:18 143:2 147:9,13 147:1 147:13			′		, ,
found 31:17,20         225:21 226:16         243:5,7,12,19         42:16,18 51:11         109:15,19           44:4 47:21         228:22 242:20         244:12 248:20         54:18,20 60:16         112:22 114:18           51:12,15,16,17         248:13 250:7         GenTeic 184:2         75:11 88:23,24         115:3,17 116:4           89:19,21 96:12         full-court         153:18         full-court         153:18         geographically         132:9 137:21         120:12 128:8         120:8,13,21           133:21 143:8         full-time 27:21         funded 32:9,17         47:23 48:1         138:17,19,20         123:25 126:6           171:16 173:23         funded 32:9,17         46:21 47:9,13         Gillson 5:4         189:5,8 195:9         120:12 128:8         127:15 129:7           197:6 206:12         46:21 47:9,13         Gillson 5:4         189:5,8 195:9         130:14 131:13         129:10,18           232:18 234:12         funding 32:12         33:10,14         195:18 221:18         227:14 246:20         134:20 133:2           35:22 101:4         further 129:23         143:7 200:16         142:21 154:18         77:24 93:16         143:20,23,25           100:14 11:19         143:7 200:16         142:21 154:18         77:24 93:16         143:20,23,25           fourd 39:18         <			,	,	
44:4 47:21         228:22 242:20         244:12 248:20         54:18,20 60:16         112:22 114:18           51:12,15,16,17         248:13 250:7         248:13 250:7         248:13 250:7         251:4         75:11 88:23,24         115:3,17 116:4           89:19,21 96:12         106:2 110:5         153:18         full-court         185:8,14,19,25         120:12 128:8         120:8,13,21           133:21 143:8         full-time 27:21         function 182:6         funded 32:9,17         46:21 47:9,13         138:17,19,20         123:25 126:6           184:7 186:2         funding 32:12         46:21 47:9,13         6illson 5:4         189:5,8 195:9         130:14 131:13           195:18 23:10         further 129:23         153:17 195:4         227:14 246:20         134:20 135:7           35:22 101:4         further 129:23         143:7 200:16         142:21 154:18         227:14 246:20         134:20 135:7           15:4,18 120:8         240:20 245:20         246:17 247:18         140:21 153:13         131:4         149:15 151:24           four 39:24 40:22         50:14         50:24         60:16 240:16         60:7.8,9 77:10         140:12 141:18           191:15 207:23         67:1 250:2,17         60:8 5:2.12         60:7.8,9 77:10         140:12 141:18           191:15 20:23		,		,	, ,
51:12,15,16,17         248:13 250:7         GenTeic 184:2         75:11 88:23,24         115:3,17 116:4           53:5 64:5,24         89:19,21 96:12         106:2 110:5         153:18         133:21 143:8         full-court         185:8,14,19,25         120:12 128:8         120:8,13,21         120:8,13,21           133:21 143:8         full-time 27:21         function 182:6         function 182:6         geographically         132:9 137:21         121:3 123:18         120:8,13,21           147:16 173:23         function 182:6         funded 32:9,17         Gillson 5:4         153:9 154:3         127:15 129:7         125:20:10:14         153:9 154:3         127:15 129:7         129:10,18           102:14 114:19         47:23 48:1         189:5,8 195:9         130:14 131:13         129:10,18         129:10,18           102:14 114:19         143:7 200:16         143:7 200:16         142:21 154:18         227:14 246:20         138:9,22           100:14 114:19         143:7 200:16         142:21 154:18         107:23 113:3         146:14 147:1           100:22         240:20 245:20         249:2         249:2         249:2         249:2         249:2         249:2         247:6         Gordon 2:6 6:6         160:8 162:2,8           four and at 19:15 207:23         238:16 243:22         247:1			, , ,	, and the second	,
53:5 64:5,24         251:4         full-court         184:12,24         93:11 96:23,24         116:11 117:21           106:2 110:5         153:18         153:18         120:12 128:8         120:8,13,21           133:21 143:8         114:me 27:21         153:18         47:23 48:1         132:9 137:21         121:3 123:18           171:16 173:23         184:7 186:2         function 182:6         funded 32:9,17         47:23 48:1         138:17,19,20         123:25 126:6           197:6 206:12         46:21 47:9,13         6illson 5:4         153:17 195:4         159:18 221:18         129:10,18           206:15,25         50:21 87:23         153:17 195:4         219:5 223:3,11         131:20 133:2           232:18 234:12         funding 32:12         33:10,14         222:3 224:15         good 7:8 69:2,7         138:9,22           foundation         35:22 101:4         further 129:23         143:7 200:16         142:21 154:18         227:14 246:20         134:20 135:7           120:22         240:20 245:20         240:20 245:20         240:21 154:18         160:16 240:16         69:7,8,9 77:10         140:12 141:18           120:22         Furthermore         247:6         Gordis 131:2         152:16 154:7           Gail 195:18         Gail 195:18         gain 56:16				,	
89:19,21 96:12 106:2 110:5 133:21 143:8 171:16 173:23 184:7 186:2 199:10:15 199:10:				,	*
106:2 110:5         153:18         full-time 27:21         geographically         132:9 137:21         121:3 123:18           133:21 143:8         171:16 173:23         184:7 186:2         function 182:6         getting 49:11,15         153:9 154:3         127:15 129:7           197:6 206:12         46:21 47:9,13         50:21 87:23         153:17 195:4         189:5,8 195:9         130:14 131:13           232:18 234:12         funding 32:12         33:10,14         195:18 221:18         222:3 224:15         god 7:8 69:2,7         134:20 135:7           foundation         35:22 101:4         143:7 200:16         142:21 154:18         222:3 224:15         god 7:8 69:2,7         138:9,22           founded 39:18         143:7 200:16         142:21 154:18         17:24 93:16         143:20,23,25           four 39:24 40:22         246:17 247:18         160:16 240:16         Gordis 131:2         152:16 154:7           four 39:24 76:19         67:1 250:2,17         Gail 195:18         173:25         Gordon 2:6 6:6         160:8 162:2,8           10urth 146:4,5         fourth 146:4,5         fourth 146:4,5         fourth 146:4,5         fourth 146:4,5         fourth 146:4,5         fourth 146:4,5	· ·			,	
133:21 143:8         full-time 27:21         47:23 48:1         138:17,19,20         123:25 126:6           171:16 173:23         function 182:6         funded 32:9,17         46:21 47:9,13         248:7         165:23 173:5         129:10,18           197:6 206:12         46:21 47:9,13         50:21 87:23         6illson 5:4         189:5,8 195:9         130:14 131:13           206:15,25         50:21 87:23         funding 32:12         153:17 195:4         219:5 223:3,11         131:20 133:2           foundation         35:22 101:4         further 129:23         143:7 200:16         122:1 154:18         227:14 246:20         134:20 135:7           152:4,18 120:8         240:20 245:20         246:17 247:18         140:21 153:13         160:16 240:16         69:7,8,9 77:10         140:12 141:18           four 39:24 40:22         246:17 247:18         140:21 153:13         131:4         149:15 151:24           four 39:24 76:19         67:1 250:2,17         Gail 195:18         gives 219:5         Gordon 2:6 6:6         66:8 7:20 11:22         162:10,19           33:10 14         73:24 76:19         Gail 195:18         Gives 219:5         Gives 219:5         Gives 219:5         Gives 219:5         153:13:10         163:5,8,11           fourth 146:4,5         framework         67:14,20,20 <t< td=""><td>· ·</td><td></td><td></td><td></td><td></td></t<>	· ·				
171:16 173:23         function 182:6 funded 32:9,17         getting 49:11,15         153:9 154:3         127:15 129:7           197:6 206:12         46:21 47:9,13         248:7         165:23 173:5         129:10,18           206:15,25         50:21 87:23         153:17 195:4         189:5,8 195:9         130:14 131:13           232:18 234:12         funding 32:12         33:10,14         219:5 223:3,11         131:20 133:2           foundation         35:22 101:4         further 129:23         143:7 200:16         222:3 224:15         good 7:8 69:2,7         138:9,22           155:4,18 120:8         143:7 200:16         142:21 154:18         77:24 93:16         143:20,23,25           120:22         246:17 247:18         140:21 153:13         131:4         149:15 151:24           four 39:24 40:22         249:2         160:16 240:16         Gordis 131:2         152:16 154:7           furthermore         127:1         Gives 219:5         Gives 219:5         6:8 7:20 11:22         162:10,19           73:24 76:19         57:1 250:2,17         Glass 124:11         15:12 20:7,11         171:18,20           191:15 207:23         Gail 195:18         Givemic 206:2         25:21 26:22         179:23 182:22           fourth 146:4,5         55:24 56:2,12         Gryp 114:5         <					
184:7 186:2         funded 32:9,17         248:7         165:23 173:5         129:10,18           197:6 206:12         46:21 47:9,13         50:21 87:23         153:17 195:4         219:5 223:3,11         131:20 133:2           232:18 234:12         funding 32:12         195:18 221:18         227:14 246:20         134:20 135:7           foundation         33:10,14         222:3 224:15         good 7:8 69:2,7         138:9,22           fourdation         143:7 200:16         142:21 154:18         77:24 93:16         143:20,23,25           115:4,18 120:8         240:20 245:20         given 128:18         107:23 113:3         146:14 147:1           120:22         246:17 247:18         140:21 153:13         131:4         149:15 151:24           fourded 39:18         249:2         160:16 240:16         Gordis 131:2         152:16 154:7           four 39:24 40:22         5urthermore         247:6         gives 219:5         6:8 7:20 11:22         162:10,19           85:19 116:21         7:1 250:2,17         Glass 124:11         15:12 20:7,11         171:18,20           191:15 207:23         Gail 195:18         173:25         24:23 25:3,19         175:25 176:3,5           209:14 231:13         garbage 55:16         55:24 56:2,12         55:24 56:2,12         27:6,12 44:22 </td <td></td> <td></td> <td></td> <td>, ,</td> <td></td>				, ,	
197:6 206:12       46:21 47:9,13       Gillson 5:4       189:5,8 195:9       130:14 131:13         206:15,25       50:21 87:23       153:17 195:4       219:5 223:3,11       131:20 133:2         232:18 234:12       33:10,14       195:18 221:18       227:14 246:20       134:20 135:7         foundation       33:10,14       222:3 224:15       good 7:8 69:2,7       138:9,22         35:22 101:4       further 129:23       143:7 200:16       142:21 154:18       77:24 93:16       143:20,23,25         115:4,18 120:8       240:20 245:20       246:17 247:18       140:21 153:13       131:4       149:15 151:24         founded 39:18       249:2       Furthermore       127:1       Gives 219:5       Gordis 131:2       152:16 154:7         four 39:24 40:22       Furthermore       127:1       gives 219:5       Gordon 2:6 6:6       160:8 162:2,8         40:23 61:9       G7:1 250:2,17       Glass 124:11       15:12 20:7,11       171:18,20         33:16 243:22       Gorli 195:18       Givemic 206:2       25:21 26:22       179:23 182:22         fourth 146:4,5       Gary 114:5       27:6,12 44:22       27:17 28:5       183:4 186:16         67:14,20,20       119:13 124:9       45:1 55:14       44:7 45:23       196:3,11 199:1 <td></td> <td></td> <td>0</td> <td></td> <td></td>			0		
206:15,25         50:21 87:23         153:17 195:4         219:5 223:3,11         131:20 133:2           232:18 234:12         33:10,14         222:3 224:15         good 7:8 69:2,7         138:9,22           6000 7:8 69:2,7         138:9,22         138:9,22         138:9,22           102:14 114:19         143:7 200:16         142:21 154:18         77:24 93:16         143:20,23,25           115:4,18 120:8         240:20 245:20         246:17 247:18         140:21 153:13         146:14 147:1           120:22         246:17 247:18         160:16 240:16         Gordis 131:2         152:16 154:7           6unded 39:18         249:2         Furthermore         247:6         Gordon 2:6 6:6         160:8 162:2,8           40:23 61:9         127:1         gives 219:5         6:8 7:20 11:22         162:10,19           73:24 76:19         73:24 76:19         73:25:20;71         15:12 20:7,11         171:18,20           85:19 116:21         73:1 250:2,17         Gail 195:18         22:17 23:5         173:5,10         163:5,8,11           191:15 207:23         209:14 231:13         238:16 243:22         67:9,22 18:25         25:21 26:22         179:23 182:22           60 rth 146:4,5         55:24 56:2,12         55:24 56:2,12         27:6,12 44:22         29:2 30:6 31:2		· · · · · · · · · · · · · · · · · · ·			,
232:18 234:12         funding 32:12         195:18 221:18         227:14 246:20         134:20 135:7           foundation         35:22 101:4         further 129:23         give 83:16         227:14 246:20         138:9,22           102:14 114:19         143:7 200:16         142:21 154:18         77:24 93:16         140:12 141:18           115:4,18 120:8         240:20 245:20         246:17 247:18         given 128:18         107:23 113:3         146:14 147:1           120:22         246:17 247:18         140:21 153:13         131:4         149:15 151:24           founded 39:18         Furthermore         127:1         60:16 240:16         Gordis 131:2         152:16 154:7           Four 39:24 76:19         5247:1         247:6         Gordon 2:6 6:6         160:8 162:2,8           85:19 116:21         7:1 250:2,17         Glass 124:11         15:12 20:7,11         171:18,20           191:15 207:23         Gail 195:18         gain 56:16         22:17 23:5         173:25         175:25 176:3,5           209:14 231:13         garbage 55:16         Gycemic 206:2         25:21 26:22         179:23 182:22           fourth 146:4,5         Gary 114:5         27:6,12 44:22         35:21 36:17         186:24 187:7           67:14,20,20         119:13 124:9         45:1 55:14<		,		,	
foundation         33:10,14         222:3 224:15         good 7:8 69:2,7         138:9,22           35:22 101:4         further 129:23         give 83:16         69:7,8,9 77:10         140:12 141:18           102:14 114:19         143:7 200:16         142:21 154:18         77:24 93:16         143:20,23,25           115:4,18 120:8         240:20 245:20         given 128:18         107:23 113:3         146:14 147:1           120:22         246:17 247:18         140:21 153:13         131:4         149:15 151:24           founded 39:18         249:2         Furthermore         160:16 240:16         Gordis 131:2         152:16 154:7           four 39:24 40:22         Furthermore         247:6         Gordon 2:6 6:6         160:8 162:2,8           40:23 61:9         131:11 191:3         145:1 250:2,17         Glass 124:11         15:12 20:7,11         171:18,20           85:19 116:21         Gril 195:18         gain 56:16         guconate-alco         173:25         24:23 25:3,19         175:25 176:3,5           19:13 24:22         garbage 55:16         Gry 114:5         27:6,12 44:22         27:17 28:5         183:4 186:16           67:14,20,20         119:13 124:9         45:1 55:14         44:7 45:23         196:3,11 199:1	· ·			,	
35:22 101:4         further 129:23         give 83:16         69:7,8,9 77:10         140:12 141:18           102:14 114:19         143:7 200:16         142:21 154:18         77:24 93:16         143:20,23,25           115:4,18 120:8         240:20 245:20         given 128:18         107:23 113:3         146:14 147:1           120:22         246:17 247:18         140:21 153:13         131:4         149:15 151:24           founded 39:18         249:2         Furthermore         60:16 240:16         Gordis 131:2         152:16 154:7           four 39:24 40:22         Furthermore         247:6         Gordon 2:6 6:6         160:8 162:2,8           40:23 61:9         127:1         Gives 219:5         6:8 7:20 11:22         162:10,19           73:24 76:19         G7:1 250:2,17         Glass 124:11         15:12 20:7,11         171:18,20           85:19 116:21         G7:1 250:2,17         Glass 124:11         15:12 20:7,11         171:18,20           19:15 207:23         Gail 195:18         Gry 12:25         Glycemic 206:2         25:21 26:22         179:23 182:22           fourth 146:4,5         55:24 56:2,12         21:21 25:13         29:2 30:6 31:2         186:24 187:7           framework         67:14,20,20         119:13 124:9         45:1 55:14         44:7 45:23 <td></td> <td>C</td> <td></td> <td></td> <td></td>		C			
102:14 114:19       143:7 200:16       142:21 154:18       77:24 93:16       143:20,23,25         115:4,18 120:8       240:20 245:20       246:17 247:18       140:21 153:13       131:4       149:15 151:24         120:22       246:17 247:18       140:21 153:13       131:4       149:15 151:24         140:23 61:9       Furthermore       127:1       Gordis 131:2       152:16 154:7         40:23 61:9       127:1       Gives 219:5       6:8 7:20 11:22       160:8 162:2,8         40:23 61:9       T3:24 76:19       G7:1 250:2,17       Glass 124:11       15:12 20:7,11       163:5,8,11         191:15 207:23       Gail 195:18       gain 56:16       guconate-alco       22:17 23:5       173:5,10         173:25       Glycemic 206:2       25:21 26:22       179:23 182:22         40:24 40:22       Gary 114:5       21:21 25:13       29:2 30:6 31:2       186:24 187:7         61x 120       119:13 124:9       45:1 55:14       44:7 45:23       196:3,11 199:1		,	give 83:16	,	
115:4,18 120:8       240:20 245:20       given 128:18       107:23 113:3       146:14 147:1         120:22       246:17 247:18       140:21 153:13       131:4       149:15 151:24         four 39:24 40:22       Furthermore       127:1       Gordis 131:2       152:16 154:7         40:23 61:9       127:1       Gives 219:5       6:8 7:20 11:22       162:10,19         73:24 76:19       G7:1 250:2,17       giving 60:17       12:1 13:10       163:5,8,11         131:11 191:3       G7:1 250:2,17       gluconate-alco       173:25       24:23 25:3,19       175:25 176:3,5         290:14 231:13       238:16 243:22       garbage 55:16       Glycemic 206:2       25:21 26:22       179:23 182:22         fourth 146:4,5       55:24 56:2,12       Gary 114:5       21:21 25:13       29:2 30:6 31:2       186:24 187:7         framework       119:13 124:9       45:1 55:14       44:7 45:23       196:3,11 199:1	102:14 114:19	143:7 200:16	U	, ,	
120:22       246:17 247:18       140:21 153:13       131:4       149:15 151:24         four 39:24 40:22       Furthermore       247:6       Gordis 131:2       152:16 154:7         40:23 61:9       127:1       gives 219:5       6:8 7:20 11:22       162:10,19         73:24 76:19       G7:1 250:2,17       Glass 124:11       15:12 20:7,11       171:18,20         131:11 191:3       G7:1 250:2,17       gluconate-alco       22:17 23:5       173:5,10         173:25       Glycemic 206:2       25:21 26:22       179:23 182:22         fourth 146:4,5       Gary 114:5       27:6,12 44:22       35:21 36:17       186:24 187:7         framework       119:13 124:9       45:1 55:14       44:7 45:23       196:3,11 199:1					
four 39:24 40:22         Furthermore         247:6         Gordon 2:6 6:6         160:8 162:2,8           40:23 61:9         73:24 76:19         6         6:8 7:20 11:22         162:10,19           85:19 116:21         G         G7:1 250:2,17         Glass 124:11         15:12 20:7,11         171:18,20           191:15 207:23         Gail 195:18         gain 56:16         guconate-alco         22:17 23:5         173:5,10           209:14 231:13         garbage 55:16         Glycemic 206:2         25:21 26:22         179:23 182:22           fourth 146:4,5         55:24 56:2,12         27:6,12 44:22         29:2 30:6 31:2         186:24 187:7           framework         119:13 124:9         45:1 55:14         44:7 45:23         196:3,11 199:1	· ·		0	131:4	
40:23 61:9       127:1       gives 219:5       6:8 7:20 11:22       162:10,19         73:24 76:19       S5:19 116:21       G       127:1 250:2,17       Glass 124:11       15:12 20:7,11       171:18,20         191:15 207:23       Gail 195:18       gain 56:16       garbage 55:16       24:23 25:3,19       175:25 176:3,5         209:14 231:13       garbage 55:16       Glycemic 206:2       25:21 26:22       179:23 182:22         fourth 146:4,5       55:24 56:2,12       Gary 114:5       27:6,12 44:22       35:21 36:17       187:14,24         67:14,20,20       119:13 124:9       45:1 55:14       44:7 45:23       196:3,11 199:1	<b>founded</b> 39:18	249:2	160:16 240:16	<b>Gordis</b> 131:2	152:16 154:7
73:24 76:19         G         giving 60:17         12:1 13:10         163:5,8,11           131:11 191:3         G7:1 250:2,17         Glass 124:11         15:12 20:7,11         171:18,20           191:15 207:23         Gail 195:18         gain 56:16         gain 56:16         24:23 25:3,19         175:25 176:3,5           209:14 231:13         garbage 55:16         Glycemic 206:2         25:21 26:22         179:23 182:22           fourth 146:4,5         55:24 56:2,12         Gary 114:5         27:6,12 44:22         35:21 36:17         187:14,24           67:14,20,20         119:13 124:9         45:1 55:14         44:7 45:23         196:3,11 199:1	four 39:24 40:22	Furthermore	247:6	<b>Gordon</b> 2:6 6:6	160:8 162:2,8
73:24 76:19         G         giving 60:17         12:1 13:10         163:5,8,11         171:18,20           131:11 191:3         G7:1 250:2,17         Gail 195:18         gluconate-alco         22:17 23:5         173:5,10           173:25         24:23 25:3,19         175:25 176:3,5           209:14 231:13         garbage 55:16         Glycemic 206:2         25:21 26:22         179:23 182:22           60 7:9,22 18:25         27:17 28:5         183:4 186:16           67:14,20,20         119:13 124:9         27:6,12 44:22         35:21 36:17         187:14,24           44:7 45:23         196:3,11 199:1					,
85:19 116:21       G       Glass 124:11       15:12 20:7,11       171:18,20         131:11 191:3       191:15 207:23       191:15 207:23       173:25       22:17 23:5       173:5,10         209:14 231:13       173:25       24:23 25:3,19       175:25 176:3,5         238:16 243:22       179:23 182:22         38:16 243:22       183:4 186:16         35:24 56:2,12       19:13 124:9       27:6,12 44:22       29:2 30:6 31:2       186:24 187:7         19:13 124:9       19:13 124:9       45:1 55:14       44:7 45:23       196:3,11 199:1			0		· ·
131:11 191:3       G 7:1 250:2,17       gluconate-alco       22:17 23:5       173:5,10         191:15 207:23       Gail 195:18       173:25       24:23 25:3,19       175:25 176:3,5         209:14 231:13       gain 56:16       Glycemic 206:2       25:21 26:22       179:23 182:22         238:16 243:22       garbage 55:16       go 7:9,22 18:25       27:17 28:5       183:4 186:16         fourth 146:4,5       55:24 56:2,12       21:21 25:13       29:2 30:6 31:2       186:24 187:7         framework       119:13 124:9       45:1 55:14       44:7 45:23       196:3,11 199:1			0		' '
191:15 207:23       Gail 195:18       173:25       24:23 25:3,19       175:25 176:3,5         209:14 231:13       gain 56:16       Glycemic 206:2       25:21 26:22       179:23 182:22         238:16 243:22       garbage 55:16       go 7:9,22 18:25       27:17 28:5       183:4 186:16         fourth 146:4,5       55:24 56:2,12       21:21 25:13       29:2 30:6 31:2       186:24 187:7         framework       119:13 124:9       45:1 55:14       44:7 45:23       196:3,11 199:1	131:11 191:3		gluconate-alco	,	· ·
238:16 243:22 <b>garbage</b> 55:16 <b>go</b> 7:9,22 18:25 <b>27:</b> 17 28:5 183:4 186:16 55:24 56:2,12 <b>Gary</b> 114:5 27:6,12 44:22 45:1 55:14 44:7 45:23 196:3,11 199:1	191:15 207:23		0	24:23 25:3,19	175:25 176:3,5
fourth 146:4,5       55:24 56:2,12       21:21 25:13       29:2 30:6 31:2       186:24 187:7         framework       Gary 114:5       27:6,12 44:22       35:21 36:17       187:14,24         67:14,20,20       119:13 124:9       45:1 55:14       44:7 45:23       196:3,11 199:1	209:14 231:13	_	Glycemic 206:2	25:21 26:22	179:23 182:22
framework         Gary 114:5         27:6,12 44:22         35:21 36:17         187:14,24           67:14,20,20         119:13 124:9         45:1 55:14         44:7 45:23         196:3,11 199:1	238:16 243:22		<b>go</b> 7:9,22 18:25	27:17 28:5	183:4 186:16
67:14,20,20 119:13 124:9 45:1 55:14 44:7 45:23 196:3,11 199:1	<b>fourth</b> 146:4,5	,	_	29:2 30:6 31:2	186:24 187:7
17.11,20,20	framework	•	27:6,12 44:22	35:21 36:17	187:14,24
<b>frankly</b> 35:5   124:18 125:14   58:5 85:18   46:12 51:2   199:7,24	67:14,20,20		45:1 55:14	44:7 45:23	196:3,11 199:1
	frankly 35:5	124:18 125:14	58:5 85:18	46:12 51:2	199:7,24
		<u> </u>	<u> </u>	<u> </u>	

204:12 207:4	222:19	109:13 113:1	heterogeneity	34:10 39:2,7
211:9 212:4	guessing 115:7	harder 161:20	200:6	39:10 86:20
214:16 215:19	<b>Guide</b> 69:13,20	Hardin 52:7,13	Hi 125:15	87:17 104:6,12
215:23 224:10	131:1	52:25 53:11	128:13	104:15,17
225:3,5,23,25	guideline 70:10	57:5	Hickson 5:2	141:10 142:7
226:18 227:16	117:1 118:3	Hardin's 55:21	193:7 194:3	149:6,8 152:14
228:5,11,17,25	205:1	55:23	242:18 245:24	160:14,23
229:13,19	guidelines 5:15	harm 43:9,16	246:21 248:3,4	179:2,4 181:7
230:21 233:7	71:7 206:5	44:5,19 45:21	HICPAC 106:12	182:13 185:15
233:13,16,18	guiding 219:4	Hartford 1:20	high 128:20	211:24 223:15
234:16 235:6		1:21	129:5 221:21	223:23 227:4
236:8 238:6,14	H	Hastings 59:2	221:23 222:12	<b>Holford's</b> 10:15
240:24 241:3,4	<b>hand</b> 104:13	hat 28:24 43:8	222:18	20:14 21:5
245:20 246:3	<b>handed</b> 8:2,10	Hawthorne	high-quality	22:4 24:12
246:14,19	34:9 39:14	152:24 153:1	173:24 174:22	39:2 86:23
247:18,22	47:3 54:9	hazards 115:13	higher 223:6	105:1 142:13
248:2,11,12,16	61:22 76:15	he'll 176:8,10,10	243:25	164:22 185:23
248:18	86:20,22 90:9	176:11	<b>Hill</b> 6:1	186:12 188:24
<b>Gordon's</b> 25:16	94:8 104:6,11	head 11:4 109:6	hindsight	217:15
government	104:15,16	186:5	123:12	honesty 236:20
41:9	113:10 119:6	head-to-head	<b>Hines</b> 23:7	hope 34:5
granted 197:15	124:7,16	177:6	<b>hip</b> 3:25 5:1	hospital 108:14
<b>graph</b> 199:14	126:17 128:7	heading 221:13	137:21 145:13	201:2 214:6
graphs 225:10	145:11 149:6,7	heads 111:15	146:13 147:17	223:5
great 23:25	154:16,23	health 4:4 34:25	147:24 154:5	hospitals 5:7
54:24 55:9	161:5 170:7	47:18,25 48:2	169:21,21	198:10,22
73:11 118:11	175:11 179:2,4	48:7,13 49:1,5	193:6,23	200:2,7,8,12
144:7	190:17 193:4	49:13,17 50:2	203:13 209:14	200:16,20
greater 219:18	195:15 198:7	50:5 51:13,22	210:16,18,19	201:10 202:13
greatly 90:2	203:4 204:24	60:2 70:13	242:25 243:8	222:21 223:4
green 131:2	215:7 230:4	73:1 104:18	246:11 247:1	223:12
198:24 199:1	236:6,13	221:19	hips 209:17	<b>Hot</b> 184:18
<b>group</b> 37:24	239:21	Healthcare	225:18 228:24	185:9,19 227:7
90:21 118:10	Hansen 114:5	104:20 105:15	hire 33:22,23	234:14 244:10
150:22,23	119:13 124:9	221:19 222:12	50:22	244:17 245:8
151:15,16	124:18 125:14	<b>heard</b> 58:24	historical 42:11	<b>hour</b> 195:9
166:11 212:1	happened 45:9	86:17	history 27:14	<b>hours</b> 60:16
247:8	58:10,11	hearing 125:9	65:3 95:14	85:19
<b>grouped</b> 166:13	121:20	<b>held</b> 15:18	<b>Hmm</b> 209:11	<b>Huber</b> 2:10
166:18	happens 57:10	<b>help</b> 44:21 150:9	hoc 154:10	huge 126:25
<b>Grove</b> 54:13	100:22 125:22	176:2	<b>Hodges</b> 113:21	<b>Hugger</b> 1:5 9:16
Grove's 55:16	187:2	<b>helpful</b> 214:25	<b>hold</b> 17:23 145:6	12:3 13:9,13
guess 7:10 38:3	happy 109:4	<b>helps</b> 36:2	154:18 239:3	13:18 14:2,9
40:24,25 41:4	200:10,15,17	hematoma	holding 15:20	14:16 15:1,9
85:19 139:1	222:4	166:7	<b>Holford</b> 20:4,19	15:21 16:6,6
146:4 183:20	harbor 113:3	heparin 207:1	20:23,24 21:1	17:5,13 28:3
196:24 222:14	harbored	207:12	21:25 22:10	29:12,21 30:4
	I	1	1	1

				_
30:9 31:1,9,21	129:6	<b>imagine</b> 103:14	impressed 82:10	122:11 123:2
33:8 70:24	<b>Hulse</b> 90:11,12	Immaculada	impugned 53:7	136:22 137:14
73:22 78:21	128:10	128:11	in-person 122:2	139:4,7 148:9
79:1,14,16,19	<b>Human</b> 104:19	impact 48:7	inactive 175:23	148:9,10 159:1
79:20 80:8,22	hundred 36:25	49:1 157:22	176:14	164:17 165:3
81:1,5,12,24	hypothermia	158:15	inadequate	185:6,9,13
82:14,25 83:4	19:18 70:6	impacts 153:5	99:23 244:3	211:6 217:2,4
86:12 87:11,24	hypothesis 98:5	231:16	inappropriate	232:14,19
89:7 91:16	hypothetical	implant 17:6	208:7	increased 12:4
92:3,15 93:3,7	82:15,16 83:3	137:21 140:6	incidence 4:21	13:9,19 14:2,9
93:13,17,21	110:20,21,22	172:5,9 179:7	78:11 181:19	14:17 15:1
94:11,23 96:4	111:17,19,22	181:10 182:2,8	190:20 191:17	16:2,10 47:18
96:13 97:3,16	112:9,12	182:17	incision 181:18	79:24 83:10,11
97:22 98:9,15	160:10,20	implantation	182:2,4,8	88:8 89:20
98:18,24 99:5	226:19	181:18	incisional 84:7	94:2 110:7
99:22 100:14	hypothetically	implementation	170:23,24	139:13 144:21
100:16 101:22	110:23 211:11	201:11 204:17	181:19 182:3	156:7,19
102:6,12	211:16,18	228:23	182:21	172:18 192:9
103:11,21,23		implemented	included 27:19	194:13 208:21
107:15,18,23	I	177:5 194:17	142:3,4 153:19	211:15,21
108:3,13 109:2	idea 46:15 101:9	197:20 198:1	200:8,20 222:8	212:2,12,13,16
109:13,22	101:11 113:3	Implementing	223:24 235:14	216:13 233:11
110:7,18	121:5 125:20	5:3 195:17	includes 200:11	234:13 235:11
111:11,17,25	154:9 191:24	implication	including 87:23	increases 30:4
113:1,4,22	identical 176:13	121:19 242:12	201:19 203:13	78:21 79:1,16
120:7,20	identification	implies 12:21	income 41:1,2	81:13 86:12
123:17,24	7:25 8:8 39:12	<b>imply</b> 215:21	incomplete	87:25 90:25
129:16,21	47:1 54:6	216:1 242:4	226:19 240:11	116:24 129:16
130:12,21	61:20 76:13	<b>import</b> 93:22	inconsistency	137:25 139:19
131:18 132:5	90:6 94:6	100:20 108:2	232:7	140:1 144:3,5
135:2,11,25	113:8 119:3	importance	incorporated	155:16,21
136:14,20	124:4 126:15	219:1	21:21	182:20
182:15,20	128:5 145:8	important 28:24	incorporating	increasing
183:2 184:18	154:13,21	30:2,14 32:21	22:2	100:25 137:15
192:9 205:18	161:3 170:4	33:2 35:14	incorrect 161:1	232:5
205:20 208:22	175:9 190:15	56:4,8 70:18	216:23	independent
211:8,17,21	193:2 195:13	74:20 75:1	incorrectly 9:13	118:19
212:18 213:14	198:5 203:2	76:10 79:15	169:11 216:24	independently
216:13 217:1	204:21 215:5	80:20 88:16	increase 9:16	185:16 190:6
227:7 232:5,15	230:2 236:4	89:1 91:15	12:14,25 15:21	<b>index</b> 75:19
233:12 234:13	239:19	92:2,25 96:8	17:6,13 79:25	indicate 41:7
235:10 239:9	identified 28:1	100:12 118:1	80:22 81:5,23	48:3,22 75:20
239:10	38:22	129:14 143:6	82:16,24 89:13	139:13 182:1
<b>Hugger-</b> 243:17	identify 45:19	155:13,18	89:14,24,25	216:17
Hugger-only	ignore 240:14	164:19 206:19	92:4 98:15	indicated 11:12
244:15 245:6	II 70:4	221:5	110:2,20,21	54:23 94:1
<b>Huggers</b> 118:23	illness 49:7	<b>impress</b> 234:15	111:12 117:10	234:3
	1	I .	1	ı

indicates 87:24	122:12 123:2	5:7,12 17:2	222:13 224:9	<b>injured</b> 43:16
144:21	129:17 130:13	27:11 28:4	225:17 231:17	inpatient 198:20
indicating 12:24	134:10,19	30:11,13 31:20	239:9,11 246:1	inquiry 128:16
158:1 220:22	135:2,5,11,12	72:2 81:2 83:4	246:10,13	219:9,11
indication	135:22 136:1	83:16,19,20,22	247:17	inside 87:8
164:18	136:12,20,22	83:23 84:21	infectious 19:11	114:1
individual 38:21	137:14,17	85:25 89:7,10	19:12,14 71:19	instance 44:16
44:6,19 45:22	140:11 141:3,4	93:3,18 96:13	71:22 72:20,23	45:19
64:2 87:3	143:3,10 144:3	96:14,16 97:14	73:4,16 84:24	Institute 51:22
229:16	144:8 145:1	97:22,24 98:4	89:15 108:4	instrument
individually	146:13 147:17	98:6 99:15	109:12 115:25	31:22
37:4	148:10 149:20	100:22 101:8	159:1 188:18	insufficient
individuals	150:22 151:15	106:16 107:24	209:14	14:11 83:6
35:19 42:15	151:23 155:8,9	108:10 110:2	inference 82:17	98:6 116:23
119:15 120:5	155:16,22,23	111:18,25	inferences 68:1	117:9 120:24
153:6 190:24	156:8,11,11,19	129:21 134:2	68:5,19	136:19 239:7
induction	156:22 157:2,3	139:7,14 141:8	influence 49:10	insurance 42:17
243:24	157:17,17,21	141:25 142:2	133:5 134:24	65:8
industrial 47:22	157:22 158:6	149:14,14,18	209:25 242:10	intellectual
industry 48:11	158:16,21,23	150:6 151:8	influences	111:15
48:15	159:2 160:22	153:23 154:4	148:21	intensively
industry's 49:10	162:23 163:2	157:1,10,11	influenza 73:11	153:4
infec 135:20	163:17 164:17	160:19 166:14	influenza-rela	<b>intent</b> 83:21
<b>infect</b> 107:6	165:9,19 166:6	166:18 167:19	73:9	intentionally
115:15	167:15 168:1	169:15,18	inform 81:24	173:7
infection 4:22	172:21,22	170:24,24	83:1,2 108:24	interaction
5:17 13:9,14	177:17 181:3	171:3,12,12,13	201:15	216:7
13:19 14:3,10	182:9 184:13	171:14,17,23	information	interactive
14:17 15:2,10	185:24,25	171:24 172:1,2	27:13 28:25	176:23
15:22 16:2,11	186:9,22	172:18 173:3,8	29:11,15 36:19	interest 33:16
17:7,14 30:4,9	187:12,22	173:13,15,15	36:21 70:16	53:2 56:20
31:1,10,23	188:6,16,18	178:1 179:7	74:24 75:3,4,9	93:23 108:2
33:9 37:23	189:1 190:20	180:20,21	76:9,10 88:20	121:25 122:5 interested 11:7
78:11 79:15,20	191:17,22	181:10,20 182:3 183:11	89:8 99:19,21	76:11 140:17
79:25 80:9,12	192:9 194:14 201:25 202:1	184:21,22,23	109:5 115:11 117:21 123:13	164:13 218:10
81:5,12 83:11 84:1,7,7,13,16	201:23 202:1	185:6,9,13	164:25 210:9	interesting 83:6
90:1,17 97:4,5	207:16,19,20	186:15 187:5	224:12,14	96:13 98:5
97:13 98:11,19	211:7,15 212:1	188:4 189:20	229:4	100:17 121:14
99:1,8,11,22	212:3 216:14	189:21,25,25	informed 68:5	121:15,17,21
99:1,8,11,22	217:9 230:14	190:5 197:19	68:19 108:22	123:8,9 129:19
104:20 105:15	231:2,25	190.3 197.19	221:19	188:4 189:7
107:21 109:14	233:11 234:13	198:25 199:14	ingredients	227:5
107.21 109.14	235:3,11	201:6,20,22	176:14	interface 17:21
111:12,21	242:11 244:23	202:8 203:13	initial 222:9	72:25
112:8 115:2	247:7,9,13	204:5,10,11	initially 27:16	interfaces
116:25 117:3	infections 4:6,17	221:24 222:10	initiated 11:11	106:13

				Page 209
intermediary	85:2,8 97:20	138:6 146:24	137:24 138:3	<b>July</b> 1:15,22
81:3 97:12	102:25 103:20	147:14 186:9	139:4,8,12,13	200:16 224:8
98:3 133:6	106:1,21 116:8	200:21 238:18	139:20 141:4,8	224:24 225:12
intern 150:17	131:17 132:16	issued 26:18	141:25 149:14	225:20 226:15
internal 18:11	132:18 147:3,7	123:22 125:6	149:19 155:8	226:25 227:6,8
19:13 48:19	184:20 223:2,8	issues 16:24	155:16,22	228:21 250:10
76:18,25 87:19	223:10,13	20:22 27:12	156:8,11,19,22	June 9:3,25
88:3 113:12	<b>invited</b> 59:1,2	31:17 57:20	157:2,11,17,22	23:17 25:7
115:22 119:7	involve 169:18	71:25,25 73:15	158:6,15,23	61:24 62:4,6
161:8,24	involved 20:4	90:3 107:14	159:2 169:18	80:6 150:3
164:24 165:16	27:1 40:17	108:1 130:12	171:14,16,23	224:4 227:9
203:19 216:5	42:7 44:25	130:17 164:10	172:2,22 173:3	junior 35:2
236:23	46:16 56:22		173:7 177:16	
International	65:24 71:21,24	J	180:20 184:21	K
90:16	71:24 72:6,15	J-o-n-a-t-h-a-n	184:22 185:9	<b>Kay</b> 69:13,18
internet 180:8	72:19 73:5,8	7:16	185:24 186:15	keep 16:14
interrupt 46:12	87:11 119:19	<b>JAMA</b> 204:25	187:5,23	102:17 205:13
interval 247:11	119:21 153:9	Jameson 4:9	189:20,25	keeps 205:18
interviewed	involvement	155:1 162:6,17	190:5 194:14	Kentucky 109:1
49:22	32:22 117:22	163:7,13,24,24	201:6,20 202:1	kept 51:10
interviews 50:1	involves 166:9	164:23 165:14	202:8,10	keywords 27:24
intraoperative	221:4	<b>Jan</b> 2:3 23:5	204:11 207:19	kilograms 244:3
70:25 73:22	involving 51:1	24:23 60:13	211:15 221:24	<b>kind</b> 30:20
intraoperatively	94:10	162:2 173:5	222:13 225:17	38:25 72:18
95:24	iodine 168:6	176:5	231:17,25	90:2 155:22
intrapleural	169:3 174:8,18	<b>Jana</b> 119:13	233:11 235:11	209:10
173:15	180:8,17	<b>January</b> 3:13,17	239:9,11 246:1	kinds 40:24
introduced	iodophor 174:1	5:19,21 61:24	246:10,12	71:24 90:3
197:15 202:9	174:4,13 177:6	76:17 94:10	247:7,13,17	142:4 149:18
introduction 4:2	180:9 206:13	194:18 195:21	<b>joints</b> 84:25	Klondex 65:22
145:14 191:15	irregularities	197:20	Jonathan 1:13	65:24
197:23 203:18	9:14 216:24	<b>Jensen</b> 4:3 141:7	1:18 3:3,6 6:5	<b>knee</b> 3:25 5:1
<b>invalid</b> 238:21	irrigation 166:6	141:11,23	7:3,16 39:22	137:21 145:13
238:23	irritative 51:18	142:1,3,9	40:1,4 41:3	146:13 147:17
investigate	issue 28:23	144:19,21,23	250:5 251:2,17	147:24 154:4
70:15 88:7,14	30:10 34:4	152:15 160:6	journal 57:11	169:21 193:6
93:6 97:23	42:22 43:2	160:17,24	journals 28:7,9	193:24 203:13
110:1 111:11	46:19 49:21	161:17,25	<b>jubilee</b> 230:12	209:13 242:25
137:20 190:6	56:23,23 59:18	162:4 164:3,16	231:1,10	243:8 246:11
investigated	65:12 66:23	<b>JNE/FLM</b> 1:9	judgment 68:2,3	247:1
103:16 146:24	69:18 73:5	<b>John</b> 119:14	69:3,7,8,9	knees 209:17,18
190:2 199:21	79:7 80:19	<b>Johnson</b> 62:9,9	111:3,7,9,10	209:18 225:18
investigating	88:24 91:1	62:16,17	220:25 221:4,5	228:24
28:23 34:4	93:4 98:8,23	joint 84:1,7,15	judgments	knew 23:1 52:4
investigation	99:12 111:15	84:16,18,21	139:1	56:20 122:15
38:15 78:16	118:2 127:9	89:7 90:17,24	<b>Judy</b> 113:21	154:9 197:4
79:6,22 84:20	131:6 135:13	116:25 137:20	<b>Julie</b> 195:18	200:21
	ı	<u>I</u>	ı	I

	•	1	1	
know 8:17 14:13	176:6,9 177:8	120:8,22	170:20 178:23	lit 41:20
15:24 16:3,15	177:11,18	129:15 201:12	180:3 216:19	literally 197:14
16:23 22:22,23	179:17 180:19	<b>land</b> 172:9	240:21 248:25	202:6
23:6 24:10	180:24 186:3	language 246:14	level 128:20	literature 10:14
30:22 34:14,19	187:16 189:19	247:21	129:5 148:19	22:25 23:25
34:21 36:6	189:23 190:1	large 27:9 30:17	219:18	27:22 28:3
37:2,4,15 38:3	192:22 194:22	30:18 42:7	liabilities 42:11	31:19 33:7
42:6 43:12	196:24 198:15	53:17,17,17	42:12,23,23	63:4,8,13
44:13,24 49:25	200:8,12,24	72:15 148:9	Liability 1:6	85:11,13 89:23
50:16 52:10	201:10 205:21	188:10 193:22	liable 240:12	92:19 93:9
60:11 67:17	207:3,19,21	242:23 246:24	librarian 27:21	117:8 131:23
69:9 71:5	213:10 217:6	large-volume	<b>library</b> 27:23,23	144:18 147:13
74:21 75:8,16	217:22 219:24	31:22	75:19	185:1
75:23 76:2,11	221:23 222:6	largely 32:9	<b>life</b> 153:5	litigation 1:6
82:9 83:14	222:11,20	220:21	<b>light</b> 52:9	40:7,15,16
84:19 86:17	223:5 224:16	largest 42:4	likelihood 63:24	41:13 43:7,8
88:18,19 89:11	224:20,20,22	late 26:15,18	158:20	43:10,12,13
90:4 92:8	227:11,24	27:4 234:19	Likewise 117:5	44:3,17 45:20
94:15,16	228:4,10,14,18	248:7	<b>limited</b> 110:10	46:16 52:6
101:10 103:9	232:10 236:18	<b>Law</b> 59:2	186:14	53:6,9,10,12
107:4 108:20	241:22 247:12	lawyer 75:10	Limiting 182:7	58:3 62:3
112:24 114:7	248:25	76:19	line 36:24 77:23	71:24 72:16,21
114:24 115:9	knowledge 8:24	lawyers 11:10	78:8 87:19	litigation-based
115:19,21	16:20 33:6	29:6 40:14,14	102:1 130:5	40:9 42:19
116:7,14	107:22 115:11	45:13 76:1	162:1,15	litigation-relat
118:21 119:15	122:8 129:12	lead 98:10,25	198:24 199:3,8	41:1
119:18 120:9	140:3 221:1	99:7 170:12	230:8 231:12	<b>little</b> 12:9 14:6
120:15 121:13	240:13,14	171:12 207:25	lines 15:10	16:17 23:5
121:16,18,19	known 26:22	247:15	link 48:12 62:25	36:13 44:2
121:22 122:1,4	35:1 43:20,20	<b>leading</b> 66:20,21	63:9,20 80:8	51:10 53:4
122:10,25	45:9 50:3,6	101:8	81:1 93:2,6,8	61:7 73:13
123:4,6,8,11	51:19 63:20	leads 117:10	linked 31:24	132:2 139:9
123:12 124:1,2	84:6 219:8	<b>leafed</b> 38:20	32:1 81:3	152:3,23
124:10,19,20	<b>Kurz</b> 3:13 73:25	learned 180:11	<b>linking</b> 79:19	153:24 209:5,6
125:21 126:8	74:4,6,9,13	leaving 102:18	83:4 96:12	210:6
127:19 129:14	76:17 77:15	<b>led</b> 108:9 135:15	liquid 124:11	load 81:21
129:19,25	125:1	<b>left-hand</b> 206:1	<b>list</b> 11:24 23:15	locate 38:21
130:9,17	Kurz/Sessler	<b>legal</b> 10:7	23:19 28:19	<b>logic</b> 83:13
132:11,14	78:17	128:19	61:23 73:23,25	long 8:19 65:3
139:11,12,18		legally 209:13	74:12 124:25	85:18
139:21,25	<u>L</u>	legitimate 34:3	165:17 166:19	<b>longer</b> 7:13
140:4,15,18	L 2:6	209:23,24	191:3 237:25	125:25
141:22 145:3	L.L.P 2:3	238:11,19	<b>listed</b> 24:4,21	look 19:5 23:11
153:7 157:24	labor 41:9 65:22	length 118:11	29:21 61:9,14	26:9 34:22
158:25 162:5,8	lack 35:22 101:3	<b>let's</b> 18:1 48:17	77:4 145:25	35:14,18 36:10
168:15 172:10	102:14 114:19	61:15,17 98:13	listing 24:21	48:17 56:3
172:16 175:24	115:3,4,18	124:12 166:23	<b>lists</b> 76:19	61:6 73:19,24
	l	<u> </u>	<u> </u>	ı

				1490 271
74:3,10 75:11	232:11	machine 30:22	236:2	111:3,9 155:24
76:24 77:20	looking 10:20	31:15 95:13	marked 3:2 7:24	mattered 80:9
78:7 80:12	30:1,12 46:1	113:1,4 114:1	8:3,7,11 9:4	89:8,10
82:5 87:16	67:25 72:17	114:17,21,23	11:19 22:4	McGothern
89:2 93:6	73:15,20 83:18	115:6	34:9 38:16	36:3
94:21 95:6	97:13 100:13	machines	39:11,14 46:18	McGov 199:22
98:8,22 99:12	106:8 113:15	115:23	46:25 47:3	McGovern 5:18
103:3,22 109:4	113:18,25	maintain 70:7	54:5,9 61:19	5:20 9:12 11:1
109:18 110:13	126:20 129:23	70:25 73:22	61:22 76:12,15	13:21 32:5,8
110:24 112:1	157:4 163:1,15	maintaining	86:22 87:17	32:17 33:9
113:5,20 114:2	166:22 173:1	78:10 132:5	90:5,9 94:5,8	34:11,23,24
114:3 115:22	188:22 189:22	major 57:13,14	104:11,17	35:2,8 36:4
119:12 125:12	201:2,9 202:12	<b>majority</b> 204:1,3	113:7,10 119:2	38:17,22 39:5
131:11 141:14	207:22 209:15	making 18:3	119:6 124:3,7	92:19 110:9,11
142:2 150:16	216:7 220:20	33:5 35:13,15	124:16 126:14	131:25 136:24
152:13 161:11	220:21,21	155:14,19	126:17 128:4,7	138:6,18 141:6
170:20 175:21	looks 36:24	187:20	145:7,11 149:1	141:10 142:5,8
177:10 181:22	126:19 209:24	<b>male</b> 91:4	149:8 154:12	142:16 143:6
186:8 191:14	losing 234:20	males 49:19	154:16,20,23	152:14,19
193:13,15	loss 65:25	malpractice	161:2,5,11	153:8 160:6
195:1,2 197:22	<b>lot</b> 17:20 33:6	71:24,25	162:17 170:3,7	163:1,16 164:9
198:14 199:6	34:16 41:18	man's 65:2	175:8,11 179:4	166:1 167:8
199:13 200:10	111:16 137:25	<b>managed</b> 165:18	190:14,17	170:18 171:10
200:15,15,17	138:1 147:10	manifestation	193:1,4 195:12	173:19 174:4
205:23 206:9	185:1	160:19	195:15 198:4,7	174:14 176:20
206:22 209:22	<b>lots</b> 20:1	manipulate	203:1,4 204:20	177:4 178:7,20
213:6,10	<b>love</b> 141:13	35:20 237:18	204:24 215:4	181:1 183:23
215:18 216:19	low-molecular	manipulating	230:1,4 236:3	185:3 190:5,9
222:4 230:7	207:1,12	123:5,6	236:6,13	190:12 192:20
231:12 236:23	<b>Lowdon</b> 153:17	manipulation	239:18,24	192:21 197:17
237:21 248:9	195:18 221:18	35:9 36:5,16	Marriott 1:20	199:23 200:21
looked 10:12,14	222:3	38:6 225:1,14	master's 228:1	201:2 204:18
10:16,17 11:18	lower 144:25	226:8,10,16	matching 39:8	206:21 208:17
22:2 24:11	158:23 182:8	227:22 228:9	material 23:17	208:20 210:22
28:3 31:19	198:21	237:13	26:12 177:15	211:5,12,19
33:6 38:18	lucky 125:16	manner 153:20	187:22	212:20,24
66:5,17 70:20	lunch 159:12	manual 131:8	materials 10:21	213:7,22 214:3
86:5,9 92:18	Luncheon	manufacturer	23:21 24:14	215:1 216:16
99:19 104:3	159:14	100:14 102:11	27:17,18 29:20	216:22 218:9
107:2 109:8,21	lung 49:11,15,20	103:9 120:11	118:17	218:20 220:5
112:4 116:10	63:21,25 64:4	183:2	mathematical	221:14 223:24
118:7 122:13	64:21	March 58:22	152:13 186:12	224:4,18
138:4,6 145:21	lying 225:19	59:10 113:17	<b>Mathieu</b> 113:22	226:11,24
161:10 177:11	226:5,14	122:2	matter 33:25	227:14 230:6
181:5 185:4		mark 7:18 114:5	62:10 64:19,21	233:5 234:2,12
188:23 200:1	M 2:3,10	128:9,10	65:5 69:2,2	235:10 237:7
201:5 223:7	141 2.3,10	227:24 228:8	89:9 90:2 95:5	238:5,11,18,21

				Page 272
238:25 241:5	medication	methods.'	47:25 48:3,5	56:21 58:3
244:10 245:18	134:25	117:11	48:13,14,22,24	moment 147:20
245:19	medications	<b>Micah</b> 23:7	49:3,6,9 50:3,6	177:7 188:8
McGovern's	134:1 135:14	Michelle 90:10	50:16,21	196:6 197:5
215:7,10	137:25	128:10	Minneapolis 2:4	211:2 215:14
McGowan 148:5	medicine 18:11	micro-organis	2:8	240:22
185:3	18:12 19:13	198:19	Minnesota 1:2	months 128:1,1
<b>MDL</b> 1:9	27:23 51:7	microbe 172:4	2:4,8 228:2	224:3 225:8
mean 13:16	72:25 75:20	microbes 107:14	250:9	<b>Morken</b> 128:16
24:10 29:22	<b>medium</b> 137:16	107:18 108:4	<b>minutes</b> 121:23	morning 7:8
32:1,3 44:11	144:7	109:12 115:25	mis 55:18 92:11	24:6,8 162:18
68:10 72:6	meet 85:15	159:1	233:14	192:11 216:20
87:5 140:14	meeting 22:11	microbiology	mischaracteri	232:12
184:17 200:17	22:12,15 58:24	150:21	129:8 171:21	Mortality 3:8
213:23 214:3	85:16,18 88:23	<b>micron</b> 103:6	182:22 214:17	47:5
219:15 245:17	90:16 122:2	Micronis 181:9	226:2 233:19	<b>Morton</b> 128:9
meaning 160:4	Melling 4:24	Microorganis	miscon 91:23	motivation
184:11	74:1,6,15,15	179:6 181:9	misconstrues	120:15
meaningful	77:21,24 78:17	Midas 65:22,24	91:23 92:12	<b>motor</b> 30:17
14:21 174:18	190:19,24	<b>middle</b> 114:4	misdescribe	mountainous
means 69:10	member 11:5	midway 170:21	81:19	47:23
105:10 140:15	32:11 35:23	203:25	misheard	move 58:16
140:16 180:1	58:17 59:7	migrating	215:17	100:10,10
meant 32:19	members 55:7	101:24 102:8	misrepresent	104:3 132:14
84:1 217:22	memory 144:20	102:13	43:18	132:15 166:23
mech 176:24	<b>mention</b> 49:16	milligrams	misrepresents	202:15 226:1
mechanical	mentioned	243:24	210:13	<b>moving</b> 15:17
29:16	19:10 24:5	mind 10:18,23	missing 99:20	MSHA 65:22
mechanism	77:13 166:4	32:17 66:21	misspeak 47:20	MSSA 175:1,14
80:21,25 96:15	mercury 8:20	82:6 147:18	misstatement	194:9,13,17
97:4,23 110:22	merit 160:16	149:20,23	220:12	195:21 196:22
112:9,12 144:2	238:13	150:2,11,13	misstates 31:3	197:7,14,19,19
144:24	message 128:25	155:7 165:25	74:17 105:19	197:25 198:2
mechanisms	130:6,8	172:19 176:4	106:6 226:2	198:25 199:14
81:7,9 98:4	met 22:20 23:2	180:13 192:23	244:25	199:22 201:4
111:20,22	34:17 85:17	241:23	mistakes 37:20	202:1,8,10
144:10	87:1,3,6,7	minds 66:20	105:11	204:9,17
mechanistic	90:12 121:7	mine 36:14	misunderstood	231:16
82:15 110:19	122:1,21,23	miner's 65:13	132:7	muc 195:2
mechanistically	methicillin	miners 49:14,17	mixing 135:15	multiple 10:24
171:13	194:17	miners' 42:13	<b>model</b> 67:3	37:17 60:5
medical 10:9	method 67:6	mines 48:10	94:24 96:4	<b>mupir</b> 196:15
11:17 18:16	methodol 59:22	49:20 73:6	113:23	mupirocin 195:2
22:25 27:12	methodology	<b>mingling</b> 136:17	modified 240:13	196:16,17
65:25 72:17	59:17,21,22	minimize 73:3	<b>module</b> 178:4	203:11
209:11 210:11	66:12,24 67:9	mining 46:9,22	<b>mold</b> 51:1,14,17	Mycobacterium
238:1	68:8,22 218:7	47:10,13,18,21	51:19 52:5	106:16
	<u> </u>	<u> </u>	I	I

myeloma 60:5	131:6	<b>notes</b> 36:10,11	234:11 235:9	102:14 107:11
myriad 115:20	new 7:20 32:2	211:4 239:14	<b>object</b> 13:10	115:4 120:8
	238:25	250:8	15:12 29:2	123:25 129:18
N	<b>NHS</b> 5:7 198:10	Notice 1:19	30:6 31:2	152:16 182:22
<b>N</b> 3:1 7:1	198:22 200:7	notion 70:5	35:21 36:17	186:24 187:7
N-a-c-h-t-s-h-t	201:1,10 202:9	196:13	44:7 45:23	228:17 229:13
26:5	<b>night</b> 106:9	November 5:23	51:2 59:19	233:16 244:25
Nachtscheim	nine 23:13,19	199:18	66:25 67:2	objections
26:3,4 143:13	24:4,16 25:8	nuanced 177:24	74:16 75:6	106:25 234:17
236:10,15,21	25:14,18 29:21	<b>number</b> 10:6,12	80:16 81:15	235:6
237:12,17	150:21 208:16	11:18 27:9	84:9 86:14	objective 68:7
Nachtsheim	225:8	38:23 43:1,19	88:11 89:4,16	68:21 179:15
5:22	<b>non-</b> 40:14	48:19 51:18	91:19,22 92:10	181:16
name 7:14,15	202:15	53:17 72:15	95:1 96:18,20	obliterans 63:25
8:17 20:6,11	non-arthropla	77:4 78:21	97:25 99:17	64:11,14
20:12 22:23	84:14	79:2,8,16	101:2,14	obscure 28:6
23:1 44:23,24	non-FAW	80:22 82:24	103:12 105:18	observation
62:7 124:20	167:20	83:10 86:12	106:5 108:6,15	153:4,5
147:21 188:8	Non-lawyers	89:15 90:11	108:18 109:15	observational
named 23:7	87:5	98:13 113:23	109:19 114:18	59:25 153:2
232:18	non-litigation	119:11 124:25	115:17 116:4	154:3 179:13
names 8:19 20:7	72:22	139:19 140:1	116:11 120:13	237:4 240:11
119:20	non-operatively	158:19 161:14	120:21 121:3	<b>obvious</b> 125:21
narrative 206:5	165:18	182:6 191:2	123:18 126:6	occasionally
nasal 4:17 204:7	non-significant	200:18,24	127:15 129:7	79:10,10
national 27:23	217:5	203:6,7 207:6	130:14 131:20	occupation
41:9 46:9,22	nonprofit 117:5	225:10 229:21	133:2 134:20	49:20
47:9,13 50:21	normally 118:11	234:24	135:7 138:9,22	occupational
51:21 75:19	169:11	numbering 7:20	140:12 141:18	18:16 51:6,7
223:6	normothermia	numbers 11:19	146:14 147:1	51:22 72:25
near 182:16	19:18 70:7,25	20:18 39:9	149:15 151:24	73:3
necessarily	73:22 78:11	88:1 141:15	154:7 160:8	occur 13:3 15:6
13:12 32:14	132:6 205:24	142:2 165:5,21	171:18,20	84:21 97:24
36:1 68:9,10	Northumberla	186:1,6 188:23	183:4 186:16	103:1 132:22
68:14,23 82:22	34:25	212:2 217:7	187:14,24	172:12 211:3
137:23 157:22	Northumbria	232:14 234:3,6	199:24 204:12	occurred 11:5
212:9 246:1	27:20 153:13	234:22,23	207:4 211:9	occurs 97:5
necessary 11:6 need 128:17	201:16 221:18	235:13	214:16 224:10	October 173:21
132:14 176:2	222:12,17	numerical	225:3,23,25	177:5 199:15
227:13 247:8	nosocomial 17:2	186:11	226:18 227:16	199:17 224:3
needed 75:16	157:3	0	228:5,11,25	odds 212:12,16
never 34:16 45:9	notable 11:3	o 7:1 218:14	229:19 233:7	217:10,21
45:14 75:18	Notary 250:19	o'clock 1:22	233:13 234:16	235:4,20
85:17 87:10	251:24	O-u-l-e-s 62:8	234:16 238:6	offense 23:9
90:12 91:14	note 52:17 222:7	oath 214:13	238:14 246:3	offer 99:4
92:13 112:5	noted 212:24 224:2	226:14 233:25	objecting 67:12 objection 74:23	178:11 232:8
) <u>D.13 112.3</u>	<i>LL</i> 4. <i>L</i>	220.11233.23	objection /4:23	offered 11:24

46:2 69:4	45:8 46:5,8,11	132:12,24	193:18 194:2,8	one's 219:10
<b>office</b> 25:16	47:8,16 49:3	133:9,11,19,21	194:16,20	ones 36:6,20
27:21 28:15	50:15,20,23	134:8,12,17,25	195:6,24	37:10,13
officially 55:15	52:3,9,15	135:10,24	196:12 197:12	147:11,20
officially' 56:11	53:13 54:15,23	136:6 137:13	197:13,13,18	ongoing 128:19
officials 122:2	55:14,22 56:6	137:18 138:2,5	198:12,16,24	224:19
122:23	59:5,11,16,24	139:22,25	199:6,13,17,20	operated 30:16
Oftentimes	60:8 62:7	140:9,22 141:9	200:25 201:3	73:5
45:11	63:15 64:18,24	141:14 142:15	203:9,16,21	operates 29:13
<b>Oguz</b> 232:18	65:5,21 67:8	142:24 143:5	205:8,13,15,23	30:5,14,23
<b>oh</b> 16:19 72:10	67:13,19,24	143:19 144:17	206:9,11,15,18	31:15
73:17 110:10	68:4,15 69:16	145:19,25	206:24 208:2	operating 16:7
113:3,18 162:7	70:3,15,22	146:7,19,23	208:19,24	27:10 101:23
183:7 184:19	71:3,10,13,16	147:7,14 148:7	210:19 211:5	102:7 105:17
197:13 200:23	73:13 74:3	148:25 149:12	211:14,23	106:3,24 107:6
210:5,19	76:24,24 77:10	149:24 150:16	212:23 213:8	179:7 181:9
215:16 236:8	77:12,18,22	150:24 151:4,5	213:12,17,20	182:6 188:16
248:16,20	78:1,7 79:6,12	151:14 152:8	214:7,12	200:7
<b>ointment</b> 176:13	80:3,10,20	152:18 153:25	215:12 216:10	operation 16:7
okay 7:12 8:17	81:22 82:19	155:6,13	217:13,17	140:2
8:23 9:2,9,22	83:7,25 84:5	157:15,19	218:2,18,25	operative 12:6
9:24 10:5,10	84:12 85:10,15	158:14,18,22	219:7,12,20,25	217:3
11:9,12,23	85:18 86:10	158:25 159:5	220:14 221:2,7	opine 9:12 30:25
12:18 13:1,8	87:13,16,22	159:11 160:13	221:17 222:11	53:11 62:21
13:13 14:6,23	88:2,7,15	162:7,13,20	222:15,20,24	66:3 81:8
15:5,20 16:4	90:14,20 91:9	163:10,12	223:2,8,19,22	83:14 96:24
17:4,11,18,23	92:14,18 93:24	164:12 165:22	224:7,22 226:6	139:17 156:17
18:1,7,13,17	94:20,24 95:8	166:16,24	226:13 227:20	182:11 188:13
18:25 19:4,21	95:10,11,16,17	167:6,13,13,23	228:13,19	218:12,21
20:3,9,13,22	95:20 96:3,7	168:4,22,25	229:16 231:12	<b>opined</b> 31:8,11
20:25 21:4,10	97:15 100:4,24	169:12 171:8	232:1,10,23	43:8 44:3,17
21:14,17,20	101:9 102:11	172:13,19	233:24 234:7	60:4,7,9,22
22:1,10,14,18	102:25 103:5	173:1,18 174:3	235:1 236:23	62:13 63:3,4
22:20,22 23:1	104:2,25 105:5	174:10,20	237:11,16	64:10 71:21
23:4,15,24	105:13,23	175:7,19	238:3,10,24,24	80:25 81:9
24:7,19,22	106:1 108:22	176:12,18	239:6,14	97:2 155:4
25:2,17,22	109:7,11	177:8,21	240:20 241:16	218:16
26:14 28:18	113:20 114:10	178:15 179:15	242:15 243:4	<b>opining</b> 30:16
29:6,11 31:8	115:22 116:7	180:23 181:22	243:10,20	43:14 96:23
32:7,16 33:10	116:15 117:20	182:19 184:1,4	244:4,13	177:22 224:25
34:2,6,18,21	118:16,19,24	184:11,19	245:20 247:14	opinion 9:18,20
34:23 35:3,7	119:18,24	185:18 186:7	old 118:6	9:21,22,23
35:11 36:13	125:12 126:23	187:17 189:4,5	once 10:24	12:3 13:8 14:1
37:6,9 38:1	127:6,12 128:3	189:15,19,23	16:13 58:20,20	14:8,16 15:8
39:4,20,25	128:15,25	190:13 191:12	58:21 85:22	17:8,12 29:1
41:5,7,12,21	129:13 130:20	192:2,7,13,18	97:7 106:1	29:18 30:20
43:7 44:22	130:25 131:6	192:25 193:13	195:20 217:4	44:12 45:5,20
	·		-	-

63:7 64:12,12	220:4 237:25	ovarian 62:14	240:8,8 241:7	33:9 75:22
65:2 66:6	238:12	62:22 63:1,9	241:8 242:19	78:17,23,24
72:22 78:20	opposed 13:14	overall 151:14	242:20 243:4	79:8,23 80:1
79:1,3,18 80:7	13:16 71:18	oversaw 51:8	246:22 248:10	94:1,3 98:14
81:11,19,20,24	155:22 173:20	overstate 222:4	248:18,18	156:9,20 157:1
83:1,9,12	189:25	overweight	PAGE/LINE	157:10 185:2
89:22,24 92:14	option 225:14	49:12	251:6	207:15,23
92:22,23 96:11	order 28:25		pages 1:14 23:16	231:18,21
96:24 97:9	133:1 179:11	P	23:20	232:17
98:16,17,19	247:8	<b>p</b> 7:1 219:19,21	paid 156:8	par 91:17
99:4,9,10	organ-space	<b>p-value</b> 150:25	panel 57:2 92:1	paragraph 9:10
101:17 106:22	171:3 173:12	151:5,9,16	paper 11:2,3	12:2,11,20
109:11 110:4,8	organism 72:23	217:25 218:7	13:20,21,21	23:13,19 24:4
111:19,24	73:16 109:2	219:2,8,13	32:9 34:11,15	24:16 25:8,14
112:7,13	organisms 84:24	220:8,16	37:16 49:21	25:18 27:8
117:15 122:17	89:15	<b>p-values</b> 220:20	51:4,9,12 53:8	48:20 55:15
125:6 129:15	organization	220:21	53:15,16,22	56:4 69:24
129:20 130:23	58:24 62:20	<b>P.A</b> 2:7	56:14,16 57:1	70:22 73:19
132:4,9,13	70:13 71:12	<b>pa</b> 109:14	57:11 73:25	82:12 94:21
136:15 140:9	105:8,9 118:5	packet 27:17	74:7 77:15	102:5 103:25
141:16 142:6	original 64:9	118:17	79:23 125:17	116:22 127:6
142:10 143:12	246:23	page 3:2 6:4 9:5	125:22 144:19	128:13 132:21
156:5 159:3,7	Orthopaedic	23:12 39:15	155:11 156:2	133:18 140:23
167:6,7 168:21	5:11	48:17,18 61:8	156:12 157:4,5	150:19 152:1
172:3,24	orthopedic 17:6	69:24 76:18,18	163:1,7,13,16	193:21 203:17
182:20,25	19:22 28:4	76:24,25,25	163:19 165:6	203:20,22
188:12 216:10	35:1 84:15	77:5,20,23	182:14,14	208:19 210:4
218:5,18	90:16 109:25	78:7 82:7	183:20 191:11	212:23 216:22
219:25 232:9	140:6 222:5	87:17,19 95:17	204:14 209:1,5	221:17 223:14
233:2 239:2	others' 33:18	95:21 113:13	209:16,23	223:16,22
opinions 11:25	ought 46:18	113:21 114:3,4	210:7,20	226:7 240:10
23:22 25:7	60:13	116:20 131:11	211:12,19	241:20 242:20
28:20 33:22,25	<b>Oules</b> 62:8	132:19 133:17	213:22 214:3,8	247:5 248:8,10
43:19,22,25	outbreak 73:2	150:17,17	214:8 215:25	248:13
50:22 78:18	108:12 109:1	152:25 161:8	216:16 217:18	paragraphs 82:7
80:2 87:14	outcome 133:8	161:12,23,24	222:3 224:16	152:9 191:15
88:21 89:2	134:5 148:20	165:3 166:25	230:10,18,24	paraphrase 82:6
91:13 92:17,25	158:2 210:1	175:25 178:23	231:8 234:2,12	paraphrasing
100:19,23	outcomes 48:2,4	181:23 183:21	235:18 236:1	63:11 210:22
103:17 104:23	48:13,23	193:13,19	238:11,18	part 19:4,12
105:14,24	outlier 221:21	194:9 198:17	242:3,18,22	21:22 34:25
108:1,23,24	221:23 222:12	203:19,20	244:10 246:4	38:20 42:10
109:9 123:22	222:18	208:16 215:18	246:21 248:3,4	51:24 68:3
124:22 133:12	outlined 196:1	216:4,5,5	papers 11:3,7	71:20 72:4
140:22 150:3	outside 14:4	221:12 230:7,8 231:12 232:2	13:25 14:5,22	78:18 110:4
179:19 191:2,8	17:9 120:18	236:23 237:22	14:24 15:3	128:9 164:25
192:4,6 205:6	125:7	230.23 231.22	27:25 31:24	188:10 191:18
	•	•	•	•

	1	1	ı	ı
201:25 221:11	81:18 97:8	169:2,16 171:6	250:5	pointed 197:9
participant 72:4	party 32:13	171:6 185:25	placebo 175:4	pointing 168:12
participants	<b>path</b> 208:1	198:21 247:10	175:16,19,22	polarized 57:6
153:8	pathogens 113:1	247:10,11,11	176:12,15,19	polarizing 55:7
participants'	113:4	<b>Perfect</b> 132:15	176:25	57:19
154:2	<b>patient</b> 17:7,14	perfluoroocta	places 83:22	policies 73:9
participating	94:23 107:6,19	42:1 46:1	<b>plaintiff</b> 42:6,20	politically 50:11
26:24	107:21 109:14	performed	62:19 64:6,15	pollution 48:10
participation	110:14 111:13	28:12 32:10	111:13	48:10 50:11
118:7	115:2,16 187:4	period 41:16	plaintiffs 2:2	<b>pool</b> 42:18
particle 87:25	205:11,19	127:22,25	86:7 97:5,10	<b>pooled</b> 165:8,11
89:8 232:4	patients 70:6	160:17 167:8	plaintiffs' 41:18	<b>poor</b> 49:12
particles 83:10	150:20 162:21	170:18 171:10	41:20,22,23	<b>popcorn</b> 63:17
86:13 88:24	185:23,24	174:4 178:7	plaintiffs'-side	63:21 64:1
140:2 232:14	204:5 205:13	181:1 183:23	41:24	population 19:2
particular 19:6	231:17 244:3	184:1 185:14	plausibility	19:7 47:18
32:13 33:11	247:8	185:19 190:5	80:13,19	49:7
42:24 43:21	paucity 120:25	190:10 209:20	<b>play</b> 81:7 242:14	populations
44:18 55:6	<b>pay</b> 42:18	212:18,25	<b>please</b> 7:15 8:18	18:24
64:15,16 65:10	156:19	223:12 243:18	54:3 104:5	portion 215:7
73:5 89:23	<b>pdf</b> 145:23	244:15,18	113:19,21	portions 22:3,3
111:15 140:10	149:2	245:6,8	116:17 124:13	<b>pose</b> 16:21
149:22 157:6	pecking 179:11	periods 244:24	159:13 180:4	107:18
182:11 193:25	peculiar 42:7	periphery 64:23	195:10 229:24	posed 231:4
196:25 205:10	<b>peer</b> 33:19 53:17	peritoneal	235:23 236:2	<b>poses</b> 98:4
236:22 243:1	59:9	173:15	239:16,23	<b>posing</b> 110:21
247:2	peer- 11:1	perjury 214:14	240:22 249:3	position 33:21
particularly	peer-review	<b>person</b> 43:17	<b>plus</b> 168:6	51:4 214:25
19:17 75:2	58:23	61:3 64:1	183:24 184:2	positive 113:24
143:15 232:21	peer-reviewed	personally 37:3	pneumoconiosis	114:17 115:25
particulate	10:13,21	pertinent 75:5	42:13 65:13,20	204:6
81:21 182:4,5	penalty 214:13	<b>PFOA</b> 46:15	<b>po</b> 169:2	possibility 48:5
particulates	<b>pending</b> 124:15	phenomenon	point 29:15	48:24 125:19
78:21 79:2,17	penetrate 187:4	11:8	31:14 33:5	223:24 225:7
79:20,24 80:22	<b>people</b> 35:15	Philadelphia	36:21 37:8	226:7 227:12
81:13,23 82:24	39:22 44:12	122:3,21	83:6 84:2	<b>possible</b> 10:18
83:5 88:8	45:11 49:11,13	phone 25:24	102:1 107:25	29:19 59:14
89:14,20,25	50:8 57:3,6,21	phrase 28:2 99:6	156:1 158:2	97:12 106:4,24
90:3,23,25	57:24 90:11	pick 27:24	165:12,13,14	114:23 118:16
91:3,5,17 92:4	91:16 92:3	piece 42:19	173:16 174:3	118:18,24
93:7 94:2	114:7 133:4	109:3 227:2,3	176:9 177:7,18	119:1 211:2
97:12 98:16	153:19 182:6	241:4	178:3 180:23	possibly 10:24
232:5	<b>people's</b> 33:19	pieces 43:1	186:1 195:24	post 154:10
parties 75:13	percent 36:25	<b>PJI</b> 202:8	196:24 197:5	190:9
<b>Partington</b> 146:2	40:3,6,25 41:2	247:12	199:9 207:10	post- 203:12
	150:22,23	place 103:2	207:18 238:17	post-hoc 58:7
parts 15:17	151:15,16	165:1 197:6	248:8	posted 51:6
L				

				Page 277
postoperative	premarked	101:19,21	72:19 153:23	216:8 242:6
141:25 144:13	236:9	102:3 117:2	problematic	properly 210:20
postoperatively	premise 33:1	205:1,2	14:13 17:12	214:14 216:2
139:14 140:8	192:17	previous 127:18	75:22,24	242:5
145:5 155:15	preoperative	previous 127.18	problematical	prophylactic
155:20,20	4:20 190:19	74:25 87:17	17:10	4:25 183:22
158:21	preparation	104:16 105:6	problems 64:6	184:8 187:11
<b>postpone</b> 240:15	158:12,15	128:19 134:3	211:11,18	187:21 188:9
pot 43:5,6	167:4,8,16	149:7	procedure 17:5	191:19,21
potential 134:4	168:2 170:17	primary 193:23	166:9 196:1	192:15 193:6
138:12 147:15	171:9 173:19	242:25 243:8	procedures	193:23 212:25
potentiality	176:20 177:3,4	243:13 247:1	27:10 200:7	242:24 244:9
80:19	177:16,23	principally	201:11	246:25
potentially 35:9	178:7 179:20	83:19	proceedings	prophylaxis
35:12	181:1,14	principle 19:8	10:8	133:19,22
potty 53:24	206:20	30:15 69:5	process 46:16	134:9 135:21
povidone-	prepare 56:24	print 151:3	51:11 58:23	138:8 139:19
180:16	prepared 57:8	<b>print</b> 131.3	59:10 81:3	140:1,5,11
povidone-iodine	prepublication	prior 25:6 40:18	88:22 125:25	141:3 143:8
4:13 169:14	225:10	104:22 106:21	197:23 209:13	155:15,21
170:9,23 174:5	presence 16:6	107:3,10 119:9	<b>produced</b> 24:3,9	160:3,22 243:7
206:16	65:19 83:5	121:22 122:24	24:11,15 25:1	243:13,16
Poviodine 169:7	98:3 107:18	123:21 129:12	25:11 29:8	proportions
poviodine-iodi	109:12	244:9 248:5	113:12	198:20
169:8 173:21	present 22:16	<b>priori</b> 140:10,14	Products 1:6	proposed 33:7
Poviodone 169:9	76:20 210:20	probability	professional	128:18 130:10
169:10	presented 43:3	116:24 151:6	19:23 41:10	prostheses
poviodone-	211:20	probably 11:1	117:2 250:18	181:19
169:2	presents 210:13	13:6 20:20	professor 7:8,9	prosthesis-rel
power 247:10	president 54:14	21:8 25:24	17:20,25 18:4	181:20
powered 230:11	press 153:18	26:15 27:19	20:4,14,19,23	prosthetic 84:25
230:25	Presumably	28:16 35:2	20:24 21:1,4	85:4 90:17
practice 18:16	191:10	40:3 46:17	21:24 22:3,10	139:4,20
72:14 191:18	<b>presume</b> 196:20	67:11,16 73:18	39:6 86:23	184:21,22
practices 48:6	202:14	77:15 88:23	105:1 142:7	187:23 194:14
49:1 104:20	pretty 126:24	106:15 134:22	143:13 152:14	202:8 247:6,13
105:16	<b>Preven</b> 205:1	144:19 149:2	160:14 185:15	247:17
preamble 226:1	prevent 70:6	160:18 167:10	185:22 211:24	Protection
predated 65:3	101:24 102:8	172:3 195:4	228:3 236:15	221:20
predecessor	102:12 120:11	205:15 206:22	236:18,20	protective
95:14	134:14	219:24 238:16	237:12,17	170:22
predicate 94:19	preventable	238:17	proffered 86:6	protocol 157:20
94:23 95:9,14	127:7	probing 112:20	progresses	158:5,10 167:8
predominantly	preventing 4:16	probity 35:17	45:14	167:15 168:1
41:19	120:1 186:15	problem 33:12	<b>project</b> 126:24	173:19 194:25
preferable	<b>Prevention</b> 5:15	50:9 57:25	prolonged 244:1	209:8,19
174:17	5:16 90:17	64:8 67:7	<b>proper</b> 113:25	210:16
	l		l	l

	1			
protocols 73:3	154:4 177:14	31:3 35:22	146:15 147:2	quite 49:24,25
171:19 173:4	180:25 208:20	36:13,14,18	148:7 149:16	57:1,9 69:10
177:16 201:11	209:1 213:22	42:12,14,15,17	149:23 150:10	118:24 200:4
201:13	publishing 55:5	42:21 44:2,8	150:14 151:9	<b>quote</b> 50:9,15,21
<b>prove</b> 148:16	<b>pull</b> 86:18 104:4	45:16,17,18,24	151:25 152:3	51:19 68:15,18
<b>proven</b> 62:24,25	138:15 142:22	46:5 51:3 53:4	153:24 154:1,8	68:22,25 143:1
<b>proves</b> 147:23	148:25 170:2	53:20 58:13,16	156:3,17 157:7	168:5 181:25
provide 9:15	175:7 178:25	59:6,20 60:20	157:8 160:9,25	190:19 213:4
72:22 210:8	240:25 242:17	62:12 63:2	162:24 167:23	215:23
216:25 243:23	242:18	64:9 67:1	167:24 174:24	quoted 50:5
provided 11:21	<b>pulled</b> 28:13,19	68:11,12 70:21	183:5,14,15	188:5 215:2
27:17 63:8	211:3	73:13,17 74:9	185:17 186:17	229:21 247:22
118:13 209:12	pulmonary	74:17 75:7,17	186:20 187:15	quotes 37:9
provides 164:23	134:15	75:25 77:8,24	187:25 190:7	
171:11,22	purely 103:14	78:2,8,25 80:2	199:25 202:4	R
pry 216:25	purports 208:21	80:17 81:16	202:17,22	<b>r</b> 7:1 169:12
<b>pub</b> 177:14	purpose 10:20	82:23 84:10	204:13 206:6	250:1 251:1
public 73:1	134:14 157:6	85:7,24 86:15	207:5 211:10	raise 67:3 202:4
250:19 251:24	196:21	87:21 88:2,12	214:17 215:14	raised 42:21
public-relations	purposes 22:2	89:5,17 91:23	215:20,24	92:1 109:22
118:9	56:25 166:13	92:11 95:2	219:23 220:12	150:9
publication 10:3	pursuant 1:19	96:21 97:7	223:9 224:11	<b>raises</b> 33:13
32:2 38:2	25:3,4	98:1,14,20	225:5 226:1,19	223:23 227:12
52:10,11 54:12	<b>pursue</b> 128:20	99:3,18 100:1	227:17 228:6	227:23
58:4 118:12	130:2	100:3,5 101:3	228:12 229:1,8	raising 57:21
119:10,19,22	<b>put</b> 37:10 57:18	101:5,15,16,16	229:15,20	ran 71:23
121:7,10	126:9 147:13	101:18 103:3	231:4,14 233:8	<b>random</b> 70:23
122:10,24	168:22 169:11	103:13 105:19	233:14,23	73:21
123:1,14	169:11 185:2	106:6,18,19	235:18 237:2,3	randomised
125:25 237:7	242:15,16	108:7,19	238:7,15	4:23 243:22
239:1 240:4	putting 43:8	109:16,20	241:10,11,18	247:7
publications	57:1	110:16 114:19	241:18 242:1,6	randomization
8:16 10:13		115:10,18	245:20 246:4	176:1
28:19 117:22	QQ	116:5,12	248:23	randomized
124:22 235:14	qualifications	120:14,22	questioned	179:8 181:24
publish 53:18	216:8 242:7	121:4,19	233:25	190:21
publishable	qualified 75:21	122:16 123:3	questioning	rare 247:7
78:3	214:15 216:2	123:19,20	215:19	rate 143:3
published 8:21	242:5 250:3	124:15 126:7	questions 13:24	144:13 151:7
36:8 38:14	quality 219:6	127:16 129:8	43:25 60:16,17	151:14 167:20
52:4 54:18,21	<b>ques</b> 100:9	130:15 131:21	69:3 72:1,16	185:24,25
56:15 70:23	question 8:13	132:2,8 133:3	240:20 241:23	188:6,16,18,19
73:20 77:15	10:23 12:9,23	134:21 135:8	246:17 248:21	189:1 231:16
79:23 117:8	13:11 14:6	135:17,18	249:2	244:23 247:9
120:2 121:10	15:13,25 16:14	138:10,23	quick 195:8	rates 70:7
125:16,21	16:21 22:1	139:9 140:13	200:15	143:10 148:10
131:22 142:17	29:3 30:7,8	140:18 141:19	<b>quickly</b> 205:21	163:3,18 186:9
	<u> </u>		<u> </u>	<u> </u>

				1490 277
187:12 191:22	147:10,13	236:19,22	65:16 94:4	188:5,15,25
209:14 223:6	151:2 166:23	237:11,14	104:9 116:17	189:6,11,19
230:14 231:3	176:8,11	243:10,15	124:12,13	193:10 194:3
ratio 164:17	183:17,19	244:4,7 251:6	142:14 154:11	197:8,13 202:7
212:12,16	185:1 186:18	reasonable 13:6	159:13 180:3,5	211:25 214:20
217:10,21	189:5 192:3,5	107:7 109:17	183:19 195:10	215:1,14,16
235:4,20	202:17,18,23	172:23 215:21	202:18,24	217:8,20
raw 197:22	202:24 213:17	215:25 237:25	215:3 229:11	222:16,17,20
<b>RCT</b> 179:11	216:9 222:9,23	240:19 241:14	229:24 232:3	223:10 224:23
182:12	229:9,11	242:3	234:18 235:24	225:19 226:5
re-evaluated	231:10 232:17	reasonably	239:16 240:21	226:13 228:15
164:20	235:22,24	197:3	244:25 246:8	242:22 245:4
re-evaluation	241:16,18,19	reasons 47:25	247:23 248:25	245:10,17,18
164:22	242:19,21	187:5 192:7	249:3	245:19
RE-RECROSS	245:4,25 246:4	201:17 208:12	records 72:17	<b>Reed's</b> 168:5,21
247:19	246:8,15,24	recall 24:7 26:8	RECROSS	168:23 196:20
<b>RE-REDIRE</b>	247:4,23 248:2	29:22,25 73:7	245:22	197:9 214:23
246:18	248:2 251:3	86:2 108:21	REDIRECT	224:14 228:20
reach 112:2,13	reading 103:24	138:13 149:22	240:23	231:23 243:11
reached 99:14	115:14 146:19	206:14,17	<b>reduce</b> 167:20	244:5
168:20 190:3	214:21 220:24	214:18,21	169:1 186:19	refer 69:15
235:9	241:17,23	244:13,19,20	191:16 203:12	128:8 165:15
reaching 79:13	reads 113:22	245:10	reduced 70:25	184:1 199:7
108:1 112:19	243:6,22	receive 29:20	73:23 167:19	213:24 214:10
read 9:19 11:12	real 125:19	received 29:14	169:14 178:1	reference 23:15
20:14,16 27:25	209:24	185:23,25	202:10 244:11	23:19 69:13,15
29:22,23 34:16	<b>really</b> 30:10	recess 54:4	reduces 70:7	69:20 73:24
35:4 37:7	59:22 84:1	116:18 124:14	78:11 158:20	77:4,21 94:15
38:11 49:2	100:2 111:14	159:14 195:11	reducing 158:19	119:10,11
52:12 68:11	128:17 224:21	229:25 239:17	187:12 191:21	124:25 131:1,4
70:19 78:6	realtime 179:24	recognition	reduction 5:11	131:8 163:12
79:8,9 80:1	reanalysis	242:13	175:3,16	169:25,25
82:10 85:1,9	142:13	recognize	178:18 247:9	173:23 175:12
86:17 89:18,19	reanalyzation	119:20 242:11	redundancy	191:2 199:9
89:21 91:8,9	142:8	recollection	153:12	203:5,7 207:15
92:21 93:9	reanalyze	118:20	Reed 4:10 34:23	207:23 208:8
94:2 95:3	141:10	recommendati	34:24 35:1,2	214:8
98:13,20 99:2	reanalyzing	205:10	36:21 37:1,15	referenced
102:1,10	152:14	recommending	142:16,25	155:4 228:9
104:24 105:4	reason 35:3	106:2,23	143:22 146:6,7	references 24:1
108:21 110:3	61:11 75:23	reconstruct	146:11 147:22	70:11,20 73:23
111:4,16	112:25 156:13	27:14 38:10	153:8 157:25	125:2 191:1,7
122:13 126:3	160:23 194:2	150:10	158:4 161:7,9	referencing 32:4
130:5 131:22	225:20 226:4	record 7:14	161:10,16	32:16 145:20
138:14,16	226:14 228:21	14:18 19:9	163:6,23	161:25 180:19
139:1,2 141:20	229:15 230:20	28:11 34:7	164:11 168:11	195:19 226:17
146:24 147:4,8	232:15,23	52:16 54:3	168:12 185:4	referred 26:8

				1490 200
38:16 202:6	<b>related</b> 10:8,13	229:17 236:16	92:17,22	147:9,19 152:2
231:23	10:21 11:13,16	relies 238:20,21	100:19 103:17	152:10,25
referring 12:7	17:22 25:25	rely 38:7 39:2	104:23 105:14	155:4 165:12
37:22 143:21	27:9,11 29:20	69:16 80:3	105:24 106:22	166:21,23
160:14 161:16	54:15 106:15	120:2 138:18	130:23 143:12	167:1 168:17
164:7 179:24	113:6 123:13	138:19 148:13	150:2 192:4,5	175:13 181:14
183:7 184:5	169:15 182:3	148:15 171:15	rendering 30:20	183:22 194:9
195:23 197:16	185:14 190:4	176:19 179:12	107:3 109:8	199:23 208:16
213:25	246:15	185:15 189:5,8	132:4,13	208:20,20
refers 73:25	relates 1:8 16:10	197:8 207:10	172:25	214:24 216:23
247:12	54:11,17 72:23	222:24 238:4	renders 199:22	217:8,18,19
reflected 25:14	73:15 75:2	relying 20:24	repeat 123:20	218:10,12,21
25:18	84:24 132:5	39:6,10 74:21	155:17 166:6	221:13 223:17
reflects 176:22	164:3 167:16	118:1 147:11	repeatedly	224:5 229:18
refused 120:20	168:2 177:23	168:10,14	75:18 100:6	232:2 239:3
121:2 129:23	186:9 189:24	188:25 223:15	229:17	reported 107:14
130:1	232:4	remain 191:22	rephrase 16:13	169:1 194:3
<b>refusing</b> 123:16	relating 29:12	remarked	230:23	197:22 198:20
123:23	60:23,24 161:9	141:23	replacement 4:1	245:2
refute 88:3	relationship	remember 11:17	90:24 145:14	reporter 54:3
228:20 229:14	12:22,23,24	21:6,8 26:15	202:10	104:14 116:17
<b>regard</b> 161:23	133:5 140:10	44:10,20 46:7	replacements	124:13,15
regarded 33:15	148:21	46:10 59:1,15	169:22 203:14	159:13 180:3
71:14	relevance	72:1 118:14,23	replica 210:21	183:18,19
regarding 50:8	174:14	131:9 132:1	report 3:3,12	195:10 202:18
72:2 154:4	relevant 30:8	143:4,15	8:4 9:3,12,25	202:24 229:10
157:1,10	40:15 99:3	146:17,19	20:14,16 21:2	229:11,24
179:19 194:9	110:23 150:14	150:14 186:5	21:5,15,21	235:24 239:16
regardless	reliability 77:14	187:19 205:12	22:4,4 23:11	240:21 249:3
204:10	reliable 78:10	205:16 213:11	23:17 24:17	250:3,18
regards 118:3,4	reliance 10:25	231:24 245:9	25:8,18 26:7	reporting 214:4
136:25	22:3	245:16	26:13,19 36:11	214:5 223:6
regimen 213:1,2	<b>relied</b> 9:13 24:1	remembrance	37:10 45:6,8	224:9,24
243:5 244:9	29:19 69:20	158:7	61:6,9,16 66:7	225:17,22
<b>region</b> 47:19	71:7,10,11	<b>Remind</b> 46:23	66:10 67:4,15	226:16 228:23
register 28:8	117:15,18	remix 142:8	69:24 70:4	reports 27:9
Registered	119:19,22	160:6,13,24	71:8 76:7,8	45:8,12 46:2,3
250:18	122:10 123:1	<b>Remove</b> 114:11	80:6 82:2	46:3 86:6,9
regularly 221:19	124:21 125:2	removed 115:6	83:16,25 86:3	99:3 116:3
regulatory	148:13 168:15	<b>render</b> 29:18	92:14 93:1	125:22 141:7
40:20	168:18 170:16	44:12 66:6	96:9 107:3,13	represent 62:15
reiterated	179:18 186:11	99:4 112:7	112:20 116:21	161:9 196:2,8
127:19	190:25 191:1,3	132:9	119:11 131:13	239:10
<b>reject</b> 55:15	191:7 197:10	rendered 25:7	131:15,25	representative
56:11	203:10 205:5	45:5,20 79:18	133:14,17	87:20 232:12
rejected 55:23	211:13 216:23	80:5 87:14	141:11,24	232:25
56:15	217:15 222:16	88:17 89:3,22	142:1,3 143:17	representative's

				Page 201
233:2	128:17 157:6	33:19 38:25	95:15 102:3,4	138:1 139:7,13
representatives	response 26:6	54:17,19,20	104:8 109:24	140:11 141:3
41:9 86:11	247:15	55:5,6 56:24	111:6,8 113:18	144:3,25
114:15 121:6	responsibility	57:11 59:9	129:22 133:16	147:17 151:23
122:1	44:1	85:11,13 110:9	133:24 136:9	155:16,21
represented	responsible 37:4	110:10 117:7	142:20,22	156:7,19
53:6,21	43:21	155:6 185:16	158:10,12	158:23 167:15
representing	responsive	216:11 232:2,8	159:11 160:7	168:1 171:23
148:3	58:16 67:17	reviewed 9:24	161:14,21	172:2,21
reputable 105:7	202:16	10:2,3,6 11:2	162:12 167:16	177:16 181:2
reputation	rested 129:20	11:24 23:18,21	168:5,14 169:4	182:2,9 183:3
127:2	rests 98:18	23:25 24:16,25	173:17 177:1	184:13 185:9
request 11:23	result 66:18	25:9 27:8	178:10,12,21	187:22 192:9
26:2 95:12	72:7 95:25	28:20 51:24	180:9,22 183:1	194:14 203:12
requested 11:10	244:1	53:15 57:4	184:9 185:21	208:21 211:7
26:1	resulted 43:14	75:23 107:9	186:21 189:6,9	211:15,21
require 238:21	137:2	117:14 118:17	189:13 191:5	212:2 213:14
required 35:24	resulting 175:3	144:18 149:21	191:14 192:10	216:14 233:11
57:13 101:6,12	175:15 183:11	207:6	191.14 192.10	234:13 235:4
200:16	results 48:3,22	reviewers 53:18	201:7 208:10	235:11
requirements	143:1 150:18	57:2,12,15,22	216:14 217:11	risks 16:23
68:3	150:21 170:20	Reviews 8:21	220:23 223:20	47:18 144:22
requires 68:1	172:17 182:1	revised 57:21	225:24 228:15	146:13
111:7	211:19 237:4	revision 57:13	233:6 246:14	rivar 156:6
research 19:3	retained 26:14	57:14	right-hand	rivar 130.0
128:20 129:5	26:17,24 42:10	revisit 223:21	48:20 203:25	4:8 144:14,15
129:24 130:1,3	42:22 72:21	rewriting 57:10	risk 12:4 13:19	144:22 145:15
130:8,10 214:2	217:24	rewrote 121:18	14:2,9,17 15:2	145:17 148:5
reservoirs	retentions 43:14	rheumatologic	15:24 16:2,10	155:2
106:14	retract 11:6	64:3	17:6,13 19:2,6	robust 168:7
resolve 112:10	retracted 11:3	<b>Richard</b> 250:2	30:4 31:1,9	224:8 225:16
respect 24:13	75:19	250:17	47:25 70:25	225:21
39:4 69:4	retraction 10:21	<b>Rick</b> 113:21,22	73:4,23 79:14	Rock 119:14
77:14 105:12	35:24	Ridgeview 10:8	79:25 81:5,12	role 51:25 54:12
120:6 130:20	retractions	11:13,16 24:25	83:11 90:1	<b>Roman</b> 70:4
147:14 184:21	10:13	25:1 209:11	93:13,20	<b>Ronald</b> 2:10
207:17 225:1	retrospective	210:11	100:15,25	room 16:7 27:10
225:15,17	77:6 224:19	<b>right</b> 14:15	107:19,21	101:23 102:7
239:6 245:24	return 3:24	15:11 19:8	109:13,23	105:17 106:4
246:7	145:13 162:22	31:14 35:13	110:8,14	106:24 179:7
respected 56:20	165:9,10	39:19 40:10	111:12 122:12	181:10 182:7
respirators 42:9	returned 57:5	48:8,12 49:11	123:2 129:17	188:16 200:7
respond 130:19	57:15 150:20	50:19 51:12	130:12,22	<b>Rothman</b> 66:16
136:18 196:23	165:19	52:19 54:13	134:9 135:1,5	66:19,21
248:24	review 11:15	55:8 56:1 60:6	135:22,25	Rothman's
responding	14:17 23:24	66:11 69:16	136:11,22	66:17
67:14,22	24:2 25:14	80:12 93:25	137:3,14,15	rough 10:15
,		_	<u> </u>	l

				1490 202
routinely 27:21	says 36:24 57:13	screens 179:24	126:21,22	140:17 157:25
<b>Rubber</b> 15:11	77:5,12 93:25	204:7	127:4,10,11	183:1 187:10
15:23,25 16:1	95:7 101:19,21	screwed 180:1	128:14,15,22	187:16 198:12
16:5,8,15,24	114:10 119:24	se 79:21 84:22	129:2 141:15	198:14 224:12
17:3	126:23 127:6	search 27:24	142:2 143:11	224:14,15
rule 48:4,24	128:11,13	28:1 185:3	145:15,25	225:9 226:21
running 212:2	130:2 151:14	searched 28:2	146:3,5 150:25	237:16
rural 47:22	162:20 163:20	searches 27:22	151:4,5,9,11	selected 25:19
	165:25 170:21	28:11	151:17 162:14	209:25
S	171:2 173:7	searching 118:5	162:20 163:21	selectickly
<b>S</b> 7:1 204:1,6	179:15 191:16	118:22 180:8	163:22 170:10	209:21
safety 3:16	193:21 204:1	second 28:17	170:25 171:4	selectively
51:22 94:9,22	206:4 210:21	56:4 68:12	172:17 174:1	209:21
95:7,18,22	230:9,17	81:19 113:13	175:4,24 177:1	self-evident 32:3
101:20 129:1,6	scenario 15:17	142:23 144:23	179:8,15	seller 42:10
130:6,8,11,16	116:25	188:4 193:20	181:10 182:9	<b>selling</b> 91:16
130:20	<b>School</b> 59:3	207:14 227:3	182:10 190:21	92:3
<b>sale</b> 34:1	science 58:23	241:18 242:20	191:25 192:1	seminar 59:8
<b>Samet</b> 10:25	125:7	248:13	193:8,10,25	seminars 58:18
26:8,13,18	scientific 27:9	Second-to-last	196:6,7,20	sen 167:17
66:18 67:17	27:12 32:13,15	240:10	198:10,22,24	send 28:5
70:4 156:14,15	53:14,22 56:23	second-to-the	199:4,9,18,19	sending 103:10
<b>Samet's</b> 26:7	59:10 68:6,20	48:18	204:7 205:24	sends 57:11
66:10,23 67:14	69:2,8,9 78:9	Secondly 97:10	206:7 208:3,6	senior 118:8
sampling 125:20	111:3 220:25	Secretary 65:22	213:2,6,10	163:11
127:8	221:4,5 227:15	<b>section</b> 46:14	216:3,6,9	sense 42:15
sandbag 162:3	236:20 238:1	67:4 95:21	218:1 221:21	112:18 160:7
<b>SARs</b> 73:10	240:10,12	102:21 167:4	223:25 224:5	165:6,6 210:12
sat 90:21	scientifically	170:20 178:22	230:14,18	219:5
satisfy 54:25	50:11 239:1	181:14 206:5	231:19 235:8	sensibility
55:10 108:1	scientist 33:21	see 11:7 21:4	235:25 237:1,9	153:16
save 166:22	34:3 56:20	24:1 35:18	237:10 238:1	sensitive 91:1
196:3	Scott 114:5	38:21 42:20	240:16 241:15	194:17
saw 91:12	125:22 128:10	56:6 61:15,17	243:3 246:12	sent 3:10 25:15
198:15 200:14	128:10,13	74:12 76:5,18	<b>seeing</b> 149:3,10	25:19,21 26:1
201:12 217:12	Scott's 125:17	83:25 86:3	151:3	26:11 53:17
235:13	scrap 114:10	88:5,6 90:14	seeking 94:18	57:1,2,14,15
saying 17:11	screening 5:10	90:17,19 91:7	seen 14:25 15:3	57:16,22,22
18:3 40:8 50:5	175:2,14	95:4,7,8,17,21	16:17 17:8	121:9
72:17 90:20	176:24 194:10	96:1 100:13	31:5,11,23	sentence 48:22
95:12 100:20	194:13,16	101:19,25	56:21 75:18	49:2 56:3 69:6
100:21 108:16	195:21 196:14	102:5 103:5,7	76:22 78:23,24	69:11 94:22
127:7 160:10	196:22 197:8	103:8 104:25	91:14 92:13	95:6 169:24
165:14 167:14	197:14,19,25	109:21 113:15	93:24 94:1,15	178:17 247:4
167:24 168:19	199:22 202:9	114:13 117:3	96:4 104:21,22	separate 127:12
178:12 192:13 217:7 229:7	204:10,17	117:12 119:24	105:4 112:5	127:13 130:17
411.1 44 <del>9</del> .1	231:16	120:3,4 126:2	127:12 137:24	136:18 164:10
	•	•	•	•

				1490 200
166:19	98:6 117:21	43:4 65:13,18	140:2 157:17	<b>sorry</b> 8:13 14:19
separated 72:13	187:6,9 208:21	65:19	181:20 182:2,5	21:6,18 23:5
September 3:10	211:14,20	similar 47:25	182:8,21 198:9	40:8 50:4 55:3
54:16 199:10	showed 146:8	207:1 208:9	205:2 232:6	56:2 86:2
199:14 225:12	150:21 177:2	<b>simple</b> 59:6	sites 83:24	132:7 135:3
227:1,6	212:14 248:5	60:20	181:18	143:4 150:8
sequence 36:20	<b>showing</b> 129:16	simply 33:3	<b>sitting</b> 15:11,23	151:2 153:25
serial 113:23	152:6 178:20	60:15 111:22	16:8 76:19	155:17 156:12
series 26:8 28:1	186:13	single 41:22	180:12,14	166:21 171:25
113:11 114:2	shown 116:13	43:14 44:4,16	181:6 197:5	176:9 210:17
124:8,17 188:1	188:9 191:16	45:19 87:3,24	situation 42:8	216:4 218:23
225:11	203:12 244:2	232:13 243:23	128:19	219:16 220:11
serve 41:7	<b>shows</b> 39:6	sir 9:7 34:9	situations 11:5	233:17 236:9
Services 104:19	168:7 209:13	39:14 47:3	six 132:20	239:23 245:12
Sess 124:10	230:11,25	54:9 61:22	skin 158:12,14	245:16
<b>SESSION</b> 160:1	232:13 233:22	69:23 76:15	158:19,22	<b>sort</b> 26:9 27:20
Sessler 73:25	side 23:9 36:23	90:9 94:8	159:7 167:4,7	125:20 192:14
74:4,9 77:12	41:20,22,24	96:19 103:18	167:15,16,25	<b>sorting</b> 138:19
78:17 124:9,10	44:21,25 48:20	104:11,16	168:2 170:17	<b>sorts</b> 39:9
124:18,19	65:23 203:25	112:2 113:10	171:9 172:4,8	sounds 19:8
125:1,6,14	206:1 217:10	116:20 119:6	173:18 174:18	39:19 42:6
126:4,11,19	248:19	124:7,16	176:20 177:3,4	46:17 50:13,19
127:13,23	sides 192:10,14	126:17 143:17	177:23 178:6,7	50:23 56:1
set 24:16 25:8	<b>Signed</b> 251:20	154:16,23	179:19 181:1	153:12
38:8 59:22	<b>signif</b> 12:24	156:5 170:7	206:20	<b>source</b> 33:15,15
133:13 138:21	significance	193:4 195:15	<b>skin-</b> 177:15	<b>Sources</b> 221:14
141:10 142:8	217:24	198:7 203:4	181:13	<b>South</b> 2:4,7
154:18 165:9	significant 9:16	222:13,25	skipped 191:4	<b>speak</b> 53:10
189:12 208:2	12:7,8,13,25	225:2 230:4	slightly 174:19	83:21,23 249:1
208:12	13:24 64:2	233:6 236:13	217:11,21,23	speaking 16:20
sets 38:16	148:9 151:12	237:21 239:21	<b>slime</b> 186:22	26:10,24 60:17
setting 14:23	151:19 164:20	241:6,9	slow 23:5	202:11 247:24
22:1 32:2	164:21 165:2	sit 33:18 44:15	<b>small</b> 30:18,19	speaks 104:1
settle 44:12	211:22 217:2,3	44:23 45:18	38:24	special 205:18
seven 60:16	227:5,8,9	57:11 177:12	smoking 65:3	specific 10:12
76:25 128:1	230:13 231:15	177:13 180:24	soap 176:12	18:9 43:12
Seventeen	233:11 235:4	228:19	social 48:6,10,15	44:20 60:23,25
162:19	239:8 244:22	site 4:6,17 5:7	48:25 49:10	92:20 157:4
Seventh 2:7	245:3	5:12,16 78:22	societies 41:10	197:6 201:5
<b>shared</b> 53:2	significantly	79:2,17,25	solid 47:17	205:14 246:7
shedding 91:4	109:22 148:20	80:23 81:14,23	somebody 26:22	specifically
shoes 153:21	148:21 170:22	82:25 83:10	42:16 57:11	26:16,21 29:25
short 160:18	188:17 203:12	86:13 88:9	64:22 146:23	30:1 36:11
shorter 141:24	212:12,13,15	89:25 92:5	146:24 232:18	52:8,25 61:14
shorthand 250:3	230:13 231:2	101:24 102:9	237:18	67:5 83:18
250:4,7 <b>show</b> 39:6 56:1	231:16	102:13 103:2	soon 53:25	103:4,22
SHOW 39:0 30:1	silica 42:14 43:3	117:2 134:24	<b>Soria</b> 128:11	105:25 109:10

				Page 204
118:15 130:24	233:5,25	229:14 231:23	Stirewalt 86:19	179:13 191:25
141:4,6 147:11	234:11 237:4	240:18 246:7	104:5 149:1	192:10,14
147:21 149:17	standard 230:11	246:22,23	179:1 235:22	203:23,24
168:15 181:5	231:1	248:2	250:2,17	204:1,3 207:6
205:16 214:22	standards 77:8	statements	stochastic 15:15	232:4 237:5
222:6,10,14	77:9,10,13	38:12 66:4	Stocks 79:23	244:2
231:24,25	78:9	153:10 185:4	80:4 89:13	study 9:14 11:1
243:5 245:16	standpoint	194:3 197:8	214:8	18:23 19:4
246:9,11	72:17	210:11 214:25	stop 54:1 159:12	32:12,17 33:11
247:16	Staphylococcus	223:16 244:5	<b>stopped</b> 179:24	35:8 46:21
spectrum 54:25	4:18 5:9	245:25	stored 153:21	47:8,13 51:1
55:10	start 68:16	states 1:1 13:2	straight-up	52:23 54:18,19
speculating	148:24 163:12	stating 98:7,22	202:22	73:14 74:14,15
200:22,23	225:2,11,13,15	statistical 177:2	straightforward	75:2 77:3,6,21
spell 7:14	236:12	227:4 244:14	84:17	77:22,25 78:1
spelling 21:19	started 178:4	statistically 12:7	strategy 126:1	87:23,24
spend 40:1	224:16 225:20	148:19 151:12	Street 2:4,7	125:20,24
spent 45:25 57:1	226:15 227:6	151:19 164:20	strength 220:16	127:8,14,23
57:9	228:21 229:3	164:21 165:2	Streptococcus	128:18 136:24
spills 124:11	starting 48:20	211:22 227:8,9	194:18	138:6 142:17
spoke 59:9 66:9	77:23,23 87:19	230:13 231:2	strictly 63:7	143:1,7 145:19
85:22 127:18	133:18 150:19	231:15 244:22	strike 49:5	146:8,12
spoken 26:23	162:14 192:17	statistician	68:16 71:5	147:23,23
85:21 105:3	193:21 221:13	19:25 20:2,12	100:10 110:25	148:4,6,11
spread 73:4	226:23 227:2,5	statisticians	113:6 146:9	149:4,9,10,12
172:11	starts 90:20	20:8	174:11 202:15	150:18 153:2,8
squames 91:3	172:8 241:20	statistics 20:1,10	226:1	153:9 154:3,10
square 165:20	state 101:11	20:19 39:8	string 3:19,20	155:1 160:17
SS 225:16	165:7 174:25	69:2,13,20	3:21,22,23	161:9,10,17,17
<b>SSI</b> 5:4 9:17	234:7	228:2	strings 28:1	161:25 162:4,6
70:7 71:1	stated 98:9,24	<b>Stefan</b> 128:16	strong 243:23	162:17,21,25
73:23 82:14,16		<b>Stender</b> 119:14	struck 38:12	163:15,25
83:25 110:19	201:17 238:4	stenographic	structure 106:11	164:3,9,16,23
169:1 175:3,16	statement 10:24	19:9 34:7	studied 147:5	165:14,23,24
195:17 208:21	12:14 14:12,20	65:16 94:4	studies 14:13	167:8 168:7
212:18 213:15	26:6,13 53:1	104:9 142:14	17:9,12 27:19	171:8,15
217:2 222:18	71:12 105:22	154:11 215:3	31:7,13,16,17	175:20 176:19
224:3 225:16	111:4 120:4	250:4	32:22 33:7	176:20 177:4
<b>SSI.</b> ' 221:21	143:4 167:18	step 17:21 40:11	59:25 66:12	177:14 178:20
<b>SSIs</b> 12:4 83:15	174:16 175:13	119:25 179:12	74:22 77:14	179:5,12
117:11 141:5	177:25 180:18	stepping 234:19	82:15 87:24	180:25 181:13
198:20 204:2	183:10,20	sterile 87:25	88:3 91:6,20	181:24 190:12
244:2 246:1,9	188:15 189:1,3	88:9	99:23 108:9	193:5 197:16
246:15	189:4,7 197:9	Stevens 90:11	110:19 118:1	208:17,21
staff 32:11 91:4	210:9 213:25	90:12 128:10	120:11,20	210:22 211:5
118:8	217:12 220:11	stipulate 196:11	123:17,23	212:25 213:13
stand 162:7,16	222:17 223:11	stir 49:24,25	126:5,12	213:21,24
		<u> </u>	<u> </u>	<u> </u>

				1490 200
216:25 217:6	116:14 142:3	supports 78:10	83:4,10,24	243:12
218:9 221:14	156:13 203:10	164:19 171:8	84:16 85:25	systems 117:10
223:25 226:11	216:12 225:10	175:13	86:13 88:9	
226:24 227:15	225:19 237:14	sure 12:1 22:12	89:25 92:5	T
232:13 233:5,6	237:17 243:25	26:20 36:25	95:24 101:24	<b>T</b> 250:1,1 251:1
233:10 237:18	suggested 20:3	38:3 44:9	102:8,13 103:2	251:1
238:5 245:24	21:24 37:11	46:24 53:10	106:17 108:13	<b>table</b> 15:23 16:8
245:25 247:8	43:22 52:10	56:7 82:7	117:2 134:2	107:6 124:11
studying 80:11	105:16 141:9	85:20 97:10	140:2 149:13	165:3,15 196:7
stuff 220:24	141:21,22	102:2 106:20	181:20 191:17	207:24
224:15	173:24 191:23	123:21 130:3,7	198:9,21	tabulated 9:13
<b>Stults</b> 63:16	226:23 235:20	131:24 140:14	203:13 205:2	216:24
<b>subject</b> 62:10	suggesting 36:4	141:22 150:13	207:16 232:6	tabulation 38:16
64:19,21 65:5	36:15 120:19	155:18 157:9	surgical- 4:16	taints 47:14
90:14 92:20	167:21 205:17	157:13,14	157:16	take 12:12 15:8
113:22 128:25	213:8	161:13,18	surgical-site	19:4 23:11,18
130:5 225:13	suggestion 70:17	164:6 183:16	4:14 83:15	23:19 30:23
subjective 212:8	suggestions	184:3 186:25	93:3,17 157:21	33:4 48:17
subjectiveness	21:15 33:13	188:7 190:1	170:10	53:24 61:6
219:6	suggests 173:2	192:5 193:17	surgical-wound	66:23 69:18
subjects 153:3	177:15 180:25	195:5 196:6	166:6	71:3 76:24
submissions	226:7 229:6	200:4 211:1	surprised	87:16 88:15
33:20	231:15 242:10	213:23 233:9	142:19	92:24 93:12
submitted 96:3	247:16	234:5	surveillance 5:4	95:6 107:17
subpoena 25:3	<b>Suite</b> 2:4,7	surgeon 35:1	5:6 195:17	113:20 116:15
subsequent	<b>sum</b> 23:20 24:15	168:5	198:9 224:8	119:12 125:12
13:21 95:13	summary 3:16	surgeries 109:25	228:23 229:4	131:11 141:13
106:10	94:9 95:18	146:13 147:18	<b>survey</b> 204:25	150:16 151:21
subsequently	206:5 237:22	187:12 201:19	<b>suspect</b> 237:11	152:4 161:11
53:11	237:24 238:13	209:14	sustain 82:17	169:12 170:20
substantial	superfer 204:4	surgery 4:23	swim 172:7,14	176:8 180:7
81:22 82:24	superficial	5:11 17:15	<b>swims</b> 172:9	181:22 184:7
211:6,14 212:3	149:19 151:8	19:22,23 83:21	<b>switch</b> 137:4,6	187:5 191:14
212:7 239:10	155:8 156:10	90:24 138:1	switching 227:7	192:3 193:13
suffering 49:13	156:21 157:1	145:13 147:24	switchover	194:12 195:8
sufficient 14:14	157:10,16,21	162:23 165:19	244:10	200:17 205:23
43:4 54:25	170:23 189:20	166:7,14	sworn 7:2,4	209:3 215:18
55:10 57:18	204:4	173:11 190:9	228:20 251:20	216:19 220:3,6
66:8 67:3,8	supplement	190:21 191:20	symptoms 61:4	220:15 223:14
70:5 82:17	206:6,9,12	191:22 192:16	syndrome 51:20	229:23 230:6
90:4 99:11	support 13:24	200:4 243:9,14	system 94:24	taken 1:19 20:1
110:6 112:12	91:6,21 166:2	surgical 4:6 5:6	134:16 201:1	23:9 38:2 54:4
sugg 139:12	204:16 222:17	5:12,16 17:5	243:12	62:3,5 74:4 76:2 105:2
suggest 31:23	supported	27:9,10 70:6	systematic 117:7	108:3 116:18
32:22 33:11	191:24	78:22 79:2,17	221:14 232:8	124:14 131:6
35:8 47:12	supportive	79:25 80:23	243:7	139:24 159:14
55:15 78:23,24	38:12	81:14,23 82:25	systemic 243:7	137.44 137.14
	-	-	-	-

				Page 200
173:16 195:11	83:23 84:24	179:3 193:18	58:22 59:10,12	173:12 174:10
229:25 232:21	140:15 173:16	199:7 203:9	60:9,13,20	173.12 174.10
239:17	212:15	204:22 212:5	61:8,13,14	176:22 177:10
takes 187:9	terms 21:14 39:8		62:5,8 66:9,21	177:24 178:14
		229:22 236:2 242:15 247:18	, ,	
talc 62:13,22	46:6 65:8 69:5 71:4 179:11	<b>Thanks</b> 191:4	67:11,23 69:7 71:3 73:17	181:10 183:7 183:10 184:6
63:1,9 talk 15:5 58:22				187:1,8,8
	188:10 <b>test</b> 144:20	theater 165:9	74:5,20,25 75:22 77:24	′ ′
59:1 61:7 66:7		theatre 3:24		188:8 192:12
70:4 83:15	218:16	150:20	79:12 80:20	192:24 195:1 196:18 200:3
130:1 152:23	tested 114:17	theoretical 81:6	82:1,7,20	
167:3 221:17	testified 7:5	81:9	83:22 84:11,13	201:13,18,24
talked 87:10	21:23 37:15,25	theory 50:10	85:22,24 86:4	202:4 203:5,6
158:9 181:11	40:22 41:23	therefrom	86:16 87:9,15	204:14 209:5,6
192:11 221:2	45:3,4 61:10	183:12	88:16 89:1,7	210:6 212:8,13
234:24	62:23 63:16	thick 38:19	90:2 91:15	212:14 214:11
talking 16:14	74:25 86:11	thing 27:20 92:6	92:2,24 95:5	214:20 218:2
54:11 77:3	105:7 134:3	143:14 164:24	97:18 98:2,12	219:4 220:20
84:14 91:2	138:11 142:25	180:16 186:11	99:20 100:5,17	221:5 224:16
102:22 138:2	146:7,11	221:6 238:9	101:6,7,18	225:13 226:22
156:1 162:4,5	211:25 214:13	things 17:22	104:24 105:6,7	226:25 227:1,4
184:23 189:20	222:20 234:11	21:22 24:14	107:2,17 111:1	227:13 228:1
218:24 220:9	245:10	27:24 33:16	112:11 113:3	231:23 232:17
222:1 225:16	testimony 11:13	35:7 38:11	114:15,21,25	233:15 234:3
talks 95:18	11:15 24:7,8	39:9 45:10	115:5,14 116:1	235:5 239:15
103:5	31:3 37:22	74:21 113:16	116:6,13	240:19 241:21
tape 101:23	60:17 61:24	133:5 136:17	117:25 118:8	242:9,18 245:9
102:7,12 103:2	62:11 63:14,23	153:22 173:14	120:5 125:11	246:16
teaching 40:2	63:24 64:19	189:11 203:10	130:16 131:4	thinking 83:2,20
teargas 60:23	65:6 74:17	211:24	133:4,6,25	119:24 201:15
61:4	78:13 161:23	think 9:1 12:6	135:19 136:20	202:5
teicoplanin	162:14 163:13	12:12 15:14	136:22 137:23	thins 136:9
183:24 184:2	168:5,23	16:1 18:19,23	141:13,20	third 132:24
185:7 188:19	182:23 196:20	19:10 20:5	142:12,20	145:25 150:17
243:21,24	214:17 228:20	22:19 24:18	143:18 144:25	150:19 203:17
244:6,11	232:12,24	25:12,15 26:1	145:24 146:18	203:20
248:20	241:4 244:14	26:10 27:5	147:20 148:4	Thirty 41:2
tell 36:19 75:10	245:4	28:21 30:2,13	148:10,11,16	thought 30:8,15
86:1 122:4	testing 115:24	32:12,21 33:1	149:2 152:11	37:23 38:10
164:14 180:22	120:2,6 121:2	35:1 36:1 38:5	153:3,22	53:16 72:18
181:4 202:13	<b>THA</b> 243:13	39:21 40:21	155:10,11	75:16 76:8
205:21 218:8	thank 23:10	41:6,11 43:18	156:25 157:9	88:20 93:2
telling 76:9	45:14 54:7	43:22,24 44:15	158:14,24	110:3 118:2
111:16	82:10 86:21	45:7,13 47:20	160:16 163:19	123:4 129:14
tempered	90:7 95:10	47:20 48:14,18	164:6,16	131:22 138:12
242:12	119:4 124:5	50:1,17 52:21	167:12 168:3	141:12 157:25
<b>Teri</b> 119:13	145:9 154:14	53:5,13,20	171:11 172:6	166:5 174:22
term 12:16,19	162:12 170:5	57:6 58:15,20	172:11,13,23	188:4,20 189:7
	I	I	<u> </u>	I

				1 490 207
197:4 198:2	197:16 200:17	203:11	208:9	245:15,17
203:20 211:25	208:25 213:21	tort 58:18 59:8	<b>troubled</b> 31:7,12	two-month
215:13,16	223:12 228:22	total 3:25 23:21	true 115:9 124:1	209:20
216:19 221:8,9	229:5,6 240:16	24:15 145:13	250:6 251:4	type 35:19
231:22 232:7	244:15 248:5	165:16 243:8,8	truncated 9:13	128:18 131:18
thoughts 115:20	248:14 250:5	totally 164:23	216:23	201:25 205:10
218:11	timeframe 119:8	toxic 51:13,19	trust 34:25	207:11,20
three 69:24	times 10:25	58:18 59:8	221:19 222:12	types 41:25
73:24 77:4	37:17 40:22	toxicology 8:22	222:21	150:5 201:22
85:19 125:1	61:9 217:8	17:22	<b>try</b> 36:14 84:2	222:10
191:15 200:20	229:21	toxin 43:9,15	98:13 151:2	
202:13 217:7	tinza 145:2	44:5,18 45:21	153:18	U
three-month	tinzap 145:2	71:22	<b>trying</b> 10:19	<b>U.K</b> 223:4
209:20	tion 4:9	toxins 71:18	27:14 30:3	<b>Uh-huh</b> 138:25
threw 115:6,8	tissue 155:8	trace 109:2	38:20 100:2	219:22 226:9
thromboprop	172:15,20	traced 108:12	112:15,18	ultimately 39:10
139:3	tissues 84:16	track 102:2	120:11 136:7	135:9 202:6
thromboprop	172:7	traction 56:16	156:5 161:19	226:12
208:3 213:2	title 46:23	trade 62:20	161:22 162:3	umbrella 40:1
244:17 245:7	142:21	64:18,23 65:3	176:3 210:25	un 142:15
thromboses	<b>TKA</b> 243:13	training 19:24	turbulence	un-opposed
134:15	today 9:22,23	transcript 4:10	92:16	125:23
thrombosis	44:15 45:18	241:8 250:6	turn 55:16 56:12	<b>unable</b> 34:20
135:1	50:24 62:2,4	251:3	65:18 82:2	165:8
thrombotic	78:3,14 87:22	transcription	181:7 183:21	unaware 125:8
133:22 137:1,7	91:9 92:9	250:7 251:5	241:7	unclear 24:24
time 25:7 26:17	100:13 112:4	transcripts	turned 55:23	130:19 187:13
28:4,4 33:14	125:9 177:13	25:10,17 29:7	twice 127:25	191:22 192:16
34:1 38:11	178:11 180:24	234:9	two 14:5,13,22	under-ascerta
39:24,25 40:6	today's 77:8,9	<b>trauma</b> 71:23	15:14 17:9	148:11
41:16,18 44:4	77:13 78:9	treated 19:19	23:12 31:6,12	undercounted
46:1 50:22	told 27:18 52:7	treatment	31:16,24 32:22	142:1
53:3 56:22	52:25 74:13	174:18 176:13	33:7 39:1	<b>undercut</b> 32:14
57:9 59:11	101:10 112:22	244:1	41:12,17 44:16	52:22,22
72:3,14 73:7	129:20 139:10	<b>Trends</b> 198:19	65:9 70:23	undercuts 32:13
73:10 78:1	200:5	<b>trial</b> 4:24 45:6	73:11,21 74:22	53:14,21 76:6
91:10 98:13	tonight 206:23	61:24 179:8	75:17 81:18	206:20
101:7 104:23	top 77:5 78:7	181:25 190:21	97:8 99:22	undergoing
105:5,13,22,23	109:6 119:12	trials 70:24	125:23 127:12	17:14
106:12,22	126:22 128:9	73:21 243:22	130:16 134:23	underlying 64:2
119:10 123:21	142:20 186:5	tried 32:20	136:24 164:10	underneath
125:5,10,17	203:19 216:6	207:22	171:19 173:3	101:20 165:17
127:1,13,22	topic 128:21	trinzaparin	176:22 177:15	206:1
130:22 131:24	129:24,25	133:23 144:4	184:16 186:10	underreporting
154:9 168:22	130:3,4	144:25 145:3,4	191:15 209:17	222:22 223:3
174:3 176:8,10	topical 195:22	156:7,18 207:2	210:2 213:1	223:11
177:11 196:3	196:15,25	207:7,13 208:4	230:6 244:23	understand
L				

				1490 200
12:15 16:19	undertaken	use 12:3,18,19	32:13,15 52:22	59:23
26:10,12 30:5	73:14 195:21	13:8,13 14:1,8	182:12 206:21	views 55:2,12
30:14 31:21	undertaking	15:1,9,21 16:5	234:1,5	174:17 209:4
36:20 39:1	75:1 140:16	16:6 17:4,12	value 186:14	violation 56:5,9
69:10 80:10,18	219:3	30:3 31:20	191:18	virtually 171:16
80:21 81:4,6	underwent	33:8 56:10,10	Van 86:24 87:1	vis-a-vis 131:18
83:13 84:5	204:6	63:1,9 67:2,19	114:4,4 232:12	132:6
89:12 91:25	unfortunately	70:24 73:21	232:24	vitae 3:5
96:15,22 97:1	35:16 213:4	78:20 79:1,14	variable 132:24	voice 55:2,11
97:4,11 102:16	246:20	79:16 80:8	variants 174:8	<b>VOLUME</b> 1:14
106:14 108:8	unfortunately'	86:12 93:7,17	variety 40:23	vote 35:24
122:14 128:17	212:24	97:3 98:9,24	47:24 48:2	vulgar 33:24
129:22 134:12	<b>unhappy</b> 47:15	100:16 101:23	153:21 201:14	
136:5 139:10	126:24	102:7 107:23	various 58:18	W
142:16 144:24	<b>uniform</b> 90:24	109:22 110:7	115:25	wait 21:18,18
145:2 149:12	unimportant	117:9 129:21	vascular 137:20	218:22
153:10 156:2,5	33:5	133:25 134:18	169:15	<b>Waite</b> 128:10
157:18 165:13	uninjured 43:23	135:13,25	vein 134:15	<b>Waiting</b> 125:25
165:23 173:9	<b>unions</b> 41:10	136:8,23	135:1	Wansbeck
174:24 176:10	unit 94:24	137:24 139:3,6	ventilation	202:12 224:9
176:25 183:23	108:13 109:13	139:18,25	29:17	<b>want</b> 7:18 8:17
184:4 185:18	113:23 114:10	140:10 142:18	veracity 39:4	15:17 56:7,11
185:22 197:21	137:3 202:10	143:7 144:2,25	53:7,14,22	58:14 75:11
205:9 213:20	UNITED 1:1	147:5 167:18	234:1,4	120:6 132:11
214:1 224:17	<b>units</b> 181:18	168:25 174:20	verbal 46:2	143:11 147:12
233:4	184:16,17	177:25 193:23	verbatim 250:3	176:6 179:25
understanding	univariate	201:15 208:8	versus 4:13 40:2	180:2 210:6
31:15 32:8	148:19 219:18	208:22 211:7	40:7 42:23	234:8 241:7
51:16 75:21	220:2	211:17 212:9	63:16 65:22	242:17 246:5
79:19 84:12,23	universally	218:19 231:16	149:14,19	248:1
85:5,13 94:12	197:3	232:4,15	151:7 165:10	<b>wanted</b> 60:11
106:8 132:10	University 228:2	233:12 235:10	170:9 180:20	121:13 122:10
132:20 137:19	unquote 51:19	242:24 243:6	184:18 185:14	122:25 123:4
140:7 144:5,12	unsurprising	243:12,23	189:20 196:25	123:11 154:18
153:17 158:4	247:6	246:25	204:4 206:16	wants 172:9
176:3,17	unusual 16:5	<b>useful</b> 52:16	218:16 246:13	warding 186:14
194:24 195:20	updated 11:24	164:25 174:23	very- 31:21	warm 205:13
234:21,25	<b>upper</b> 198:21	219:4	<b>vetting</b> 40:17	warmed 205:20
understood 25:5	<b>upset</b> 240:13		videotape 1:20	warmer 205:19
30:15 53:10	<b>uptick</b> 197:25	<b>V</b>	Videotechnician	warmers 118:22
56:22 75:15	199:18	v 62:8	2:10	<b>warming</b> 1:5 4:5
80:24 87:7	URGENT	<b>vague</b> 130:9	view 17:4 45:12	4:21 27:10
93:10 141:8	126:21	<b>valid</b> 82:13	96:8 138:7	70:6,17 90:15
154:2 205:20	<b>urging</b> 126:4,11	110:17 211:5	165:22 199:21	90:25 94:23,24
221:25	127:13,23	233:10 238:5,8	201:4 206:19	116:24 117:10
undertake 11:9	128:2	239:2	219:1,9	117:11 122:11
75:11 85:10	<b>usable</b> 165:14	validity 13:25	viewpoints	123:2 129:1
	<u> </u>	l	l	l

				1490 207
132:6 134:2	125:21 144:23	witness 6:4 7:2,4	20:12	<u> </u>
135:14 136:25	145:6 199:7	23:8,10 54:7	worried 115:1	<b>X</b> 3:1
137:3 184:16	246:23 249:1	86:20,21 90:7	115:15	xarelto 133:23
184:17 190:19	we're 28:18	104:6,15 119:4	worth 210:14	142:18 143:2,7
205:11 242:10	84:14 184:23	124:5 145:9	wouldn't 35:14	143:22 144:3
warned 100:14	218:24 220:9	149:6 154:14	47:12 77:15	144:15 145:1
114:25,25	239:15 246:20	162:9 163:6,9	78:3 139:24	145:17 146:12
183:2	we've 34:11	170:5 179:2,3	152:25 153:1	147:6,14,24
<b>warning</b> 100:24	85:17 195:8	204:22 233:17	162:8 201:6,8	151:22 155:14
125:18	web 118:4,22	wondered 11:4	201:15 239:3	155:20 156:7
Washington	website 3:6	wondering	wound 4:7,22	156:18 161:10
22:11,15	39:16 40:18	200:12	84:13 95:25	163:2,17 164:8
<b>washout</b> 209:20	122:14	Woodwick-Si	134:24 142:17	166:1 207:2
wasn't 24:8 35:5	week 8:21 87:7	119:13	144:6,6 145:5	208:4
59:15 62:25	<b>weekend</b> 119:25	word 12:6,10,12	149:13,14,18	<b>Xarox</b> 147:6
63:2 81:21	weighing 244:3	28:2 49:4 56:1	149:19 150:6	
83:7 100:25	<b>well-</b> 71:13	56:7 69:7	155:2,23	Y
103:16 108:22	well-recognized	169:12 212:7	156:10,11,21	Yale 27:22
109:7 110:5	160:18	217:3	156:22 157:1	<b>yeah</b> 7:22 8:15
112:15 136:2	well-regarded	words 23:18	157:10 165:10	24:13 26:4,4
139:22 174:6	71:12	36:12 160:4	165:16 171:12	31:4 44:9
174:13 177:8	went 27:2 63:4	245:5	171:12,22	52:19,21 54:1
178:20 187:17	67:13 73:7	work 17:21	180:20 189:21	60:19 66:15
190:2 192:8,22	86:3 98:2	20:10 22:22	189:25 190:9	87:6 105:9
221:9 224:7,23	163:13 188:6	33:17 34:16	190:20 191:17	108:17 161:14
<b>waste</b> 60:16	188:16 189:1	40:15,15,20,24	191:21	162:12 180:15
114:12 115:7	197:19 199:14	41:13,18,24	write 45:11 51:9	180:16 199:6
water 42:1	216:19 217:8	42:19 43:1	51:23 55:8	210:19 236:11
106:13	248:14	49:19 50:20	56:8 181:25	241:22
way 12:19 14:21	Wenzel 17:1	54:24 55:9	213:12 216:22	year 9:25 58:23
16:14 25:6,9	22:17,20 81:8	69:14 71:16	writes 114:5	59:10 62:4
32:25 33:24	85:14,15 96:23	72:7,24 82:10	writing 20:18	126:19 127:8
65:18 71:6	172:3 177:20	87:4 124:24	76:6,8 142:12	year's 210:14
79:4,5 80:21	188:11	130:3 131:3,4	writings 56:21	<b>years</b> 18:16
81:25 83:1	weren't 49:23	143:7 152:14	66:17	26:23 38:2
114:8 136:3	94:3 103:2	214:4 226:21	written 43:11	40:23 52:17,20
146:10 162:11	108:25 213:8	240:5,11,12	45:8 46:3 51:5	61:10 71:23
174:12 179:17	Westlin 114:6	worked 33:14	51:21 69:19	72:24 118:6
205:9 209:25	119:13	105:11	133:4	125:23 126:5
210:5 215:9	wet 106:14	worker 64:22,25	wrong 36:23	209:14
220:1 234:7	white-collar	workers 73:6	146:18,20	yesterday 86:19
235:7	73:10	workplaces 73:3	215:17 223:19	104:5,25 106:9
ways 110:1	willing 56:24	73:9,10	223:19,21	107:10 149:1
111:11,17	wish 100:18	works 34:21	235:12,16	178:25
we'll 7:22 11:23	withdraw	World 64:18,23	238:8	yield 59:25
21:21 44:22	112:17 235:25	65:3 70:13	wrongly 167:20	<b>Yup</b> 160:12
58:16 110:25	withhold 10:19	world-class	wrote 82:12	
			•	•

		İ	I	i
$\overline{\mathbf{z}}$	126:14,18	2	161:12,24,24	<b>30</b> 5:24 40:25
	194:9	<b>2</b> 3:5 8:7,11,24	162:14	57:3 104:4,6
0	<b>14</b> 3:23 128:4,8	103:6 150:23	<b>22</b> 4:25 150:23	104:12,12,17
<b>05</b> 217:25 219:8	133:17 150:23	151:16 165:15	193:1,5 208:19	104:22 198:17
219:13,16,19	162:15 166:25	247:10	237:22 242:18	203:6,7 236:8
<b>06</b> 3:10	<b>145</b> 4:3	<b>2.5</b> 151:16	246:21	239:18,24
<b>07</b> 224:3	<b>15</b> 3:24 52:17	2.5-to-one	<b>225</b> 2:4	<b>30-day</b> 148:12
<b>08</b> 224:4 225:20	145:7,12	148:10 164:17	<b>23</b> 5:3 9:5	<b>30(b)(6)</b> 86:24
226:15 228:21	<b>15-2666</b> 1:9	<b>2.76</b> 212:2,10	195:12,16	<b>3000</b> 247:8
	<b>154</b> 4:6,9 48:19	<b>2.86</b> 212:4,5	<b>230</b> 5:21	<b>31</b> 104:14,15,17
1	<b>1556</b> 165:3,16	<b>20</b> 1:15,22 4:16	<b>236</b> 5:23	104:22
<b>1</b> 1:14 3:3 7:23	<b>16</b> 4:4 38:17,22	57:3 175:8,12	<b>2385</b> 203:19	<b>33</b> 169:25 181:4
7:24 8:3 9:4	39:5 77:23	<b>200</b> 1:20	<b>239</b> 6:1	<b>350</b> 236:23
22:9 23:13,17	78:8 152:19,25	<b>2002</b> 3:10 52:19	<b>24</b> 5:6 23:16,20	<b>39</b> 3:7
69:25 95:23	154:12,17	54:16	198:4,8 210:4	<b>3M</b> 11:10 29:7
116:21 131:14	16/Albrecht	<b>2006</b> 209:15,18	212:23	37:11 75:11
150:22 151:15	224:18	<b>2007</b> 209:15,21	<b>240</b> 6:6	76:1 86:6,11
151:15 206:6	<b>161</b> 4:11	<b>2008</b> 199:10,15	<b>245</b> 6:7	87:3,8,11,20
208:16 247:10	<b>17</b> 4:7 154:20,24	200:16 209:15	<b>246</b> 6:8	87:23 88:7
<b>1.92</b> 185:24	162:18 230:8	209:18 221:20	<b>247</b> 6:9	90:11,11
<b>10</b> 3:17,19 27:8	<b>170</b> 4:15	224:8,24	<b>25</b> 5:9 203:1,5	113:12 114:16
38:17,19 39:5	<b>175</b> 4:19	<b>2009</b> 113:17,18	213:12	115:23 116:2
113:7,11	<b>177</b> 76:25	199:15,17	<b>2500</b> 2:7	117:20 118:13
152:19 224:18	<b>178</b> 77:21,23	209:15,18	<b>251</b> 1:14	118:16,25
<b>102</b> 151:16	<b>179</b> 78:8	221:20	<b>258</b> 87:19	119:8 120:5,19
<b>10th</b> 94:10	<b>18</b> 4:10 132:21	<b>2010</b> 173:22	<b>26</b> 5:14 202:11	121:2,6,10,18
<b>11</b> 3:20 86:18,20	161:2,6,24	177:5 194:18	204:20,25	121:23 122:1,6
86:23 87:18	<b>186</b> 193:13,19	195:21 197:20	<b>26th</b> 250:9	122:23 123:4
119:2,7 175:25	242:20 246:22	<b>2011</b> 119:9	<b>27</b> 5:18 23:16,20	123:13,16,22
198:19 221:12	<b>19</b> 4:12 149:2,6	122:3 199:18	215:4 221:17	125:7,14 126:5
<b>113</b> 3:19	149:8 161:11	<b>2013</b> 61:24	241:1	126:11 127:14
<b>114</b> 215:19	170:3,8 203:22	63:17	<b>28</b> 5:20 223:14	127:23 129:5
216:6	203:24	2015/16 5:8	223:16 230:1,5	129:23 232:25
<b>115</b> 216:5,6	<b>190</b> 4:24	<b>2016</b> 4:11 5:23	<b>29</b> 5:22,23	<b>3M's</b> 117:22
241:7,8	<b>19137</b> 113:24	<b>2017</b> 1:15,22	223:22 226:7	3M00580475
<b>119</b> 3:20	<b>193</b> 5:2	3:14 5:17,19	236:3,7,7,8,14	3:15
<b>11a</b> 70:4	<b>195</b> 5:5	5:21 9:4 25:8	<b>2nd</b> 9:4,25 23:17	3MBH000246
<b>12</b> 3:14,21 124:3	<b>198</b> 5:8	61:25 76:17	25:8 80:6	3:19
124:8,17	<b>1980</b> 72:14	205:2 250:10	150:3	3MBH000473
125:13 178:23	<b>1988</b> 39:18	251:21		3:18
183:21 240:8	<b>1990</b> 72:12,12	<b>203</b> 5:13	3	3MBH001304
<b>12,000</b> 162:21	72:14	<b>204</b> 5:17	<b>3</b> 3:6 39:11,15	3:22
<b>124</b> 3:21	<b>1996</b> 3:18 77:11	<b>21</b> 4:20 82:7	<b>3.13</b> 185:25	3MBH001325
<b>126</b> 3:22	77:15 94:10	190:14,18	<b>3.8</b> 212:11	3:21
<b>128</b> 3:23	<b>1st</b> 61:24,25	191:6 232:2	234:13,24	3MBH005447
<b>12th</b> 76:17	62:4	<b>215</b> 5:19 161:8	235:20	3:20
<b>13</b> 3:22 34:10			<b>3.8-fold</b> 211:20	3МВН013305
	<u> </u>	<u> </u>	<u> </u>	<u> </u>

			Page 291
3:23	7 2.4 12 6.5		
3:23 <b>3rd</b> 113:17	<b>7</b> 3:4,13 6:5		
3ru 115:1/	76:12,16 150:25 151:5,6		
4	150.23 131.3,0		
<b>4</b> 3:8 4:11 5:19	<b>70</b> 244:3		
46:25 47:4	<b>71</b> 82:12		
<b>4.4</b> 171:6	<b>74c</b> 9:10 12:3,11		
<b>4.5</b> 171:6	12:20 216:22		
<b>40</b> 169:2	<b>74e</b> 238:25		
<b>400</b> 243:24	239:2		
<b>408</b> 230:8	<b>74f</b> 239:7		
<b>409</b> 231:12	<b>750</b> 94:11,14		
<b>41</b> 133:18	96:4 100:14		
<b>42</b> 152:1,9	113:23		
<b>431</b> 2:7	<b>76</b> 3:14		
<b>44</b> 38:23 140:23	<b>7th</b> 119:9		
<b>46</b> 3:9			
<b>4600</b> 2:4	8		
<b>49</b> 169:15	<b>8</b> 3:5,15 90:5,10		
5	<b>8:09</b> 1:22		
<del></del>	<b>84</b> 202:11		
<b>5</b> 3:10 5:21 54:5 54:10	<b>85</b> 40:3,6		
<b>50</b> 118:6	<b>86</b> 39:21		
<b>500</b> 41:8 94:13	8th 22:11,13		
94:24	23:2 85:16		
<b>510(k)</b> 3:16 94:9	9		
94:17,18	<b>9</b> 3:16 62:6 94:5		
101:10 183:9	94:9 178:25		
<b>512(k)</b> 183:8	179:2,5 181:8		
<b>523</b> 150:17	182:13 224:3		
<b>54</b> 3:10	<b>90</b> 3:15 247:10		
<b>55.5</b> 150:22	<b>94</b> 3:18		
<b>55402</b> 2:4	<b>95</b> 151:15		
<b>55415</b> 2:8	198:21 247:11		
<b>5th</b> 119:8	9th 122:2		
6			
<b>6</b> 3:11 61:19,23			
<b>61</b> 3:12			
<b>63.6</b> 150:23			
<b>68</b> 82:8			
<b>69</b> 82:8			
6th 2:4 54:16			
119:8,8			
7			
	l		